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Abstract: Background: Deep brain stimulation (DBS) of the subcallosal 
cingulate white matter (SCC) has shown promise as an intervention for 
patients with chronic, unremitting depression (TRD). To test the safety 
and efficacy of DBS for TRD, a prospective, randomized, sham-controlled 
trial was conducted.  
Methods: Participants with TRD were implanted with a DBS system targeting 
bilateral SCC white matter and randomized to six months of active versus 
sham DBS followed by six months open-label SCC DBS. The primary outcome 
was response rate at the end of the six-month double-blind phase. 
Response was defined as a 40% or greater reduction in depression severity 
from baseline. A futility analysis was performed when approximately half 
of the proposed sample received DBS implantation and completed the 
double-blind phase. At the conclusion of the 12-month study, a subset of 
patients continued to be followed for up to 24 months. 
Findings: Prior to the futility analysis, 90 participants were randomized 
to active (N=60) versus sham (N=30) stimulation. Both groups showed 
improvement, but there was no statistically significant difference in 
response rate during the double-blind, sham-controlled phase. 
Participants continued to improve during the six months open-label phase. 
Long-term response and remission rates for all participants receiving 
active DBS open-label were, respectively, 40% and 19% at 12 months, 51% 
and 17% at 18 months, and 48% and 25% at 24 months. Twenty-eight patients 
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experienced 39 adverse events; eight of these (in seven patients) were 
deemed to be related to the study device and/or surgery.  
Interpretation: This study confirmed the safety and feasibility of SCC 
DBS as a treatment for TRD but failed to show statistically significant 
antidepressant efficacy in a six months double-blind, sham-controlled 
trial. Long-term (up to 24 months) open-label SCC DBS was associated with 
a response rate of nearly 50%, with 25% of participants remitted. These 
rates are clinically meaningful and higher than those expected in this 
patient population with treatment-as-usual.   
 
 
 
 
 
  
Introduction 
 Brodmann Area 25 (BA25) within the subcallosal cingulate has been strongly implicated in the pathophysiology of treatment-resistant 
depression.1 In depressed patients who respond to antidepressant treatments, BA25 activity shows a consistent change associated with 
antidepressant response. However, in patients with treatment-resistant depression, BA25 activity does not change with adequate 
antidepressant treatment compared to treatment responders. Anatomically, BA25 shows a pattern of structural connectivity that supports its 
role in the pathophysiology of depression and treatment-resistant depression, with monosynaptic connections to the medial prefrontal cortex, 
perigenual and dorsal anterior cingulate gyri, hippocampus/amygdala, ventral striatum, thalamus, hypothalamus and monoaminergic nuclei 
within the brain stem.1 Therefore, direct modulation of BA25, and especially its white matter connections to other brain regions involved in 
depression, is a potential treatment target for patients with treatment-resistant depression. 
 Deep brain stimulation (DBS) of the subcallosal cingulate white matter has shown promising safety and efficacy for patients with 
treatment-resistant depression.2-9 Open-label, chronic, high-frequency (>100 Hz) subcallosal cingulate DBS has demonstrated six-month 
response rates of about 50% and long-term remission rates (over two to six years) around 50%.4-7, 10 Patients enrolled in these studies were 
highly treatment-resistant (typically not responding to at least four antidepressant medications in the current episode, and no consistent 
response to psychotherapy and/or electroconvulsive therapy (ECT)), chronically depressed (average episode duration of about five years) and 
severely ill due to their treatment-resistant depression, with the vast majority effectively disabled. These preliminary findings are clinically 
meaningful and compare favorably to response and remission rates in patients with treatment-resistant depression receiving treatment-as-
usual, other neuromodulation interventions or ablative procedures such as cingulotomy.11-17 Given these encouraging open-label data, a 
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prospective, randomized, double-blind sham-controlled trial of subcallosal cingulate DBS for treatment-resistant depression was conducted. It 
was hypothesized that six months of subcallosal cingulate DBS would be associated with statistically significant antidepressant efficacy 
compared to sham stimulation.  
 
 Methods 
Study overview 
 A six-month, multi-center, randomized, double-blind, sham-controlled trial was conducted to evaluate the safety and efficacy of 
subcallosal cingulate DBS (Libra®XP Deep Brain Stimulation System, St. Jude Medical, Plano, Texas) for patients with treatment-resistant 
depression. A six-month open-label phase followed the double-blind phase. Planned enrollment was 201 participants randomized at up to 20 
sites. The study was registered at clinicaltrials.gov (NCT00617162). Study procedures were approved by the Institutional Review Board at each 
site and the U.S. Food and Drug Administration under an Investigational Device Exemption (G070107, sponsored by St. Jude Medical). The study 
was monitored by an independent Data and Safety Monitoring Board. Recruitment occurred from April 10, 2008 to November 21, 2012. 
 
Participants 
 Inclusion criteria included: 1) men and women aged 21-70 years; 2) unipolar, non-psychotic major depressive disorder (MDD) diagnosed 
before age 45 with a current episode >12 months duration; 3) lack of antidepressant response (via medical and/or pharmacy records) to a 
minimum of four adequate antidepressant treatments, including at least three medications from three different classes, evidence-based 
  
psychotherapy, and/or ECT, 4) lack of sustained response to a course of psychotherapy; 5) Montgomery-Asberg Depression Rating Scale 
(MADRS) score >22 at each of three separate baseline visits, rated by two separate psychiatrists; baseline visits 2 and 3 were separated by no 
more than 6 weeks, and eligible participants must have demonstrated absence of notable improvement (≤20% lessening of MADRS score) 
between these visits; 6) Global Assessment of Function (GAF) score <50; 7) Mini-Mental State Examination (MMSE) score >24; 8) medication free 
or current antidepressant/ psychotropic medication regimen stable for >4 weeks prior to study entry; 9) able and willing to give written 
informed consent.  
 Exclusion criteria included: 1) bipolar or psychotic disorder; 2) obsessive compulsive disorder, post-traumatic stress disorder, panic 
disorder, bulimia or anorexia nervosa; 3) generalized anxiety disorder (GAD) as the primary diagnosis during the current depressive episode; 4) 
substance use disorder (excluding caffeine, nicotine) within the last 12 months; 5) borderline or antisocial personality disorder; 6) substantial risk 
of suicide; 7) received ECT within 3 months prior to enrollment, or likely to require ECT during the study; 8) central nervous system disease 
impairing motor, sensory or cognitive function or requiring intermittent or chronic medication; 9) fibromyalgia, chronic fatigue syndrome or 
current condition requiring chronic narcotic use; 10) unstable, uncontrolled medical illness; 11) past ablative or other intracranial surgery; 12) 
contraindication to magnetic resonance imaging (MRI) scanning; 13) contraindication to general anesthesia or deep brain stimulation surgery; 
14) pregnant, intending to get pregnant during the study or breastfeeding; 15) currently participating in another investigational device, drug or 
surgical trial; and 16) unable to comply with study visit schedule and timeline. 
 
Concomitant treatments 
  
 Participants could continue psychotherapy and medications during the study but were required to maintain a stable medication regimen 
as well as regularly scheduled psychotherapy visits. Medication changes or the initiation of psychotherapy were not allowed during the six-
month double-blind phase. Minor adjustments to sedative/hypnotic and anxiolytic medications were allowed.  
 
Screening and baseline assessments 
 Potential participants were screened according to the eligibility criteria above. At least two years of medical records were reviewed. 
Potential participants were provided a detailed informed consent document, had an initial screening, and completed three baseline evaluations. 
These evaluations occurred no less than two weeks apart from each other, and baseline visits 2 and 3 were not separated by more than six 
weeks. The first two baseline visit evaluations were performed by independent psychiatrists. Baseline assessments included the MADRS; the 17-
item Hamilton Depression Rating Scale (HRSD-17); the Self-Rated Quick Inventory of Depressive Symptomatology (QIDS-SR); subsection for 
cluster B personality disorder of the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II); Systematic Assessment for 
Treatment Emergent Events (SAFTEE); the 30 item Inventory of Depressive Symptomatology (IDS-C30); the Young Mania Rating Scale (YMRS); 
the Work and Social Adjustment Scale (WSAS); GAF; the short form Quality of Life Enjoyment and Satisfaction Questionnaire (QOL); Clinical 
Global Impression of Severity and Improvement (CGI); Patient Global Impression Index (PGI); Health and Labor Questionnaire (HLQ); Hamilton 
Anxiety Rating Scale (HAM-A) and Columbia Suicide Severity Rating Scale (C-SSRS). After the baseline visit was completed, the lead study 
psychiatrist (PEH) performed an external review of the participant’s data to ensure eligibility. After the third baseline visit, a neuropsychological 
  
battery was administered to assess attention/working memory and other executive functions. A high-resolution magnetic resonance imaging 
(MRI) scan and pre-surgical evaluation were also performed.  
 
Surgery and target localization 
 The DBS system consisted of two leads, extension wires and an implantable pulse generator (IPG). Each DBS lead consisted of a four 
electrode array with a 3 mm electrode at the tip and three 1.5 mm electrodes, each separated by 1.5 mm. At least two of three experts (HSM, 
CH, PEH) manually selected and agreed upon the optimal surgical target, defined as a region in the subcallosal cingulate white matter 
approximately 75% of the distance from the anterior commissure to the plane defined by the gray matter edge of the genu of the corpus 
callosum and in the transition from the white matter to the gray matter in the medial-lateral axis.2, 3, 18 Target selection was performed in native 
MRI space (i.e., not in an atlas-defined space) and involved identifying a target region at the gray matter-white matter transition area in the 
subcallosal cingulate gyrus. Optimal target location was provided to the site neurosurgeon to assist with surgical targeting, and each 
neurosurgeon was trained on targeting by a team of experts (HSM, CH, AML).  
 Bilateral DBS system implantation occurred no less than two weeks and no more than four weeks after the final baseline evaluation 
using the standard stereotactic surgical procedures at each site. Impedance of the system was tested intraoperatively, but no stimulation was 
delivered during surgery.  
 Post-operative computed tomography (CT) was obtained to assess for intracranial hemorrhage and lead localization. The post-operative 
CT scan was then merged with the pre-operative high-resolution MRI used for initial target selection. At least two of three expert consultants 
  
(HSM, CH, PEH) reviewed these merged images and selected an optimal contact sequence for chronic monopolar stimulation. The first contact 
chosen was the one in closest proximity to the predefined target (described above), and the second contact chosen was the one in the next 
closest proximity to the predefined target. No participant had more than two contacts within the predefined target region. Four subjects had an 
additional surgery to reposition the leads due to the leads not being in the ideal target region; in all cases, this occurred prior to randomization. 
Post-operative CT scans were merged with baseline MRI scans.  
 
Randomization 
 Approximately two weeks after device implantation, participants were randomized to receive immediate active stimulation (Stimulation 
group) or 6-month delayed stimulation (sham; Control group) using a ratio of 2:1 (Stimulation:Control). Randomization was computer-generated 
(SAS version 9.2) with a block size of three at each site before the site started the study. At each site, an unblinded DBS programmer was 
informed of treatment allocation; all other team members and the patient were blinded to treatment allocation.  
 
DBS programming 
 For participants randomized to the Stimulation group, stimulation was initiated at the completion of the randomization visit (week 2 
following implantation). Initial parameters included monopolar stimulation at the optimal first contact selected on each side at 130 Hz, 91 
microsecond pulse width (PW), 4 milliamperes (mA). For Controls, a sham programming session was performed, but stimulation was not 
initiated. Participants were not formally assessed for whether they had acute effects from stimulation.  
  
 For participants receiving active stimulation, programming changes were made based on the change in MADRS from the previous rating. 
Two weeks after the initial programming session, no parameter changes were made if the MADRS score reduction was ≥10% from the previous 
evaluation. If the MADRS value was ≤10% lower than that on the previous evaluation, amplitude was increased to 6 mA. After another four 
weeks (if the MADRS was again ≤10% lower than that from the previous evaluation), the amplitude was increased to 8 mA. After another four 
weeks, if the MADRS was again ≤10% lower than that from the previous evaluation, the second contact from the pre-selected contact sequence 
would be added for monopolar stimulation (i.e., the patient would have two contacts providing active monopolar [8 mA] stimulation in each 
hemisphere). If intolerable side effects occurred following a parameter change, parameters were returned to the previous settings. No 
modifications were allowed in pulse width or frequency. No further parameter changes were allowed beyond 10 weeks following initiation of 
stimulation. Participants randomized to sham had similar programming visits, but stimulation remained off during the double-blind phase.  
 
Randomized, double blind, sham-controlled phase 
 Following randomization, participants returned for evaluations at weeks 4, 6, and 8, then every month until the 6-month endpoint. At 
each visit, the following evaluations were completed: MADRS; SAFTEE; DBS programming form; IDS-C30; QIDS-SR; WSAS; GAF; CGI; PGI; HAM-A; 
and C-SSRS. At the 3 month and 6 month visits, the following additional evaluations were completed: HRSD-17; YMRS; QOL; and HLQ. The 
neuropsychological battery was repeated at the 6 month visit. Outside of regularly scheduled, in-person evaluations, each patient was contacted 
by phone or in person by study personnel every one to two weeks to assess for safety. Participants experiencing worsening of suicidal ideation 
could remain in the study if stability (“rescue”) could be achieved within seven days. Participants experiencing a ≥25% worsening in MADRS 
  
score from baseline were considered treatment failures, exited from this phase of the study and enrolled in the open-label or long-term follow-
up study based on whether they were already receiving active stimulation.  
 
Open-label phase 
 Following the 6-month double-blind phase, participants entered the 6-month open-label phase. All participants in the Control group 
(including responders and remitters) had stimulation initiated at this time with the identical algorithm employed for contact and parameter 
selection and changes as described above for the active treatment group. Participants in the Stimulation group continued with active 
stimulation. In the open-label phase, patients and study staff (except the unblinded programmer) were not provided any information about 
randomization status during the first 6 months of the study. At each monthly visit the following evaluations were completed: DBS programming 
form; MADRS; IDS-C30; QIDS-SR; WSAS; GAF; CGI; PGI; HAM-A; and C-SSRS. At the 9 month and 12 month visits, the following additional 
evaluations were completed: SAFTEE; YMRS; QOL; and HLQ. The neuropsychological battery was performed again at the 12 month visit. 
Parameter adjustments were constrained as described above. Changes in medications and psychotherapy were allowed in this open-label phase.   
 
Long-term follow-up phase 
 Participants completing the 12 month study were invited to continue in a long-term, naturalistic follow-up study. Study visits occurred 
every six months. Changes in stimulation parameters, medications and psychotherapy were allowed. For patients continuing with chronic DBS, a 
rechargeable battery was provided as needed.  
  
 
Efficacy measures 
 The primary efficacy endpoint for the study was defined as difference in response rate between the Stimulation and Control groups. 
Response was defined as a ≥40% reduction in MADRS and no worsening in GAF from baseline (average of 3 baseline MADRS assessments) to the 
average scores at months 4, 5, and 6. The average of months 4, 5, and 6 was chosen as the primary endpoint due to the aim to assess for a 
sustained change over time. Secondary measures of efficacy included changes from baseline to endpoint for the HRSD-17, IDS-C30, QIDS-SR, 
WSAS, PGI, CGI, QOL and HAM-A. For the 6-month open-label and long-term follow-up studies, response was defined as a ≥40% reduction in 
MADRS from the baseline average to the score at the time point of interest (e.g., 12 months, 18 months, 24 months). Remission at all time 
points was defined as a MADRS score ≤10. 
 
Safety measures 
 The incidence of all adverse events (e.g., hospitalization due to worsening depression, suicidal ideation or behavior, unanticipated 
medical treatment for psychiatric reasons, and device related events) that occurred over study duration were used as the primary safety 
endpoints for the study. 
 
Statistical considerations and data analyses 
  
 Based on preliminary data7, a ≥40% response rate was anticipated for the active subcallosal cingulate DBS group. A ≤18.5% response rate 
for the Control group was expected.12 Therefore, 159 participants randomized 2:1 (106 in the active group and 53 in the sham group) would 
provide 80% power to reject the primary efficacy null hypothesis at a 5% significance level. Sample size calculations were performed based on 
the Z test method with pooled variance using PASS 2005. To allow for a dropout rate as high as 20%, the sample size for recruitment was 
increased to 201 participants (134 in the active stimulation group and 67 in the sham stimulation group). 
 The primary efficacy outcome assessed was difference in response rate between the groups (as defined above). Participants who were 
missing one or two of the assessments at months 4, 5 or 6 had data from the available visits used. Participants missing MADRS scores for Months 
4, 5 and 6 were considered non-responders. A logistic regression model including effects of treatment group, study site, level of treatment 
resistance (as defined by ATHF criteria), and baseline MADRS was fitted. Data from study sites with fewer than three participants in either 
treatment group were pooled.    
 
Planned futility analysis 
 In approving this study, the U.S. FDA required a futility analysis be completed once ≥75 participants had reached the primary endpoint 
by either completing the month 6 visit or exiting the study. No more than 125 participants could be enrolled prior to the futility analysis.  The 
futility analysis was performed using the average of the revised alternative hypothesis and the observed interim results. With the current sample 
size of 201 participants, the alternative hypothesis was a 40% response rate for participants receiving active stimulation and a 20.7% response 
rate for participants receiving sham (the proportions providing 80% power to reject the primary hypothesis given the smaller sample size at the 
  
time of the futility analysis). Based on these revised population proportions, 5000 sets of simulation results among the remaining approximately 
84 stimulation participants and 42 control group participants were run. Each set of simulated results was added to the observed results, and a 
two-tailed Fisher’s exact p-value was calculated. The probability of a successful outcome of the study was the proportion of these p-values 
<0.05. If the probability of a successful study outcome was <10%, the study would be stopped for futility. Additionally, the study could be 
stopped at the sponsor’s discretion, even if this formal definition for futility was not met.   
 
Results 
 A total of 128 participants were enrolled (i.e., signed informed consent) from 15 investigational sites prior to the completion of the 
futility analysis (Figure 1). Of the 128 participants enrolled into the study, only 90 from 13 investigational sites received DBS system implantation 
and were randomized to treatment. Of these, 60 participants were randomized to active stimulation, and 30 were randomized to sham 
stimulation. There were no statistically significant differences between the groups in demographic or clinical variables (Table 1).  
 On average, patients in both groups showed a statically significant improvement in depression and global functioning over 6 and 12 
months. At the endpoint for the 6-month blinded, controlled phase, there was no statistically significant difference in efficacy between the 
Stimulation group (20% response rate; 10% remission rate) and the Control group (17% response rate; 7% remission rate)(Figure 2, Tables 2 and 
3; analyses of primary and secondary outcome measures are shown in Supplementary Tables S1-S8). In participants randomized to sham 
stimulation for the first six months of the study, six months of active stimulation did not result in additional statistically significant within group 
antidepressant efficacy (i.e., no statistically significant decrease in MADRS score from month 6 to month 12). By the 12 month visit, response and 
  
remission rates did not statistically significantly increase compared to the 6 month visit in either group, though response rates numerically 
increased in both groups (Stimulation group: 30% response rate; Control group: 27% response rate), and remission rates remained stable to 
slightly increased (Stimulation group: 18%; Control group: 7% remission rate). Medication and/or psychotherapy changes were only allowed in 
the 6 month open-label phase, but did not correlate with efficacy or differential efficacy in the groups.  
 Adequacy of blinding was confirmed based on questioning participants about which group they were assigned to after 4 weeks, 8 weeks, 
3 months and 6 months of the blinded, randomized, controlled phase of the study. There was no difference between the Stimulation and 
Control group in proportion of participants guessing they were receiving active stimulation, with approximately 30%-40% of each group 
(Stimulation, Control) guessing they were receiving active stimulation at each time point. About 50% of participants in each group guessed 
accurately, and there was no difference in accuracy of guessing between the groups. No participant reported any acute effects with the initiation 
of active stimulation, nor were any effects of initial activation of stimulation observed by study staff, including the unblinded programmer.  
 For the futility analysis, based on the first six months’ data, the response rate for the Stimulation group was predicted to be 40%, and 
the response rate for the Control group was predicted to be 18.5% (see Methods above). In the actual futility analysis, the Stimulation group 
showed a 20% response rate, and the Control group showed a 17% response rate. It was concluded that the study had a 17% chance of success if 
continued. Although this did not meet the formal definition for futility described above (<10% chance of success), the sponsor chose to end 
study enrollment following the futility analysis. 
 Following the initial 12-month study, seventy-seven (77) participants entered into a four-year follow-up study. Eight participants from 
the Active group and five participants from the Control group dropped out; all were nonresponders at the 12 month endpoint. For long-term 
  
assessment of efficacy, response was defined as a ≥40% decrease in MADRS score from baseline to each endpoint, and remission was defined as 
a MADRS score ≤10. For assessment of long-term efficacy, patients in both groups (Stimulation and Control) were combined for analysis; 
therefore and by example, six months of stimulation refers to six months of active stimulation regardless of whether this started initially (in the 
Stimulation group) or six months later (in the Control group). With long-term, active subcallosal cingulate DBS, response and remission rates 
were 40% and 19% at 12 months, 51% and 17% at 18 months, and 48% and 25% at 24 months, respectively. Mean MADRS and GAF scores by 
months of stimulation are shown in Figure 3. 
 To assess whether stimulation parameter and/or medication changes were associated with efficacy, two post-hoc analyses were 
performed. For the first 12 months data, a generalized linear mixed effects model was fitted that included treatment group, medication change 
and stimulation parameter change at each follow-up visit as independent fixed effects, subject as a random effect and responder status at each 
follow-up visit as the dependent variable. Based on this model, neither stimulation parameter change nor medication change was associated 
with response rate (p=0.2176 and p=0.4891, respectively). Separately, a generalized linear mixed effects model was fitted for the 18-30 months 
(open-label) data that included medication change and stimulation parameter change at each follow-up visit as independent fixed effects, 
subject as a random effect and responder status at each follow-up visit as the dependent variable. This analysis showed that stimulation 
parameter change was associated with increased response rate (p=0.0127), but medication change was not (p=0.3955). 
 Twenty eight (28) participants experienced 39 serious adverse events (SAE) during the 12 month study (Table 3). Eight (8) SAEs occurring 
in seven patients were judged to be definitely related to the study device and/or surgery, including six infections (in five patients), one skin 
erosion over the extension wires, and one post-operative seizure. The remainder of SAEs were attributed to the primary mood disorder and 
  
deemed unrelated to the device or active stimulation; i.e., there appeared to be no clear temporal relationship between the onset and 
resolution of these events and the initiation or adjustment of stimulation. There were two deaths by suicide in the study; both were in the 
Control group during the 6-month open-label phase. No unanticipated device related adverse events were reported. No episodes of hypomania 
or mania occurred during the study. There were no adverse neuropsychological effects at 6 or 12 months; a full description of 
neuropsychological findings will be reported separately. No side effects occurred with DBS programming, and no parameter adjustments were 
required due to side effects following a parameter change.  
 Ten out of 90 participants receiving DBS system implantation terminated the study early (five prior to the primary endpoint/six-month 
visit and five before the 12-month visit). Six early exits were due to adverse events (worsening depression [n=1], suicide attempt [n=1], increased 
suicidal ideation with failed “rescue” (see Methods) [n=1], death by suicide [n=2], and head pain [n=1]). Three early exits were due to patient 
preference and one was due to the sponsor closing the study. Four out of the 10 subjects that exited the study early chose to have the device 
fully explanted shortly after study exit.  
 No demographic or clinical characteristics were associated with 6 month, 12 month or 24 month response or remission rates. Presence 
of melancholic features, duration of illness and/or current episode, history of ECT did not differ between responders and nonresponders at any 
time point. Eventual responders versus non-responders did not differ in use or change in psychotherapy, medications or stimulation parameter 
adjustments. No systematic difference in electrode placement between responders and non-responders was identified, consistent with prior 
studies.18, 19 Additionally, distance between actual vs. planned target placement did not differ significantly between eventual responders versus 
nonresponders, and there were no significant differences between sites in accuracy of electrode placement.   
  
 
Discussion 
 This study helps confirm the feasibility and safety of subcallosal cingulate DBS as a treatment for treatment-resistant depression 
patients. However, this study failed to demonstrate that six months of active versus sham stimulation was associated with statistically significant 
antidepressant effects. Additionally, participants initially treated with sham stimulation during the first six months of the study did not show 
statistically significant antidepressant benefit with an additional six months of open-label active stimulation. In participants with up to two years 
of open-label active DBS stimulation, 48% achieved an antidepressant response and 25% achieved remission. These long-term outcomes are 
clinically meaningful and greater than would be expected with treatment-as-usual in this highly treatment-refractory patient population.12 
 These findings are disappointing given the encouraging data from earlier open-label studies of subcallosal cingulate DBS, and no 
demographic or clinical characteristics were associated with response versus nonresponse. However, it is noted that participants in this study 
had an average current episode duration of about 12 years. This is much longer than the average duration of current episode in prior subcallosal 
cingulate DBS studies (approximately five years)3, 6 and may have contributed to the low overall response rate. Although subcallosal cingulate 
DBS has shown enduring, open-label efficacy in chronic depression,4, 6 it is possible that this intervention is less effective for patients with 
extremely chronic depression. 
 Interpreting these findings must also consider study design. For studies of invasive interventions for neuropsychiatric disorders, placebo 
effects can be surprisingly high and may actually be quite long-lasting.20, 21 However, the placebo response rate in this study was not significantly 
greater than what was anticipated; in fact it was lower than projected. Indeed, the major difference in this study compared to prior subcallosal 
  
cingulate DBS studies was the lower response rate to active stimulation during the blinded phase of the study. Again, this may be due to the 
more chronic nature of disease in this cohort compared to prior samples. Additionally, it is not uncommon for the response to active treatment 
to be lower in a randomized, blinded, placebo-controlled trial than in open-label studies. Additionally, prior studies and data from this cohort 
suggest delayed and progressive antidepressant effects over time with subcallosal cingulate DBS. Therefore, it is possible that differences in 
benefit between active and sham stimulation may not be seen until after one to two years of treatment in this group. However, such a time 
frame makes sham-controlled studies much more challenging. Other study designs may need to be considered, such as open-label stimulation 
followed by blinded discontinuation.22 
  Targeting for this study was based on an algorithm derived from early subcallosal cingulate DBS studies.18 Neurosurgical placement of 
the DBS electrodes, based on this algorithm, was highly accurate and did not differ between eventual responders and nonresponders. However, 
gross anatomical placement of subcallosal cingulate DBS electrodes may not be adequate for optimal treatment delivery. Recently, important 
subtleties in electrode placement have been described based on the white matter tracts impacted.19 These data suggest that, for maximal 
efficacy, the active subcallosal cingulate DBS electrode must be placed such that it impacts a critical network of white matter tracts connecting 
key brain regions, including the forceps minor, cingulum bundle and uncinate fasciculus. Therefore, it is possible that prospective targeting 
based on individual DTI tractography could optimize subcallosal cingulate DBS electrode placement.23, 24  
 Given the strength of the preliminary data leading to this study, and the emerging data suggesting ways to optimize targeting for this 
intervention, the negative outcome of this trial should not be simply interpreted as a failure of subcallosal cingulate DBS for treatment-resistant 
depression. Subsequent studies are merited to determine whether active subcallosal cingulate DBS failed to differentiate from sham due to 
  
clinical features of the patient population (e.g., extremely chronic depression) or suboptimal electrode placement. Additionally, identification 
and use of a physiological metric to verify engagement of the appropriate neural circuit could assist with targeting. Importantly, the long term 
response and remission rates in this and prior studies suggest that this intervention continues to have promise. 
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FIGURE LEGENDS 
Figure 1. Participant disposition. 
 
Figure 2. Depression severity over time in each treatment arm. Note that at months 9 and 12, the Control group was receiving active stimulation; 
therefore, for the Control group, 9 months refers to 3 months of active stimulation, and 12 months refers to 6 months of active stimulation. 
 
Figure 3. Overall function over time in each treatment arm. Note that at months 9 and 12, the Control group was receiving active stimulation; 
therefore, for the Control group, 9 months refers to 3 months of active stimulation, and 12 months refers to 6 months of active stimulation. 
 
Figure 4. Long-term outcomes (depression severity and overall function) in all participants receiving active stimulation during the study. These 
results include participants initially randomized to active stimulation and participants initially randomized to no stimulation for the double-blind 
phase of the study. For the participants initially randomized to no stimulation, the data used for this graph are solely those collected after active 
stimulation had been initiated in the open-label study phase. 
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Introduction 
 Brodmann Area 25 (BA25) within the subcallosal cingulate (SCC) has been strongly implicated in the pathophysiology of treatment-
resistant depression (TRD).1 In depressed patients who respond to antidepressant treatments, BA25 activity shows a consistent change 
associated with antidepressant response. However, in patients with TRDtreatment-resistant depression patients, BA25 activity does not change 
with adequate antidepressant treatment compared to treatment responders. Anatomically, BA25 shows a pattern of structural connectivity that 
supports its role in the pathophysiology of depression and TRDtreatment-resistant depression, with monosynaptic connections to the medial 
prefrontal cortex, perigenual and dorsal anterior cingulate gyri, hippocampus/amygdala, ventral striatum, thalamus, hypothalamus and 
monoaminergic nuclei within the brain stem.1 Therefore, direct modulation of BA25, and especially its white matter connections to other brain 
regions involved in depression, is a potential treatment target for patients with TRDtreatment-resistant depression. 
 Deep brain stimulation (DBS) of the subcallosal cingulate white matter (SCC) has shown promising safety and efficacy for patients with 
TRDtreatment-resistant depression.2-9 Open-label, chronic, high-frequency (>100 Hz) SCCsubcallosal cingulate DBS has demonstrated six-month 
response rates of about 50% and long-term remission rates (over two to six years) around 50%.4-7, 10 Patients enrolled in these studies were 
highly treatment-resistant (typically not responding to at least four antidepressant medications in the current episode, and no consistent 
response to psychotherapy and/or electroconvulsive therapy (ECT)), chronically depressed (average episode duration of about five years) and 
severely ill due to their TRDtreatment-resistant depression, with the vast majority effectively disabled. These preliminary findings are clinically 
meaningful and compare favorably to response and remission rates in patients with TRDtreatment-resistant depression receiving treatment-as-
usual, other neuromodulation interventions or ablative procedures such as cingulotomy.11-17 Given these encouraging open-label data, a 
*Manuscript with revisions highlighted
  
prospective, randomized, double-blind sham-controlled trial of SCCsubcallosal cingulate DBS for TRDtreatment-resistant depression was 
conducted. It was hypothesized that six months of SCCsubcallosal cingulate DBS would be associated with statistically significant antidepressant 
efficacy compared to sham stimulation.  
 
 Methods 
Study overview 
 A six-month, multi-center, randomized, double-blind, sham-controlled trial was conducted to evaluate the safety and efficacy of 
SCCsubcallosal cingulate DBS (Libra®XP Deep Brain Stimulation System, St. Jude Medical, Plano, Texas) for patients with TRDtreatment-resistant 
depression. A six-month open-label phase followed the double-blind phase. Planned enrollment was 201 participants randomized at up to 20 
sites. The study was registered at clinicaltrials.gov (NCT00617162). Study procedures were approved by the Institutional Review Board at each 
site and the U.S. Food and Drug Administration under an Investigational Device Exemption (G070107, sponsored by St. Jude Medical). The study 
was monitored by an independent Data and Safety Monitoring Board. Recruitment occurred from April 10, 2008 to November 21, 2012. 
 
Participants 
 Inclusion criteria included: 1) men and women aged 21-70 years; 2) unipolar, non-psychotic major depressive disorder (MDD) diagnosed 
before age 45 with a current episode >12 months duration; 3) lack of antidepressant response (via medical and/or pharmacy records) to a 
minimum of four adequate antidepressant treatments, including at least three medications from three different classes, evidence-based 
  
psychotherapy, and/or ECT, 4) lack of sustained response to a course of psychotherapy; 5) Montgomery-Asberg Depression Rating Scale 
(MADRS) score >22 at each of three separate baseline visits, rated by two separate psychiatrists; baseline visits 2 and 3 were separated by no 
more than 6 weeks, and eligible participants must have demonstrated absence of notable improvement (≤20% lessening of MADRS score) 
between these visits; 6) Global Assessment of Function (GAF) score <50; 7) Mini-Mental State Examination (MMSE) score >24; 8) medication free 
or current antidepressant/ psychotropic medication regimen stable for >4 weeks prior to study entry; 9) able and willing to give written 
informed consent.  
 Exclusion criteria included: 1) bipolar or psychotic disorder; 2) obsessive compulsive disorder, post-traumatic stress disorder, panic 
disorder, bulimia or anorexia nervosa; 3) generalized anxiety disorder (GAD) as the primary diagnosis during the current depressive episode; 4) 
substance use disorder (excluding caffeine, nicotine) within the last 12 months; 5) borderline or antisocial personality disorder; 6) substantial risk 
of suicide; 7) received ECT within 3 months prior to enrollment, or likely to require ECT during the study; 8) central nervous system disease 
impairing motor, sensory or cognitive function or requiring intermittent or chronic medication; 9) fibromyalgia, chronic fatigue syndrome or 
current condition requiring chronic narcotic use; 10) unstable, uncontrolled medical illness; 11) past ablative or other intracranial surgery; 12) 
contraindication to magnetic resonance imaging (MRI) scanning; 13) contraindication to general anesthesia or deep brain stimulation surgery; 
14) pregnant, intending to get pregnant during the study or breastfeeding; 15) currently participating in another investigational device, drug or 
surgical trial; and 16) unable to comply with study visit schedule and timeline. 
 
Concomitant treatments 
  
 Participants could continue psychotherapy and medications during the study but were required to maintain a stable medication regimen 
as well as regularly scheduled psychotherapy visits. Medication changes or the initiation of psychotherapy were not allowed during the six-
month double-blind phase. Minor adjustments to sedative/hypnotic and anxiolytic medications were allowed.  
 
Screening and baseline assessments 
 Potential participants were screened according to the eligibility criteria above. At least two years of medical records were reviewed. 
Potential participants were provided a detailed informed consent document, had an initial screening, and completed three baseline evaluations. 
These evaluations occurred no less than two weeks apart from each other, and baseline visits 2 and 3 were not separated by more than six 
weeks. The first two baseline visit evaluations were performed by independent psychiatrists. Baseline assessments included the MADRS; the 17-
item Hamilton Depression Rating Scale (HRSD-17); the Self-Rated Quick Inventory of Depressive Symptomatology (QIDS-SR); subsection for 
cluster B personality disorder of the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II); Systematic Assessment for 
Treatment Emergent Events (SAFTEE); the 30 item Inventory of Depressive Symptomatology (IDS-C30); the Young Mania Rating Scale (YMRS); 
the Work and Social Adjustment Scale (WSAS); GAF; the short form Quality of Life Enjoyment and Satisfaction Questionnaire (QOL); Clinical 
Global Impression of Severity and Improvement (CGI); Patient Global Impression Index (PGI); Health and Labor Questionnaire (HLQ); Hamilton 
Anxiety Rating Scale (HAM-A) and Columbia Suicide Severity Rating Scale (C-SSRS). After the baseline visit was completed, the lead study 
psychiatrist (PEH) performed an external review of the participant’s data to ensure eligibility. After the third baseline visit, a neuropsychological 
  
battery was administered to assess attention/working memory and other executive functions. A high-resolution magnetic resonance imaging 
(MRI) scan and pre-surgical evaluation were also performed.  
 
Surgery and target localization 
 The DBS system consisted of two leads, extension wires and an implantable pulse generator (IPG). Each DBS lead consisted of a four 
electrode array with a 3 mm electrode at the tip and three 1.5 mm electrodes, each separated by 1.5 mm. At least two of three experts (HSM, 
CH, PEH) manually selected and agreed upon the optimal surgical target, defined as a region in the subcallosal cingulate white matter 
approximately 75% of the distance from the anterior commissure to the plane defined by the gray matter edge of the genu of the corpus 
callosum and in the transition from the white matter to the gray matter in the medial-lateral axisTargeting the SCC for DBS for TRD has been 
previously described.2, 3, 18  Target selection was performed in native MRI space (i.e., not in an atlas-defined space) and involved identifying a 
target region at the gray matter-white matter transition area in the subcallosal cingulate gyrus. Optimal target location was provided to the site 
neurosurgeon to assist with surgical targeting, andE each neurosurgeon was trained on targeting by a team of experts (HSM, CH, AML).  
 .Each neurosurgeon was trained on targeting by a team of experts (HSM, CH, AML). At least two experts (HSM, CH, PEH) manually 
selected and agreed upon the optimal bilateral SCC DBS targets for each patient using the baseline MRI scan. These data were provided to the 
site neurosurgeon to assist with surgical targeting. Bilateral DBS system implantation occurred no less than two weeks and no more than four 
weeks after the final baseline evaluation using the standard stereotactic surgical procedures at each site. Impedance of the system was tested 
intraoperatively, but no stimulation was delivered during surgery.  
  
 Post-operative computed tomography (CT) was obtained to assess for intracranial hemorrhage and lead localization. The post-operative 
CT scan was then merged with the pre-operative high-resolution MRI used for initial target selection. Four subjects had an additional surgery to 
reposition the leads due to the leads not being in the ideal target for stimulation; in all cases, this occurred prior to randomization. Post-
operative CT scans were merged with baseline MRI scans. At least two of three expert consultants (HSM, CH, PEH) reviewed these merged 
images and selected an optimal contact sequence for chronic monopolar stimulation. The first contact chosen was the one in closest proximity 
to the predefined target (described above), and the second contact chosen was the one in the next closest proximity to the predefined target. 
No participant had more than two contacts within the predefined target region.  
Four subjects had an additional surgery to reposition the leads due to the leads not being in the ideal target regionfor stimulation; in all cases, 
this occurred prior to randomization. Post-operative CT scans were merged with baseline MRI scans.  
 
Randomization 
 Approximately two weeks after device implantation, participants were randomized to receive immediate active stimulation (Stimulation 
group) or 6-month delayed stimulation (sham; Control group) using a ratio of 2:1 (Stimulation:Control). Randomization was computer-generated 
(SAS version 9.2) with a block size of three at each site before the site started the study. At each site, an unblinded DBS programmer was 
informed of treatment allocation; all other team members and the patient were blinded to treatment allocation.  
 
DBS programming 
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 For participants randomized to the Stimulation group, stimulation was initiated at the completion of the randomization visit (week 2 
following implantation). Initial parameters included monopolar stimulation at the optimal first contact selected on each side at 130 Hz, 91 
microsecond pulse width (PW), 4 milliamperes (mA). For Controls, a sham programming session was performed, but stimulation was not 
initiated. Participants were not formally assessed for whether they had acute effects from stimulation.  
 For participants receiving active stimulation, programming changes were made based on the change in MADRS from the previous rating. 
Two weeks after the initial programming session, no parameter changes were made if the MADRS score reduction was ≥10% from the previous 
evaluation. If the MADRS value was ≤10% lower than that on the previous evaluation, amplitude was increased to 6 mA. After another four 
weeks (if the MADRS was again ≤10% lower than that from the previous evaluation), the amplitude was increased to 8 mA. After another four 
weeks, if the MADRS was again ≤10% lower than that from the previous evaluation, the second contact from the pre-selected contact sequence 
would be added for monopolar stimulation (i.e., the patient would have two contacts providing active monopolar [8 mA] stimulation in each 
hemisphere). If intolerable side effects occurred following a parameter change, parameters were returned to the previous settings. No 
modifications were allowed in pulse width or frequency. No further parameter changes were allowed beyond 10 weeks following initiation of 
stimulation. Participants randomized to sham had similar programming visits, but stimulation remained off during the double-blind phase.  
 
Randomized, double blind, sham-controlled phase 
 Following randomization, participants returned for evaluations at weeks 4, 6, and 8, then every month until the 6-month endpoint. At 
each visit, the following evaluations were completed: MADRS; SAFTEE; DBS programming form; IDS-C30; QIDS-SR; WSAS; GAF; CGI; PGI; HAM-A; 
  
and C-SSRS. At the 3 month and 6 month visits, the following additional evaluations were completed: HRSD-17; YMRS; QOL; and HLQ. The 
neuropsychological battery was repeated at the 6 month visit. Outside of regularly scheduled, in-person evaluations, each patient was contacted 
by phone or in person by study personnel every one to two weeks to assess for safety. Participants experiencing worsening of suicidal ideation 
could remain in the study if stability (“rescue”) could be achieved within seven days. Participants experiencing a ≥25% worsening in MADRS 
score from baseline were considered treatment failures, exited from this phase of the study and enrolled in the open-label or long-term follow-
up study based on whether they were already receiving active stimulation.  
 
Open-label phase 
 Following the 6-month double-blind phase, participants entered the 6-month open-label phase. All participants in the Control group 
(including responders and remitters) had stimulation initiated at this time with the identical algorithm employed for contact and parameter 
selection and changes as described above for the active treatment group. Participants in the Stimulation group continued with active 
stimulation. In the open-label phase, patients and study staff (except the unblinded programmer) were not provided any information about 
randomization status during the first 6 months of the study. At each monthly visit the following evaluations were completed: DBS programming 
form; MADRS; IDS-C30; QIDS-SR; WSAS; GAF; CGI; PGI; HAM-A; and C-SSRS. At the 9 month and 12 month visits, the following additional 
evaluations were completed: SAFTEE; YMRS; QOL; and HLQ. The neuropsychological battery was performed again at the 12 month visit. 
Parameter adjustments were constrained as described above. Changes in medications and psychotherapy were allowed in this open-label phase.   
 
  
Long-term follow-up phase 
 Participants completing the 12 month study were invited to continue in a long-term, naturalistic follow-up study. Study visits occurred 
every six months. Changes in stimulation parameters, medications and psychotherapy were allowed. For patients continuing with chronic DBS, a 
rechargeable battery was provided as needed.  
 
Efficacy measures 
 The primary efficacy endpoint for the study was defined as difference in response rate between the Stimulation and Control groups. 
Response was defined as a ≥40% reduction in MADRS and no worsening in GAF from baseline (average of 3 baseline MADRS assessments) to the 
average scores at months 4, 5, and 6. The average of months 4, 5, and 6 was chosen as the primary endpoint due to the aim to assess for a 
sustained change over time. Secondary measures of efficacy included changes from baseline to endpoint for the HRSD-17, IDS-C30, QIDS-SR, 
WSAS, PGI, CGI, QOL and HAM-A. For the 6-month open-label and long-term follow-up studies, response was defined as a ≥40% reduction in 
MADRS from the baseline average to the score at the time point of interest (e.g., 12 months, 18 months, 24 months). Remission at all time 
points was defined as a MADRS score ≤10. 
 
Safety measures 
  
 The incidence of all adverse events (e.g., hospitalization due to worsening depression, suicidal ideation or behavior, unanticipated 
medical treatment for psychiatric reasons, and device related events) that occurred over study duration were used as the primary safety 
endpoints for the study. 
 
Statistical considerations and data analyses 
 Based on preliminary data7, a ≥40% response rate was anticipated for the active SCCsubcallosal cingulate DBS group. A ≤18.5% response 
rate for the Control group was expected.12 Therefore, 159 participants randomized 2:1 (106 in the active group and 53 in the sham group) would 
provide 80% power to reject the primary efficacy null hypothesis at a 5% significance level. Sample size calculations were performed based on 
the Z test method with pooled variance using PASS 2005. To allow for a dropout rate as high as 20%, the sample size for recruitment was 
increased to 201 participants (134 in the active stimulation group and 67 in the sham stimulation group). 
 The primary efficacy outcome assessed was difference in response rate between the groups (as defined above). Participants who were 
missing one or two of the assessments at months 4, 5 or 6 had data from the available visits used. Participants missing MADRS scores for Months 
4, 5 and 6 were considered non-responders. A logistic regression model including effects of treatment group, study site, level of treatment 
resistance (as defined by ATHF criteria), and baseline MADRS was fitted. Data from study sites with fewer than three participants in either 
treatment group were pooled.    
 
Planned futility analysis 
  
 In approving this study, the U.S. FDA required a futility analysis be completed once ≥75 participants had reached the primary endpoint 
by either completing the month 6 visit or exiting the study. No more than 125 participants could be enrolled prior to the futility analysis.  The 
futility analysis was performed using the average of the revised alternative hypothesis and the observed interim results. With the current sample 
size of 201 participants, the alternative hypothesis was a 40% response rate for participants receiving active stimulation and a 20.7% response 
rate for participants receiving sham (the proportions providing 80% power to reject the primary hypothesis given the smaller sample size at the 
time of the futility analysis). Based on these revised population proportions, 5000 sets of simulation results among the remaining approximately 
84 stimulation participants and 42 control group participants were run. Each set of simulated results was added to the observed results, and a 
two-tailed Fisher’s exact p-value was calculated. The probability of a successful outcome of the study was the proportion of these p-values 
<0.05. If the probability of a successful study outcome was <10%, the study would be stopped for futility. Additionally, the study could be 
stopped at the sponsor’s discretion, even if this formal definition for futility was not met.   
 
Results 
Participants and study flow 
 A total of 128 participants were enrolled (i.e., signed informed consent) from 15 investigational sites prior to the completion of the 
futility analysis (Figure 1). Of the 128 participants enrolled into the study, only 90 from 13 investigational sites received DBS system implantation 
and were randomized to treatment. Of these, 60 participants were randomized to active stimulation, and 30 were randomized to sham 
stimulation. There were no statistically significant differences between the groups in demographic or clinical variables (Table 1).  
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Efficacy of randomized, controlled DBS (6 months) followed by open-label treatment (6 months) 
 On average, patients in both groups showed a statically significant improvement in depression and global functioning over 6 and 12 
months. At the endpoint for the 6-month blinded, controlled phase, there was no statistically significant difference in efficacy between the 
Stimulation group (20% response rate; 10% remission rate) and the Control group (17% response rate; 7% remission rate)(Figure 2, Tables 2 and 
3; analyses of primary and secondary outcome measures are shown in Supplementary Tables S1-S8). In participants randomized to sham 
stimulation for the first six months of the study, six months of active stimulation did not result in additional statistically significant within group 
antidepressant efficacy (i.e., no statistically significant decrease in MADRS score from month 6 to month 12). By the 12 month visit, response and 
remission rates did not statistically significantly increase compared to the 6 month visit in either groupimprove, though response rates 
numericallyhad increased in both groups (Stimulation group: 30% response rate; Control group: 27% response rate), and remission rates 
remained stable to slightly increased (Stimulation group: 18%; Control group: 7% remission rate). Medication and/or psychotherapy changes 
were only allowed in the 6 month open-label phase, but did not correlate with efficacy or differential efficacy in the groups.  
 Adequacy of blinding was confirmed based on questioning participants about which group they were assigned to after 4 weeks, 8 weeks, 
3 months and 6 months of the blinded, randomized, controlled phase of the study. There was no difference between the Stimulation and 
Control group in proportion of participants guessing they were receiving active stimulation, with approximately 30%-40% of each group 
(Stimulation, Control) guessing they were receiving active stimulation at each time point. About 50% of participants in each group guessed 
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accurately, and there was no difference in accuracy of guessing between the groups. No participant reported any acute effects with the initiation 
of active stimulation, nor were any effects of initial activation of stimulation observed by study staff, including the unblinded programmer.  
 
Futility analysis 
 For the futility analysis, based on the first six months’ data, the response rate for the Stimulation group was predicted to be 40%, and 
the response rate for the Control group was predicted to be 18.5% (see Methods above). In the actual futility analysis, the Stimulation group 
showed a 20% response rate, and the Control group showed a 17% response rate. It was concluded that the study had a 17% chance of success if 
continued. Although this did not meet the formal definition for futility described above (<10% chance of success), the sponsor chose to end 
study enrollment following the futility analysis. 
 
Long-term outcomes 
 Following the initial 12-month study, seventy-seven (77) participants entered into a four-year follow-up study. Eight participants from 
the Active group and five participants from the Control group dropped out; all were nonresponders at the 12 month endpoint. For long-term 
assessment of efficacy, response was defined as a ≥40% decrease in MADRS score from baseline to each endpoint, and remission was defined as 
a MADRS score ≤10. For assessment of long-term efficacy, patients in both groups (Stimulation and Control) were combined for analysis; 
therefore and by example, six months of stimulation refers to six months of active stimulation regardless of whether this started initially (in the 
Stimulation group) or six months later (in the Control group). With long-term, active SCCsubcallosal cingulate DBS, response and remission rates 
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were 40% and 19% at 12 months, 51% and 17% at 18 months, and 48% and 25% at 24 months, respectively. Mean MADRS and GAF scores by 
months of stimulation are shown in Figure 3. 
 To assess whether stimulation parameter and/or medication changes were associated with efficacy, two post-hoc analyses were 
performed. For the first 12 months data, a generalized linear mixed effects model was fitted that included treatment group, medication change 
and stimulation parameter change at each follow-up visit as independent fixed effects, subject as a random effect and responder status at each 
follow-up visit as the dependent variable. Based on this model, neither stimulation parameter change nor medication change was associated 
with response rate (p=0.2176 and p=0.4891, respectively). Separately, a generalized linear mixed effects model was fitted for the 18-30 months 
(open-label) data that included medication change and stimulation parameter change at each follow-up visit as independent fixed effects, 
subject as a random effect and responder status at each follow-up visit as the dependent variable. This analysis showed that stimulation 
parameter change was associated with increased response rate (p=0.0127), but medication change was not (p=0.3955). Stimulation parameter, 
medication and/or psychotherapy changes were allowed during the follow-up study, but these changes, when they occurred, had no discernible 
impact on efficacy over time.  
 
Safety 
 Twenty eight (28) participants experienced 39 serious adverse events (SAE) during the 12 month study (Table 3). Eight (8) SAEs occurring 
in seven patients were judged to be definitely related to the study device and/or surgery, including six infections (in five patients), one skin 
erosion over the extension wires, and one post-operative seizure. The remainder of SAEs were attributed to the primary mood disorder and 
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deemed unrelated to the device or active stimulation; i.e., there appeared to be no clear temporal relationship between the onset and 
resolution of these events and the initiation or adjustment of stimulation. There were two deaths by suicide in the study; both were in the 
Control group during the 6-month open-label phase. No unanticipated device related adverse events were reported. No episodes of hypomania 
or mania occurred during the study. There were no adverse neuropsychological effects at 6 or 12 months; a full description of 
neuropsychological findings will be reported separately. No side effects occurred with DBS programming, and no parameter adjustments were 
required due to side effects following a parameter change.   
 Ten out of 90 participants receiving DBS system implantation terminated the study early (five prior to the primary endpoint/six-month 
visit and five before the 12-month visit). Six early exits were due to adverse events (worsening depression [n=1], suicide attempt [n=1], increased 
suicidal ideation with failed “rescue” (see Methods) [n=1], death by suicide [n=2], and head pain [n=1]). Three early exits were due to patient 
preference and one was due to the sponsor closing the study. Four out of the 10 subjects that exited the study early chose to have the device 
fully explanted shortly after study exit.  
  
Response predictors 
 No demographic or clinical characteristics were associated with 6 month, 12 month or 24 month response or remission rates. Presence 
of melancholic features, duration of illness and/or current episode, history of ECT did not differ between responders and nonresponders at any 
time point. Eventual responders versus non-responders did not differ in use or change in psychotherapy, medications or stimulation parameter 
adjustments. No systematic difference in electrode placement between responders and non-responders was identified, consistent with prior 
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studies.18, 19 Additionally, distance between actual vs. planned target placement did not differ significantly between eventual responders versus 
nonresponders, and there were no significant differences between sites in accuracy of electrode placement. Although not statistically significant, 
it was noted that nonresponders tended to have an electrode placement that was more posterior and inferior to that of responders based on 
review by two experts (HSM, RG, CH).  
 
Discussion 
 This study helps confirm the feasibility and safety of SCCsubcallosal cingulate DBS as a treatment for TRDtreatment-resistant depression 
patients. However, this study failed to demonstrate that six months of active versus sham stimulation was associated with statistically significant 
antidepressant effects. Additionally, participants initially treated with sham stimulation during the first six months of the study did not show 
statistically significant antidepressant benefit with an additional six months of open-label active stimulation. In participants with up to two years 
of open-label active DBS stimulation, 48% achieved an antidepressant response and 25% achieved remission. These long-term outcomes are 
clinically meaningful, similar to those seen in earlier open-label studies and greater than would be expected with treatment-as-usual in this 
highly treatment-refractory patient population.12  
 These findings are disappointing given the encouraging data from earlier open-label studies of SCCsubcallosal cingulate DBS, and no 
demographic or clinical characteristics were associated with response versus nonresponse. However, it is noted that participants in this study 
had an average current episode duration of about 12 years. This is much longer than the average duration of current episode in prior 
SCCsubcallosal cingulate DBS studies (approximately five years)3, 6 and may have contributed to the low overall response rate. Although 
  
SCCsubcallosal cingulate DBS has shown enduring, open-label efficacy in chronic depression,4, 6 it is possible that this intervention is less effective 
for patients with extremely chronic depression. 
 Interpreting these findings must also consider study design. For studies of invasive interventions for neuropsychiatric disorders, placebo 
effects can be surprisingly high and may actually be quite long-lasting.20, 21 However, the placebo response rate in this study was not significantly 
greater than what was anticipated; in fact it was lower than projected. Indeed, the major difference in this study compared to prior 
SCCsubcallosal cingulate DBS studies was the lower response rate to active stimulation during the blinded phase of the study. Again, this may be 
due to the more chronic nature of disease in this cohort compared to prior samples. Additionally, it is not uncommon for the response to active 
treatment to be lower in a randomized, blinded, placebo-controlled trial than in open-label studies. Additionally, As prior studies and data from 
this cohort suggest delayed and progressive antidepressant effects over time with SCCsubcallosal cingulate DBS. Therefore, , it is possible that 
differences in benefit between active and sham stimulation may not be seen until after one to two years of treatment in this group. However, 
such a time frame makes sham-controlled studies much more challenging. Other study designs may need to be considered, such as open-label 
stimulation followed by blinded discontinuation.22  
  Targeting for this study was based on an algorithm derived from early SCCsubcallosal cingulate DBS studies.18 Neurosurgical placement 
of the DBS electrodes, based on this algorithm, was highly accurate and did not differ between eventual responders and nonresponders. 
However, gross anatomical placement of SCCsubcallosal cingulate DBS electrodes may not be adequate for optimal treatment delivery. Recently, 
important subtleties in electrode placement have been described based on the white matter tracts impacted.19 These data suggest that, for 
maximal efficacy, the active SCCsubcallosal cingulate DBS electrode must be placed such that it impacts a critical network of white matter tracts 
  
connecting key brain regions, including the forceps minor, cingulum bundle and uncinate fasciculus. It is notable that SCC DBS responders in this 
study tended to have a more anterior and superior electrode placement compared to nonresponders – a placement that, in theory, would be 
more likely to allow direct stimulation of the forceps minor. Therefore, it is possible that prospective targeting based on individual DTI 
tractography could optimize SCCsubcallosal cingulate DBS electrode placement.23, 24  
 Given the strength of the preliminary data leading to this study, and the emerging data suggesting ways to optimize targeting for this 
intervention, the negative outcome of this trial should not be simply interpreted as a failure of SCCsubcallosal cingulate DBS for TRDtreatment-
resistant depression. Subsequent studies are merited to determine whether active SCCsubcallosal cingulate DBS failed to differentiate from 
sham due to clinical features of the patient population (e.g., extremely chronic depression) or suboptimal electrode placement. Additionally, 
identification and use of a physiological metric to verify engagement of the appropriate neural circuit could assist with targeting. Importantly, 
the long term response and remission rates in this and prior studies suggest that this intervention continues to have promise. 
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FIGURE LEGENDS 
Figure 1. Participant disposition. 
 
Figure 2. Depression severity over time in each treatment arm. Note that at months 9 and 12, the Control group was receiving active stimulation; 
therefore, for the Control group, 9 months refers to 3 months of active stimulation, and 12 months refers to 6 months of active stimulation. 
 
Figure 3. Overall function over time in each treatment arm. Note that at months 9 and 12, the Control group was receiving active stimulation; 
therefore, for the Control group, 9 months refers to 3 months of active stimulation, and 12 months refers to 6 months of active stimulation. 
 
Figure 4. Long-term outcomes (depression severity and overall function) in all participants receiving active stimulation during the study. These 
results include participants initially randomized to active stimulation and participants initially randomized to no stimulation for the double-blind 
phase of the study. For the participants initially randomized to no stimulation, the data used for this graph are solely those collected after active 
stimulation had been initiated in the open-label study phase. 
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Manuscript reference number: THELANCETPSYCH-D-17-00261 
 
Title: Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multi-site, 
randomized, sham-controlled trial 
 
Dear Dr. Marsh, 
 
Please see our responses to the editor’s and reviewers’ comments below. 
 
1. All Lancet group journals should contain a Research in context panel.  
***Done.  
 
2. Can you include a statement that the neuropsychiatric findings will be published separately. 
***This has been added to the safety section of the results.  
 
3. For each author, please provide just one (highest) degree. 
***Done 
 
4. We need written confirmation, including a signature, from everyone who is mentioned in the 
Acknowledgments section to confirm that they are happy to be quoted in your paper. The following 
format can be used: 
 
"I permit <corresponding author> et al to list my name in the acknowledgments section of their 
manuscript and I have seen a copy of the paper <full article title>" 
 
All authors are required to provide a signed author contribution statement form, available to be 
downloaded from http://download.thelancet.com/flatcontentassets/authors/tlp-author-signatures.pdf . 
 
All authors should complete and return an ICMJE conflict of interest form, available from 
http://www.icmje.org/conflicts-of-interest/ 
 
***These should have been sent to you directly by DeLea Peichel from Abbott (formerly St. Jude 
Medical Neuromodulation). If you have not received, please let me know ASAP.  
 
5. Please remove subheadings from the Results section 
***Done.  
 
6. Please write out TRD and SCC. 
***Done throughout, though this is awkward in some places.  
 
7. Please give details of the safety outcomes in the abstract and check that the abstract contains all 
information required by CONSORT. 
***We have added information on safety in the abstract.  
 
8. Please state the role of the funder. 
***Abbott previously known as St. Jude Medical was the study Sponsor.  This role included protocol 
design with assistance of the consultants, FDA negotiations and communication, study execution 
including monitoring, data analysis, and statistical analysis.  
*Reply to Reviewers Comments
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9. Please provide the appendix as a pdf file with numbered pages. 
***This is supplied as a separate document. 
 
10. One of my editorial colleagues requested:  please add to the discussion the fact that methods vary a 
lot between DBS trials so can't really say they work / don't work as a general rule unless you know the 
methods, as they are very heterogenous and perhaps some techniques work and others don't. E.g., “the 
methods could use more info on precise lead localisation measurements, types of electrodes used, how 
variability between surgeons was rated, etc. Or, if this level of detail is not available, the discussion 
could use a bit on how things like missing the target, variability between surgeons, etc could have 
affected the outcome.” 
 
***More detail is provided on the parameters of the electrode array and targeting. As described in the 
manuscript, lead placement was assessed by a team of experts; in four cases, leads were repositioned 
due to inadequate placement. This team of experts also identified the optimal sequence of contacts to 
be used for active/sham stimulation; this is now described in more detail. We did perform a post-hoc 
imaging analysis of lead placement and location of the contacts used for stimulation. In terms of gross 
anatomical location, there was no statistically significant difference in lead placement between 
responders and nonresponders. This is described in the last paragraph of the results section. 
 
***Results for all secondary outcome measures are now provided in Supplementary Tables S2-S8.  
 
Reviewer #2: 
 
1. I think these results deserve some more discussion than it currently receives. On p.16 the authors 
state: "Indeed, the major difference in this study compared to prior SCC DBS studies was the lower 
response rate to active stimulation during the blinded phase of the study." I completely agree with this 
statement, but the authors explain this difference by stating "(…) it is possible that differences in benefit 
between active and sham stimulation may not be seen until after one to two years of treatment". 
However, I miss a direct comparison between this study and previous open-label studies. For instance, in 
Lozano et al (2008, Biological Psychiatry) the response rate after 6 months was 60% (12/20), in 
Holtzheimer et al (2012, Archives of General Psychiatry), response was 58,9% (10/17), in Puigdemont et 
al (2012, Internation Journal of Neuropsychopharmacology) it was 87.5% (7/8). These are all 
substantially higher response rates, which did not take 1-2 years to reach. Even after 6 months of open-
label stimulation in this study (i.e. the 12-month point), the response rates were approximately 30% in 
both groups. Could the authors discuss this point some more? Might there be some essential differences 
with these open-label studies, e.g. other ways of DBS programming or more supportive or 
psychotherapeutic sessions? 
 
***We share the reviewers perplexity, yet it is not uncommon for placebo-controlled studies to show 
lower response rates to active treatment compared to prior open-label studies (please refer to the VNS 
studies in depression, where placebo-controlled response rates to active VNS over 3 months was half of 
what was seen in the prior open-label study). However, this alone does not fully explain the overall 
lower response rate even at the later time points. It is plausible that the more chronic nature of these 
patients compared to prior samples plays some role, as this cohort has a notably longer duration of the 
index episode compared to the average duration of other published small studies. These points have 
been emphasized in the discussion.    
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2. One explanation given in the discussion is the longer episode duration. Do you have any evidence 
from this study that patients with shorter episode duration responded better or faster? If so, could this 
be added to the paper? 
 
***In this study, episode duration did not correlate with response, and we likely did not have the power 
to adequately test for this. However, it is notable that this sample had, on average, a much longer 
duration of current episode than in previous studies. This may have impacted the response rate to active 
stimulation, but this is purely speculative at this point.  
 
3. In addition to the long episode duration, Table 1 shows participants in the active group are on average 
67.73 years (3.8) and in the control group 67.37 years (3.29). This means the patients in this study are on 
average 20 years older than the patients in the open-label studies. I think this and its possible influence 
on the results should be mentioned in the discussion. 
 
***This was an error in the original table. This has been corrected. 
 
4. The response rates do seem to increase after one year of open-label stimulation to approximately 
50% (i.e. at the 18-month point). On p.14, the authors state: "Stimulation parameter, medication and/or 
psychotherapy changes were allowed during the follow-up study, but these changes, when they 
occurred, had no discernible impact on efficacy over time." Could the authors explain how this was 
measured or analyzed, and also add this analysis to the manuscript? Can the authors give any indication 
what did cause the increase in response rates? 
 
***Below we provide a full description of the data analyses, and we have added this to the results 
section. We defer to the editors whether to include all of this text in the manuscript. As stated in the 
original manuscript, neither stimulation parameter nor medication changes were associated with 
efficacy for the first two phases of the study (6 month sham-controlled phase and 6 month open-label 
phase). However, an analysis of the 18-30 month period (when all participants had received active 
stimulation for 12-24 months) did show that stimulation parameter changes associated with efficacy 
(including reevaluating contact location and stimulating at a single contact (different from the initial 
optimal contact)). Details of the analyses include: 
 
“For the first 12 months data, a generalized linear mixed effects model was fitted that included 
treatment group, medication change and stimulation parameter change at each follow-up visit as 
independent fixed effects, subject as a random effect and responder status at each follow-up visit as the 
dependent variable. Neither stimulation parameter change nor medication change were associated with 
response rate (p=0.2176 and p=0.4891, respectively). Separately, a generalized linear mixed effects 
model was fitted for the 18-30 months data (open-label stimulation) that included medication change 
and stimulation parameter change at each follow-up visit as independent fixed effects, subject as a 
random effect and responder status at each follow-up visit as the dependent variable. Stimulation 
parameter change was associated with increased response rate (p=0.0127), but medication change was 
not (p=0.3955).” 
 
5. Some details of the surgery and target localization (p.6) were a bit unclear. Which electrodes were 
implanted and how many contacts did the electrode have? How was the targeting done (by use of an 
anatomical landmark or axon bundles?) and can you give a short description of where the contacts were 
approximately placed? If possible, could you add a figure or schematic of a typical placement? On p.6 
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the following remark is made: "(…) using the standard stereotactic surgical procedures at each site." 
Were there any systematic differences between sites? 
 
***Details on the electrode array/lead and target selection have been added to the Methods. The same 
targeting approach was used at every site; differences in stereotactic surgical procedures between sites 
did not affect target selection or location of the implanted leads and primarily involved the surgeon’s 
preference regarding details of the procedure unrelated to target placement (e.g., location of scalp 
incision, angle of lead insertion).  
 
6. In addition, I had some question on the DBS programming (p.7). I understand no more than four 
different settings (4, 6 and 8 mA and addition of contact?) were allowed and no changes were made 
after 10 weeks. What happened in case of side effects? Did you change it to a previous setting or was a 
setting in between allowed?  
 
***In the case of side effects, parameters could be changed to those used previously. However, this 
occurred in no cases. (But, this clarification has been added to the manuscript.) 
 
7. And assuming the use of a 4-contact electrode, why was decided not to try different contacts besides 
these two contacts? 
 
***This has been clarified by providing a more detailed description of targeting, as above. Prior studies 
of SCC DBS strongly suggested that the optimal contact for chronic stimulation was the contact best 
situated in the subcallosal cingulate white matter. The contact selection was guided by this. The contact 
best situated in the SCC white matter was selected as the first contact to be used. The contact next best 
situated in the SCC white matter was selected as the second contact to be added. In no case were the 
third or fourth contacts situated in or near the SCC white matter so there were never considered as 
viable options for long term stimulation. Additionally, due to the experience that antidepressant effects 
of SCC DBS occur over weeks to months, we chose to limit parameter changes to the first 10 weeks of 
the study, and this necessarily limited the number of steps included in the algorithm.  
 
8. Furthermore, no DBS parameters were changed in case of >10% decrease on MADRS. Does this mean: 
once >10% decrease has been achieved, DBS parameters were fixed? Or could amplitude be increased 
two weeks later, if no further improvement had been achieved? As a concrete example: if a patient 
decreases from 40 to 36 on the MADRS on 4 mA after 2 weeks, is the amplitude fixed on 4 mA, or did 
you have the opportunity to increase to 6 mA if the patient did not show further improvement in the 
weeks after? 
 
***As described in the methods, the 10% MADRS change was assessed based on the previous MADRS 
assessment. So yes, the amplitude could continue to be increased if the MADRS following 4 weeks was 
less than 10% lower than the MADRS at 4 weeks’ time point.  
 
9. Table 3 presents the responder rates. At 18, 24 and 30 months percentages are presented out of a 
total of 52 and 25 patients. What about the 8 and 5 dropping out? Were these responders / non-
responders? Could the authors add the intent-to-treat percentages (e.g. by using the response status at 
last follow-up)? 
 
***The response rates presented are the intent-to-treat percentages. Of the eight patients that dropped 
out of the Active group, all were nonresponders at all time points up to the 12 month endpoint. Of the 
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five patients that dropped out of the Control group, three were nonresponders at all time points up to 
the 12 month endpoint. One was a responder at 3, 6, and 9 months, but not at the 12 month endpoint. 
One was a responder at the 9 month time point but not at any other time point. We believe this level of 
detail is not needed in the manuscript. However, we have added the following to the Results section: 
“Eight participants from the Active group and five participants from the Control group dropped out; all 
were nonresponders at the 12 month endpoint.”  
 
Reviewer #3: 
 
1. Why did the authors choose MADRS rather than the more standard (eg in the pilot papers) HAMD? 
Table 2 is missing HAMD data from months 9 and 12 and it's not explained why. 
 
***The MADRS was chosen as the primary measure because it has been shown to be unifactorial, hence 
more sensitive to symptom change. Per the protocol, the HAMD and several other secondary measures 
were were only administered every 6 months per the FDA approved protocol.  
 
2. Authors state that expert consultants selected optimal contact sequences for monopolar stimulation. 
What constituted an optimal sequence? Proximity to anatomic SCC? 
 
***The optimal sequence essentially included the first and second contacts best situated in or near the 
SCC white matter. Please see response to Reviewer 2 above. More detail on targeting has been added to 
the Methods, as described above.  
 
3. Did the authors assess the effect, if any, of cumulative stimulation dose, i.e compare outcomes of 
those who were stimulated the longest compared to the shortest? 
 
***Response and remission rates increased over time, though a few participants responded sooner than 
others. From the data collected, there is no meaningful way to assess the effect of cumulative dose 
beyond noting that antidepressant efficacy increased over time in the sample. 
 
4. I would consider removing or re-wording the line in the Discussion that intervention may be less 
effective in the extremely chronically depressed. The authors state in the preceding paragraph that no 
demographic or other features predicted clinical response to DBS, and duration of illness is an illness 
feature. For many in the psychiatry community, brain surgery ought to be specifically for patients who 
are extremely chronically depressed, to justify it's risk and invasiveness. Is this not the very definition of 
TRD? 
 
***We included this comment to reflect the difference in duration of current episode between this 
current cohort and the samples enrolled in prior studies of SCC DBS for TRD. We do believe this is a 
potential explanation for active DBS not achieving a mean effect as large as that seen in prior studies. If 
SCC DBS were clinically available, we do not think this comment implies that it should not be considered 
for patients with extremely chronic depression. However, this should perhaps be considered as a 
potentially negative prognostic factor (as it currently is when considering ECT and TMS).  
 
5. Only one reference is made to DBS trials done at targets other than the SCC. Several have been tried, 
including the VC/VS, NAcc, Habenula, and MFB. In addition SCC DBS has been tried in different 
indications, including bipolar disorder and anorexia nervosa. Do the authors feel a different target 
should be tried? Why or why not? 
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***We feel it is most appropriate to focus this manuscript on the findings of this trial. We believe it is 
beyond the scope of this manuscript to weigh in on the relatively strengths of the various DBS targets 
for TRD, and that this discussion is more appropriate for a commentary or later review. However, we 
defer to the editors on this and would be happy to include more discussion on this point if the editors 
feel it would strengthen the manuscript.  
 
Reviewer #4: 
 
1. It is a little frustrating that the authors did not ensure a more similar patient population to prior 
studies. 
 
***As noted above, the age of this sample was incorrectly reported in the previous manuscript. The 
mean age for this sample is similar to that of prior studies. All other clinical features are also similar to 
previous studies except for duration of current episode. This was unanticipated, since no limits for 
episode duration were used in prior studies, and therefore the same approach was used in this study. 
This approach unexpectedly resulted in a sample with a longer mean duration of current episode than 
seen in prior studies.  
 
2. Despite no advantage of 6 months DBS when comparing to sham to active, transition to open-label 
DBS showed marked improvement over 2 years. It is unclear whether there are significant differences 
when compared to baseline in this open-label phase but this would be worth indicating. 
 
***There was an overall statistically significant within group decrease in depression severity over time. 
This comment has been added to the manuscript in the Results section.  
 
2. It is certainly reasonable that a microlesion effect was durable and that a better design would have 
been open-label stimulation followed by blinded discontinuation as the authors indicated as the authors 
indicate. 
 
***We agree that this is an interesting alternative design. However, this was not the FDA-approved 
protocol for this study.  
 
3. Could there not have been a significant change between groups because there was frequent, 
supportive contact (every 1-2 weeks) from the study team?  Any involvement in clinical trials has been 
found to improve outcomes in patients across disciplines.  
 
***This is indeed possible, though the change in depression severity over the first 6 months in the sham 
group was not dramatic.  
 
4. Might the clinical scales used not be sensitive to detect a clinically meaningful effect in very ill 
subjects? 
 
***It is possible that the MADRS may not capture the meaningful symptom change in these very ill 
patients. However, the use of standard depression rating scales is typically expected from the field at 
large, and especially the FDA. 
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5. Interestingly, this study was like the Reclaim VC/VS depression study in that it used the MADRS, 
showed no effect, and was halted by study sponsor. Also, could lack of more robust response be the 
result of not changing DBS settings after 10 weeks? 
 
***This is possible. However, we chose to err in favor of longer stimulation time at what were deemed 
to be optimal settings (based on prior studies) versus additional settings changes that would not have 
allowed for a longer period of stimulation at the final parameters.  
 
6. The authors indicate that the demographics did not impact outcome - I was curious however how 
closely they looked at sex differences? 
 
***Change in primary and secondary measures were compared between men and women in the study 
and were not found to be statistically significantly different. A logistic regression model was used to 
examine the effect of treatment (Stimulation or Control) while adjusting for the baseline demographic 
variables (study site, level of treatment resistance as defined by ATHF criteria and baseline MADRS). 
Based on the logistic regression model results, gender did not impacted the outcomes (p=0.3164). The 
full model for the primary outcome measure (MADRS) is provided below and is now included as 
Supplementary Table S1.  
 
Source DF Chi-Square Pr > ChiSq Method 
Treatment group 1 0.12 0.7274 LR 
Sex 1 1.00 0.3164 LR 
Site category 2 5.65 0.0593 LR 
Average Baseline MADRS 1 0.39 0.5303 LR 
Total number of lifetime 
antidepressant medications and 
acceptable medication 
augmentation strategies 
1 0.68 0.4087 LR 
Total number of lifetime 
antidepressant medications rated 
3 or higher with at least good 
confidence 
1 0.00 0.9686 LR 
Total number of lifetime 
antidepressant treatments rated 3 
or higher 
(can include psychotherapy, ECT, 
VNS, TMS) 
1 0.19 0.6602 LR 
Total number of lifetime 
treatments for depression 
(including all others listed on this 
document 
1 1.81 0.1783 LR 
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7. The inclusion of patients with medication-free or stable regimens for only >4 weeks may have been 
too little? 
 
***Presuming the reviewer means that 4 weeks of medication stability may be too short for “true” 
stability, we partially agree. However, for clinical and practical reasons, a longer period of stability was 
deemed not feasible. Also, a four week period of medication stability is common in depression clinical 
trials, including studies of patients with TRD.  
 
8. Did revision patients have any difference in outcomes on average? There were 4 revisions. Would be 
interesting to know if there was a more robust lesion effect in these revisions as well. The authors have 
not proven that DBS is better than implant alone, so ruling out lesion effects by looking at patients with 
perhaps MORE robust lesion effects would help. 
 
***There was no difference in efficacy in patients with and without revisions. In these 4 revisions, 3 
were in the control group and 1 was in the treatment group. Their responder status at each visit was 
summarized in the below table.  
 
Study 
Subject 
ID 
Responder 
based on 
4,5,6M 
average 
Responder 
6m open-
label 
Responder 
9m open-
label 
Responder 
12m open-
label group 
074005 Non-
responder 
 
Non-
responder 
Non-
responder 
Non-
responder 
Ctrl 
278003 Non-
responder 
Non-
responder 
Responder Non-
responder 
 
Ctrl 
214002 Non-
responder 
Non-
responder 
Non-
responder 
 
Responder Ctrl 
277015 Non-
responder 
Non-
responder 
Non-
responder 
Non-
responder 
Stim 
 
 
Within the control group, a logistic model which included an indicator of system revision as independent 
variable and responder status at 6M as dependent variable was fitted to the data. It shows that there 
was no difference in efficacy in patients with and without system revisions (p-value = 0.2817).  A 
generalized linear mixed-effect model was fitted to the longitudinal data and it shows that was no 
difference in long-term efficacy in patients with and without system revision (p=0.6792).  
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9. Given this staggered randomized onset design, were revision patients in each group? 
***Yes. 
10. Why wouldn't the treatment/control groups be of the same size? They were 2:1 I believe - is this 
ethically driven as more patients in the experimental group will be exposed to potential therapy earlier 
on? 
 
***In consultation with the FDA, this design was chosen to reduce the chances of patients receiving 
sham treatment. Statistical analyses accounted for this difference in group size.  
 
11. For patients who needed increase in mA during the blinded phase, were there outcome differences? 
 
***There were not.  
 
12. Are certain patients simply super responsive but those who don't respond at a low dose, don't 
respond or worsen at a higher dose? This would support a blinded randomization of responders. 
 
***This is unknown, and the study was not designed to test this.  
 
13. How many subjects worsened and moved to open label? 
 
***None.  
 
14. How many had revisions were in the control group? 
 
***There were 4 subjects who had revisions: 3 were in the control group and 1 was in the stimulation 
group.  
 
15. To me it seems disease stability is necessary before interpreting a stimulated response. Shouldn't the 
investigators have waited until the subjects returned to a predefined baseline? It seems patients in the 
control group were improving as I am sure the stimulated group would have had they not been 
stimulated. I recognize it must be challenging to wait and funding was likely a major limitation, but if 
patients are on a downward trend in disease severity without stimulation, I feel the design 
compromised any interpretation of stimulation induced effects on depression severity. Some discussion 
is needed on this. 
 
***This is an interesting design option, but again, this was not the protocol approved by the FDA. A 
more standard, prospective, randomized, controlled trial was deemed to be most appropriate for testing 
the hypotheses, especially given the state of the field at the time the study was designed. This is already 
mentioned in the discussion.  
 
16. "Stimulation parameter, medication and/or psychotherapy changes were allowed during the follow-
up study, but these changes, when they occurred, had no discernible impact on efficacy over time." How 
was this confirmed to be true? 
 
***Please see the response to Reviewer 2 above.   
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17. "However, it is noted that participants in this study had an average current episode duration of 
about 12 years. This is much longer than the average duration of current episode in prior SCC DBS 
studies (approximately five years)3, 6." But this wasn't significant as a correlation, right? The authors 
seem to be looking for trends (and I understand why) but they stated previously that demographics did 
not impact outcome. Have they consulted with a statistician to ensure these correlations were not 
significant? 
 
***As stated in the manuscript, there was no correlation between duration of current episode and 
efficacy in this study; this was indeed confirmed by statistical analyses. It is possible we did not have 
power to show an association of episode duration and efficacy. However, this sample, as a whole, had a 
mean duration of current episode much longer than prior studies which we believe is an important point 
to note as a potential explanation for why patients in this study were less responsive to active DBS than 
in prior trials.  
 
18. "It is notable that SCC DBS responders in this study tended to have a more anterior and superior 
electrode placement compared to nonresponders - a placement that, in theory, would be more likely to 
allow direct stimulation of the forceps minor. Therefore, it is possible that prospective targeting based 
on individual DTI tractography could optimize SCC DBS electrode placement." I agree - but wonder why 
this targeting is such a challenge across institutions. It is a bit concerning that if targeting is difficult, that 
this potential therapy could not be broadly adopted. I suspect this is not the case, but it would provide 
clarity if the authors could explain why this error occurred despite the training they claimed was 
performed. 
 
***Since lead placement did not differ significantly (only a slight trend) between responders and 
nonresponders, we have taken this statement out of the manuscript. Regarding surgical targeting, there 
are a number of reasons why this might vary within and between sites. A full discussion of this is beyond 
the scope of this manuscript. To be clear, there was no systematic error in targeting and this is described 
in the last paragraph of the results section.   
 
Reviewer #5: 
 
1. This study mainly reported descriptive statistics and simple comparison results between means. 
Multilevel modeling is a standard analysis method for longitudinal data, which is known to be more 
powerful than simple comparison between two time points. In the Section Statistical Consideration and 
Data Analysis, a logistic regression model was mentioned. However it is not clear what is the outcome 
variable in this logistic regression. Was it used to examine responders versus non-responders? No results 
from this logistic regression were reported in the Results Section. 
 
***The full logistic regression model is provided above in response to Reviewer 4. This is now included 
in the supplementary information as Table S1.  
 
2. Efficacy measures were collected at baseline (weeks 4, 6, ad 8) and at months 4, 5, and 6. To evaluate 
efficacy, average of 3 baseline MADRS assessments and average of months 4, 5, and 6 were used. For 
this type of longitudinal data, it is a common practice to use multilevel modeling to examine the change 
trajectory. The stimulation group can be added as a moderator to see whether the trajectory is 
significantly different between the two groups. Multilevel modeling has advantages of handling missing 
data and is known to be a more powerful analysis method than simple averaging. 
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***A linear mixed effects model was constructed which included treatment group and visit as fixed 
effects and subject as a random effect and was fitted to the MADRS assessment over the first 12 months 
(Figure 2 in the manuscript). It shows that MADRS decreased over time (p-value <0.0001) in both groups 
and the Control group have a 2.95 point higher MADRS score across all visits as compared to the 
Stimulation group (p=0.0038), however there was no significant difference in change over time between 
the groups. A similar model was fitted to the GAF and it shows that GAF improved over time (p-value 
<0.0001) in both groups and there was no difference between two groups over time (p=0.2417). 
 
  Treatment effects on MADRS in the first 12 months based on Linear mixed effect models 
Effect GROUP VISIT Estimate 
Standard 
Error Pr > |t| 
GROUP  Ctrl . 2.9474 1.0123 0.0038 
GROUP Stim . 0 . . 
 
  Treatment effects on GAF in the first 12 months based on Linear mixed effect models 
Effect GROUP VISIT Estimate 
Standard 
Error Pr > |t| 
GROUP Ctrl . -1.4687 1.2528 0.2417 
GROUP Stim . 0 . . 
VISIT  0 -12.5339 1.8961 <.0001 
VISIT  3 -7.1333 1.8912 0.0002 
VISIT  6 -3.0101 1.9168 0.1171 
VISIT  9 -1.7980 1.9336 0.3530 
VISIT  12 0 . . 
 
4. When examining long-term outcomes, it makes more sense to run multilevel models for data shown 
in Figure 3. Words describing change trajectories such as "efficacy over time" and "temporal 
relationship" appeared several times in the paper. It seems that the authors were trying to investigate 
the change trajectory. If so, I strongly recommend multilevel modeling as an effective approach for 
longitudinal data. 
 
***Please see the above responses.  
 
Reviewer #7: 
 
1. To my mind, using a responder criteria of 40% improvement is problematic. I realize that 40% 
improvement in this refractory population is significant. However, essentially ALL prior depression 
studies use 50% improvement as a measure of response. For example, you reference Lozano (2012) 
which is reference #7. Using 50% criteria, the one year response rate in that study was 29%. With the 
40% criteria, it was 62%! The more lenient criteria makes comparison to prior and future studies highly 
problematic. A greater explanation needs to be given for choosing this threshold. It also makes 
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comparison to the only other sham controlled trial (Dougherty, 2015, Reclaim) very difficult. In looking 
at that study, there appear to be a number of patients who would be responders at 2 years at 40%, but 
were not at 50%. I'm not sure how to resolve this given that the 40% threshold was chosen a priori. I 
would like to see the response rate results given for the 50% threshold as well, if for nothing more than 
comparative purposes. At a minimum, the difference has to be completely clear when comparing to 
prior studies. It also needs to be very clearly addressed in the discussion. 
 
*** The requested 50% response rate data has been added to the table. 
 
2. Per Table 1, the mean age in this study was over 67 years. I'm assuming this is an error, given that the 
inclusion criteria were ages 21-70. My apologies if I am misreading the Table. Please explain. Obviously, 
an average age of 67 would make this population dramatically different than other DBS studies or your 
own open label trials. 
 
***This was an error in the Table and has been corrected. The mean age of this group is very similar to 
prior studies of DBS for TRD.  
 
3. Please provide mean reductions in MADRS scores and increases in GAF scores for Figure 3. These 
appear to be much less than in prior open-label studies. This would allow for some direct comparison to 
other studies that used different response threshold criteria. I would also suggest adding a 2-year time 
point for Table 2. 
 
***Since not all patients at 12 months entered the long-term follow-up study, we deemed it not 
appropriate to put the 2 year data in Table 2 and the Figures. Long term effects are presented in Table 3. 
As discussed in the manuscript, the change over time with active stimulation is less than that seen in 
prior studies. We do not believe reporting the percent change in MADRS and GAF adds much to the 
presentation of results since these could easily be calculated from the data presented. However, we 
defer to the editors on this, and could easily add these to Table 2 (though we feel this would make the 
table much more visually complicated).  
 
4. How was your stimulation adjustment paradigm arrived at? Was it based on data from prior studies or 
more on clinical experience? Please explain. 
 
***This was based on prior studies showing that a single contact in the SCC white matter was sufficient 
for antidepressant benefit and that no more than 8 mA was typically needed to achieve effects.  
 
5. The first paragraph of the discussion states that response/remission rates here are similar to open 
label studies. This really isn't true, especially when the 40% threshold is considered. Please rephrase. 
 
***This sentence has been revised.  
 
6. The only other sham controlled trial of DBS in TRD(Dougherty, 2015) isn't even referenced in the 
discussion. Granted, it is a different target. However, it appears to have a very similar design, and many 
similarities in the results. It is critical to emphasize and discuss why two sham controlled studies based 
on solid open label data both failed to demonstrate efficacy. This group of highly experienced authors 
must at least comment on where this treatment sits after these two trials and where the field goes from 
here. 
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***We believe it is beyond the scope of this paper to comment on the other sham-controlled trial given 
the major differences between these studies (different targets, different time points, different 
programming paradigms, etc.). To us, this discussion seems more appropriate for a commentary or 
review. We have focused this manuscript on describing the results of this clinical trial and prefer to defer 
to others on placing this in the broader context of DBS for TRD. However, we see this as an editorial 
decision. If the editors believe that this discussion should be added to this manuscript, we will add it.  
 
7. Were both suicides on active stimulation at the time of suicide? Please clarify. 
 
***As stated in the results, both deaths by suicide occurred in the Control group during the open-label 
phase, so both patients were receiving active stimulation but had previously received sham stimulation.  
 
8. One patient was exited due to sponsor study closure. Was this decision forced upon the patient or did 
they concur with exiting? Did they want to continue but weren't able? This concern has been brought up 
in several ethics commentaries on DBS. It's a crucial point when designing future studies and what the 
funding agencies will be responsible for. Please clarify and discuss. 
 
***This patient was exited from the 12-month study but was enrolled in the long-term follow-up study. 
Therefore, the sponsor continues to provide care related to DBS for this patient.  
 
9. Please explain why a 2:1 randomization was chosen. 
 
***In consultation with the FDA, this design was chosen to reduce the chances of patients receiving 
sham treatment. Statistical analyses accounted for this difference in group size. 
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Confidentiality Statement 
 
The confidential information in the following document is provided to you as an 
Investigator, potential Investigator, or Consultant for review by you, your staff and 
an appropriate Institutional Review Board or Independent Ethics Committee.  By 
accepting the document you agree that the information contained herein will not 
be disclosed to others without written authorization from Advanced 
Neuromodulation Systems, Inc., except to the extent necessary to obtain informed 
consent from those persons to whom the products may be administered. 
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Protocol Summary 
 
Title: A clinical evaluation for the management of patients with Major 
Depressive Disorder, single or recurrent episode, with deep brain 
stimulation. 
 
Test Articles:  ANS Libra®
 
 Deep Brain Stimulation System 
Objectives: To demonstrate the safety and efficacy of deep brain stimulation 
(DBS) to the subgenual white matter (Brodmann Area 25WM) as an 
adjunctive treatment for single or recurrent Major Depressive 
Disorder (MDD). 
 
Patient 
Population: Patients who have single or recurrent Major Depressive Disorder 
(MDD) complying with specific inclusion/exclusion criteria. 
 
Sample Size: A total of 201 patients will be randomized to treatment from up to 20 
investigational sites. 
 
Structure: Prospective, controlled, multi-centered, double blind, randomized, 
study with endpoint evaluation at 6 months post device implantation.  
Control group patients will not have the investigational device 
activated for the first 6 months of study. 
 
Method of 
Assignment: All patients who meet the inclusion/exclusion criteria will be 
randomized.   
 
Randomization: Randomization will be performed according to a computer 
generated scheme after device implant in a 2:1 ratio (Active 
Stimulation vs. Control Group). 
 
Statistical  
Analysis: The primary endpoint, at least a 40% decrease from baseline to 6 
months in Montgomery and Asberg Depression Rating Scale 
(MADRS) and no worsening in Global Assessment of Functioning, 
will be analyzed by logistic regression that includes the effects of 
treatment group, study site, and baseline MADRS, and will be 
tested at the 5% level of significance. 
    
Adverse Events: Volunteered and solicited. 
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1  Introduction 
Depression, also known as major depressive disorder (MDD), is a serious medical 
illness that affects a person’s physical and mental state.  When a person is 
clinically depressed, his or her ability to function both mentally and physically is 
drastically affected. This impaired functional and symptomatic state may last for 
weeks, months, or even years. Typical symptoms of depression include: an 
"empty" feeling, sadness and anxiety, tiredness, lack of energy or interest in 
activities, sleep disturbances, including early morning awakening or oversleeping, 
and thoughts of death or suicide, a suicide attempt.  These problems can become 
chronic or recurrent and lead to substantial impairments in an individual’s ability to 
take care of their daily responsibilities.  MDD is one of the leading causes of 
disability in the United States and established market economies worldwide 
(Murray et al. 1996). The World Health Organization (2006) estimates that at its 
worst, depression can lead to suicide, a tragic fatality associated with 
approximately 850,000 lives every year.   
Major depressive disorder affects approximately 9.9 million American adults or 
about 5.0 percent of the U.S. population age 18 and older in a given year (Narrow 
1998).  While MDD can develop at any age, the average age of onset is the mid-
20s (American Psychiatric Association – APA, 1994).  Among this disease 
population, a large number of patients are consistently resistant to the many and 
different therapies utilized to treat depression.  This subgroup is diagnosed as 
having treatment resistant depression (TRD) and treatment alternatives are 
desperately needed for this growing population of severely depressed patients.  
Modern brain imaging technologies are revealing that in depression, neural circuits 
responsible for the regulation of moods, thinking, sleep, appetite, and behavior fail 
to function properly, and that critical neurotransmitters—chemicals used by nerve 
cells to communicate—are out of balance (Nestler et al. 2002).  Genetic research 
indicates that vulnerability to depression results from the influence of multiple 
genes acting together with environmental factors (NIMH Genetics Workgroup).  
Ongoing studies of brain chemistry and of mechanisms of action with 
antidepressant medications continue to inform the development of new and better 
treatments.  
Antidepressant medications are widely used and often partially effective treatments 
for depression (Mulrow et al. 1998).  Available antidepressant drugs influence the 
functioning of certain neurotransmitters in the brain, primarily serotonin and 
norepinephrine, known as monoamines. Older medications such as tricyclic 
antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs), affect the 
activity of both of these neurotransmitters simultaneously. The disadvantage of 
these older medications is that they can be difficult to tolerate due to side effects 
or, in the case of MAOIs, dietary and medication restrictions.  Newer medications, 
such as the selective serotonin reuptake inhibitors (SSRIs) or selective 
serotonin/norepinephrine reuptake inhibitors (SNRIs), appear to have fewer side 
effects than the older drugs, making it easier for patients to adhere to treatment. 
Unfortunately, no single medication is effective for all depressed patients as 
Page 6 of 291
C-07-01 Libra® IPG DBS 10/05/2011 
Major Depressive Disorder Pivotal Study Final 
  
Confidential Page 7 
various groups of patients will respond to one drug while other patients will require 
different agents.  Fava (2003) states that treatment resistant depression typically 
refers to an occurrence of an inadequate response following adequate 
antidepressant therapy among patients suffering from unipolar depressive 
disorders; which further shows that adequate treatment strategy is extremely 
difficult for this group of depressed patients. A recent, overall assessment of the 
nation’s largest real world study of treatment-resistant depression (Sequenced 
Treatment Alternatives to Relieve Depression – STAR*D) suggests that a patient 
with persistent depression can get well after trying multiple treatment strategies, 
but his or her odds of “beating” depression lessen as additional strategies are 
needed (Rush et al. 2006).  The STAR*D study, which has studied thousands of 
patients, further proves that the task of finding the correct treatment for severely 
depressed patients, can be extremely daunting.   
Certain types of psychotherapy can be an effective treatment option for 
depression. Cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT) 
have shown to be particularly useful. Approximately two thirds of adults with 
depression improve when they receive appropriate treatment with medication, 
psychotherapy, or the combination (Hollon et al. 2006), whereas only one third of 
treatments result in a full remission. 
Despite available pharmacologic and psychotherapeutic treatments, a large 
number of depressed patients do not have an acceptable or sustained response to 
these treatments.  Despite the advances in brain-neurobiology research and the 
growing number of available antidepressant therapies, fewer than 50% of these 
patients achieve remission, and up to 20% develop treatment resistant depression 
(Kennedy & Lam, 2003). Not only do these patients remain treatment resistant, 
they are also chronically and severely disabled.   
For these severely ill patients who do not respond to psychotherapy and 
medication, Electroconvulsive Therapy (ECT), is often prescribed.  Although this 
therapy has been shown to have short-term efficacy, many patients experience 
acute or sustained side effects as a result of the feature (Fink, 2001).  Some 
patients indicate memory loss which can occur for days, weeks and even months 
after ECT sessions. More recently, other somatic interventions such as 
Transcranial Magnetic Stimulation (rTMS) and Vagus Nerve Stimulation (VNS) 
have become available, although sustained response rates are relatively modest 
according to research studies.   
Although still investigational, the rTMS method appears to only provide temporary 
relief of symptoms; thus many aspects will need to be refined for programming 
parameters and targeting of regional locations when utilizing this technology, if it is 
ultimately approved by FDA.  A recent FDA panel meeting addressing rTMS’ 
safety and efficacy, showed that rTMS has a favorable safety profile but did not 
show efficacy at the specific primary endpoint of the clinical trial.  The FDA panel 
recommended to FDA that this therapy not be approved for the treatment of Major 
Depressive Disorder (FDA Panel Meeting, January 2007).   
Alternatively, vagus nerve stimulation has been used for the indication of Epilepsy 
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in the United States since 1997 (George 2000 and Sackeim et al. 2007).  Due to 
the fact that many epileptic drugs also work for bipolar depressed patients, there 
was belief that there may be a correlation in the disease process between these 
two conditions (Elger 2000).  These hypotheses led to clinical trials researching the 
use of the VNS system for major depressive disorder.   VNS was ultimately 
evaluated and approved by the FDA in July of 2005, for the adjunctive long-term 
treatment of chronic or recurrent depression for patients 18 years of age and older, 
who are experiencing a major depressive episode and have not had an adequate 
response to four or more adequate antidepressant treatments (Cyberonics 
Labeling).  VNS is now one of the limited new options for this depressed, treatment 
resistant patient population.  Although this therapy was recently approved by the 
FDA, longer-term, well designed clinical trials are needed to confirm the safety and 
efficacy of this treatment alternative.  Furthermore, since the VNS device has 
shown limited efficacy in small numbers of patients, it has certainly not proven to 
be the ultimate solution for treatment of these severely depressed patients.  
For the most severely, treatment resistant of these patients, several invasive 
ablative neurosurgical procedures have also been available; although they are now 
infrequently used due to perceived side effects and the unfortunate irreversibility of 
the treatment.  Well-established procedures involve the production of lesions that 
interrupt distinct frontal-cingulate, fronto-striatal, and thalamo-frontal white matter 
tracts, resulting in therapeutic benefit for some patients (Cosgrove et al. 1995; and 
Sachdev and Sachdev, 2005). Several of these procedures, including subcaudate 
tractotomy, cingulotomy and anterior capsulotomy have been found to be effective 
in some patients, although all involve the permanent destruction of neural 
structures.  Furthermore, there is also a considerable time delay between surgery 
and symptom improvement.   
Recently, destructive procedures to treat Parkinson’s disease, such a 
thalamotomies and paladotomies have been replaced by applying high frequency 
electrical stimulation to these targets. Deep brain stimulation (DBS) has been 
found to have distinct advantages over ablation with the major advantage being its 
reversibility, as well as the option to modify specific stimulation parameters when 
necessary.  Pathological studies further demonstrate that chronic DBS produces 
little to no tissue damage (Haberler et al. 2000). In theory, DBS can be seen as a 
potentially safe, effective, flexible and reversible alternative to ablative surgery for 
treatment resistant depression, if the optimal target can be defined and evaluated.  
Functional neuroimaging studies have revealed changes in cortical (frontal, 
parietal), paralimbic (cingulate, insula) and subcortical (caudate, thalamus) activity 
following various types of treatments [medication, psychotherapy, sleep 
deprivation, ECT, repetitive transcranial magnetic stimulation (rTMS), ablative 
surgery] (Mayberg, 2003).  Normalization of frontal abnormalities (both increases 
and decreases) is the best-replicated finding. Decreases in paralimbic regions, 
while variable, are also consistently reported. While there is not yet a common 
pattern that characterizes depression remission across all of the available 
treatment modalities, medications and all of the available somatic treatments such 
as ablative surgery, TMS and VNS, changes have been seen in the paralimbic 
Page 8 of 291
C-07-01 Libra® IPG DBS 10/05/2011 
Major Depressive Disorder Pivotal Study Final 
  
Confidential Page 9 
regions. Specifically, changes have been found in the hippocampus and ventral 
medial frontal/cingulate areas, having known projections through specific 
subcaudate tracts (Mayberg et al. 2000).   
Regions affected by these white matter interruptions are widespread, as the 
subcaudate tractotomy is quite large.  Specific tracts are less well characterized, 
but likely involve connections linking orbital frontal, subgenual cingulate, ventral 
striatum/caudate, thalamus brainstem, hypothalamus and hippocampus/amygdala.  
The precise optimal target(s) within the subcaudate that mediate antidepressant 
response is not known at this time. However, imaging studies suggest that 
disturbances involving more specific connections between the subgenual cingulate 
and medial frontal, ventral striatum, anterior thalamus, hippocampus, 
hypothalamus and brainstem may be particularly critical (Seminowicz et al. 2004).  
Brodmann Area 25WM (BA25WM), also known as the subgenual cingulate region, 
subgenual white matter, or Cg25, has been shown to be involved in both acute 
sadness and antidepressant treatment effects; hence indicating its role in 
modulating mood states (Mayberg et al. 1999).  These findings further suggest that 
DBS may be most effective if these medial pathways are selectively modulated, as 
this hypothesis has been further verified in a preliminary study in treatment-
resistant depressed patients.  Mayberg et al. 2005, reported that in a small group 
of severe refractory depressed patients, DBS induced clinical response in 4 out of 
6 patients, with 2 patients achieving full remission. Although these preliminary 
findings are encouraging, much larger, controlled clinical trials are necessary to 
show the safety and efficacy of deep brain stimulation of Brodmann Area 25WM.    
Deep brain stimulation is considered safe, non-destructive and reversible. The 
frequency and severity of procedural risks and complications with DBS 
implantation for depression are expected to be similar to those for Parkinson’s 
Disease and Essential Tremor.  An extensive review of Manufacturer and User 
Facility Device Experience (MAUDE) reports, regarding deep brain stimulation 
from 1997 to present, has shown no evidence of tissue damage due to excessive 
electrical stimulation.  To date, over 30,000 Deep Brain Stimulation devices have 
been implanted worldwide. Furthermore, a recent paper by Haberler et al. (2000) 
concluded that chronic DBS, defined as continuous deep brain stimulaton for up to 
70 months, does not cause damage to neural tissue in Parkinson’s Disease 
patients when applied at therapeutic levels.   
Unfortunately, there are a limited number of new treatment options for the 
treatment resistant patient population.  Considering the severity of treatment 
resistant depression and its debilitating effect on patients’ and family’s lives, Deep 
Brain Stimulation provides an optimistic opportunity for significant symptom relief 
and potential quality of life improvement, with minimal risk.  Further, this evaluation 
of DBS’ safety and efficacy, gives patients with treatment resistant depression an 
additional treatment option.  The purpose of this proposed clinical study is to 
evaluate safety and efficacy of subgenual white matter (Brodmann Area 25WM) 
deep brain stimulation for the treatment of single or recurrent, Major Depressive 
Disorder, using standard psychiatric rating scales and questionnaires as outcome 
measures.   
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2 Objective 
2.1 Primary Objectives 
To demonstrate the safety and efficacy of deep brain stimulation (DBS) to the 
subgenual white matter (Brodmann Area 25WM) as an adjunctive treatment 
for Major Depressive Disorder (MDD), single or recurrent episode. 
2.2  Secondary Objectives 
To evaluate changes in the following:  Hamilton Rating Scale for Depression 
(HRSD-17), the 30-item Inventory of Depressive Symptomatology (IDS-C30), 
Quick Inventory of Depressive Symptomatology (QIDS-SR), Young Mania 
Rating Scale (YMRS), Work and Social Adjustment Scale (WSAS), Quality of 
Life and safety.  
2.3 Primary Variable 
Primary Efficacy:  Change from Baseline (defined as mean of 3 Montgomery 
and Asberg Depression Rating Scale (MADRS) scores) to the mean of 
months 4, 5, and 6 between treatment groups. 
The primary endpoint
2.4 Secondary Variables 
 will be defined as at least a 40% reduction in MADRS 
and no worsening in Global Assessment of Functioning (GAF). 
• Change from baseline in GAF over time;  
• Change from baseline in the MADRS over time; 
• Change from baseline in the Hamilton Rating Scale for Depression - 17 
item (HRSD-17) over time; 
• Change from baseline in the Inventory of Depressive Symptomatology 
(IDS-C30) over time; 
• Change from baseline in Quick Inventory of Depressive Symptomatology 
(QIDS-SR) over time; 
• Change from baseline in the Work and Social Adjustment Scale (WSAS) 
over time; 
• Change from baseline in Patient Global Impression of Severity over time; 
• Change from baseline in Clinician Global Impression of Improvement over 
time; 
• Change from baseline in quality of life over time; 
• The incidence of all adverse events (i.e. hospitalization due to worsening 
depression, suicidal ideation or behavior, medical treatment, and device 
related events) that occur over study duration. 
• Change from baseline in Hamilton Anxiety Rating Scale (HAM-A) over 
time. 
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2.5 Other Variables 
• Number of patients who have a 40% reduction in Baseline HRSD-17 over 
time; 
• Number of patients who have a 40% reduction in IDS-C30 over time; 
• Number of patients who have a 40% reduction in QIDS-SR over time; 
• Number of patients in Remission (as defined by a score of ≤ 14 on the 
IDS-C30) over time; 
• Number of patients in Remission (as defined by a score of ≤ 5 on the 
QIDS-SR) over time; 
• Number of patients in Remission (as defined by a score of ≤ 10 on the 
MADRS) over time; 
• Number of patients in Remission (as defined by a score of ≤ 7 on the 
HRSD-17) over time.  
• Change from baseline in the Young Mania Rating Scale (YMRS) over 
time; 
• Number of patients with hypomania (defined as present when YMRS > 
15.); 
• Change in the Neuropsychological Battery test results at 6 and 12 months; 
• Change from baseline in the Health and Labor Questionnaire (HLQ) over 
time; 
• Change from baseline in the Columbia Suicide-Severity Rating Scale (C-
SSRS) over time 
3 Study Design 
3.1 Design 
This study is designed as a prospective, multi-centered, double-blind, 
randomized, controlled 12-month pivotal study to evaluate the safety and 
efficacy of the ANS Libra®
 
 Deep Brain Stimulation System for patients with 
major depressive disorder who have failed at least 4 treatments in the current 
episode. The primary outcome assessment will occur at 6 months: however, 
all patients will be followed for 1 year. A total of 201 patients will be 
randomized from up to 20 sites. 
Each potential patient will be pre-screened according to the 
inclusion/exclusion criteria.  A narrative of what study participation entails, will 
be used to educate potential participants on study requirements. Prior to on-
site baseline evaluations, the patient will sign the informed consent. Patients 
will then undergo 3 baseline evaluations, with each of these evaluations to 
occur no less than 2 weeks apart from each other. The first 2 baseline visit 
evaluations will be performed by separate psychiatrists in order to confirm the 
patient’s diagnosis.  The patient must score an average ≥ 22 on the MADRS, 
across 3 evaluations.  All patients will be scheduled for surgery, to occur no 
less than two weeks and no more than 1 month after final baseline evaluation, 
to implant the ANS Libra® Deep Brain Stimulation system.  After device 
implantation, patients will be randomly assigned to 1 of 2 groups in a 2:1 ratio 
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(Active Treatment Group & Control Group).  
   
Group 1:
  
 DBS Active Treatment Group – implanted with investigational device 
and activated for stimulation. 
Group 2:
 
 DBS Control Group – implanted with investigational device, but will 
not receive active stimulation for the first 6 months of the study.  At the end of 
6 month visit, these patients will have the investigational device programmed 
and activated.    
After system implant (Week 0), the patient will return to clinic approximately 2 
weeks after surgery for evaluation and treatment randomization into either 
Group 1 or Group 2 (Group 1 = Active Treatment Group; Group 2 = Control 
Group).  Patient will then return to clinic for subsequent evaluations at 2 
weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 6 months, 
7 months, 8 months, 9 months, 10 months, 11 months, and 1 year post 
system implantation. 
 
Study Visit Schedule 
 
Timing of visit Activities at visit Case Report Forms to be completed 
(Appendix C). 
Phone Screen Participant study education  
Inclusion/Exclusion criteria 
screening review. 
Inclusion/Exclusion Criteria. 
Baseline #1 prior to 
system implantation 
Patient signs informed 
consent; 
Request/Review - Medical 
records over last 2 years 
looking at treatment history 
and non-compliance issues; 
Patient screened; 
Patient completes baseline; 
Session videotaped. 
 
 
 
Confirmation of MDD via DSM-IV-TR 
criteria will occur combined with 
extensive medical record review; 
Montgomery and Asberg Depression 
Rating Scale (MADRS); 
Demographics and prior history; 
Medical history; 
Physician exam; 
Family history and medications 
(Antidepressant Treatment History Form 
- ATHF); 
Systematic Assessment for Treatment 
Emergent Events (SAFTEE); 
Inventory of Depressive 
Symptomatology (IDS-C30); 
Hamilton Rating Scale for Depression - 
17 item (HRSD-17);  
Quick Inv. of Depress. Symptom. 
(QIDS-SR); 
Subsection for Cluster B of the 
Structured Clinical Interview for DSM-IV 
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Personality Disorders (SCID-II 
Subsection); 
Young Mania Rating Scale (YMRS);  
Work and Social Adjustment Scale 
(WSAS);  
Global Assessment of Functioning 
(GAF); 
Quality of Life Enjoyment and 
Satisfaction (QOL); 
M.I.N.I. Plus; 
MMSE; 
Clinical Global Impression of Severity 
and Improvement (CGI); 
Patient Global Impression Index (PGI); 
Health and Labor Questionnaire (HLQ); 
Hamilton Anxiety Rating Scale (HAM-
A); 
Columbia Suicide-Severity Rating Scale 
(C-SSRS). 
Baseline #2 two 
weeks after Baseline 
#1, and prior to 
system 
internalization 
Patient completes 2nd
Evaluations done by a 
different psychiatrist 
(evaluator). 
 
baseline visit.  
Confirmation of MDD via DSM-IV-TR 
criteria; 
MADRS; 
QIDS; 
SAFTEE; 
HAM-A; 
C-SSRS. 
 
Baseline #3 
Two weeks after 
Baseline #2, and 
prior to system 
internalization. 
 
Patient completes 3rd
MRI scheduled. 
 
baseline visit; 
If the 3 baseline MADRS 
values are not ≥ 22 the 
patient will be excluded 
from re-evaluation for 
entrance into the study for 6 
months.  
 
MADRS; 
QIDS; 
SAFTEE; 
MRI;  
Neuropsychological Battery (if MADRS 
values deem patient eligible for study 
continuation.) 
HAM-A; 
C-SSRS. 
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Day of system 
internalization 
(Week 0)  
Device implanted according 
to standard operating 
procedures. 
 
Surgery Form. 
 
2 weeks after system 
implant -  
-Active Group
- 
: will 
have device 
activated. 
Control Group
Randomization; 
 will 
have device system 
test performed, but 
will not get activated. 
Report any complications; 
 
Office Visit; 
MADRS; 
HAM-A; 
C-SSRS; 
Programming form. 
 
4 weeks after system 
internalization 
Report any complications;  
Optimize programming, if 
necessary.  
 
Office Visit; 
Programming form; 
MADRS; 
IDS-C30; 
QIDS-SR; 
SAFTEE; 
WSAS; 
GAF; 
CGI; 
PGI; 
HAM-A; 
C-SSRS. 
6 weeks after system 
internalization 
Report any complications;  
Optimize programming, if 
necessary. 
Office Visit;  
MADRS; 
Programming form; 
QIDS-SR; 
CGI; 
PGI; 
HAM-A; 
C-SSRS. 
8 weeks after system 
internalization 
Report any complications;  
Optimize programming, if 
necessary. 
 
Office Visit; 
Programming form;  
MADRS; 
IDS-C30; 
QIDS-SR; 
WSAS; 
GAF; 
CGI; 
PGI; 
HAM-A; 
C-SSRS. 
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3 months after 
system 
internalization 
Report any complications;  
Optimize programming, if 
necessary.  
Session will be videotaped 
 
Office Visit; 
Programming form;  
MADRS; 
HRSD-17; 
IDS-C30; 
QIDS-SR; 
SAFTEE; 
YMRS;  
QOL; 
WSAS; 
GAF; 
CGI; 
PGI; 
HLQ;  
HAM-A; 
C-SSRS. 
4 months after 
system 
internalization 
Report any complications;  
Optimize programming, if 
necessary. 
Office Visit;  
Programming form; 
MADRS; 
IDS-C30; 
QIDS-SR; 
WSAS; 
GAF; 
CGI; 
PGI; 
HAM-A; 
C-SSRS. 
5 months after 
system 
internalization 
Report any complications;  
Optimize programming, if 
necessary. 
Office Visit; 
Programming form;  
MADRS; 
IDS-C30; 
QIDS-SR; 
WSAS; 
GAF; 
CGI; 
PGI; 
HAM-A; 
C-SSRS. 
6 months after 
system 
internalization  
 
Report any complications;  
Optimize programming, if 
necessary;  
Session will be videotaped 
 
Office Visit; 
Programming form; 
MADRS; 
HRSD-17; 
IDS-C30; 
QIDS-SR; 
SAFTEE; 
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YMRS; 
QOL; 
WSAS; 
GAF 
CGI; 
PGI; 
HLQ; 
HAM-A; 
C-SSRS; 
Neuropsychological Battery. 
7-11 months after 
system 
internalization 
Report any complications;  
Optimize programming, if 
necessary. 
Office Visit;  
MADRS; 
Programming form; 
IDS-C30; 
QIDS-SR; 
WSAS; 
GAF; 
CGI; 
PGI; 
HAM-A; 
C-SSRS;  
 
Month 9 Only: 
YMRS; 
QOL; 
HLQ; 
SAFTEE. 
12 months after 
system 
internalization 
Report any complications;  
Optimize programming, if 
necessary.  
Session will be videotaped 
Office Visit;  
MADRS; 
Programming form; 
HRSD-17; 
IDS-C30; 
QIDS-SR; 
SAFTEE; 
YMRS; 
QOL; 
WSAS; 
GAF; 
CGI; 
PGI; 
HLQ; 
HAM-A; 
C-SSRS; 
Neuropsychological Battery; 
Study Exit Form; 
Long-Term Follow-up consent form. 
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3.2 Baseline Evaluations  
A thorough review of medical records, over at least the previous two years for 
each patient, will be necessary to review treatment history and any non-
compliance to treatment issues.  These baseline measurements will be taken 
after the patient signs the informed consent and complies with all the 
inclusion/exclusion criteria, prior to device implantation and randomization to 
treatment. Patient baseline measurements include the Montgomery and 
Asberg Depression Rating Scale (MADRS); the Hamilton Depression Rating 
Scale - 17 item (HRSD-17); the Self-Rated Quick Inventory of Depressive 
Symptomatology (QIDS-SR); Subsection for cluster B personality disorder of 
the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II); 
Systematic Assessment for Treatment Emergent Events (SAFTEE); the 30 
item Inventory of Depressive Symptomatology (IDS-C30); the Young Mania 
Rating Scale (YMRS); the Work and Social Adjustment Scale (WSAS); Global 
Assessment of Function (GAF); the short form Quality of Life Enjoyment and 
Satisfaction Questionnaire (QOL); Clinical Global Impression of Severity and 
Improvement (CGI); Patient Global Impression Index (PGI); Health and Labor 
Questionnaire (HLQ); Hamilton Anxiety Rating Scale (HAM-A) and Columbia 
Suicide-Severity Rating Scale (C-SSRS). Two different psychiatrists will 
confirm the diagnosis of MDD via DSM-IV-TR criteria. Previous medical 
history and psychiatric history will be assessed and recorded including the 
M.I.N.I. Plus, MMSE, and psychotherapy treatments.  A Neuropsychological 
Battery will be performed after Baseline #3 if patient has met MADRS study 
inclusion criteria. Portions of these baseline sessions may be videotaped.  An 
initial MRI will occur after Baseline #3 in order to (1) exclude patients 
presenting with brain abnormalities that might be contributing to severity and 
treatment resistance of depression or which would not be compatible with the 
surgery; and (2) to perform surgical lead placement targeting and surgical 
pre-planning.  
 
3.3 Justification for Study Design 
The normal study design to investigate the effect of treatment above and 
beyond natural history of the condition and the placebo effect is to perform a 
double blind, randomized controlled study. The present study design fits 
these criteria.  All patients will be implanted with the investigational device 
bilaterally within Brodmann Area 25WM, according to surgical procedure.  
The 2-arm study design will allow for a control group to be followed 
simultaneously with a treatment group.  The only difference between these 2 
groups will be that 1 group will be receiving active stimulation and the other 
group will not be receiving active stimulation.  We believe that this controlled 
study design will allow both within patient and between treatment group 
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comparisons of the effect of DBS on the successful reduction of symptoms 
from treatment resistant depression. 
 
We will require 3 separate psychiatric baseline evaluations to meet eligibility 
criteria.  Thus, no one person in the study will have the ability to judge if 
patients are diagnosed properly and meet the baseline scores to be part of 
this study; hence improving the consistency/reproducibility of the data for the 
study.  
 
The MADRS was chosen as the primary measurement tool because it has 
been shown to be unifactorial, hence more sensitive to symptom changes; 
has been demonstrated to have more individual items that have been shown 
to be sensitive to change; and is an easy scale to administer.   
 
A statistically significant greater number of patients who meet the response 
criteria according to MADRS, in the Deep Brain Stimulation group, than in the 
control group at 6 months, will demonstrate the benefit of Deep Brain 
Stimulation in the treatment resistant depression patient population.   A 
responder analysis will be performed on this data.  The primary endpoint 
criterion of 40% is a clinically meaningful benefit due to the protracted and 
disabling nature of this treatment resistant population (Rush et al. 2003; 
Nahas, 2005).   
 
We believe that this study design will effectively eliminate bias, by addressing 
the following concerns: 
 
1.  The selection criteria for the study will favor placebo non-responders, 
due to the fact that it naturally selects patients that have undergone 
multiple therapies with little success; 
2.  A control group will be used to prove the treatment effect; 
3.  Active stimulation will not be tested intraoperatively, in order to ensure 
that patient does not receive any response prior to randomization;  
4.  The Investigator will be blinded to which treatment the patient will 
receive in order to minimize bias; 
5.  The patient will be blinded to which treatment they will receive in order 
to minimize bias; 
6.  To help diminish placebo effect over time, all patients will be followed 
for 12 months and treatment effects will continue to be monitored;  
7.  All patients will be followed for 12 months post-implant and all willing 
patients will be followed at 6-month intervals after completing the 
study. 
Finally, a one year study is sufficient to determine safety and efficacy due to 
the nature of this device and the severity of the patient population.  This 
treatment is not a direct life saving intervention.  However, if this therapy is 
successful it will provide an alternative treatment to those patients who have 
tried all conventional therapies and failed.  In a select group of patients, this 
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treatment may be able to reduce the suicide rate and provide depressive 
symptom relief, thus drastically improving their quality of life.  In addition,  
previous device studies of this type that have been undertaken have 
demonstrated their treatment effect and supported their safety profile by 
supplying either 6-month, or 1-year of data to obtain PMA approval. We feel 
this study design supports the collection of valid scientific evidence to support 
a new device, seeking Pre-Market Approval of this indication.  We feel that if 
this study is successful, DBS will provide physicians with an additional 
treatment option.   
 
Study Success defined as: 
3.4 IPG Implantation 
 Achieving a statistically significant greater number 
of patients who meet the response criteria as compared to the control group 
at the 6 month endpoint.      
The ANS Libra Deep Brain Stimulation (DBS) System consists of an 
Implantable Pulse Generator (IPG) designed to be connected to 4 or 8 
electrode leads and extensions and programmed by an external programmer. 
The DBS system for the purposes of this study is to be used for the treatment 
of severe major depressive disorder. The ANS pulse generator is implanted in 
a subcutaneous pocket, and receives radio frequency (RF) programming 
signals by means of the external programmer. The ANS IPG decodes the 
programmed information and delivers stimulation pulses to a selected 
combination of output electrodes, on the lead.  The Implantation Visit will be 
classified as “Week 0”. 
3.5 Patient Evaluation 
All patients will be evaluated 3 times, by at least 2 separate psychiatrists, 
prior to being considered for device implantation.  All patients will be assigned 
a case manager/counselor to follow the patient for the duration of the study.  
This case manager will be blinded to the study therapy for the duration of the 
study. 
 
After system implant (Week 0), the patient will return to clinic approximately 2 
weeks after surgery for evaluation and treatment randomization into either 
Group 1 or Group 2 (Group 1 = Active Treatment Group; Group 2 = Control 
Group).  Patient will then return to clinic for subsequent evaluations at 4 
weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 6 months, 7 
months, 8 months, 9 months, 10 months, 11 months, and 1 year post system 
implantation. 
 
At the end of the 6 month visit, all control group patients will have the option 
to receive active stimulation and will be followed on a monthly basis until the 
end of the 1 year study.   
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4 Test Articles 
4.1 System Components 
The components of the DBS System to be used in this study include an 
Implantable Pulse Generator (ANS, Libra and LibraXP DBS IPG), leads 
(ANS, Libra DBS Lead Kits), extensions, the ANS MTS trial stimulator, the 
clinician programmer, the patient controller (ANS, QuikLink Controller).  The 
Libra system is comprised of implanted and non-implanted components that 
include: 
• Implantable Pulse Generator (IPG) – generates low-current electrical 
pulses. 
• Lead - contains electrodes to deliver stimulation 
• Lead Extension – make the electrical connection between the lead 
and the generator 
• Trial Stimulator - for intraoperative and post operative testing 
• Clinician Programmer – for programming the generator 
• QuikLink Patient Controller  - controls off/on function and amplitude 
4.2 Regulatory Status 
The ANS Libra DBS system is predicated on the currently approved Genesis 
neuromodulation system (Approved in US under PMA P010032, Registered 
in Canada under License No. 67516, CE Marked in Europe and Registered in 
Australia, and meets ISO 13485), which is indicated for Spinal Cord 
Stimulation (SCS) and distributed around the world.  The ANS device to be 
used in this study is not currently approved for marketing and distribution in 
the United States for Deep Brain Stimulation for Major Depressive Disorder.  
However, the Libra DBS System has received Health Canada approval for 
investigational testing for treatment-resistant major depressive disorder.  The 
ANS DBS system is categorized in the United States as a class III medical 
device and the purpose of this clinical trial is to provide safety and efficacy 
data to support the PMA submission for the ANS Deep Brain Stimulation 
System.  
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5  Patient/Subject Selection  
5.1 Inclusion Criteria 
Patients enrolled in this study must comply with the following inclusion criteria: 
 
1.   Men and women (non-pregnant) age is 21-70 years; 
2.   Diagnosed with non-psychotic major depressive disorder, single or 
recurrent episode by DSM-IV-TR criteria derived from the MINI;  
3.  First episode onset before age 45; 
4. Current episode > 12 months duration; 
5.    In the current episode: Documented resistance (i.e. persistence of the 
major depressive episode) to a minimum of 4 adequate depression 
treatments from at least 3 different treatment categories (e.g. SSRI’s, 
SNRI’s, TCA’s, MAO-inhibitors, Mirtazipine, Nefazodone, Trazodone, 
Bupropion, lithium augmentation, thyroid augmentation, ECT); Adequacy 
of treatments as defined by a score of at least 3 according to the 
amended Antidepressant Treatment History Form (ATHF) criteria; 
6. In Lifetime:  Received a course of psychotherapy for depression; 
7. Montgomery Asberg Depression Rating Scale (MADRS) of > 22 at 3 
separate baseline visits, rated by 2 separate psychiatrists, Baseline 2 
and Baseline 3 MADRS scores cannot be separated by > 6 weeks and 
cannot improve ≥ 20%; 
8.   Global Assessment of Function, score <50; 
9.  Modified mini-mental state examination (MMSE) score >24; 
10.   No change in current antidepressant medication regimen or medication 
free >4 weeks prior to study entry (with exception to sleep, cholesterol, 
blood pressure, sexual dysfunction, non-migraine headache medication, 
or medication for other medical reasons not related to depression, in 
which changes to dose or type will be allowed during course of study); 
11.  Able to give informed consent in accordance with institutional policies; 
12.   Able to comply with all testing and follow-up requirements as defined by 
the study protocol; 
13.   Must be determined medically stable by surgeon, to undergo deep brain 
stimulation surgical procedure.  
14.    Must have platelet count, PT and PTT within normal limits of the 
laboratory. 
15.    During last 6 months in the current episode documented treatment 
under the care of a licensed psychiatrist/psychologist. 
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5.2 Exclusion Criteria 
Patients will be excluded from participation in this study if they meet any one 
of the following criteria: 
 
1. A diagnosis of a bipolar I or bipolar II disorder by DSM-IV-TR criteria, 
derived from the MINI; 
2. Meets criteria for borderline or antisocial personality disorder in the last 
12 months by DSM-IV-TR criteria, derived from the Cluster B Personality 
Disorders Sections 301.7 – 301.83, and screened via SCID-II at 
Baseline visit; 
3. In the current depressive episode, has been diagnosed with General 
 Anxiety Disorder (GAD) -  as defined by the DSM-IV-TR, and GAD is the 
 primary diagnosis; 
4. Has an intracranial Central Nervous System (CNS) disease that impairs 
motor, sensory or cognitive function or that requires intermittent or 
chronic medication (e.g., Parkinson’s Disease, chronic migraine, stroke, 
Huntington’s, head trauma, etc.) with exception to non-migraine 
headaches; 
5. Has been diagnosed with fibromyalgia or has a current condition which 
requires chronic pain narcotic usage (e.g. morphine, methadone); 
6. Has been currently diagnosed with chronic fatigue syndrome; 
7. Substantial suicidal risk as defined by (1) MADRS item 10 score of 5 or 
6, (2) a current plan and intent, (3) clinician judgment that there is a clear 
immediate intent for self-harm, (4) more than 3 suicide attempts within 
the last 12 months; 
8. Co-morbid obsessive compulsive disorder, post-traumatic stress 
disorder, panic disorder, bulimia or anorexia nervosa if previously 
present, must be in remission for 6 months as defined by DSM-IV-TR 
criteria, derived from the MINI; 
9. Alcohol, medication, or illegal substance dependence or abuse within 
last 12 months derived from the MINI; 
10. Diagnosis of sleep apnea confirmed by a sleep test that is not 
adequately treated; 
11. Advanced cardiovascular disease which renders anesthesia and surgery 
as unsafe as determined by neurosurgeon;  
12. Clinically relevant abnormality (e.g. tumor or growth) on study MRI; 
13. Has cardiac pacemaker/defibrillator or other implanted active stimulator; 
14. Has a medical condition requiring a repetitive MRI body scan;  
15. Requires chemotherapy for the treatment of malignancy or requiring 
chronic oral or intravenous (immunosuppressive or)  steroid therapy; 
16. Is unable to comply with study visit schedule and timeline; 
17. Past ablative or relevant intracranial surgery; 
18. A female lactating or of child bearing potential, with a positive pregnancy 
 test or not using adequate contraception;  
19. Lifetime psychotic disorders, schizophrenia, or schizoaffective disorder 
 defined by DSM-IV-TR; 
Page 22 of 291
C-07-01 Libra® IPG DBS 10/05/2011 
Major Depressive Disorder Pivotal Study Final 
  
Confidential Page 23 
20. Psychotic features in current depressive episode as diagnosed by DSM-
IV-TR criteria; 
21. Other medical conditions likely to require hospitalization within the next 
 year;   
22. Received ECT within 3 months prior to enrollment, or requires ECT for 
the duration of the study; 
23. Has a history of epilepsy or history of status epilepticus; 
24. Plans to use diathermy; 
25. Has any metallic implants such as aneurysm clips or cochlear implants; 
26. Currently participating in another investigational device, drug or surgical 
 trial. 
 
6 Subject Assignment to Treatment and Blinding 
Each patient who is willing to consider study participation and who provides 
informed consent will be evaluated with the inclusion/exclusion criteria for 
eligibility.  Each patient will be enrolled chronologically on a patient screening log 
and given a screening number until device implantation. The patient will be given 
a randomization number after device implantation has occurred and the patient 
has been shown to meet all inclusion criteria and not violate any exclusion 
criteria.  Patients will be block-randomized with a separate randomization number 
for each study site.  Patients will be randomly assigned to a treatment group in a 
2:1 ratio, to either: 
Group 1: DBS Active Treatment Group – Implanted with DBS system and 
activated for 6 months of DBS. 
Group 2
 
:  Control Group - Implanted with DBS system, device not activated for 
stimulation for the first 6 months of study. 
The patients will be blinded to the functioning of the DBS system.  The patient 
will not be able to tell if they have been randomized to active treatment or to the 
control group.   
 
The evaluating psychiatrist (Investigator) and/or qualified designee and the case 
manager will be blinded to the functioning of the DBS system in order to minimize 
bias.  The device will be programmed by one clinician and the information 
regarding the device will not be given to the evaluating psychiatrist or qualified 
designee.  All efforts will be made to ensure that the evaluating psychiatrist is the 
same throughout the patient study treatment and follow-up visits, in order to 
reduce variability in the evaluators scoring.  All evaluators will be trained prior to 
study initiation as well as re-trained on a scheduled basis throughout study 
duration.   
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7 Methods and Procedures 
7.1  Informed Consent 
Written Informed Consent will be obtained from each patient prior to 
enrollment into the study. All potential patients/subjects will be properly 
informed as to the purpose of the study and the potential risks and benefits 
known, or that can be reasonably predicted or expected. The Investigator will 
retain the original copy of the Informed Consent Form signed by the patient, a 
duplicate will be provided to the patient and a document signed by the 
Investigator confirming receipt of patient consent will be returned to the 
Sponsor. Only the consent form approved by the IRB/IEC will be used. 
(Appendix A: Sample Informed Consent) 
7.2 Screening/Baseline 
Study candidates will be screened according to the inclusion/exclusion criteria 
prior to enrollment in the study. All study participants must provide informed 
consent. Evaluations will include the following: 
 
• Confirmation of MDD via DSM-IV-TR criteria will occur combined with 
extensive medical record review by evaluating psychiatrist;  
• Montgomery and Asberg Depression Rating Scale (MADRS); 
• Demographics and prior history; 
• Medical system review; 
• Brief physical exam, neurological exam;  
• Pregnancy test (if necessary); 
• Family history, medication history – antidepressant treatment history form 
(ATHF - modified);  
• MINI Plus; 
• HRSD-17; 
• SAFTEE; 
• Mini Mental State examination (MMSE); 
• Subsection for cluster B personality disorder of the Structured Clinical 
Interview for DSM-IV Personality Disorders (SCID-II) ; 
• Inventory of Depressive Symptomatology (IDS-C30); 
• Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR);  
• Work and Social Adjustment Scale (WSAS); 
• Short form Quality of Life Enjoyment and Satisfaction Questionnaire 
(QOL); 
• Young Mania Rating Scale (YMRS); 
• Clinical Global Impression of Severity and Improvement (CGI); 
• Patient Global Impression Index (PGI); 
• Health Labor Questionnaire (HLQ); 
• Hamilton Anxiety Rating Scale (HAM-A); 
• Columbia Suicide-Severity Rating Scale (C-SSRS). 
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7.2.1 Baseline 2/Baseline 3  
A second baseline will be performed no less than 2 weeks and no more 
than 4 weeks after Baseline #1. Evaluations will include the following: 
 
• Confirmation of MDD via DSM-IV-TR criteria will occur combined with 
 extensive medical record review by evaluator;  
• Montgomery and Asberg Depression Rating Scale (MADRS); 
• The Quick Inventory of Depressive Symptomatology (QIDS); 
• Systematic Assessment for Treatment Emergent Events (SAFTEE-SI); 
• Hamilton Anxiety Rating Scale (HAM-A); 
• Columbia Suicide-Severity Rating Scale (C-SSRS). 
 
A third baseline will be performed no less than 2 weeks and no more than 
6 weeks after Baseline #2. Evaluations will include the following: 
 
• Montgomery and Asberg Depression Rating Scale (MADRS); 
• The Quick Inventory of Depressive Symptomatology (QIDS); 
• Systematic Assessment for Treatment Emergent Events (SAFTEE-SI); 
• Hamilton Anxiety Rating Scale (HAM-A); 
• Columbia Suicide-Severity Rating Scale (C-SSRS); 
• Neuropsychological Battery – performed only if
• MRI scan will be performed after patient has meet eligibility 
requirements (to exclude brain abnormalities, plan for surgery, and 
targeting); 
 patient meets eligibility 
 for study participation after scoring ≥ 22 on three baseline MADRS 
 evaluations. 
 
The patient will also be assigned a case manager to follow each patient’s 
care for the duration of the study. 
 
*If the patient does not have three MADRS values ≥ 22, they will be 
considered a screen failure and may not
 
 be re-evaluated for study 
participation for a minimum of 6 months.  
7.2.2 Outcome measures 
 
The Montgomery and Asberg Depression Rating Scale is a 10 item 
severity scale constructed to be sensitive to change with treatment. It was 
designed to be sensitive for individual items and is therefore useful for 
measuring differential profiles of action. Ratings of patients on a 65 item 
comprehensive psychopathology scale were used to identify the 17 most 
commonly occurring symptoms in primary depressive illness, and ratings 
on these 17 items for 64 patients participating in studies of four different 
antidepressant drugs were used to create a depression scale consisting of 
Montgomery and Asberg Depression Rating Scale (MADRS) 
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the 10 items which showed the largest changes with treatment and the 
highest correlation to overall change. (Montgomery & Asberg 1979)  An 
interrater evaluation will also be performed on multiple study visits to 
increase consistency and reduce variability. 
 
The Hamilton Rating Scale for Depression is a 17-item scale that 
evaluates depressed mood, vegetative and cognitive symptoms of 
depression, and comorbid anxiety symptoms. The HRSD-17 was one of 
the first rating scales developed to quantify the severity of depressive 
symptomatology. First introduced by Max Hamilton in 1960, it has since 
become the most widely used and accepted outcome measure for 
evaluating depression severity. It provides ratings on current DSM-IV 
symptoms of depression, with the exceptions of hypersomnia, increased 
appetite, and concentration/indecision. The HRSD-17 was designed to be 
administered by a trained clinician using a semi-structured clinical 
interview. The 17-items are rated on either a 5-point (0-4) or a 3 point (0-
2) scale.   
Hamilton Rating Scale for Depression (HRSD-17) 
 
The construction of the IDS-C30 was intended to remedy deficits in the 
Hamilton Scale for Depression (HRSD-17) and Montgomery and Asberg 
(MADRS) depression rating scales by, among others, including all nine 
symptom domains needed to diagnose a DSM-IV major depressive 
episode in order to assess symptom remission, improve ability to detect 
milder levels of symptoms than the HRSD-17, and provide unconfined and 
more equivalent weighting among items. There are two versions of the 
IDS with identical items: a clinician rating (IDS-C30) and a self-report 
(IDS-SR30). Items were selected to represent mood, cognitive, vegetative, 
anxious, and endogenous symptoms common in depression. Each of the 
30 items is rated from 0 to 3, with increasing severity represented by a 
higher rating. (Rush et al. 1996) 
Inventory of Depressive Symptomatology (IDS-C30) 
 
The Quick Inventory of Depressive Symptomatology Self Report
 
 (QIDS-
SR) is a 16-question shortened self-test, derived from the 30-item IDS, 
which measures 9 different criterion domains of major depression.  Each 
of the 4 possible answers to each quiz is given an ascending numerical 
value from 0-3.  
The SAFTEE is a structural clinical interview developed by the National 
Institute of Mental Health which exams possible treatment-emergent side 
effects for clinical studies.  The SAFTEE-SI looks at specific adverse 
symptoms for a particular treatment. 
Systematic Assessment for Treatment Emergent Events (SAFTEE-SI) 
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The MINI is a short structured diagnostic interview, developed jointly by 
psychiatrists and clinicians in the United States and Europe, for DSM-IV 
and ICD-10 psychiatric disorders. With an administration time of 
approximately 15 minutes, it was designed to meet the need for a short 
but accurate structured psychiatric interview for multi-centered clinical 
trials and epidemiology studies and to be used as a first step in outcome 
tracking in non-research clinical settings.  The MINI Plus is a more 
detailed edition of the MINI.  
The Mini-International Neuropsychiatric Interview (M.I.N.I.) Plus 
 
The mini-mental state examination (MMSE)
 
 or Folstein test is a brief 30-
point questionnaire test that is used to assess cognition. It is commonly 
used in medicine to screen for dementia.  In the time span of about 10 
minutes, it samples various functions, including arithmetic, memory and 
orientation.  It was introduced by Folstein et al in 1975 and is widely used 
with small modifications. 
 
The SCID-II is a semi-structured interview for making DSM-IV Axis II 
(Personality Disorder) diagnoses and is designed to be administered by a 
clinician or trained mental health professional. A SCID II takes 1/2 to 1 
hour to administer. There are 3 components to the SCID-II. The interview 
itself covers the 11 DSM-IV Personality Disorders. The SCID-II Personality 
Questionnaire is available as a screening tool to shorten the time it takes 
the clinician to administer the SCID-II. After the subject fills out the 
Personality Questionnaire (which usually takes 20 minutes), the clinician 
simply circles the numbers to the left of the SCID-II items that correspond 
to items answered "yes" on the questionnaire. When the SCID-II is 
administered, the clinician needs only to inquire about the items screened 
positive on the questionnaire. The assumption is that a subject who 
responds with a "no" on the questionnaire item would also have answered 
"no" to the same question had it been read aloud by the interviewer.  For 
this study, only the subsection for Cluster B will be administered. 
Structural Clinical Interview for Personality Disorders (SCID II) 
 
The YMRS is an 11-item instrument used to assess the severity of mania 
in patients with a diagnosis of bipolar disorder. The 11 items are: Elevated 
Mood, Increased Motor Activity Energy, Sexual Interest, Sleep, Irritability, 
Speech (Rate and Amount), Language - Thought Disorder, Content, 
Disruptive - Aggressive Behavior, Appearance, and Insight. 
The Young Mania Rating Scale (YMRS) 
Ratings are based on patient self-reporting, combined with clinician 
observation (accorded greater score).  (Young 1978) 
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The short form of the Quality of Life Enjoyment and Satisfaction 
Questionnaire is a self-report form composed of 16 items each rated on a 
5-point scale that indicates the degree of enjoyment or satisfaction 
experienced during the past week.  A total score of items 1 to 14 is 
computed and expressed as a percentage of the maximum possible score 
of 70.  The 14 items evaluated each subjects’ satisfaction with his or her 
physical health, social relations, ability to function in daily life; ability to get 
around physically; mood; family relations; sexual drive and interest; ability 
to work on hobbies, work, leisure time activities; economic status; 
household activities; living/housing situation; and overall sense of well 
being.  (Rapaport et al. 2005) 
Quality of Life Enjoyment and Satisfaction Questionnaire (QOL) 
 
The WSAS-SR is used to measure functional impairment attributed to a 
identified problem (Mundt, 2002).  There are 5 questions that are 
associated with work, home, social leisure, private leisure and ability to 
form and maintain relationships.  
Work and Social Adjustment Scale Self Report (WSAS) 
 
The Global Assessment Scale is a hypothetical continuum of mental 
health illness that looks at psychological, social and occupational 
functioning. The GAF scale is divided into 10 ranges of functioning in 
which the clinician picks a single value that best reflects the individual’s 
overall level of functioning. The GAF does not include “impairment in 
functioning due to physical (or environmental) limitations.” (American 
Psychiatric Association – APA, 1994) 
Global Assessment of Functioning (GAF) 
 
The CGI is used to measure the global impression of a treatment 
response in a psychiatric patient’s illness by a clinician (Guy 1976).  Two 
of three sub-scales are being used to measure severity of the illness and 
improvement of the illness. Items in the two-subscales being administered 
are rated on a seven-point scale ranging from “1=normal” to “7=extremely 
ill” for severity subscale and “1=very much improved” to “7=very much 
worse” for improvement sub-scale. 
Clinical Global Impression of Severity and Improvement (CGI) 
 
The PGI is used to measure the global impression of a treatment 
response in a psychiatric patient’s illness by the patient.  Two sub-scales 
are being used to measure severity of the illness and improvement of the 
illness. Items in the two-subscales being administered are rated on a 
seven-point scale ranging from “1=normal not ill at all” to “7=among the 
Patient Global Impression Index (PGI) 
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most extremely ill” for severity sub-scale and “1=very much improved” to 
“7=very much worse” for improvement sub-scale. 
 
 
Health and Labor Questionnaire (HLQ)
The HLQ is designed to collect quantitative data on the relation between 
illness and treatment and work performance. The HLQ data permits the 
estimation of production losses (costs) of paid and unpaid labor. It 
contains also an indicator for impediments for paid and unpaid labor, one 
of the indicators for quality of life. The HLQ is divided into 4 modules to 
collect data about absence from work, reduced productivity at paid work, 
unpaid labor production and impediments to paid and unpaid labor. The 
modular structure permits the omission of questions that are not 
applicable to the study population. The questionnaire is suitable for self-
assessment.  
  
 
A 14 item test designed to assess the severity of anxiety symptoms.  All 
questions are rated on a 5 point (0-4) scale, with 7 questions on psychic 
anxiety and 7 questions on somatic anxiety.  Total scores range from 0 to 
56.  Patients with anxiety and panic disorder tend to have a score greater 
than 20.    
Hamilton Anxiety Rating Scale (HAM-A) 
 
The C-SSRS is a semi-structured clinical interview that utilizes a set of 
prompts and questions to help an interviewer get more complete 
information on events suggestive of suicidality.  This prospective tool aims 
to standardize terminology and articulate suicidality assessment in a 
straightforward manner. 
Columbia Suicide-Severity Rating Scale (C-SSRS) 
7.2.3 Neuropsychological Battery 
 
Neuropsychological Examination: 
 
The following neuropsychological 
tests will be performed and evaluated at or after baseline #3, 6 
months, and 1 year visits during the study to assess the safety of 
Deep Brain Stimulation.  The following is a description of all the tests 
to be performed:   
 
Attention/Working Memory 
Wechsler Memory Scale –Working Memory Index Test (Wechsler, 
1997) 
 
Letter-Number Sequencing  
Examinees are presented with strings of alphanumeric sequences 
(e.g., 6-B-3-Z) of increasing length (2-8 letter-number pairs). The task 
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of the examinee is to repeat the letters and then the numbers in 
alphabetical and numerically ascending order. This test of working 
memory thus requires re-sequencing of information while holding in 
memory the original sequence. This task takes 3-5 minutes to 
complete. 
 
Stroop Color and Word Test (Golden, 1978) 
This version of the well-known Stroop test has 3 parts, each 
consisting of 1 page of 100 stimuli (arranged in 5 columns of 20 
items). The first sheet contains the words red, green, and blue, printed 
in black ink, in random order with the constraint that a word cannot be 
followed by the same word. The examinee is asked to read the words, 
and the variable of interest is how many items are completed correctly 
in 45 sec. On page 2 are 100 “XXXX” printed in either red, green or 
blue ink, with the constraint that a given item number could not 
correspond to the same color on the first page, and the same color 
cannot occur on consecutive items. The examinee is given 45 sec to 
name the color of the ink in which each stimulus is printed. On the 
final part, the page consists of the words red, green, and blue, and 
each word is printed in red, green, or blue ink, but in a manner that 
the word and color ink are always incongruent. The score is the 
number of items completed correctly in 45 sec. The whole test takes 
about 5 minutes. 
 
Ruff 2 & 7 Selective Attention Test (Ruff & Allen, 1996) 
This test of sustained and selective attention consists of 20 15-second 
trials during which patients cross out 2 target stimuli (the numbers 2 
and 7) among three rows of either numeric or alphabetic stimuli (each 
row contains 10 targets and 40 distracters in quasi-random order). 
The targets embedded among letters are considered “automatic” 
conditions (because the patient can identify targets simply by the 
category they belong to), whereas the tasks embedding the targets 
among numbers are considered “Controlled” conditions requiring 
effort and working memory since targets and distracters belong to the 
same stimulus category (numbers). The test evaluates both accuracy 
(considering errors of omission and commission) and speed.  
Normative data (based on 360 persons) are available for ages 16-70 
years, stratified by education. Test-retest reliability is estimated to be 
.89 for speed, and .59 to .69 for accuracy on automatic and controlled 
search tasks (with stability coefficients ranging from .76 to .93). The 
test is typically completed in 5 minutes. 
 
 
Executive Functions 
Delis-Kaplan Executive Function System (D-KEFS) Verbal 
Fluency Tests 
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The D-KEFS contains 3 verbal fluency tests assessing timed oral 
production of items from lexical and semantic categories. In the Letter 
fluency task the patient is asked to say as many words as possible 
(excluding proper names and numbers) beginning with a given letter 
of the alphabet. There are 3 trials, each using a different letter, of 60 
seconds each. In the Category Fluency task, the examinee is asked to 
say as many words as possible belonging to a category (such as 
animals) in 60 seconds.  There are 2 trials using different categories. 
On the final task (Category Switching), the patient is asked to orally 
generate consecutive words from 2 alternating categories for 60 
seconds.  The tasks can be completed in about 8-10 minutes. 
 
The tests are normed on over 2000 individuals, are standardized, are 
applicable to persons up to 89 years of age, and are co-normed with 
the WASI. This co-norming feature means that cognitive strengths 
and weaknesses can be ascertained with confidence given 
comparability of scores and normative data. Another strength of this 
instrument is the availability of alternate forms, thus minimizing 
practice effects (although not eliminating possible familiarity and 
carry-over effects). Test-retest data are available to facilitate 
interpretation of score changes over time. 
 
 
Memory 
Hopkins Verbal Learning Test – Revised (HVLT-R; Brandt & 
Benedict, 2001) 
This verbal learning test has six equivalent, alternate forms, making it 
ideal for repeat administration. It is normed on persons aged 16-92 
years and was designed to be tolerated by even significantly impaired 
individuals. The examinee is provided 3 learning trials to remember an 
orally presented 12-word list (four nouns from each of 3 semantic 
categories). Following a 20-25 minute interval, delayed recall and 
yes/no recognition are assessed. The test takes about 15 minutes 
excluding the delay interval which is preferably filled with intervening 
visuospatial tasks. Test-retest reliability is weaker for recognition and 
retention (.40 and .39; probably limited by skewed 
Score distributions), but adequate for recall (.66-.74). Test-retest 
gains, even when persons were tested as little as 2 weeks apart, were 
only about 0.5 standard deviations. 
 
Brief Visual Memory Test – Revised (BVMT-R; Benedict, 1997) 
Like any of its word list learning analogs (e.g., the HVLT-R), this test 
involves multiple trial learning followed by delayed recall and 
recognition trials. However, the stimuli are abstract line drawings 
rather than words. The patient is shown a set of 6 abstract line 
drawings (in a 2x3 array) for 10 seconds and is then asked to draw 
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them in their correct location. This procedure is repeated for a total of 
3 learning trials. After 25 minutes, delayed recall and recognition 
(identifying which 6 of 12 drawings were seen) trials are administered. 
The brevity of the task and the availability of 6 alternate forms make 
the test useful for repeated administrations. It is normed for persons 
aged 18-79 years. Reliability coefficients exceed .90, and test-retest 
reliability ranges from .60 to .84. Excluding the delay, which is filled 
with verbal tests, the BVMT-R can be completed in 15 minutes. 
 
 
Self and Informant Rating of Executive Functions 
Behavior Rating Inventory of Executive Function – Adult Version 
(BRIEF-A; Roth et al. 2005) 
The self-and informant-report forms consist of 75 items asking the 
person to report the frequency (never, sometimes, or often) with which 
certain behaviors have occurred during the month prior to evaluation. 
The behaviors measured relate to a variety of executive functions 
(e.g., self-monitoring, emotional control, behavioral inhibition and 
shifting, planning and organization) and are expressed in 2 indices 
(Behavioral Regulation Index and Metacognition Index) and an overall 
summary score (Global Executive Composite). There are also 3 
response validity scales. Normative data are available for 1,050 
persons for self-report and 1,200 informant reports. The test can be 
used with adults aged 18-90 years. Test-retest reliability for self-report 
clinical scores ranged from .82 to .93 over an average re-test interval 
of about 4 weeks, while informant report test-retest reliability ranged 
from .91 to .94. Test-retest values were still higher for the summary 
indexes. Patients and informants usually complete these forms in 
about 15 minutes. 
 
 
Testing order: 
The above tests should be performed in the following order: 
 
1. HVLT-R immediate recall (3 trials); 
2. Ruff 2 & 7; 
3. Stroop; 
4. Fill rest of 20-25 minute delay with starting the BRIEF; 
5. HVLT-R Delayed recall and recognition; 
6. BVMT-R Immediate recall (3 trials); 
7. DKEFS verbal fluency tests; 
8. Letter-Number Sequencing; 
9. Continue the BRIEF as needed to fill the BVMT-R delay; 
10. BVMT-R Delay recall and recognition; 
11. Finish BRIEF. 
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7.3 DBS System Implantation 
 
The DBS system implant visit should be performed no less than 2 weeks and 
no more than 1 month after the baseline #3 visit.  
 
Implantation of the DBS system will be performed according to standard 
surgical procedure for Brodmann Area 25WM (Cg25) DBS implantation. 
 
Pre-Operative Imaging:
 
 High resolution, 3D T1 weighted images will be 
obtained.  On or before the day of surgery patients will have a stereotactic 
frame or appropriate bone fiducials applied using local anesthesia.  Additional 
CT imaging for fusion is optional, as is the use of IV contrast.   
Pre-Operative Planning:
 
 Standard software (e.g. Framelink, Brainlab, or 
other) is used to reconstruct the images in axial, coronal, and sagittal views, 
relative to the AC-PC plane.    
The sagittal images will be used first.  Surgeon will select an image several 
millimeters (mm) off midline clearly showing the white and gray matter of the 
cingulate gyrus.  A tentative target point is selected at the center of the 
subgenual cingulate (Brodmann Area 25WM).  
 
Next, the surgeon will convert to the coronal images perpendicular to the AC-
PC plane.  The midpoint of the subgenual cingulate gyrus is typically found in 
the coronal image containing the anterior-most section of the caudate 
nucleus.  Thus the A-P position of the target can be confirmed by scanning a 
few images anterior and posterior to confirm proximity to this section.  
 
Precise targets can then be selected bilaterally in this same coronal section.  
A point is selected on each side at the border of the white and grey matter, 
midway between the superior and inferior banks of the cingulate gyrus. The 
intended site is approximately 5-7 mm from the midline and 10 mm below the 
corpus callosum. After targets have been selected, the appropriate frame 
coordinates can be calculated and used for the stereotactic procedure. 
 
Entry points can also be selected on the stereotactic planner if desired.  This 
practice is variable at different centers.  If entry planning is performed it is 
recommended that an entry site that is slightly anterior to the more typical 
burr hole used for STN-DBS. This is necessitated by the more anterior nature 
of this target.  Anterior entry (~2cm anterior to the coronal suture) will avoid a 
difficult approach angle.   
 
DBS Implantation: After sterile preparation of the operative field, burr holes 
are placed under local or general anesthesia.  Again the slightly more anterior 
entry is recommended. A lateral position of 2-3cm from midline is also 
recommended. Dura and pia are opened under direct visualization.  The 
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remainder of the operation is performed using an appropriate stereotactic 
frame or frameless guidance system. 
  
One or more cannulas are inserted to the target coordinate. Microelectrode 
recording may be performed, at this point, to confirm the location of the grey-
white junction within the target area.  This procedure is optional.  
 
A DBS electrode will be inserted into the target under fluoroscopic 
visualization.  Once the electrode has been placed in the calculated target 
intra-operative diagnostic testing will be performed; however, no active deep 
brain stimulation will be delivered to the patient in order to protect the study 
blinding process.  After confirmation of position the end of the lead is 
protected and excess lead is coiled in a sterile subgaleal pocket made by 
blunt dissection. The procedure is then repeated for the contralateral side.  
 
Intraoperative Device Diagnostic Testing:
 
 The implanted leads will be tested 
for proper connectivity as well as impedance; however, no active stimulation 
will be delivered, so as to not break the blinding of the study.   
IPG Implantation:
 
 The second stage of the operative procedure involves the 
implantation of lead extensions and the IPG. This will be performed 
immediately following the above procedure. The patient is given a general 
anesthetic and a sterile preparation is performed. The lead ends are 
accessed either by reopening the scalp incision or by making a smaller 
incision over the subgaleal pocket.  The lead extension is then tunneled 
subcutaneously to a second incision just below the clavicle (can be left or 
right depending on patient preference). The extension wire is attached to the 
DBS leads proximally and to the battery distally.  The implantable pulse 
generator is placed in a subcutaneous pocket that is made below the clavicle.  
Excess wire is coiled behind the IPG.  Once again, a device diagnostic test 
will occur but no active stimulation will be delivered to the patient at this time. 
Lead Localization
7.4 Concomitant Treatments 
:  The lead will be imaged post-implantation to confirm lead 
location according to current neurosurgical procedures and/or CT scans.  
These images must be given to the Sponsor for future analysis. 
 
All patients will have the ability to maintain their depression medication 
regimen as well as regularly scheduled psychotherapy to ensure study and 
therapy controls are maintained.  For the 1-year study, all psychiatric 
care/decisions must be transferred to the study psychiatrist.  For the first 6 
months of the study, patients will not be able to add new medications 
(excluding sleep aids and other meds to manage non-depression related 
conditions) nor increase current antidepressant medication doses.  
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Medication additions: 
For temporary insomnia, zaleplon, zolpidem, zopiclone, or chloral hydrate (a 
single dose nightly) or trazodone (< 100 mg) may be used, for a maximum of 
14 nights during the study. Lorazepam (< 2 mg/d) may also be administered 
for treatment emergent anxiety for up to 14 days. 
 
Rescue medications: 
The study psychiatrist should first identify a need for a rescue based on 
his/her clinical judgment of worsening depression.  In the event that a patient 
needs to be “rescued” due to a severe worsening of their depression (defined 
as patients who score 25% worse than their baseline average on the MADRS 
or worsening of suicidal ideation), prior to the completion of 6 months in the 
study, appropriate intervention may be initiated at the principal investigator’s 
discretion considering the protocol-specified guidance.  The following 
guidance should be adhered to when the rescue protocol is initiated: 
 
 
 
If a patient is rescued based on a 25% worsening of their MADRS score 
compared to the average MADRS Scores: 
• The patient will be considered a treatment failure. 
• The visit will serve as the patient’s endpoint data and the patient will be 
exited from the study.  All end-of-study procedures should be 
performed. 
• At the principal investigator discretion, medications may be added or 
changed as deemed in the best medical interest of the patient. 
• Patients who were in either the control group or received active 
stimulation should enter a separate open-label protocol for long-term 
follow-up. 
 
 
If a patient is rescued based on a worsening of suicidal ideation 
• A patient who shows imminent suicidal intent but does not attempt 
suicide will be treated for the acute exacerbation of their symptoms.  If 
the event can be treated with an acute intervention (less than 7 days) 
then the patient should resume participation in the trial and not be 
unblinded as to treatment. 
• After the acute intervention, the patient must have a MADRS item 10 
score of less than 5 to resume participation in the trial. 
• After the acute intervention, the patient must resume their previous 
medication regimen if medications were changed. 
• Patient’s medications must be stable for a minimum of 7 days prior to 
an effectiveness visit 
• If the patient attempts suicide, or requires a long-term medication 
change he/she will be considered and followed as a treatment failure.  
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Patients who were in either the control group or received active 
stimulation should enter a separate open-label protocol for long-term 
follow-up. 
 
At any time during the study the patient feels suicidal or in any danger from 
worsening depressive symptoms, they, or their caretaker should call their 
study psychiatrist immediately.    
7.5 Postoperative Visits  
All patients should be called in advanced to remind them of all study visits 
and to complete the necessary paperwork if applicable.  Patients will be 
assigned a case manager to follow their care for the duration of the study.  
The patient may schedule visits with the case manager a minimum of every 2 
weeks and a maximum of weekly for the study duration.  Patients should call 
the study physician and/or study staff if they are having any complications 
related to surgery, programming, or related study activities.  
 
 
Post surgery visit  
Patient will return to Neurosurgeon for a postoperative visit approximately 2 
weeks post implantation for normal follow up patient care including suture 
removal and wound evaluation. 
 
7.5.1  Study Visits: 
Patients will visit the clinic to have their device tested or programmed 
and activated (active group) within approximately 2 weeks, after 
surgery. Patients randomized to the control group will only have device 
diagnostics performed at this visit.  All patients may be seen at any 
time during the study for device device diagnostics.  
Two weeks after system implant – system diagnostics or 
programming and activation: 
 
For the treatment group, parameters of stimulation will be reassessed 
with minor adjustments in amplitude made to optimize clinical effects 
(as measured by the MADRS). Criteria for adjustment will include 
changes in amplitude if there is either an absence or a loss of 
improvement since the last adjustment.  If a patient is stable or shows 
evidence of clinical improvement according to the MADRS the settings 
will be unchanged. If a patient deteriorates following an increase in 
amplitude or after the introduction of stimulation, the settings will be 
changed according to the programming plan below.  Changes in the 
specific contact will only be done if there are no behavioral effects at 
the target contact following adjustments of amplitude.   
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General Guidelines
Contacts: #2, monopolar on each side (in most cases unless post-
operative lead placement shows a different contact to be more 
optimal), will be used in the initial programming session, and amplitude 
will be adjusted in 2.0 mA increments. 
: Device Programming for Active DBS Stimulation 
Group:    
Initial Device Settings: 4.0mA, 130Hz, 91uSec 
Relative Change in MADRS from previous rating will dictate changes 
as follows. 
 
If the MADRS value is better 2 weeks after the initial programming 
session, (better defined as a decrease in MADRS score by ≥ 10% from 
previous evaluation) do not change electrode settings, frequency, or 
pulse width).   
 
If the MADRS value has decreased by less than 10% 2 weeks after the 
initial programming session, Amplitude can be increased by 2.0mA.  
If after 4 weeks at this new amplitude setting, the MADRS value has 
not changed or has not started to decrease, amplitude may be 
increased by 2mA again.   
 
In the event that the MADRS value has increased by >10% (worsened 
state), the amplitude should be decreased by 2.0mA.  If after 2 weeks, 
the MADRS is still unchanged or continues to deteriorate (increased 
MADRS score); a new contact should be selected.   
 
Contact pairs (matched right and left) will be tested consecutively.   A 
change in contacts or addition of contacts will be made if there is either 
no response or worsening using either higher (8.0mA) or lower 
(2.0mA) current as described above.  If a patient experiences clinical 
worsening in the context of no history of response to any setting, a 
careful safety evaluation will occur every 2 weeks. Stimulation will 
continue at the previous best contacts only if the patient and the 
investigator conclude that it is safe for the patient to continue in the 
open stimulation phase of the study.  
  
This visit will include the following: 
• MADRS; 
• Programming form (for active stim. group); 
• Device diagnostics form (for control group); 
• HAM-A; 
• C-SSRS; 
• Office Visit Form. 
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Patient evaluation will take place 4 weeks after system implant. This 
visit will include the following: 
Week 4 – post-implantation visit 
• Office Visit Form; 
• MADRS; 
• SAFTEE; 
• Programming form (by programmer); 
• IDS-C30;  
• QIDS-SR; 
• WSAS; 
• GAF 
• CGI; 
• PGI 
• HAM-A; 
• C-SSRS. 
 
 
Week 6 - post-implantation Visit
Patient evaluation will take place 6 weeks after system implant. This 
visit will include the following: 
: 
• Office Visit Form; 
• MADRS; 
• Programming form (by programmer); 
• QIDS-SR; 
• CGI; 
• PGI; 
• HAM-A; 
• C-SSRS. 
 
 
Week 8 - post-implantation Visit
Patient evaluation will take place 8 weeks after system implant. This 
visit will include the following: 
: 
• Office Visit Form; 
• MADRS; 
• Programming form (by programmer); 
• IDS-C30; 
• QIDS-SR 
• WSAS; 
• GAF; 
• CGI; 
• PGI; 
• HAM-A; 
• C-SSRS. 
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Month 3 - post-implantation Visit
Patient evaluation will take place 12 weeks after system implant. This 
visit will include the following: 
: 
• Office Visit Form; 
• MADRS; 
• Programming form (by programmer); 
• HRSD-17; 
• IDS-C30; 
• QIDS-SR; 
• SAFTEE; 
• YMRS; 
• QOL; 
• WSAS; 
• GAF; 
• CGI; 
• PGI; 
• HLQ; 
• HAM-A; 
• C-SSRS. 
 
 
Months 4 and 5 - post-implantation visit
Patient evaluation will take place at 16 and 20 weeks after system 
implant.  These visits will include the following: 
s: 
• Office Visit Form; 
• MADRS; 
• Programming form (by programmer); 
• IDS-C30; 
• QIDS-SR; 
• WSAS; 
• GAF; 
• CGI; 
• PGI; 
• HAM-A; 
• C-SSRS. 
 
Month 6 - post- implantation visit
Patient evaluation will take place 24 weeks after system implant. This 
visit will include the following: 
: 
• Office Visit Form; 
• MADRS; 
• HRSD-17;  
• IDS-C30; 
• QIDS-SR; 
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• SAFTEE; 
• YMRS; 
• QOL; 
• WSAS; 
• GAF; 
• CGI; 
• PGI; 
• HLQ; 
• HAM-A; 
• C-SSRS. 
• Neuropsychological Battery (Note:  Control Group must have this 
completed prior to device activation); 
• Programming form (by programmer); 
• A hand held device will be given to patients at this visit to allow 
the patient to check their device status (i.e. if the device is “on” or 
“off”) and indicate battery life. 
 
Months 7, 8, 9, 10 and 11 - post- implantation visit
Patient evaluation will take place every four weeks after the 6 month 
visit. This visit will include the following: 
s: 
• Office Visit Form; 
• MADRS; 
• Programming form (by programmer); 
• IDS-C30;  
• QIDS-SR; 
• WSAS; 
• GAF; 
• CGI; 
• PGI; 
• HAM-A; 
• C-SSRS. 
 
 At Month 9 the SAFTEE, YMRS, HLQ and QOL will also be 
administered. 
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Patient evaluation will take place 52 weeks after the system is 
implanted. This visit will include the following: 
Final Evaluation and exit from the Study 
• Office Visit Form; 
• MADRS; 
• Programming form (by programmer); 
• HRSD-17; 
• IDS-C30; 
• QIDS-SR; 
• SAFTEE; 
• YMRS; 
• QOL; 
• WSAS; 
• GAF; 
• CGI; 
• PGI; 
• HLQ; 
• HAM-A; 
• C-SSRS; 
• Neuropsychological Battery; 
• Study Exit form. 
 
7.5.2  Control Group (Non-Active Stimulation): 
  At the end of the 6 month visit, patients will be given the option to have 
 device programmed and activated for DBS.  Patient will then be 
 followed monthly, until the end of the 52 week study.  
7.6 Long-Term Follow-Up 
All patients will be encouraged to enroll in a long-term follow-up study under a 
separate protocol sponsored by ANS to monitor the continued efficacy and 
safety of this system. Efficacy assessments and device related adverse 
events will be collected on all willing participants at specific intervals after they 
exit the currently proposed study.  A separate study protocol and patient 
informed consent will be signed for this long term follow up study. 
 
All study patients may have access to the device at no cost for battery 
replacement and or revision(s) until the device is commercially available in the 
United States.  The patients/physicians must make a request to the study 
sponsor to have the device shipped to the appropriate location.  
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8 Adverse Events (AEs)  
8.1  AE Definitions 
 
An ADVERSE EVENT is “Any change, undesired, noxious or pathological in a 
patient or subject illustrated by signs, symptoms and /or laboratory changes 
that occur during a clinical trial, whether or not considered drug/treatment 
related.” 
 
A SERIOUS/SEVERE AE is where the event is/causes: 
Life threatening or fatal 
Requires or prolongs hospitalization 
The patient to be disabled 
 
A DEVICE RELATED AE is an anticipated (those events listed in section 8.4) 
or unanticipated (those events that occur that are not listed in section 8.4) 
event that occurs that is considered device related.  A device-related event is 
one that the Investigator feels that the device (i.e. IPG, extension or lead) 
contributed in any way to the adverse event occurring.  A stimulation-related 
event is one that resolves when stimulation is turned off or turned down. 
 
A NON SERIOUS AE is an event other than one described above. 
8.2 AE Recording 
All Adverse Events volunteered by the Subjects/Patients or elicited by the 
Investigator must be recorded on the AE forms provided.  All serious/severe 
AEs must be recorded whether or not considered device/treatment related.  
All device related complications that occur during the study duration and/or 
malfunctions of study device should be recorded on the AE forms provided.  
Device complications are defined as those complications relating directly to 
the functioning of the stimulation system (i.e. IPG, extension or lead). 
8.3 Reporting AEs 
Throughout the course of the proposed study, all serious/severe adverse 
events and device related adverse events would be recorded and monitored 
by the Sponsor and the Investigator. Every effort will be made to remain alert 
to possible adverse experiences and unexpected findings. If adverse 
experiences occur, the first concern will be the safety of the subject. 
Appropriate medical intervention will be made.  All completed suicides and 
suicide attempts (defined by the Columbia Suicide Severity Rating Scale 
(CSSRS) > 3) must be reported to the Sponsor immediately (less than 10 
days) upon discovery.  Once the Sponsor is notified of these events, the 
Sponsor will report these events to the FDA within 10 days. 
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Individual reports of device related complications will be documented and 
reported appropriately.  The investigator must report all serious AEs to the 
Sponsor immediately upon discovery by telephone and forward the completed 
AE form as soon as it is available. The Investigator must also promptly report 
the resolution to all reported serious or device related AEs. 
8.4  Anticipated Adverse Events and Complications 
Implantation of a deep brain stimulation lead is a surgical procedure that may 
expose the patient to the risks of post-operative pain, stress, or discomfort, 
intracranial hemorrhage, subcutaneous hemorrhage, intracranial infarctions, 
venous air embolism (air entering the veins), venous infarctions, symptomatic 
neumocephalus (intracranial air causing confusion requiring an extra day stay 
in the hospital), seizure or convulsions, seroma, infection, aphasia, paralysis, 
stroke, death, cerebrospinal fluid leakage or abnormality.  An additional 
neurosurgical procedure may be necessary to manage one of the above 
complications or to replace a fractured lead or to replace the pulse generator 
 
The anticipated adverse events associated with the use of this device may 
include the following: 
  
• Neuropathy;  
• Neuralgia;  
• Headache; 
• Asthenia, hemiplegia or hemiparesis; 
• Cognitive impairment, including confusion, abnormal thinking, 
hallucinations, alteration of mentation, amnesia, delusions, or dementia; 
• Infection; 
• Fever; 
• Disequilibrium; 
• Ataxia;  
• Myoclonus;  
• Hearing and visual disturbance; 
• Paresis;  
• Dystonia; 
• Attention deficit; 
• Dysarthria; 
• Sleep disturbance; 
• Suicide or Suicide attempt; 
• Increase in drug side effects; 
• Autonomic instability (change in vital signs); 
• Urinary incontinence; 
• Worsening depression symptoms (will not be considered an AE); 
• Anxiety; 
• Ruminativeness; 
• Hypomania; 
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• Mania; 
• Panic attacks; 
• Obsessive compulsive disorder (OCD) symptoms; 
• Psychosis; 
• Seizure; 
• Apathy; 
• Eye disorder; 
• Sweating; 
• Diarrhea;  
• Sensory deficit; 
• Drowsiness; 
• Difficulty breathing; 
• Increased salivation; 
• Nausea and/or vomiting; 
• Rapid heart rate; 
• Pneumonia; 
• Skin disorder; 
• Edema including periorbital; 
• Syncope; 
• Persistent pain or redness at the IPG site or the surgery site/extension; 
• Pulling sensation along extension site; 
• Allergic or rejection response to implanted materials; 
• General erosion or local skin erosion over the pulse generator (IPG), burr 
hole cap, and/or extension; 
• Undesirable changes in stimulation possibly related to cellular changes in 
tissue around the electrodes, changes in the electrode position, or loose 
electrical connections and/or lead fracture; 
• Initial jolt or tingling during stimulation; 
• Paresthesia;  
• Loss of therapeutic benefit as a result of change in electrode positions, 
lead fracture, loose electrical connections, DBS system battery failure, 
DBS system malfunction, or inadvertent turning off of device; 
• Lead fracture; 
• Lead migration; 
• System dislodgement; 
• DBS battery failure; 
• DBS system malfunction. 
 
8.5  AE Classification 
Each adverse event will be classified by the Investigator and reported to the 
Sponsor using the Adverse Event Form of the patient’s Case Report Form. 
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9 Data Analysis and Statistical Plan 
9.1  Statistical Plan 
The study design for this investigation is a prospective, double-blind, 
randomized, and controlled study.  The primary objective is to demonstrate 
the safety and efficacy of using subgenual white matter (Brodmann Area 
25WM) deep brain stimulation as an adjunctive treatment for Major 
Depressive Disorder, single or recurrent episode. 
 
9.2 Sample Size 
Data in an uncontrolled pilot study of Deep Brain Stimulation showed that 
greater than 40% of the patients improved with a minimum of a 40% reduction 
in MADRS score following 6 months of deep brain stimulation.  For this study, 
the population response rate among patients treated with deep brain 
stimulation is assumed to be 40%.  If the population response rate in the 
placebo group is assumed to be 18.5% then 159 patients randomized 2:1 
(106 in the deep brain stimulation group and 53 in the placebo group) will 
provide 80% power to reject the primary effectiveness null hypothesis.  
Sample size calculations were performed using the inequality of proportions 
option in PASS 2005 and the Z test pooled.   To allow for a dropout rate as 
high as 20%, the sample size will be increased to 201 patients (134 in the 
deep brain stimulation group and 67 in the placebo group). 
 
9.3 Datasets 
The primary analysis of effectiveness will be intent to treat and will include all 
randomized patients.  Analyses of safety will include all patients who are 
implanted. 
9.4 Primary Effectiveness Analysis 
The primary effectiveness variable is change from baseline (mean of 
Baselines 1, 2, and 3) to the mean of Months 4, 5 and 6 in the MADRS.  
Patients who are missing one or two of the assessments at Months 4, 5 or 6 
will have the available visits used.  The primary endpoint is a clinical response 
defined as a 40% or greater reduction from baseline in the MADRS plus no 
worsening in Global Assessment of Functioning.  Patients missing the 
MADRS for Months 4, 5 and 6 will be considered as non-responders.  The 
primary hypothesis is as follows: 
 
HO: ПDBS = П
vs. 
control 
HA: ПDBS ≠ Пcontrol
 
, 
where ПDBS and Пcontrol are the population response rates in the Deep Brain 
Stimulation and control groups, respectively.  This hypothesis will be tested 
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by a logistic regression that includes the effects of treatment group, study 
site, level of treatment resistance as a continuous variable (as defined by 
ATHF criteria), and baseline MADRS, and will be tested as a two-sided test 
at the 5% level of significance.  Study sites with fewer than three patients in 
either treatment group will be pooled.  
 
A number of exploratory analyses are planned for the primary endpoint and 
are described in a separate Statistical Analysis Plan. 
9.5 Secondary Effectiveness Analyses 
The following secondary endpoints will be compared between the treatment 
and control groups, in the order that they will be tested : 
 
1. Change from baseline to Month 6 in GAF  
2. Change from baseline to Month 6 in Patient and Clinician Global 
Impression of Severity  
3. Change from baseline to Month 6 in Patient and Clinician Global 
Impression of Improvement  
4. A comparison of the  active and control groups at month 6 on the Short 
form Quality of Life Enjoyment and Satisfaction Questionnaire (QOL) 
5. Change from baseline to Month 6 in the Inventory of Depressive 
Symptomatology (IDS-C30) 
6. Change from baseline to Month 6 in the Quick Inventory of Depressive 
Symptomatology (QIDS-SR) 
7. Change from baseline to Months 6 in the Work and Social Adjustment 
Scale (WSAS) 
8. Change from baseline to Month 6 in the Hamilton Rating Scale for 
Depression - 17 item (HRSD-17) 
9. A 50% or greater reduction from baseline in the MADRS plus no 
worsening in Global Assessment of Functioning and no attempted suicide 
at 6 months 
10.The proportion of subjects in the active as compared to the control group 
at the end of month 6 who had a 50% or greater reduction in MADRS 
score from baseline 
11.A 50% or greater reduction from baseline in the HRSD-17 at 6 months 
12.A 40% or greater reduction from baseline in the MADRS at 6 months 
13.A remitter analysis will be performed with remitter defined as HAM-D 
score < 
14.The proportion of subjects in the active as compared to the control group 
at the end of month 6 who are remitters defined as MADRS score <10 
7 at 6 months 
 
 
The first eight secondary endpoints are continuous variables based on 
quantitative scales.  Each of these variables will be analyzed based on the 
multiple imputation procedure and pooling of study sites described under the 
secondary analyses of the primary variable.  An analysis of covariance that 
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includes the effects of treatment group, study site, and the corresponding 
baseline measure will be used to analyze each variable.   
 
The last six secondary endpoints will be analyzed first in the same manner 
as described for the primary endpoint and then after the multiple imputation 
procedure described for the primary endpoint.  
 
The secondary endpoints will be tested in the order they are presented 
above using a step down procedure to maintain an overall error of 5%.  This 
step down procedure will only be performed if the primary endpoint is 
statistically significant and only descriptive information will be provided if the 
primary endpoint is not statistically significant.  If the primary endpoint is 
statistically significant (p<0.05) then the first secondary endpoint will be 
tested at a significance level of 5%.  If that is significant, the second 
secondary endpoint will be tested at a significance level of 5%.  This 
procedure will continue until an endpoint is found to be nonsignificant 
(p>0.05), or all 14 secondary endpoints are found to be significant.   
 
The above imputation procedure described for the primary endpoint will be 
used for all secondary endpoints to create a complete dataset of values over 
the entire course of the study.  A mixed effects repeated measures analysis 
will then be used to estimate the time course of mean changes from 
baseline.  This will be used as supportive information only.. 
9.6  Other Analyses 
The ability of patients to correctly guess their assigned treatment will be 
done by comparing the patients’ perceived treatment with the actual 
treatment and estimating kappa statistics.  An estimated kappa statistic 
>0.60 will be deemed substantial strength of agreement35
 
.  In addition, to 
assess whether the patients’ perceived treatment is related to disease 
improvement, rather than stimulation effects, patients’ perceived treatment 
will be compared with whether or not they reached the primary endpoint and 
kappa statistics will also be estimated.  Other analyses will be performed 
according to the Statistical Analysis Plan. 
9.7  Safety Analyses 
9.7.1  Primary Safety Analysis 
The primary safety analysis will include a descriptive analysis of all adverse 
events during the controlled phase, comparing active stimulation with the 
placebo group.  Adverse events with sufficient incidence will be compared 
between treatment groups by a two-sided Fisher’s Exact Test at the 5% level 
of significance.  In addition, all adverse events among patients treated with 
active stimulation during either the controlled phase or the open label phase 
will be summarized along with their exact two-sided 95% confidence interval. 
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A total of 134 patients receiving active stimulation during the controlled 
phase will provide a 74% chance of observing at least one patient with an 
adverse event rate of 1%.  Moreover, a total of 201 patients exposed to 
active stimulation during either the controlled phase or the open label phase 
will provide an 87% chance of observing at least one patient with an adverse 
event rate of 1%.   
 
9.7.2  Other Analyses of Safety  
An additional safety evaluation will be performed on the Neuropsychological 
battery.  The Neuropsychological battery will be completed at baseline, 
Month 6 and Month 12.  Changes from baseline at Month 6 will be compared 
between treatment groups by an analysis of covariance that includes the 
effects of treatment group, study center, and corresponding baseline value.  
P-values will be reported only as summary statistics and no inference of 
statistical significance will be made from these data.  Changes from baseline 
to Month 12 will be presented as summary statistics for all patients from both 
original treatment groups combined.  Only available data will be used in 
these analyses with no imputation of missing data. 
 
The numbers of patients with Columbia Suicide-Severity Rating Scale (C-
SSRS) scores >3 will be tabulated by treatment group for each study visit 
throughout the blind and open label phases, and for both treatment groups 
combined in the open label phase.  
 
9.8 Stopping Rule for Futility 
The futility analysis will be done when 75 to 100 patients have achieved the 
primary endpoint by either completing their Month-6 visit or have terminated 
from the trial prior to their Month 4 visit.  No more than 125 patients will be 
enrolled into the trial until the results of the futility analysis have been 
completed and reviewed by FDA. 
 
The futility analysis will be performed using the average of the revised 
alternative hypothesis (HA) and the observed interim results.  With the 
current sample size of 201 patients, the alternative hypothesis becomes a 
40% response rate for patients on stimulation and a 20.7% response rate 
among patients in the control group because these population proportions 
provide 80% power to reject the primary hypothesis.  The futility analysis will 
be performed under the assumption that the remaining patients will be drawn 
from populations with response rates that are the average of HA and the 
interim results.  Based on these revised population proportions, 5000 sets of 
simulation results among the remaining approximately 84 stimulation 
patients and 42 control group patients will be run.  Each set of simulated 
results will be added to the observed results and a two- sided Fisher’ Exact 
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p-value will be calculated.  The probability of a successful outcome of the 
study is then the proportion of these p-values that are <0.05.  If the 
probability of a successful study outcome is <10% the study will be stopped 
for futility.   
 
10 Withdrawal of Subjects from Study 
Subjects may be discontinued from the study for non treatment-related reasons 
only when no other option is possible. Reasons for discontinuation include, but are 
not necessarily limited to: 
• Voluntary withdrawal from the study by the subject; 
• Subject has moved from the area and is determined to be lost-to-follow-up; 
• Investigator may discontinue the Subject’s participation in the study for reasons 
including, but not limited to: subject noncompliance, unwillingness or inability to 
cooperate with study requirements (therapy regimen, follow-up visits, study 
determination, etc...). 
 
The reason for discontinuation will be recorded on the appropriate case report 
form.  
Prior to discontinuing a subject, every effort should be made to contact the subject 
in an effort either to get the subject back into compliance with the protocol, or to 
obtain as much follow-up data as possible.  If a subject decides to discontinue from 
the study, the subject shall have the option of having the system surgically 
removed followed by normal psychiatric care.  Once the patient exits the study, the 
device will be turned off (no matter what the randomized treatment was assigned).  
The device can only be reactivated by the study psychiatrist after the patient enters 
a separate open-label protocol for long-term follow-up.  The patient must sign a 
separate informed consent and must satisfy the inclusion criteria of the long-term 
follow up study prior to being enrolled.  The study psychiatrist must also deem the 
subject fit to begin or continue with stimulation.  
11 Data Safety Monitoring Board 
A Data Safety Monitoring Board (DSMB) will be appointed to review all SAE data 
and ensure the appropriate follow up actions necessary.  Keeping in mind the 
safety of patients the status of the study will be evaluated based on a risk to benefit 
ratio.  The Board will create a guidance document prior to the first patient being 
implanted.  This guidance document will indicate the frequency of DSMB meeting, 
stopping rules and other pertinent information to guide study review. 
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12 Modification of Protocol 
Any amendments to this protocol must be prepared by the study monitor and 
approved by ANS, the Investigator and the local authority (FDA/IRB/IEC) before 
implementation. 
13 Discontinuation of Study 
ANS reserves the right to discontinue any study for administrative reasons at any 
time, such as but not limited to, a decision to discontinue further clinical 
investigations with the test article, improper conduct of the study by the 
Investigator, inability to obtain the number of patients required by the protocol, etc.  
Reimbursements for reasonable expenses will be made if such action is 
necessary. 
This study may be terminated by the DSMB if an unacceptable number of 
intracranial hemorrhages or an unacceptable number of completed suicides or 
suicide attempts is reached without an appropriate explanation.  Guidance 
regarding event evaluation is provided in the DSMB Plan 
 
Study enrollment will be suspended if the following criterion is met until the Data 
Safety Monitoring Board and FDA can review the safety and effectiveness data to 
determine whether the study should be halted, modified, or continued. 
 
• If the lower bound of the two-sided 95% confidence interval (based on the normal 
approximation) for the rate of completed suicides in the combined patient 
population exceeds 2% at any point during the study. 
 
This study may be terminated if the number of the following events is reached 
without an appropriate explanation by the 6 month primary endpoint: 
 
• If greater than 24 patients experience an intracranial hemorrhage. This would 
assume that during the study at the specified interval the rate of intracranial 
hemorrhage would exceed 12% then the study would be terminated. 
 
 
14 Administrative Requirements and Quality Assurance 
 
14.1 Institutional Review Board (IRB)/Independent Ethics Committee (IEC) 
 
Before the study can begin the Investigator must provide the Sponsor with a 
copy of the approval notice for the protocol and informed consent forms,   
signed by the appropriate committee chairperson. 
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14.2 Clinical Supplies 
 
The Investigator agrees to keep all test articles in a secure location with 
restricted access.  The Investigator will maintain an inventory of test article 
receipt and distribution.  The Sponsor will provide an itemized inventory of all 
supplies dispatched.  The Investigator or appropriate designee will provide 
written confirmation of receipt.  Investigational devices and device 
accessories required for maintenance of the implanted devices will be made 
available to all patients enrolled in this study, at the request of the study 
Investigator, during the period the patient has completed study participation 
and prior to PMA approval.   
 
14.3 Reporting and Recording of Data 
 
All study data will be recorded on electronic Case Record Forms (eCRF).  
Electronic data capture (EDC) will also be utilized to monitor, correct, and 
store the collected data. 
 
14.4 Monitoring 
 
The Investigator will permit the Study Monitor to visit the Investigational Site 
at regular intervals to review all the CRFs, study related adjunctive data, and 
study management.  These reviews are for the purpose of verifying the 
adherence to the protocol and the completeness and exactness of the data 
being entered as required by Federal Regulations.  The Study Monitor must 
be kept informed of all issues pertinent to the study.  The Study Monitor will 
be available to discuss by telephone questions regarding adverse events, 
removal of patients/subjects from the study, conduct of the study or any other 
questions that should arise.  At the final monitoring visit the Study Monitor 
must resolve any outstanding data deficiencies and retrieve all used and 
unused test articles. 
 
14.5 On-site Audits 
 
The various National Regulatory Authorities (including the United States Food 
and Drug Administration) in the person of a scientifically trained and properly 
authorized employee of the department, may request access to all study 
records, including source documents, for inspection and copying.  Similar 
auditing procedures may also be conducted by a representative of the 
Sponsor. 
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14.6 Record Storage and Retention 
 
Federal law and GCP requires that a copy of all study records (e.g., Informed 
Consent documents, source documents, study records, etc.) which support 
CRFs of this study, must be retained in the files of the responsible 
Investigator for a minimum of two years following notification by ANS that all 
Investigations (not merely the Investigators portion) are completed, 
terminated, or discontinued, or that the Food and Drug Administration has 
approved the submission.   
If the Principal Investigator retires, relocates, or for other reasons withdraws 
from the responsibility of keeping the study records, custody must be 
transferred to a person who will accept responsibility.  ANS must be notified in 
writing of the name and address of the new custodian. 
 
14.7 Clinical Monitors 
 
DeLea Peichel 
Director, Clinical Research 
Advanced Neuromodulation Systems, Inc. 
6901 Preston Rd. 
Plano, Texas 75024  
Telephone:  (972) 309-8094  
Fax: (972) 309-8244 
 
Traci Brooks 
Clinical Project Manager 
Advanced Neuromodulation Systems, Inc. 
6901 Preston Road 
Plano, Texas 75024 
Telephone:  (972) 309-8505 
Fax: (972) 309-8655 
 
Tiffany Ream 
Clinical Monitor 
Advanced Neuromodulation Systems, Inc. 
6901 Preston Road 
Plano, Texas 75024 
Telephone:  (972) 309-8091 
Fax: (972) 309-8241 
 
Janet Hargett 
Clinical Research Associate I 
Advanced Neuromodulation Systems, Inc. 
6901 Preston Road 
Plano, Texas 75024 
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Telephone:  (972) 309-2131 
Fax: (972) 309-2231 
 
Kathy Stamback 
Clinical Research Associate III 
Advanced Neuromodulation Systems, Inc. 
6901 Preston Road 
Plano, Texas 75024 
Telephone:  (972) 309-8557 
Fax: (972) 309-8707 
 
Charlotte Forister, CCRA 
Clinical Research Associate III 
Advanced Neuromodulation Systems, Inc. 
6901 Preston Road 
Plano, Texas 75024 
Telephone:  (972) 526-8285 
Fax: (972) 526-8385 
 
Elvira Espinoza, CCRA 
Clinical Research Associate III 
Advanced Neuromodulation Systems, Inc. 
6901 Preston Road 
Plano, Texas 75024 
Telephone:  (972) 309-2197 
Fax: (972) 309-2297 
 
Jala Zinck, CCRA 
Clinical Research Associate II 
Advanced Neuromodulation Systems, Inc. 
6901 Preston Road 
Plano, Texas 75024 
Telephone:  (972) 309-8597 
Fax: (972) 309-8747 
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16.1  Appendix A: Product Labeling 
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D e e p  B r a i n
S t i m u l a t i o n  S y s t e m
MAJOR DEPRESSIVE 
DISORDER STUDY
CAUTION: Investigational device limited by federal 
(United States) law to investigational use.
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SYMBOLS AND DEFINITIONS
The following symbols are used in this documents and on some of the products and packaging:
 Denotes that the user should pay special attention to avoid serious consequences. This document presents 
the symbol, the word WARNING or CAUTION, and a brief explanation of the seriousness of the 
situation.
 A warning alerts the user to a situation which, if not avoided, could result in (1) death or serious injury, 
(2) serious or adverse reactions, or (3) safety hazards.
 A caution alerts the user to a situation which, if not avoided, may result in (1) minor or moderate injury 
or (2) damage to the equipment or other property.
 This symbol advises the reader to consult this document for important safety-related information.
 Denotes device contains a type BF applied part to protect you from shock. The device is internally powered 
and is intended for continuous operation.
 Denotes single use only
 Denotes expiration date
 Denotes date of manufacture
 Denotes temperature limits for storage conditions
 Denotes humidity limits
 Denotes pressure limits
 Denotes ethylene oxide gas sterilization
 Denotes do not use if the product sterilization barrier or its packaging is compromised
 Denotes catalog number
 Denotes manufacturer
 Denotes content, the number of items contained in the package
PN  Denotes code that uniquely identifi es an inventory item
SN  Denotes serial number
 Denotes batch code
Rx only  Denotes for prescription use only
 Indicates that the Libra Deep Brain Stimulation System is listed by the Canadian Standards 
Association (CSA) International as certiﬁ ed.223857
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ABOUT THIS MANUAL
This manual provides information about the Advanced Neuromodulation Systems, Inc.™ (ANS™) Libra™ Clinician 
Programmer (model 6850), and Libra (model 6608) and LibraXPTM (model 6644) implantable pulse generators. For 
information about other components of the Libra Deep Brain Stimulation (DBS) System, see the manuals packaged 
with those products.
BRIEF  SYSTEM DESCRIPTION
The ANS Libra DBS System consists of an implantable 8-channel Libra or dual  4-channel LibraXP 
neurostimulator, known as an implantable pulse generator (IPG). The IPG is used in conjunction with leads and 
extensions of various lengths and is programmed by an external programmer. This system is designed to deliver 
electrical stimulation, in various combinations of amplitude, pulse width, and frequency, to specific targets in the 
brain. The IPG, lead, and extension comprise the implantable components of the Libra DBS System. The Libra 
Clinician Programmer and QuikLink™ Controller support the operation of 
the IPG.
INVESTIGATIONAL INDICATIONS
The ANS Libra DBS system is intended for clinical investigation purposes only. The system is being investigated 
for the management of patients with Major Depressive Disorder, single or recurrent episode, with deep brain 
stimulation.
CONTRAINDICATIONS
Implantation of an ANS Libra DBS System is contraindicated for use by patients who are unable to operate the 
system. It is also contraindicated for use with
●
 Pacemakers—Patients with demand-type cardiac pacemakers should not be implanted with a DBS system.
●
 Magnetic Resonance Imaging (MRI)—Do not use a full body radio-frequency (RF) coil or other extremity 
coils on patients implanted with a deep brain stimulation system. Because energy from MRI can be transferred 
through the implanted system, the potential for heat generation at the location of the electrodes exists. This 
isolated temperature rise may cause tissue damage at the location of the implanted electrodes, possibly 
resulting in severe injury or death. Injury can occur during MRI treatment whether the deep brain stimulation 
system is turned on or off. All patients are advised to inform their health care professional that they should not 
be exposed to MRI. In the instance that MRI must be performed, precisely follow the guidelines provided in 
Appendix E.
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 WARNINGS
Other System Components—Refer to the individual system component manuals for additional warnings and 
precautions related to those devices.
Diathermy—Do not use short-wave diathermy, microwave diathermy, or therapeutic ultrasound diathermy (all 
now referred to as diathermy) on patients implanted with a deep brain stimulation system. Energy from diathermy 
can be transferred through the implanted system and can cause tissue damage at the location of the implanted 
electrodes, resulting in severe injury or death. Diathermy is further prohibited because it may also damage the deep 
brain stimulation system components. This damage could result in loss of therapy, requiring additional surgery for 
system replacement. Injury or damage can occur during diathermy treatment whether the deep brain stimulation 
system is turned on or off.  
Poor Surgical Risks—Deep brain stimulation systems should not be implanted in patients who are poor surgical 
risks or patients with multiple illnesses or active general infections.
Implanted Defibrillators—Deep brain stimulation systems may adversely affect the programming and operation 
of implanted cardioverter defibrillators.
Explosive or Flammable Gases—Do not use programming devices in an environment where explosive or 
flammable gas vapors are present. The operation of programming devices could cause these vapors to ignite, 
resulting in severe burns, injury, or death.
Theft Detectors and Metal Screening Devices—Certain types of antitheft devices, such as those used at entrances 
and exits of department stores, libraries, and other public establishments, and/or airport security screening devices 
may affect stimulation. It is recommended that patients use caution when approaching such a device and request 
assistance to bypass the device. If they must proceed through the device, patients should move through the device 
quickly and check the stimulator after passing through to verify if it is turned on or off.
Operation of Machinery and Equipment—Patients should not operate potentially dangerous machinery, power 
tools, or vehicles or engage in any activity that would be potentially unsafe if their symptoms were to return 
unexpectedly. 
Device Components—The use of non-ANS components with this system may result in damage to the system and 
increased risk to the patient.
Case Damage—If the IPG case is pierced or ruptured, severe burns could result from exposure to the battery 
chemicals.
Anticoagulants—Physicians should use extreme care with lead implantation in patients with a heightened risk of 
intracranial hemorrhage. Physicians should also consider underlying factors, such as previous neurological injury 
or prescribed medications (anticoagulants), that may predispose a patient to the risk of bleeding.
High Charge Density—A potential risk of tissue damage exists with stimulation parameter settings of high 
amplitudes and wide pulse widths. Higher amplitude and pulse width settings required to achieve therapy may 
indicate a system problem or less than optimal lead placement.
If the stimulation parameters exceed the charge density limit of 30 µC/cm2, a warning will appear on the 
Clinician’s Programmer. Parameter values exceeding the charge density limit should only be programmed with 
due consideration of the warnings concerning charge densities. Charge density can be reduced by lowering the 
stimulation amplitude or pulse width. 
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PRECAUTIONS
GENERAL PRECAUTIONS
Surgeon Training—Implanting physicians should be experienced in stereotactic and functional neurosurgery. 
Physician Training—Clinicians should undergo device programming training and be experienced in the diagnosis 
and treatment of  the indication for which the DBS components are being used.
Patient Selection—It is extremely important to select patients appropriately for deep brain stimulation. 
Infection—It is important to follow proper infection control procedures. Infections related to system implantation 
might require that the device be explanted.
Implantation of Two IPGs—If two IPGs are implanted, ensure that at least 8 inches (20 cm) separates the 
implanted IPGs to minimize the possibility of interference during programming. Verify programmed parameters in 
both devices at the end of each programming session.
High Stimulation Outputs—Stimulation at high outputs may cause unpleasant sensations or motor disturbances or 
may render the patient incapable of controlling the stimulator. If unpleasant sensations occur, the device should be 
turned off immediately.
HANDLING, IMPLANTATION, STERILIZATION, STORAGE, AND EXPLANTATION
Single-Use Device—The implanted components of the Libra DBS System are intended for a single use only. Do 
not resterilize or reimplant an explanted component for any reason.
Expiration Date—Do not implant a system component if the use-before date has expired.
Care and Handling of Components—Use extreme care when handling system components prior to implantation. 
Excessive heat, excessive traction, excessive bending, excessive twisting, or the use of sharp instruments may 
damage and cause failure of the components.
Package and Component Damage—Do not implant a device if the sterile package or its components shows signs 
of damage, if the sterile seal is ruptured, or if contamination is suspected for any reason. Return the components to 
ANS for evaluation.
Exposure to Body Fluids or Saline—If the metal contacts on the proximal end of the lead or extension are 
exposed to body fluids or saline prior to connection, corrosion can occur. If exposure occurs, clean the metal 
contacts with sterile deionized water or sterile water (not saline) and dry completely prior to lead connection and 
implantation.
System Testing—The system should always be tested after implantation and before the patient leaves the surgery 
suite to ensure correct operation.
Component Disposal—Return all explanted components to ANS for safe disposal.
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HOSPITAL AND MEDICAL ENVIRONMENTS
High Output Ultrasonics and Lithotripsy—The use of high output ultrasonic devices, such as an electrohydraulic 
lithotriptor, may cause damage to the electronic circuitry of an IPG. If lithotripsy must be used, do not focus the 
energy near the IPG.
Ultrasonic Scanning Equipment—The use of ultrasonic scanning equipment may cause mechanical damage to an 
implanted deep brain stimulation system if used directly over the implanted device.
External Defibrillators—The safety of discharging an external defibrillator on patients with implanted deep brain 
stimulation system components has not been established.
Therapeutic Radiation—Therapeutic radiation may damage the electronic circuitry of an implanted deep brain 
stimulation system, although no testing has been done and no definite information on radiation effects is available. 
Sources of therapeutic radiation include therapeutic x-rays, cobalt machines, and linear accelerators. If radiation 
therapy is required, the area over the IPG should be shielded with lead.
Electrosurgery Devices—Electrosurgery devices should not be used in close proximity to an implanted deep brain 
stimulation system. Contact between an active electrode and an IPG, lead, or extension can cause direct stimulation 
of the tissue at the electrode site and cause severe injury to the patient. If the use of electrocautery is necessary, 
turn the IPG off.
Psychotherapeutic Procedures—The safety of electromagnetic psychotherapeutic procedures (such as 
electroshock therapy and transcranial magnetic stimulation) in patients implanted with DBS system components has 
not been established.
HOME AND OCCUPATIONAL ENVIRONMENTS
Electromagnetic Interference (EMI)—Certain commercial electrical equipment (e.g., arc welders, induction 
furnaces, and resistance welders), communication equipment (e.g., microwave transmitters, linear power amplifiers, 
and high power amateur transmitters), and high voltage power lines may generate sufficient EMI to interfere with 
the deep brain stimulation system operation if approached too closely.
Household Appliances—Household appliances that contain magnets (e.g., refrigerators, freezers, stereo speakers, 
mobile telephones, cordless telephones, standard wired telephones, AM/FM radios, and some power tools) may 
unintentionally cause the deep brain stimulation system to turn on or turn off.
Patient Activities/Environmental Precautions—Patients should take reasonable care to avoid devices that 
generate strong electromagnetic interference (EMI), which may cause the deep brain stimulation system to 
unintentionally turn on or off. Patients should also avoid any activities that would be potentially unsafe if their 
symptoms were to return unexpectedly.
Therapeutic Magnets—Patients should be advised to not use therapeutic magnets. Therapeutic magnets (e.g., 
magnets used in pillows, mattress pads, back belts, knee braces, wrist bands, and insoles) may unintentionally cause 
the deep brain stimulation system to turn on or off.
Mobile Phones—The effect of mobile phones on DBS systems is unknown; patients should avoid placing cellular 
phones directly over the device.
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ANTICIPATED ADVERSE EVENTS AND COMPLICATIONS
The implantation of a deep brain stimulation system involves risk. In addition to those risks commonly associated 
with surgery, implantation of a DBS system may expose the patient to the risks of post-operative pain, stress, 
or discomfort, intracranial hemorrhage, subcutaneous hemorrhage, intracranial infractions, symptomatic 
neumocephalus (intracranial air causing confusion requiring an extra day stay in the hospital), seizure or 
convulsions, seroma, infection, aphasia, paralysis, stroke, death, cerebrospinal fluid leakage or abnormality. An 
additional neurosurgical procedure may be necessary to manage one of the above complications.
DBS Complications—may occur leading in some cases to surgical revision or explantation of the system. DBS 
complications include, but are not limited to the following:
• Neuropathy; 
• Neuralgia; 
• Headache;
• Asthenia, hemiplegia or hemiparesis;
• Cognitive impairment, including confusion, 
abnormal thinking, hallucinations, alteration of 
mentation, amnesia, delusions, or dementia;
• Cerebrospinal fluid abnormality;
• Disequilibrium;
• Ataxia; 
• Myoclonus; 
• Hearing and visual disturbance;
• Paresis; 
• Dystonia;
• Attention deficit;
• Dysarthria;
• Sleep disturbance;
• Suicide or Suicide attempt;
• Increase in drug side effects;
• Autonomic instability (change in vital signs);
• Urinary incontinence;
• Worsening depression symptoms;
• Anxiety;
• Ruminativeness;
• Hypomania;
• Mania;
• Panic attacks;
• Obsessive compulsive disorder (OCD) symptoms;
• Psychosis;
• Seizure;
• Apathy;
• Eye disorder;
• Sweating;
• Diarrhea; 
• Sensory deficit;
• Drowsiness;
• Difficulty breathing;
• Increased salivation;
• Nausea and/or vomiting;
• Rapid heart rate;
• Pneumonia;
• Skin disorder;
• Edema including periorbital;
• Syncope;
• Persistent pain or redness at the IPG site or the 
surgery site/extension;
• Pulling sensation along extension site;
• Allergic or rejection response to implanted 
materials;
• General erosion or local skin erosion over the 
pulse generator (IPG), burr hole cap, and/or 
extension;
• Undesirable changes in stimulation possibly 
related to cellular changes in tissue around the 
electrodes, changes in the electrode position, or 
loose electrical connections and/or lead fracture;
• Initial jolt or tingling during stimulation;
• Paresthesia; 
• Loss of therapeutic benefit as a result of change in 
electrode positions, lead fracture, loose electrical 
connections, DBS system battery failure, DBS 
system malfunction, or inadvertent turning off of 
device;
• Lead fracture;
• Lead migration;
• System dislodgement;
• DBS battery failure;
• DBS system malfunction.
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SYSTEM DESCRIPTION
A Libra DBS System consists of four primary components: IPG (neurostimulator), lead(s), extension(s), and 
programmer.
IPG
The Libra IPG is designed to be connected to one DBS extension. The LibraXP IPG is designed to be connected 
to two DBS extensions. The IPGs are powered by a hermetically sealed battery within a titanium case and use 
microelectronic circuitry to generate constant current electrical stimulation.
The IPG is insulated on all sides except the side with the markings. This allows the IPG case to be used as an 
anode for monopolar stimulation. Ensure that the marked side is implanted facing up and away from muscle.
The Libra IPG contains a radiopaque identification tag. The identification tag is visible inside the IPG header block 
using standard x-ray procedures. The tag contains a code: “ANS” identifies ANS as the manufacturer; “P” or “R” 
identifies the device as a Libra IPG Model 6608 or LibraXP Model 6644; and the two numbers following the “P” 
denote the year of manufacture (see Figure 1).
For year 2006, the code is P06.
P = Model 6608
R = Model 6644
FIGURE 1
LEADS AND EXTENSIONS
ANS DBS leads consist of electrodes on the distal end, connected by individually insulated wires to contact bands 
on the proximal end. The proximal end has a nonoperational metal band (the most distal band) that serves as an 
insertion handle. The insulated wires are covered by a biocompatible polymer. ANS DBS leads are designed for 
introduction into the brain using standard stereotactic neurosurgery techniques. 
The DBS extension is designed to connect the lead to the IPG. One end of the extension is designed to receive the 
proximal end of the lead, and the opposite end of the extension is designed for insertion and connection with the IPG.
Consult the Lead and Extension manual for more information and directions for use of these devices.
PROGRAMMER
The Libra Clinician Programmer controls the creation and adjustment of all programming parameters. The 
programmer uses radio-frequency signals to communicate with the IPG.
STERILIZATION INFORMATION
Sterile components in this kit have been sterilized using ethylene oxide (EtO) gas before shipment and are supplied 
in sterile packaging to permit direct introduction into the operative field. An expiration date (or ‘use-before date’) is 
marked on the label of each package.
 CAUTION:  ANS implantable components are intended for single use only. Do not resterilize.
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SUGGESTED IMPLANT GUIDELINES
The implanting surgeon should carefully review the following suggested guidelines for implantation of a Libra system.
CONNECTING THE EXTENSION TO THE IPG
 1. If needed, clean the proximal end of the extension with sterile, deionized or distilled water and dry it 
completely. Use clean gloves and ensure that all body fluids and saline residue are cleaned from the proximal 
end of the extension. This is important to prevent future corrosion and potential failure of the system.
 CAUTION: Exposure of the internal IPG contacts to body fluid or saline can affect stimulation. If this 
occurs, clean the contacts with sterile, deionized or distilled water (not saline) and dry completely prior to 
extension connection and subsequent implantation.
 2. Slide a connector strain relief on to the proximal end of the extension, being careful not to sharply bend the 
extension (see Figure 2).
FIGURE 2
 3. Carefully slide the proximal end of the extension into the IPG header until it stops (see Figure 3).
Window is clear Insertion handle flush
    
Partially blocked window
Insertion handle 
protruding 1 mm  or 
more beyond header
 Correct Insertion Incorrect Insertion 
FIGURE 3
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 4. Use the torque wrench to tighten the setscrew clockwise until the torque wrench clicks (see Figure 4).
NOTE: After the torque wrench is removed, check the septum to ensure it has closed. If the septum is not 
closed, gently reseat the septum flaps.
 CAUTION: Use only the torque wrench included in the extension kit, IPG kit, or torque wrench kit (Model 
1101). If you need to loosen the setscrew, turn the setscrew (in quarter turns counterclockwise) only as far as 
necessary to remove the extension from the IPG header. Retracting the setscrew too far could cause damage 
to the septum.
Tighten
clockwise
FIGURE 4
 5. Slide the connector strain relief into position over the O-ring at the proximal end of the IPG (see Figure 5). 
Tie a 2-0 nonabsorbable suture around the connector strain relief.
LibraSN 123456
Suture
Connector
strain
relief
FIGURE 5
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IPG PLACEMENT
 1. Carefully place the IPG in a subcutaneous pocket, at a depth not to exceed 4 cm (1.5 inches), with the logo 
side facing toward the skin surface.
NOTE: The logo side of the IPG is uninsulated to enable monopolar stimulation. Implanting the IPG 
backwards may increase undesired muscle stimulation.
 2. Carefully coil any excess extension in loops no smaller than 2.5 cm (1 inch) in diameter and place them 
behind the IPG (see Figure 6). The loop(s) are intended to provide strain relief for the lead, extension, and 
IPG connections.
SN
 12
34
56
Li
br
a
FIGURE 6
 3. To stabilize the IPG within the pocket and prevent movement, pass a suture through the hole at the top of the 
IPG header and secure it to the connective tissue.
 4. Before closing, verify that the system is operational by placing the wand from the Libra Clinician Programmer 
(6850) in a sterile bag and positioning the wand over the IPG site. 
NOTE: If a communication error occurs during programming, reposition the wand farther away from the 
IPG.
 5. Close the IPG pocket incision. The IPG in the pocket should be positioned away from the pocket incision 
suture line (see Figure 7).
S/N 123456
Libra
FIGURE 7
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 6. Complete the patient registration information and identification card, and give the identification card to the 
patient.
IPG REPLACEMENT
 1. After ensuring that the IPG is turned off, open the IPG pocket per normal surgical procedure, and carefully 
remove the IPG from the pocket.
 CAUTION: Exercise extreme caution when using sharp instruments and electrocautery around the 
extension.
 2. Carefully remove the suture from the strain relief, being careful to not damage the extension (see Figure 5).
 3. Insert an ANS torque wrench into the IPG header septum and loosen the setscrew by turning it 
counterclockwise in quarter turns.
 4. Gently retract the extension from the IPG header. Clean and dry all contacts on the extension, ensuring they 
are free of fluid and tissue.
NOTE: If an extension needs to be replaced, do the following:
1.  Make an incision above the extension connector assembly and disconnect the extension 
from the lead.
2.  Sever the distal end of the extension just proximal to the extension connector assembly.
3.  Carefully pull the extension out through the IPG pocket.
 5. Place a new strain relief over the extension. 
 6. Insert the extension into the new IPG.
 7. Tighten the setscrew clockwise until the torque wrench clicks.
 8. Remove the torque wrench and ensure the septum is closed.
 9. Slide the connector strain relief into position over the O-ring at the proximal end of the IPG. Tie a 2/0 non-
absorbable suture over the strain relief. 
 10. Place the new IPG into the pocket, at a depth not to exceed 4 cm (1.5 inches) with the logo side facing 
outward away from the muscle layer.
 11. Carefully coil any excess extension in loops no smaller than 2.5 cm (1 inch) in diameter and place them 
behind the IPG. 
 12. To stabilize the IPG within the pocket and minimize movement, pass a suture through the hole at the top of 
the IPG header and secure it to the connective tissue.
 13. Before closing, verify that the system is operational by placing the wand from the Libra Clinician Programmer 
(6850) in a sterile bag and positioning the wand over the IPG site. 
 14. Close the IPG pocket incision.
 15. Complete the patient registration and identification card, and give the identification card to the patient. 
 16. Return any explanted components to ANS. Refer to “Explanted Component Disposal” for more information.
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EXPLANTED COMPONENT DISPOSAL
Explanted products should be returned to ANS for proper disposal. Returned product must be decontaminated and 
placed in a container with a biohazard label. Please include an explanation on the “Returned Product Information 
Report” that is packaged with the IPG. Contact ANS Customer Service to obtain suitable containers and biohazard 
labels.
Return explanted products to
Advanced Neuromodulation Systems, Inc.
6901 Preston Road
Plano, TX 75024
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CLINICIAN PROGRAMMER
OVERVIEW
The Libra Clinician Programmer (Model 6850) is an external device that is used to program the stimulation 
parameters of Libra neurostimulators via radio frequency telemetry. The major parts of the Clinician Programmer 
are shown in the following illustration.
The general flow of the programmer operation is as follows:
●
 the programmer provides a series of choices arranged in a loop. There are two types of choices: parameters 
(which have a value that can be adjusted) and actions (which cause an action to occur).
●
  and  buttons are used to move forward and backward between the choices.
●
 the  and  buttons are used to change the value of the highlighted choice.
●
 the  button is used to initiate or select the highlighted choice.
●
 the  and  buttons are used only for very infrequent, special actions.
Display
Decrease Button Increase Button
On/Off
Button
Balance
Button
Back 
Button
Scroll 
Buttons
Select
Button
Battery
Pack
Battery Release 
Latch
Wand
Receptacle
Wand
Connector
FIGURE 8
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DEMO MODE
A demo mode is available in the clinician programmer. Demo mode is intended as a training tool to practice 
using the programmer prior to using it during an actual programming session. All of the major functions of the 
programmer are simulated in demo mode.
NOTE: Demo mode simulates programming a LibraXP (6644).
To enter demo mode
 1. Place the programmer wand at least 8 inches away from all neurostimulators.
 2. Press the red  button to turn the programmer on.
 3. Press the green  button when the following screen appears.
 
 4. The Home screen (shown below) will appear when you have entered demo mode.  Follow the directions in 
The Home Screen section of this manual to enter programming mode, and the directions in the Programming 
Mode section to practice programming.
 
To exit demo mode
 1. Return to the Home screen by
  
●
 using the scroll  buttons to highlight EXIT then pressing the green  button.
  
●
 then highlighting SAVE AND EXIT and pressing the green  button.
 2. From the Home screen, press the red  button to turn the programmer off.
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BASIC OPERATION
This section provides an overview of the most commonly used features of the programmer. For more details, see 
the Programming Mode and Amplitude Adjustment Mode sections of this manual.
Turning Stimulation Off
To turn stimulation off
 1. Press the red  button to turn the programmer on.
 2. Place the wand over the neurostimulator.
 3. Wait for the Home screen to appear.
 4. Use the scroll  button to highlight STOP in the lower right corner.
 5. Press the green  button. The stimulation output indicator will change from ~ON~ to ~OFF.
Turning Stimulation On
To turn stimulation on
 1. Press the red  button to turn the programmer on.
 2. Place the wand over the neurostimulator.
 3. Wait for the Home screen to appear.
 4. Use the scroll  button to highlight START in the lower right corner.
NOTE: The START option will not appear if the programmer detects a problem with the stimulation 
program. Instead, the programmer will only give the MENU option, so that the problem can be fixed by 
reprogramming the neurostimulator.
 5. Press the green  button. The stimulation output indicator will change from ~OFF to ~ON~, and the 
RAMP symbol will flash as stimulation increases from zero to the programmed amplitude.
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Typical Programming Session
This section provides an overview of the steps for a basic programming session in which the neurostimulator 
parameters will be adjusted. See the Programming Mode section of this manual for more information about the full 
functionality of the system.
To: Do the following:
1. Turn the programmer on
Press the red  button.
2. Establish telemetry with the 
neurostimulator
Place the wand over the neurostimulator.
3. Check the neurostimulator 
battery status an d stimulation 
parameters
Read the information on the Home screen. See the Home screen section of 
this manual to interpret the information on the screen.
4. Start a programming session Use the scroll buttons to highlight “MENU” in the lower right corner, then 
press the green  button. 
With the “P” highlighted, press the gree n  button. A message will 
appear, and stimulation will turn off.
5. Turn stimulation back on There are two ways to turn stimulation back on:
Choice 1:  Highlight JUMPTO and press the green  button. 
Stimulation will immediately turn on at the amplitude it was at prior to 
starting the programming session.
Choice 2:  Highlight AMP and press the  button. Stimulation will 
increase from zero in increments of STEP. In this way, stimulation can be 
turned on gradually.
6. Change parameters
Use the scroll  buttons to move between choices and highlight the 
desired parameter. The choices span several screens. If you continue to scroll 
in the same direction you will eventually move through all screens.
When the desired parameter is highlighted, use the  /  buttons to 
change the value of the parameter.
7. Initiate actions
Use the scroll  buttons to highlight the desired action.
Press the green  button to initiate the action.
8. End the programming 
session
Highlight EXIT, then press the green  button. 
Press the green  button again when “SAVE AND EXIT’ is 
highlighted.
Stimulation will then be ramped on and the Home screen will be displayed.
9. Turn the programmer off
Press the red  button.
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THE HOME SCREEN
When the Clinician Programmer is off and the red  button is pressed, a series of self-tests are started. These 
tests take approximately 5 seconds and are designed to ensure that the programmer is functioning properly. 
Next, the programmer attempts to establish communication with the neurostimulator. If it is able to establish 
communication, it will display the Home screen.
The Home screen (shown below) is displayed whenever the Programmer is turned on and successfully establishes 
communication with the neurostimulator. This screen provides a summary of the stimulation parameters, 
stimulation on/off status, and neurostimulator battery status.
Home option window
Stimulation output status
Neurostimulator 
battery status
Frequency
Pulse width
Amplitude
Can polarity
Charge density 
warning
Cycle mode 
indicator
Polarities 1-4
Libra
Stimulation Output Status Option Window
Polarities 5–8
Lead 1
Pulse width Lead 1 
Amplitude
Lead 2 
Amplitude
Polarities 1–4
Lead 2
Pulse width
LibraXP
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Use the scroll  buttons to change the function displayed in the option window in the lower right corner, then 
use the green  button to select that action. The option window choices are shown below. The programmer 
hides (does not offer) choices that are incompatible with the current stimulation program and neurostimulator 
status. The choices are arranged in a loop, so that, continuing to scroll in the same direction will ultimately bring 
you back around to the first choice.
  Turns stimulation on
  Turns stimulation off
  Enters amplitude adjustment mode
  Provides access to programming mode and programmer preferences
When MENU is selected the following screen will be displayed. Use the scroll  buttons to move the selector 
arrow until it is positioned under the desired action, then press the green  button.
Volume Brightness Contrast
Programmer and 
Neurostimulator 
Information
Access 
Programming 
Mode
Selecting  provides access to the programming mode. Selecting  provides information about the programmer 
and the neurostimulator. The other icons adjust the sound volume, screen brightness and screen contrast on the pro-
grammer. Pressing the  button returns to the Home screen.
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PROGRAMMING MODE
Programming mode is used to change the parameters of the stimulation program, and to interrogate the 
neurostimulator for certain diagnostic information. Programming mode provides a series of choices (parameters 
and actions) arranged in a loop that spans multiple screens. The scroll 
 
 buttons are used to move forward 
and backward between the choices. Scrolling forward at the bottom of one screen moves the cursor to the top of 
the next screen. Likewise, scrolling backward at the top of one screen moves to the bottom of the prior screen. The 
sequence of the choices is shown below.
NOTE: LibraXP offers the choice to GO TO LEAD 1 (POL1-4) or GO TO LEAD 2 (POL5-8) upon entry 
into programming mode.
(LibraXP only)
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There are two types of choices in programming mode: actions and parameters. The following pages provide a 
description of the action and parameter choices available within programming mode.
 AMP
Use this to set the amplitude of the stimulation generated by the neurostimulator.
Highlighting this line and pressing:
  increases AMP by an amount equal to STEP
  decreases AMP by an amount equal to STEP
This line shows the amplitude of the stimulation being generated by the neurostimulator, and allows it to be 
changed. When AMP is zero, it will display OFF. Stimulation amplitude can be adjusted in the following ways:
●
 Highlight the AMP line and press  or  to increase or decrease amplitude by an amount equal to 
STEP
●
 Press the red  button to turn amplitude off.
●
 Highlight JUMPTO, and then press  to change amplitude to the value shown on the JUMPTO 
line.
NOTE:  The  on the AMP or PW lines means that the charge density is above 30 µC/cm2 at the 
current AMP and PW settings. 
 WARNING: A potential risk of tissue damage exists with stimulation parameter settings of high amplitudes 
and wide pulse widths. High amplitude and pulse width settings required to achieve therapy may indicate a 
system problem or sub-optimal lead placement.
 CAN
Use this to set the polarity of the neurostimulator (can) case.
Highlighting this line and pressing:
 
 
toggles the can polarity between ANODE and OFF
  toggles the can polarity between ANODE and OFF
The neurostimulator case can be programmed to be either:  ANODE (a positive electrode, for monopolar 
stimulation), or OFF (not part of the stimulation circuit, for bipolar stimulation). Keep in mind the following when 
adjusting CAN:
●
 AMP will be turned off whenever CAN is changed
●
 AMP limits will be disabled whenever CAN is changed
●
 When CAN is set to ANODE, none of the electrodes on the lead can be set to anode. When CAN is 
changed to ANODE all electrodes on the lead set to anode will be automatically switched OFF.
●
 LibraXP: Both leads must have the same CAN setting. The CAN parameter can only be changed when 
programming lead 1. When programming lead 2, ANODE or OFF will be shown in brackets “[ ]” 
indicating that it cannot be changed.
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 CHECK IMPEDANCE
Use this to obtain an estimate of the impedance of the system with the current stimulation parameters and electrode 
configuration. Also use this to obtain the impedance factor to calculate device longevity.
Highlighting this line and pressing:
  starts a sequence that measures the system impedance
Impedance measurements can be helpful for troubleshooting problems, or estimating device longevity. See the 
Troubleshooting section of this manual for information on interpreting impedance measurements and Appendix C 
and D for information on calculating device longevity.
Before an impedance measurement can be taken, the programmer waits for the neurostimulator impedance 
measurement circuitry to stabilize. The programmer automatically calculates the required stabilization time, and 
displays a countdown on its screen. At any time after the stabilization time, position the wand over the 
neurostimulator and press the green  button to obtain the impedance measurement.
Impedance in Ohms
Impedance factor
  
NOTE: It is only necessary to hold the wand over the neurostimulator when the green  button is 
pressed. It is NOT necessary to hold the wand over the neurostimulator while the programmer is counting 
down.
NOTE: The stabilization time can be reduced by increasing AMP, FREQ or PW.
 DIA/LEN  (ELECTRODE DIAMETER AND LENGTH)
Use this to specify the dimensions (diameter and length) of the electrodes on the lead.
Highlighting this line and pressing:
  moves between the electrode diameter and length choices
  moves between the electrode diameter and length choices
The programmer uses the electrode dimensions to calculate the average charge density, and displays a warning 
when it exceeds 30 µC/cm2. Each time the programmer is turned on, it resets this parameter to the smallest electrode 
dimensions. See the manual packaged with the DBS lead to determine the lead dimensions.
37-1128-01C.indd   21 1/12/2011   11:18:16 AM
Page 82 of 291
22 Libra DBS System Clinician’s Manual
 EXIT
Use this to exit programming mode and return to the Home screen.
Highlighting this line and pressing:
 exits programming mode and provides the choice to save or discard the changes made to the program
After finishing programming the neurostimulator, you must select EXIT to leave programming mode. Otherwise, 
the programmer will not turn off, and it will periodically beep to remind you to EXIT programming mode.
After selecting EXIT, you will be given the option to keep or discard the program changes you have just made. In 
certain circumstances when amplitude limits are enabled, you will also be prompted to adjust/confirm the amplitude 
limits.
 CAUTION: Always  EXIT programming mode and turn the programmer off and back on before attempting to 
program a different IPG. Failing to do so, can abruptly change stimulation parameters in the second IPG.
 FREQ
Use this to set the stimulation frequency.
Highlighting this line and pressing:
 
 increases the stimulation frequency in increments of 10 Hz
  decreases the stimulation frequency in increments of 2 Hz
This line shows the frequency of the stimulation currently being generated by the neurostimulator, and allows it 
to be changed. FREQ (frequency) is the number of stimulation pulses delivered each second. Keep in mind the 
following points when adjusting FREQ:
●
 The highest frequencies may not be programmed with long pulse widths. The maximum frequencies are:
Max. FREQ for:
1 Lead 2 Leads
PW ≤ 248 µsec 240 Hz 200 Hz
PW > 248 µsec 220 Hz 180 Hz
●
 LibraXP: Both leads must have the same FREQ setting. FREQ can only be changed when programming 
lead 1. When programming lead 2, the FREQ parameter value will be shown in brackets “[ ]” indicating 
that it cannot be changed.
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 GET STIM TIME
Use this to get information about stimulator use.
Highlighting this line and pressing:
  reports the current values of TOTALDAYS and STIMDAYS
TOTALDAYS is the number of days since the neurostimulator was manufactured—whether or not stimulation 
output is on.
STIMDAYS is the number of days that stimulation was actually turned on. For example, if stimulation was turned 
on for 12 hours per day for 48 hours, then STIMDAYS counts this as one day, while TOTALDAYS counts it as two.
STIMDAYS and TOTALDAYS can be useful for troubleshooting and assessing patient compliance. See the 
Troubleshooting section of this manual for details.
 GO TO LEAD 1 / GO TO LEAD 2 (LIBRAXP ONLY)
Use this to move to (and program) the other lead on LibraXP neurostimulators.
Highlighting this line and pressing:
 turns lead 1 stimulation off, and retrieves the stimulation parameters of lead 2 (and vice versa when 
going from lead 2 to lead 1)
When entering programming mode, a prompt will appear allowing you to select which lead to program. Stimulation 
output from the other lead is turned off while you program this lead, and vice versa.
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 JUMPTO
Use this to immediately turn stimulation on at the amplitude shown on this line.
Highlighting this line and pressing:
 immediately changes AMP to the amplitude displayed on the JUMPTO line
JUMPTO provides an alternate, shortcut method of adjusting the stimulation amplitude. Some of the uses for this 
feature may include:
●
 The JUMPTO line displays the value that the stimulation amplitude was at when the programming session 
was started, thereby providing a continuous reminder of the last programmed stimulation amplitude.
●
 The programmer automatically turns stimulation off when a programming session is started. JUMPTO 
provides a fast way to turn stimulation back on. This may be useful for patients that are sensitive to 
stimulation being turned off, but are tolerant of stimulation being quickly turned on.
 CAUTION: Some patients may be startled by abruptly turning on stimulation. Use the AMP line to 
gradually turn on stimulation in patients who are sensitive to abruptly turning on stimulation.
 MAGNET
Use this to set how the neurostimulator will respond if it senses a magnet.
Highlighting this line and pressing:
  toggles magnet mode between OFF and ON/OFF
  toggles magnet mode between OFF and ON/OFF
The neurostimulator contains a sensor that detects the presence of a strong magnet. It can be programmed to 
respond to a magnet in two different ways:
●
 OFF: The neurostimulator will turn stimulation output OFF the first time it detects a magnet. Stimulation 
cannot be turned back on with the magnet.
●
 ON/OFF: The neurostimulator will toggle stimulation output between ON and OFF each time it detects a 
magnet.
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 MODE
Use this to set the stimulation mode.
Highlighting this line and pressing:
 enters the stimulation mode adjustment screen
The neurostimulator has two stimulation modes: continuous and cycle.
●
 Continuous mode produces stimulation until the neurostimulator is turned off via a magnet, programmer or 
QuikLink. 
●
 Cycle mode produces stimulation in a repeating cycle of a defined on time followed by a defined off time. 
The Home screen will display a “C” in the lower left corner when the neurostimulator is in cycle mode.
After entering the mode adjustment screen, use the  /  buttons to toggle between CONT (continuous) and 
CYCLE modes. When CYCLE is selected use the scroll butt ons and  /  buttons to adjust the H (hours), M 
(minutes) and S (seconds) cycle on and cycle off times in the stimulation mode adjustment screen. When finished, 
highlight DONE and press  to leave stimulation mode adjustment screen.
 POL
Use this to set the polarity of the electrodes on the lead.
Highlighting this line and pressing:
 
when CAN is OFF, changes the polarity of the electrode from 0 (OFF) to + (anode) to – (cathode)
 
when CAN is ANODE, changes the polarity of the electrode from 0 (OFF) to – (cathode)
 when CAN is OFF, changes the polarity of the electrode from 0 (OFF), to – (cathode) to + (anode) 
 when CAN is ANODE, changes the polarity of the electrode from 0 (OFF), to – (cathode)
The electrodes on ANS leads are numbered 1 through “X”, with the most distal electrode designated electrode 
#1. The programmer supports programming Libra neurostimulators with a single lead with up to 8 electrodes, and 
LibraXP neurostimulators with two leads with 4 electrodes each.
Electrode 2 = (–) CATHODE
Electrode 1 = OFF
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PW
Use this to set the pulse width of the stimulation produced by the neurostimulator.
Highlighting this line and pressing:
  increases the width of the stimulation pulse by 13 microseconds
  decreases the width of the stimulation pulse by 13 microseconds
This line shows the pulse width of the stimulation currently being generated by the neurostimulator, and allows it to 
be changed. The longest pulse widths may not be programmed with the highest frequencies (see FREQ for details).
 RAMPTIME
Use this to set how long stimulation will take to ramp up to the programmed amplitude when the neurostimulator is 
turned on.
Highlighting this line and pressing:
  moves to the next longer ramp time
  moves to the next shorter ramp time
Some patients may find it more comfortable to have stimulation gradually ramp up when the neurostimulator is 
turned on, as opposed to jumping directly to the programmed amplitude. This line allows you to set how quickly 
stimulation is increased when the neurostimulator is turned on. The ramp time choices are 0, 2, 4, 8, 15, 30, 45, and 
60 seconds. Both leads on a LibraXP use the same ramp time.
NOTE: RAMPTIME is not used in programming mode. In programming mode, amplitude changes are 
made as fast as practicable.
 SET AMP LIMITS
Use this to enable and set the values of the amplitude limits, or disable amplitude limits.
Highlighting this line and pressing:
 enters the amplitude limits configuration screen
Libra neurostimulators give you the option to allow your patients to adjust their stimulation within your prescribed 
amplitude limits using their controller. This feature is enabled from the amplitude limits configuration screen by 
changing MIN or MAX so that they are not equal to AMP. Amplitude limits are disabled by setting MIN and MAX 
equal to AMP. When finished, highlight DONE and press  to leave stimulation mode adjustment screen.
●
 MAX is the maximum amplitude to which patients will be able to increase their stimulation amplitude.
●
 MIN is the minimum amplitude (other than OFF) to which patients will be able to decrease their 
stimulation amplitude.
●
 STEP is the increment by which stimulation amplitude will be adjusted each time the increase amplitude 
or decrease amplitude button is pressed.
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Each time the increase amplitude or decrease amplitude button is pressed, stimulation amplitude is adjusted by 
an amount equal to STEP. This allows you to control both the range (from MIN to MAX) and the number of 
amplitude choices that you prescribe. Some patients may find it easier to have only a few choices whereas others 
may need the fine-tuning that can be provided with more, smaller increments.
NOTE: STEP should be adjusted before entering the amplitude limits configuration screen. Adjusting 
STEP afterward may cause MIN and/or MAX to reset.
NOTE: STEP, MIN and MAX should be set just prior to exiting programming mode. Upon exiting 
programming mode, the programmer will automatically prompt you to change MIN if it is no longer less 
than or equal to AMP, or MAX if it is no longer less than or equal to AMP.
 STEP
Use this to set the increment by which AMP will be adjusted both in programming mode, and in amplitude 
adjustment mode.
Highlighting this line and pressing:
  increase STEP by 0.05mA
  decrease STEP by 0.05mA
This line shows the increment by which the stimulation amplitude will be increased or decreased when the AMP 
line is highlighted and the  or  button is pressed. This allows you to change how stimulation is stepped up. 
A larger step size can be used to quickly make large amplitude changes, and a smaller step size allows fine tuning 
of the amplitude.
This parameter is also used to set the increment by which amplitude will be increased or decreased when using 
amplitude limits. Keep in mind the following points when using STEP for amplitude limits:
●
 STEP can be increased to reduce the number of amplitude steps offered to a patient. This may make it 
easier for patients to use and understand.
●
 LibraXP:  The STEP value for lead 1 can be different than the STEP value for lead 2.
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AMPLITUDE ADJUSTMENT MODE
Amplitude adjustment mode is accessible from the Home screen when amplitude limits have been enabled. See 
SET AMP LIMITS for information on enabling amplitude adjustment mode. See the Home screen section for 
information on accessing amplitude adjustment mode. 
In this mode, the  and  buttons can be used to adjust stimulation amplitude in the same way that a patient 
provided with a QuikLink controller would do so.
Adjusting amplitude via amplitude adjustment mode is slightly different than doing so through programming mode, 
which may provide you with additional flexibility. Specifically:
●
 Programming mode must be used to enable and configure amplitude limits, and to set all parameters. 
Amplitude adjustment mode only allows amplitude to be adjusted.
●
 Stimulation is turned off when entering programming mode, but not when entering amplitude adjustment 
mode.
●
 LibraXP:  In amplitude adjustment mode, amplitude can be adjusted while stimulation is being delivered to 
both leads, whereas in programming mode it cannot.
Highlighting an AMP value and pressing:
  increases stimulation amplitude by an amount equal to STEP
  decreases stimulation amplitude by an amount equal to STEP
Highlighting EXIT and pressing 
 
returns to the Home Screen.
     
 Libra, Model 6608 LibraXP, Model 6644
CLEANING THE PROGRAMMER
Clean the programmer by wiping off the outer surface using a moist cloth and a small amount of mild soap. Do not 
submerge the controller in liquids or use a cloth that is saturated. Do not use alcohol, cleaning solutions, or solvents 
to cleanthe programmer.
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TROUBLESHOOTING
DAILY CHANGE IN STIMULATION SENSATION
The Libra and LibraXP IPGs perform a battery diagnostic every 24 hours, which momentarily interrupts 
stimulation. If a patient reports a sensation that occurs at the same time every day, he or she is most likely sensing 
the battery diagnostic. For help reprogramming the IPG to alleviate this sensation, contact ANS Customer Service 
at +1-972-309-8000.
NEUROSTIMULATOR BATTERY WARNINGS
Libra neurostimulators contain circuitry to detect when their battery voltage has fallen below a preset “low battery” 
level, and when it has fallen below a preset “battery depleted” level. When this occurs, the programmer will display 
the corresponding warning.
IPG Battery Depleted Warning (EOL – End of Life)
When the “EOL warning” is displayed, the neurostimulator battery is depleted and stimulation may stop abruptly 
without further warning.
 WARNING: Schedule neurostimulator replacement surgery NOW. 
 The EOL Warning indicates that the neurostimulator battery is depleted and stimulation can abruptly stop at 
any time without further warning. Consider the effects that an abrupt cessation of stimulation and return of 
the underlying symptoms would have on this patient, and as appropriate, place the patient under continuous 
monitoring until surgery and/or make plans to manage the underlying symptoms.
IPG Battery Very Low Warning
When the “IPG Battery Very Low” warning appears, do the following
 1. Enter programming mode.
 2. Use GET STIM TIME to obtain the value of STIMDAYS. Write down this value.
 3. Use CHECK IMPEDANCE to obtain the current value of the impedance factor.
 4. Use APPENDIX C or D to calculate the estimated device longevity at the current stimulation parameters.
 5. If STIMDAYS and the calculated longevity are approximately equal, then schedule replacement IPG surgery. 
Otherwise, call ANS Customer Service for assistance in determining whether or not to clear the IPG low 
battery flag.
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CLEARING AN IPG LOW BATTERY FLAG
In certain situations, particularly when using low stimulation parameters and/or regularly turning the 
neurostimulator off, a neurostimulator may prematurely trigger a battery warning. This is caused by a battery 
passivation layer that will dissipate after the neurostimulator is used more. The neurostimulator is fully 
functional, and the battery has its full specified capacity. This situation may recur multiple times with the same 
neurostimulator.
To clear a low battery flag proceed as follows
 1. While the low battery warning is displayed on the screen, press the  button, then the  button.
 2. When the following screen appears, press the  button.
  3. Instruct the patient to use their controller to check the battery status regularly and contact you if the low 
battery warning reappears. The low battery flag may need to be cleared more than once.
IMPEDANCE MEASUREMENTS
Impedance measurements can be helpful for troubleshooting problems, or estimating device longevity. To obtain an 
impedance measurement, enter programming mode and use the CHECK IMPEDANCE action. After the impedance 
measurement is taken, the screen will appear as shown below. The impedance in ohms is displayed followed by the 
impedance factor in parentheses.
  
Impedance in Ohms
Impedance factor
  
Keep in mind the following when interpreting impedance measurements:
●
 When the impedance factor is zero: A zero impedance factor indicates that the neurostimulator output is very 
low. When the patient is receiving effective stimulation at this output, the device longevity will be very good 
(use Appendix C or D to calculate longevity). However, because the neurostimulator output is very low, it is 
not possible to obtain a definitive impedance measurement—only an estimate of the maximum value. For this 
reason, the impedance reading is always reported as being “< xxxx” (less than xxxxΩ) when the impedance 
factor is zero.
NOTE: If the patient can tolerate it, AMP can be temporarily increased to the point that the impedance factor 
becomes non-zero, and thereby obtain a better impedance estimate. This value of the impedance factor should 
not be used for estimating longevity.
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●
 Erratic sequential impedance measurements: Sequential impedance measurements taken at the same 
stimulation parameters should be consistent (±1 impedance factor). If you obtain very different impedance 
measurements at the same stimulation parameters, this may indicate a system problem. Contact ANS customer 
service for assistance.
●
 HIGH impedance readings: There are two situations in which the impedance will be reported as “HIGH.” 
One is when the impedance is over 3000 Ohms. The other is when the impedance factor is 31. Impedance 
factor 31 indicates that the neurostimulator cannot deliver the required current. This may indicate that there is 
an open circuit. Contact ANS customer service for assistance. 
TEMP PROGRAM
     
 Libra, Model 6608 LibraXP, Model 6644
The temp program message indicates that the stimulation program was not correctly saved at the end of the prior 
programming session. When the programmer detects a temp program, it will not allow the neurostimulator to be 
turned on. Instead, the only option the programmer gives is to enter programming mode so that the stimulation 
parameters can be adjusted as necessary, and the program properly saved.
NOTE: For Libra neurostimulators (Model 6608), the temp program stimulation parameters are retained when 
entering programming mode. So, if the patient was getting acceptable results from the temp program, then you 
can simply enter programming mode, and then immediately EXIT to properly save the program and correct 
this situation.
For LibraXP neurostimulators (Model 6644), the program stimulation parameters are reset to factory defaults 
and stimulation is turned off. Enter programming mode and reprogram the IPG.
HIGH CHARGE DENSITY
The programmer automatically checks every amplitude and pulse width increase request to determine if it will 
cause the maximum average charge density to be exceeded. If so, the programmer first asks you to confirm the 
electrode size (diameter and length). Then, if after the electrode size is confirmed, the charge density is too high, it 
displays the charge density warning shown below.
     
Selecting YES sends the requested increase to the neurostimulator and allows you to exceed the maximum 
recommended charge density. While the charge density is being exceeded, a warning symbol will appear next on 
the AMP and PW lines, and on the Home screen. Selecting NO cancels the requested increase.
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OTHER ERROR AND WARNING MESSAGES
This message appears if the programmer detects a problem with its circuitry or software. Try restarting the 
programmer and replacing the batteries. If that fails, call ANS Customer Service to arrange service.
This message appears if the programmer detects an ANS neurostimulator that cannot be programmed with this 
model programmer. Call ANS Customer Service for instructions.
This message appears if the programmer detects an error in the neurostimulator or stimulation program. When this 
happens the neurostimulator is reset to its factory settings and turned off. Use the programmer to reprogram the 
neurostimulator and call ANS Customer Service for assistance as required.
This message appears when the programmer detects that its batteries are low. Remove the battery pack from the 
back of the programmer and replace the batteries with 3 new AAA batteries as shown below.
Battery pack
3 AAA
alkaline
batteries
NOTE: ANS recommends that you do not use rechargeable batteries. They may display an inaccurate battery 
capacity when you check your programmer’s batteries. They will not affect a check of your IPG’s 
battery capacity. 
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This message appears when the frequency or pulse width requested would exceed the capabilities of the IPG. (See 
Freq for details.) Decrease frequency so that pulse width can be increased, or vice versa.
This error occurs when the programmer was unsuccessful in its attempt to communicate with the neurostimulator. 
It may be possible to correct this by repositioning the wand over the neurostimulator, or moving away from sources 
of electromagnetic interference.
NOTE: If the COMM error occurs while you are in programming mode, you will be taken to the Home 
screen and required to re-enter programming mode. In addition, the LibraXP will lose the changes made since 
the program was last saved.
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CUSTOMER SERVICE INFORMATION
For help with an ANS product, including technical service or repairs, contact Customer Service using 
the following information:
Advanced Neuromodulation Systems
6901 Preston Road
Plano, TX 75024
USA 
+1-972-309-8000
+1-972-309-8150 Fax
RETURNED MERCHANDISE POLICY
All returns must be accompanied by a Return Merchandise Authorization (RMA) number, which is available by 
contacting ANS Customer Service at 972-309-8000. Customer Service can only issue RMAs after receiving the 
original purchase order number, invoice date, and serial number information for the product.
REGISTRATION AND PATIENT IDENTIFICATION CARD
At time of implantation, the registration form included in the product’s packaging should be completed and 
returned to ANS. This registration process will activate the system warranty and allow tracking of the product.
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LIMITED WARRANTY
I. GENERAL WARNING
A. Advanced Neuromodulation Systems, Inc. Libra Deep Brain Stimulation (DBS) Systems are comprised of implantable 
components, programmers, controllers, and patient accessories. The patient accessories may include a magnet. The 
implantable components include leads, lead kits, IPGs, IPG kits, extensions, and accessories. Upon being implanted, 
these components must withstand exposure to an extremely hostile and unpredictable environment in the human body. 
The implanted components may fail during or following implantation into the body for any one or a number of reasons, 
including, but not limited to, medical complications, body rejection phenomena, lead breakage, or improper handling, 
implantation, or use, or insulation breach.
B. Advanced Neuromodulation Systems, Inc. makes no representations or warranties that failure or cessation of function 
of any component, or the system, will not occur, that the body will not react adversely to implantation, or that medical 
complications will not develop.
II. LIMITED WARRANTY
A. LIMITATION OF WARRANTY
1. Advanced Neuromodulation Systems, Inc., 6901 Preston Road, Plano, TX 75024, warrants the Advanced 
Neuromodulation Systems, Inc.’s Libra DBS System to be free from defects in material or workmanship within 
one year from the date of implantation or ownership, subject to the terms and conditions contained in this warranty. 
Only patient-customers who receive an Advanced Neuromodulation Systems, Inc. Libra DBS System and return a 
properly completed warranty registration card to Advanced Neuromodulation Systems, Inc. within 60 days from the 
date of surgery may enforce this limited warranty.
2. THIS WRITTEN LIMITED WARRANTY CONTAINS THE FINAL, COMPLETE AND EXCLUSIVE 
STATEMENT OF WARRANTY TERMS FOR ADVANCED NEUROMODULATION SYSTEMS, INC. LIBRA 
DBS SYSTEMS, AND IT APPLIES IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED. 
ADVANCED NEUROMODULATION SYSTEMS, INC. DISCLAIMS ALL IMPLIED WARRANTIES, 
INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR 
PURPOSE. NO PERSON IS AUTHORIZED TO MAKE ANY OTHER GUARANTEES, WARRANTIES OR 
REPRESENTATIONS ON BEHALF OF ADVANCED NEUROMODULATION SYSTEMS, INC. This limitation 
may not apply to you because some states and countries prohibit the limitation or exclusion of implied warranties. 
You may have other rights under state law not specifically addressed in this limited warranty.
B. THIS LIMITED WARRANTY FOR THE LIBRA DBS SYSTEM DOES NOT APPLY TO
1. Any damage caused by misuse, neglect, accident, modification, improper application, or from other than normal and 
ordinary use.
2. Any damage caused by any repair or attempted repair by anyone other than an authorized Advanced 
Neuromodulation Systems, Inc.-trained technician.
3. Any damage resulting from failure to clean or use in accordance with the Operating Instructions and/or Services 
Manual furnished by Advanced Neuromodulation Systems, Inc.
C. LIMITATION OF DAMAGES
 ADVANCED NEUROMODULATION SYSTEMS, INC. DISCLAIMS LIABILITY FOR ANY DIRECT,  INDIRECT, 
INCIDENTAL, OR CONSEQUENTIAL DAMAGE ARISING OUT OF, OR IN CONNECTION WITH, THE USE OR 
PERFORMANCE OF THE SYSTEM, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT, WARRANTY, 
OR OTHERWISE. This limitation of liability applies to all warranty claims. No waiver or amendment of this limited 
warranty shall be valid unless in writing signed by Advanced Neuromodulation Systems, Inc. Some states, and countries, do 
not allow the exclusion or limitation of incidental or consequential damages, so the above limitation may not apply to you.
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III. IMPLANTABLE COMPONENTS
A. Subject to Sections I and II and paragraph III(B) of this Limited Warranty, if any of the implantable components should 
fail to function due to a defect in material or workmanship during the warranty period, Advanced Neuromodulation 
Systems, Inc. will, at its option:
1. Replace the implantable component with an equivalent, or functionally equivalent, implantable component at no 
charge to the patient-consumer; or
2. Issue a credit to the patient-consumer for a replacement Advanced Neuromodulation System, Inc. implantable 
component, the credit being equal to the net invoice price for the replaced implantable component.
B. For repair, replacement, or credit under this limited warranty
1. The implantable component must be implanted prior to the expiration date indicated on the component’s packaging, 
and
2. If the implantable component is explanted, the patient-consumer, his or her authorized representative, physician 
or hospital, must return the component to Advanced Neuromodulation Systems, Inc. The patient-consumer, or his 
or her authorized representative, must, at his or her own expense, mail or ship the product together with a Return 
Merchandise Authorization number obtained from Customer Service to Advanced Neuromodulation Systems, Inc. 
within 30 days after explantation. If the implantable component is not explanted, the component’s serial number or 
lot number must be provided within 30 days after discovery of the defect.
3. Upon Advanced Neuromodulation Systems, Inc.’s receipt of the product, the returned implantable component shall 
become the exclusive property of Advanced Neuromodulation Systems, Inc.
IV. PROGRAMMERS, CONTROLLERS, AND PATIENT ACCESSORIES
A. Subject to Sections I, II, and paragraph IV(B) of this Limited Warranty, if any Libra DBS System programmer, 
controller, or patient accessory fails to function due to a defect in material or workmanship during the warranty period, 
Advanced Neuromodulation Systems, Inc. will, at its option
1. Repair any defective part of the programmer, controller, or accessory at no charge to the patient-consumer; or
2. Replace the programmer, controller, or accessory with an equivalent, or functionally equivalent, programmer, 
controller, or accessory at no charge to the patient-consumer; or
3. Issue a credit to the patient-consumer for a replacement Advanced Neuromodulation Systems, Inc. programmer, 
controller, or accessory in an amount equal to the net invoice price for the defective programmer, controller, or 
accessory.
B. For repair, replacement or credit under this limited warranty:
1. The patient-consumer, or his or her authorized representative, must, at his or her own expense, mail or ship the 
product together with a Return Merchandise Authorization number obtained from customer service to Advanced 
Neuromodulation Systems, Inc. within 30 days after discovery of the defect.
2. Upon Advanced Neuromodulation Systems, Inc.’s receipt of the product, the returned component shall become the 
exclusive property of Advanced Neuromodulation Systems, Inc. 
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APPENDIX A: IPG SPECIFICATIONS AND KIT COMPONENTS
IPG SPECIFICATIONS
Model No: 6608 6644
 
Libra
SN 123456
 
8
4
5
1
S/N 123456
3644
Libra
 Libra LibraXP
Height: 1.96 in. (50 mm) 2.98 in. (76 mm)
Width:   2.11 in. (54 mm) 2.27 in. (58 mm)
Thickness:   0.54 in. (14 mm)  0.54 in. (14 mm)
Weight:   1.8 oz. (53 g) 2.93 oz. (83 g)
Volume:   1.75 in.3 (29 cm3) 2.99 in.3 (49 cm3 )
Power Source:   Lithium Thionyl Chloride Cell
Storage Temperature:   -10°C (14°F) and 55°C (131°F) 
Storage Humidity:   10% to 90%
Storage Pressure: 70-150 kPa (10.2-21.8 psi) 
Connector Strength:   Exceeds EN45502-1 Requirements
OPERATIONAL SPECIFICATIONS
Libra
Parameter Range Steps
Pulse Width 52–507 µs 13 µs
Frequency 2–240 Hz 2 Hz
Amplitude 0–12.75 mA  0.05–.75 mA
LibraXP
Parameter Range Steps
Pulse Width 52–507 µs 13 µs
Frequency 2–200 Hz 2 Hz
Amplitude 0–12.75 mA  0.05–.75 mA
KIT COMPONENTS
Each model #6608 kit includes the following: Each model #6644 kit includes the following:
1 each 8-Channel Libra IPG 1 each Dual 4-Channel LibraXP IPG
2 each Connector Strain Reliefs 2 each Connector Strain Reliefs
1 each Torque Wrench 1 each Torque Wrench
1 each Port Plug 2 each Port Plugs
1 each Registration Form 1 each Registration Form
1 each Clinician’s Manual 1 each Clinician’s Manual
1 each Temporary Identification Card 1 each Temporary Identification Card
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APPENDIX B: LIBRA CLINICIAN PROGRAMMER SPECIFICATIONS AND KIT COMPONENTS
SPECIFICATIONS
Dimensions: 6.8 cm (2.7”) x 10.77 cm (4.2”) x 2.6 cm (1”)
Weight: 128 grams (4.6 oz.)
Storage Temperature: -20°C to + 60°C (-4°F to + 140°F)
Storage Humidity: 10% to 90%
Storage Pressure:  70-150 kPa (10.2-21.8 psi)
Operating Temperature: 10ºC to 40º C (50ºF to 104ºF)
Operating Humidity: 30% to 70%
Operating Pressure: 70-106 kPa (10.2-15.4 psi)
Each model #6850 kit includes the following:
●
 1 each Libra Clinician Programmer
●
 1 each Battery Pack
●
 3 each AAA Batteries
●
 1 each Programming Wand
●
 1 each Magnet
●
 1 each Carrying Case
●
 1 each Manual 
FCC statement (FCC ID: PX 2001). This neurostimulation equipment has been tested and found to comply with 
the limits for a Class B digital device, pursuant to part 15 of the FCC Rules, if this programmer does interfere with 
other equipment, which can be determined by turning the programmer off and then on again, either: reorient or 
relocate the equipment; or increase the separation between the programmer and the equipment. 
NOTE: Changes or modifications to this product not authorized by ANS could void the FCC certification and 
negate your authority to operate this product.
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APPENDIX C: BATTERY LONGEVITY FOR LIBRA
The battery life of the IPG depends on the parameters you have selected, the impedance that the current encounters 
in the neurostimulation circuit, and the hours per day it is used. To optimize the Libra IPG battery life for patients 
who require programming parameters resulting in Impedance Factors equal to or greater than one (1), try reducing 
the amplitude slightly and increasing the pulse width. Doing so may lower the impedance factor and reduce battery 
drain. This Appendix provides the information necessary to calculate the initial estimated life of the Libra IPG. 
These estimates are based on the selected stimulation parameters and will account for the electrode impedance. 
LIBRA DBS SYSTEM LONGEVITY CALCULATION
To estimate the battery life of an implanted Libra DBS System, perform the following calculations:
NOTE: Please contact ANS to determine the longevity for any reading with an impedance factor greater than 
8 or for any frequency above 200 Hz.
Step One - Determine Value 1 using the Libra Clinician Programmer and the following chart.
Impedance Factor Value 1
0 1
1 1.76
2 1.72
3 1.73
4 1.78
5 1.84
6 1.92
7 2.01
8 2.10
Step Two - Use Value 1 and the parameters currently set on the patient’s Libra DBS System to solve the following 
equation:
Pulse Width  
x
  Frequency  
x
  Amplitude  
x
  Value 1  
=
   
=  A
Step Three - Determine Value 2 by matching the patient’s Frequency to the Impedance Factor using the 
following chart:
Value 2 Calculation
Impedance Factor
Frequency 0 1–4 5–8
2–50 0 3,200 3,600
52–100 0 6,400 7,000
102–150 0 9,600 10,500
152–200 0 12,500 13,500
 Value 2 =    =  B
37-1128-01C.indd   39 1/12/2011   11:18:18 AM
Page 100 of 291
40 Libra DBS System Clinician’s Manual
Step Four - Determine Value 3 using the Libra Clinician Programmer and the following chart:
Impedance Factor Value 3
0 203
1 205
2 213
3 221
4 231
5 242
6 253
7 265
8 278
 Value 3 = 
Step Five - Solve the following equation:
(Pulse Width  +  200) 
 x
  Frequency 
 x  
Value 3 
 =
 1,000 
=  C
Step Six - Use results A, B, and C from the previous steps to find the total energy units.
       15,000
 A 
+
 B 
+
 C 
+
 Constant 
=
 
TOTAL ENERGY UNITS =
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Step Seven - Using the Total Energy Units from Step Six, find the corresponding energy units along the x-axis of 
the Libra Battery Longevity Chart, follow the vertical line up until it intersects with the longevity curve, and then 
follow the horizontal line over to the y-axis to find the estimated longevity (years).
Battery Longevity Chart
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NOTE: The battery longevity chart above is a logarithmic chart. Each vertical line to the left of the center 
line labeled “100,000” is equal to 10,000 energy units. Each vertical line to the right of the center line labeled 
“100,000” is equal to 100,000 energy units.
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APPENDIX D: BATTERY LONGEVITY FOR LIBRAXP
BATTERY LONGEVITY—LIBRAXP IPG 
The battery life of the IPG depends on the parameters you have selected, the impedance that the current encounters 
in the neurostimulation circuit, and the hours per day it is used. To optimize the LibraXP IPG battery life for 
patients who require programming parameters that result in Impedance Factors equal to 1 or greater, try reducing 
the amplitude slightly and increasing the pulse width to compensate. This may result in a lowing the impedance 
factor and reducing battery drain. This appendix provides the information necessary to calculate the initial 
estimated life of a LibraXP IPG. These estimates are based on the selected stimulation parameters and account for 
electrode impedance.
LIBRA SYSTEM LONGEVITY CALCULATION
To estimate the battery life of an implanted LibraXP IPG, perform the following calculations:
NOTE: Please contact ANS to determine the longevity for any reading with an impedance factor greater than 
8 or for any frequency above 190 Hz.
Step One - Determine Value-1 using the Libra Clinician Programmer and the following chart:
Impedance Factor Value-1
0 1
1 1.76
2 1.72
3 1.73
4 1.78
5 1.84
6 1.92
7 2.01
8 2.10
Step Two - Use Value-1 and the parameters currently set on the patient’s Libra DBS System to solve the following 
equation:
Pulse Width  
x
  Frequency  
x
  Amplitude  
x
  Value-1  
=
   
=  A1
(Stim Set 1)  (Stim Set 1)
Pulse Width  
x
  Frequency  
x
  Amplitude  
x
  Value-1  
=
   
=  A2
(Stim Set 2)  (Stim Set 2)
A1_____________ + A2_____________  = A _____________
NOTE: If only one side is implanted and turned on, the value for the other side will be zero.
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Step Three - Determine Value-2 by matching the patient’s Frequency to the Impedance Factor (see page 34) 
using the following chart:
Value-2 Calculation
Impedance Factor
Frequency 0 1-4 5-8
2–50 0 3,200 3,600
52–100 0 6,400 7,000
102–150 0 9,600 10,500
152–190 0 12,500 13,500
 Value-2 =    =  B
Step Four - Determine Value-3 using the Libra Clinician Programmer and the following chart:
Impedance Factor Value-3
0 203
1 205
2 213
3 221
4 231
5 242
6 253
7 265
8 278
 Value-3 = 
Step Five - Solve the following equation:
 (Pulse Width  
x
 Frequency 
x
 Value-3 
=  
1,000 
=  C1
 
[Stim Set 1] + 200)
 (Pulse Width  
x
 Frequency 
x
 Value-3 
=  
1,000 
=  C2
 
[Stim Set 2] + 200)
C1_____________ + C2_____________  = C _____________
NOTE: If only one side is implanted and turned on, the value for the other side will be zero.
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Step Six - Use results A, B, and C from the previous steps to find the total energy units.
        15,000
  A 
+
 B 
+
 C 
+
 Constant 
=
 
= TOTAL ENERGY UNITS
Step Seven - Using the Total Energy Units from Step Six, find the corresponding energy units along the x-axis 
of the LibraXP Battery Longevity Chart, follow the vertical line up until it intersects with the longevity curve, and 
then follow the horizontal line over to the y-axis to find the estimated longevity.
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NOTE: The Battery Longevity Chart above is a logarithmic chart. Each vertical line to the left of the center 
line labeled “100,000” is equal to 10,000 energy units. Each vertical line to the right of the center line labeled 
“100,000” is equal to 100,000 energy units.
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APPENDIX E: LIBRA SYSTEM AND MRI SAFETY FOR THE LIBRA IPG
MRI ASTM Guidelines
Risks
MRI machines have the potential to induce deflection, torque, and heating of implanted medical devices. 
Additionally, implanted medical devices can interfere with the MRI to create artifacts in the resulting image. 
ASTM Test Standards have been developed to quantify these effects in order to evaluate the safety concerns 
involving MRI scans on patients with an implanted medical device.
Testing and Results
Testing was conducted on the Libra DBS Systems (Libra and LibraXP IPGs) to determine the affect of the MRI 
environment on the implanted system. The induced mechanical forces, torque and deflection, were evaluated under 
worst-case conditions in a 1.5T MRI magnet. The MRI scanner, the software used, and the parameters under which 
the scans were conducted are inherent to the results of any testing. The following testing was performed using a 
1.5T GE Medical Systems LX Echospeed System with 9.0 software. The system’s magnet was a superconducting, 
cylindrical self-shielded, LCC magnet (CX-K4) manufactured by GE Medical Systems. The MRI environment 
induced no mechanical forces on the leads or extensions used with the Libra DBS System. This is explained by the 
lack of magnetic materials in the lead and extension. The Libra and LibraXP IPGs experienced mechanical forces 
less than the maximum torque and deflection on the device due to gravity. The maximum mechanical force due to 
gravity is considered to be a conservative criteria by the ASTM standards.
Quantitative analysis of RF heating on the Libra DBS Systems was conducted in vitro using a 16-rung, quadrature 
birdcage, transmit/receive headcoil (GE Medical Systems, Model 46-282118G2). Although this testing following 
the applicable ASTM standard showed minimal heating at higher SAR levels, the maximum recommended SAR 
level of 0.4 W/kg should be followed for clinical MRI scanning of patients with implanted medical devices. All 
scanning should be limited to a head-only, transmit and receive head coil in a 1.5T MR System. Configurations 
were tested with one loop approximately 3–4 cm in diameter at the burr hole site and 1–1.5 loops approximately 
4–4.5 cm in diameter beneath the IPG. 
For the Libra IPG: At a Specific Absorption Rate (SAR) of  3.1 W/kg, the maximum temperature rise was 4.6 
degrees Celsius when testing a unilateral implant; at an SAR of 1.7 W/kg, the maximum temperature rise was 2.5 
degrees Celsius for a unilateral implant. At an SAR of 3.1 W/kg, the maximum temperature rise was 6.2 degrees 
Celsius when testing a bilateral implant; at an SAR of 1.7 W/kg, the maximum temperature rise was 2.4 degrees 
Celsius for a bilateral implant.
For the dual header LibraXP IPG: At an SAR of 3.1 W/kg, the maximum temperature rise was 3.8 degrees 
Celsius when testing a unilateral implant. For a bilateral configuration with the extensions less than 0.25 cm apart, 
the maximum heating at an SAR of 1.6 W/kg was 4 degrees Celsius at the left tip electrode and 2.9 degrees Celsius 
at the right tip electrode.
Artifact testing was conducted on the Libra DBS Systems to determine the extent of image distortion. Image 
distortion occurs within 1.0 cm of the lead, 2.8 cm of the extension, 10.4 cm of the Libra IPG, and 12.7 cm of 
the LibraXP IPG. These distortion areas should be used as a guideline to anticipate image disruption due to the 
implanted device. Implanted devices are unlikely to impair the diagnostic use of MR imaging when the area of 
interest is beyond the distortion area listed for the specific device. Artifact testing was conducted at worst-case 
conditions and followed the applicable ASTM standard.
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MRI Safety Guidelines
Implant Recommendations
●
 The Libra DBS Systems should be implanted as close to the centerline of the patient as possible. Avoid 
unnecessary offset of the IPG and extensions. Safety testing was conducted with the lead tip within 0.5 cm, the 
extension within 5.7 cm, and the IPG center within 9 cm of the centerline.
●
 Placing a loop in the lead and beneath the IPG allows for strain relief of the system at the connection points. 
Heating tests were conducted with a loop approximately 3–4 cm in diameter at the burr hole and one and a half 
loops approximately 4–4.5 cm in diameter beneath the IPG.
●
 Avoid implanting the IPG in the mid to lower torso of the patient and avoid unnecessary offset of the system. 
Safety testing was conducted with the IPG in the upper torso, 28 cm below the landmark and within 9 cm of 
the centerline.
●
 Avoid separation of the extensions when using a LibraXP IPG for bilateral stimulation. Separation of the 
extensions increases the distance of one extension along the y-axis away from the centerline of the magnet 
when scanning a patient in the upright, supine position.
Pre-scan Preparation
An appropriate health care professional with access to a Libra Clinician Programmer should be available to assist 
and prepare the patient’s device for the MRI procedure as described below:
●
 The patient should be in the supine position when in the magnet to bring the implant as close to the centerline 
of the magnet as possible.
●
 If the IPG has already been implanted, record the patient’s current therapeutic settings, set the IPG’s amplitude 
to 0 mA, set the Magnet mode to Off, and turn the IPG output to Off.
●
 Instruct the patient to alert the MRI system operator of any problems (heating, shocks, vision impairment, etc.) 
so the operator can terminate the MRI if needed.
 CAUTION: Due to the risk of localized heating that may result in tissue damage, an MRI procedure should 
not be performed on a patient with a Libra DBS System that is suspected to have a broken lead or extension 
wire. If a broken lead or extension wire is suspected, an x-ray should be obtained prior to an MRI to verify the 
presence of the broken wire. Additionally, the test procedure detailed in Appendix I may be run on the Libra 
DBS System to test for an open circuit due to broken lead or extension wires.
MRI Scanner Parameters and Settings
●
 Use only MRI systems operating at a static magnetic field strength of 1.5 Tesla.
●
 Use only a transmit and receive type RF head coil to minimize the exposure of the Libra DBS System to the 
MRI RF fields. Do not use a whole body RF coil, a head coil that extends over the chest area, a head coil that 
is not both a transmit and receive type RF coil.
●
 Select imaging parameters to perform MRI at a specific absorption rate (SAR) that does not exceed 0.4W/kg in 
the head.
●
 Carefully perform continuous verbal and visual monitoring of the patient throughout the MRI procedure.
●
 Discontinue the MRI if the patient experiences any pain or discomfort or if you suspect heating or other 
problems with the implanted components.
Post-scan Evaluation
●
 Verify that the IPG is functional.
●
 Reprogram the stimulation parameters to pre-MRI values, if necessary.
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SUBJECT INFORMATION AND CONSENT FORM 
 
NAME OF RESEARCH STUDY:   A clinical evaluation for the management of patients with 
Major Depressive Disorder, single or recurrent episode, 
with deep brain stimulation. 
 
SPONSOR:  Advanced Neuromodulation Systems, Inc. (ANS) 
 6901 Preston Rd. 
 Plano, TX 75024 
 
PRINCIPAL INVESTIGATOR:   
  
RESEARCH STUDY ADDRESS:   
 
This consent form may contain words that you do not understand.  Please ask the study 
doctor or the study staff to explain any words or procedures that you do not clearly 
understand.  
 
You are being asked to take part in a research study.  However, before you agree to take part in 
this study, please read this consent form.  Please ask as many questions as you need to be sure 
you understand the possible risks and benefits.  
 
It is important for you to understand that, if you participate in the study, you are required to 
transfer your psychiatric care to the study psychiatrist for the length of the study.  The study 
psychiatrists will need to be able to have access to a sufficient amount of your psychiatric 
medical history in order to verify eligibility for the study. 
 
This consent form contains important facts to help you decide if it is in your best interest to take 
part in this study.  If you have any questions that are not answered in this consent form, one of 
the research staff will be happy to give you further information.  
 
Introduction 
 
You are being asked to participate in a one year research study of a new surgical procedure to 
treat severe depression. The procedure is called Deep Brain Stimulation (DBS). This procedure 
requires an operation on your brain to place DBS electrodes.  The DBS system used in this study 
(trade name Libra Deep Brain Stimulation System from Advanced Neuromodulation Systems) 
is not approved by the Food and Drug Administration (FDA) for clinical use and is considered a 
“significant risk” device.  This system has been approved by the FDA for use in this experiment. 
 
The DBS electrodes will provide electrical stimulation to a part of your brain called the 
subgenual cingulated cortex or Brodmann Area 25 (cg25).  You are being asked to participate in 
the study because you have a severe form of depression that has not responded to several 
standard treatments. 
 
The goal of the present study is to evaluate the safety and efficacy of DBS (stimulating 
Brodmann 25) in the treatment of severe depression. DBS refers to the electrical stimulation of 
structures deep within the brain.  Brodmann Area 25 is a part of your brain about the size of a 
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sugar cube near the front and middle of your brain thought to control mood.  DBS is not 
currently approved to treat severe depression.  You will be one of 201 people, from up to 20 
sites, who take part in this study. 
 
The study doctor in charge of this study or a member of the study staff has discussed with you 
the requirements for participation in this study.  It is important that you are completely truthful 
with the study doctor and staff about your health history.  You should not participate in this study 
if you do not meet all qualifications.   
 
CRITERIA FOR PARTICIPATION 
To participate in this study you must be currently depressed. You must be a male or female 
between the ages of 21-70. You must have failed several treatments for depression.  If you are 
currently taking antidepressant medications, you must have been on these medications at the 
same doses for the 4 weeks prior to enrolling in the study and the first six months of the study 
(unless side effects require a decrease in dose).  You must currently be receiving care from a 
psychiatrist. You must be willing to transfer your psychiatric care to the study psychiatrist for the 
length of the study.  You must also be willing to sign a written release of information to allow 
the study team to share information with your psychiatrist about your participation in this study 
and for your psychiatrist to share information with us. 
 
You cannot participate in this study if it is not safe for you to have general anesthesia required 
for surgery. You cannot participate if you are currently suicidal or have had more than 3 serious 
attempts in the past 12 months.  You cannot participate if you have been diagnosed with 
fibromyalgia, chronic fatigue disorder, a history of major psychotic episodes, chronic pain 
disorders requiring certain medication, substance abuse or dependence in last 12 months (e.g. 
alcohol, medication, cocaine, marijuana), neurological disorder that impairs motor, sensory or 
cognitive functions, bipolar I or II disorder, and other types of psychiatric disorders.  You cannot 
participate if you have a diagnosis of sleep apnea that is not currently treated. You cannot 
participate if you are pregnant or planning to become pregnant during the study.  You cannot 
participate if you have a cardiac pacemaker or other implanted electrical device. You cannot 
participate in this study if you have had electroconvulsive therapy (ECT) in the last three months 
or will require ECT for the duration of this study. You cannot participate if you have a history of 
epilepsy or status epilepticus. You cannot participate if you plan to use diathermy at any time 
during the study. You cannot participate if you have any metallic implants such as aneurysm 
clips in the vicinity of Brodmann Area 25 or cochlear implants your study doctor feels may 
interfere with the implant of the ANS device. You cannot participate in this study if you are 
currently participating or plan to participate in another investigational device, drug or surgical 
study. You also may not participate in this study if you have any medical conditions requiring an 
MRI; Conditions that require chemotherapy for the treatment of a malignancy or requiring 
chronic oral or intravenous steroid therapy; Females lactating or of child bearing potential, with a 
positive pregnancy test or not using adequate birth control; and/or a medical condition requiring 
hospitalization in the next year. 
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Procedures 
 
Screening Visits 
After enrolling in the study, you will have three screening visits in order to determine your 
eligibility to be in this study.  There will be at least two weeks between each visit.   
 
During the first screening visit, your doctor will determine whether you are eligible for the study.  
This visit will include recording your current condition and symptom.  The first screening visit 
will take about four hours to complete.  At this visit, the following procedures will occur: 
• You will be asked about your medical and family history, current health problems and 
medications; 
• You will have a physical exam; 
• If you are female, you may be asked to provide a urine sample for a pregnancy test; 
• You will be asked to complete several questionnaires regarding your mood and your 
quality of life; 
• The study psychiatrist will ask you questions about your mood, functioning, physical 
symptoms and quality of life. 
 
Some of your answers will be videotaped. 
 
During the second screening visit, the doctor will ask you several questions about your mood and 
symptoms.  You will also be asked to complete some questionnaires.  This visit will take about 
60 minutes. 
 
The third screening visit will occur at least two weeks before surgery. During this visit, the 
doctor will ask you several questions about your mood and symptoms. If you qualify for the 
study after answering the questions, you will meet with the neurosurgeon that will explain the 
procedure, and perform an exam to make sure you can have surgery.  You will schedule a time 
for several tests on your memory and cognitive function (how your thought processes are 
working). You may also schedule a Magnetic Resonance Imaging (MRI) scan before the surgery.  
This is a picture of your brain, which will allow the neurosurgeon to rule out any problems. You 
will not feel any pain as part of this scan. Because of the number of these tests, this visit could 
take up to four hours.   
 
Medications 
You may continue to take antidepressant and other medications during this study. However, you 
must stay on the same medications at the same doses during the four weeks prior to enrolling 
into the study and during the 6 months following surgery (excluding sleep aids and other meds to 
manage non-depression related conditions). 
 
Neurosurgical Exam 
You will meet with the neurosurgeon who will explain the planned surgical procedure.  The 
neurosurgeon will perform a detailed physical examination. A small amount of blood (about 30-
40 milliliters or 3-4 tablespoons) will be drawn. The neurosurgeon will review your blood and 
urine tests to make sure that you are medically able to undergo brain surgery. You will sign a 
separate surgical consent just prior to the operation. 
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Surgery 
You will be admitted to the hospital on the morning of the surgery. A MRI scan will be obtained 
and used in the operating room to place the surgical frame and the DBS electrodes.  
DBS system includes: 
• Two leads, which consists of insulated wires with four electrodes at the end 
• Two extensions, which connects the lead to the power source 
• Implantable Pulse Generator (IPG), which is the power source. 
 
The IPG is a metal “can” about 2 inches in diameter and about ½ inch thick that is inserted like a 
pacemaker under the skin. It contains a small battery and produces the electrical impulses needed 
for stimulation. Battery life varies for each patient, depending on the type and intensity of 
stimulation needed for good symptom relief. For patients using electrical stimulation to treat 
disabling tremor and chronic pain, battery life has typically been three to five years when used 
continuously. When it is time to replace the battery, minor surgery is required to remove the used 
IPG and insert a new one. 
 
In the operating room, local anesthesia will be used to numb your scalp, an incision measuring 
approximately 2 inches long will be made on each side of your head, and then two holes will be 
placed in the top of your skull (one on each side of your head) to obtain access to your brain. The 
neurosurgeon will then insert two small electrodes into your brain. The electrodes contain special 
contacts attached to tiny wires that come out of the holes made in your skull. 
 
Immediately after insertion of the electrodes, you will have a second procedure (approximately 
45 minutes under general anesthesia) to connect the electrodes to the extension cable that is 
tunneled under the skin behind your ear, and this is then connected to the IPG which will be 
placed below your collarbone, just under your skin. Following surgery, you will have an image 
taken to make sure that the electrodes are in the right place.  
 
Randomization 
There will be 2 groups in the study.  The group you are assigned to will be chosen by chance 
(like flipping a coin). This will happen only after the surgery is completed. At that time, you will 
be randomly assigned to treatment Group A or Group B.  You have a 67% chance (2 out of 3) of 
being in Group A.  You have a 33% chance (1 out of 3) of being in Group B.  If you are 
randomly assigned to Group A your doctor will turn your DBS system on.  If you are randomly 
assigned to Group B your DBS system will not be turned on until 6 months after your system has 
been fully implanted. 
 
Neither you nor the study doctor will know which group you are in. 
 
 
Follow-up visits 
After the system implant, the study period will last approximately 12 months.   
You will return to the neurosurgeon’s office within 2 weeks after surgery to check your wounds 
and healing process.  You will also need to return to the study psychiatrist’s office 14 times for 
study related visits, which will occur 2 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 
months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months and 1 year after your 
Page 114 of 291
  ANS C-07-01 
  
5 of 11  Patient Initials ______ 
 
system has been fully implanted.  You will receive a phone call a few days before each visit, to 
remind you of your upcoming appointment. You will also be assigned a case manager from the 
study psychiatrist’s office who will keep in contact with you throughout the length of the study. 
 
Case Manager Visits 
You will have scheduled visits with your case manager a minimum of every two weeks to a 
maximum of weekly for the length of the study.  The case manager will follow your care for the 
duration of the study. 
 
Post-operative follow up visit (within weeks after surgery) 
This visit will occur within two weeks after surgery at the neurosurgeon’s office.  The following 
procedures will occur: 
• Your neurosurgeon will ask if you have had any complications since surgery 
• Your neurosurgeon will check your wounds for any sign of infection, to possibly 
remove sutures and to make sure you are healing properly. 
 
Weeks 2, 4, 6 and 8, and Months 3, 4, 5, 7, 8, 9, 10 and 11 Visits 
At these visits, the following procedures will occur: 
• You will be asked if you have had any complications since your last visit 
• The doctor will ask you several questions about your mood, in order to assess your 
level of depression 
• You will be asked to complete a questionnaire to assess your mood and quality of life 
• This visit will include programming on your system, if necessary, to optimize your 
system. 
The visit will take about 60 minutes.  Some of your answers at 3 month visit will be videotaped. 
 
6 Month Visit 
This visit will include the following procedures: 
• You will be asked if you have had any complications since your last visit 
• You will have a psychiatric evaluation.  The doctor will ask you several questions 
about your mood and symptoms.  This is in order to assess your level of depression 
• You will be asked to complete a questionnaire to assess your mood and quality of life 
• Your visit will include programming to optimize your system, if necessary 
• You will also have several tests on your memory and cognitive function (how your 
thought processes are working) 
This visit will take about four hours.  Some of your answers will be videotaped.   
 
12-Month Visit 
This visit will include the following procedures: 
• You will be asked if you have had any complications since your last visit 
• You will have a psychiatric evaluation.  The doctor will ask you several questions 
about your mood and symptoms.  This is in order to assess your level of depression 
• You will be asked to complete a questionnaire to assess your mood and quality of life 
• Your visit will include programming to optimize your system, if necessary 
• You will also have several tests on your memory and cognitive function (how your 
thought processes are working) 
This visit will take about four hours.   
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At the end of this study, you will be asked to participate in a long-term study.  The study staff 
will tell you more about that study at that time.  You will be given a separate informed consent 
form for that study. 
 
Risks and Discomforts 
 
This study is designed to test a new treatment for your depression.  There may be some risks, 
discomforts, or side effects that are not yet known. 
 
Risk of Surgery 
As with any surgery, there are risks involved from the surgery and/or the anesthesia.  Your 
doctor will discuss these with you. The risk of serious complications from surgical placement of 
the electrodes is estimated at 8-10%. This is based on known risks of similar surgery done in 
different brain targets for the treatment of Parkinson’s disease and other conditions. The most 
serious risk of surgery is bleeding into the brain (7-8%). Bleeding into the brain can lead to death 
or stroke that may result in permanent neurological deficits (8-9%), including weakness, 
paralysis, seizures or convulsions, difficulty speaking, impaired thinking and loss of feeling. The 
risk of death with the general anesthesia for implantation of the pacemaker is small. Damage to 
brain tissue might also be experienced. There is also a possibility of bleeding under the skin of 
your scalp. You may experience pain, discomfort and/or swelling at the sites of the incisions in 
the head and chest, and at the sites where the pins of the stereotactic frame go. These problems 
generally go away within 1 week.  You can also have air entering the veins or brain which can 
cause damage.  Air entering the brain may cause confusion leading to an extra day stay in the 
hospital.  Cerebrospinal fluid or fluid around the brain may leak or be found to be abnormal 
during the surgery. An additional surgery may be necessary to manage some complications.  
 
Risk of DBS Treatment  
While using the device several complications can occur. Occasionally, you might experience 
headache, disequilibrium (unbalance feeling), paresis (partial loss of limb movement), sleep 
disturbance, and sensory deficit. Less common complications would include neuralgia (painful 
feeling of nerves), cognitive impairments (confusion, abnormal thinking, hallucinations, 
alteration of mentation, amnesia, delusions or dementia), ataxia (loss of coordination of legs or 
trunk muscles), hearing and visual disturbance, apathy, eye disorder, drowsiness, difficulty 
breathing, increased salivation, rapid heart rate, pneumonia, edema including periorbital 
(swelling), and syncope (fainting).  Some rare complications include neuropathy (problems with 
nerves) and myoclonus (jerking or twitching movements). Other complications that might occur 
during the study include fever, attention deficit, dysarthria (slowed or slurred speech), suicide or 
suicide attempt, increase in drug side effects, autonomic instability (change in vital signs), 
urinary incontinence, worsening depression symptoms, anxiety, ruminativeness, hypomania, 
mania, panic attacks, obsessive compulsive disorder (OCD) symptoms, psychosis, sweating, 
diarrhea, and nausea and/or vomiting. 
 
Risk of Device 
It is also possible that an implanted electrode or IPG may move, break or become dislodged. 
There is also the chance of allergic reaction to the device. Care must be taken to see that 
implanted devices do not become infected. This could cause an infection not only in the area of 
the implanted device, but an infection that involves the whole body. Such an infection would 
require treatment with antibiotics and possibly surgery to remove the stimulation system. The 
risk of infection or malfunction of the DBS device and/or IPG is about 10.6%. It may be 
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necessary to remove the DBS device. Reasons for removing the device include damage to device 
or infection that does not respond to antibiotics. If your depression does not improve over time or 
you experience a worsening in your clinical condition, the investigators will discuss with you the 
options of removing the device. Removal of the device has a very low risk of serious 
complications but they are the same as those associated with surgical implantations of the device 
(see above).  The loss of therapeutic response, tingling sensation, initial jolt or tingling during 
start of the device, undesirable changes in stimulation, or wearing away of skin over IPG site, 
burr hole cap or extensions, persistent pain or redness at IPG site or extension may result as a 
complication related to the device. 
 
At a Neurological Devices Advisory Panel held in March 2000, data was presented that found 
that during a study of Parkinson’s disease patients receiving deep brain stimulator implantations 
(in a different part of the brain), 139 of 159 patients experienced one or more adverse events. 
Serious adverse events were experienced by 52.2% of patients including 6.3% of patients who 
experienced hemiparalysis or hemiparesis in the one study. The rate of any adverse event was 
about 88%. In that study the system was implanted into either the globus pallidus or the 
subthalamic nucleus, which are two different locations in the brain. In 2002, the device was 
approved by the FDA for “bilateral stimulation of the internal globus pallidus (Gpi) or the 
subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of 
advanced, levodopa-responsive Parkinson’s disease that are not adequately controlled with 
medication.” The device used in the study reported was made by a different manufacturer but is 
similar to the ANS device you will be receiving. It cannot be determined at this time whether the 
risks will be more, less or the same as those reported at the panel meeting. If you have any 
questions regarding the risks that could occur, please discuss your concerns with your implanting 
physician. 
 
You may require additional neurosurgical procedures to manage one of the complications listed 
above, or to replace a fractured lead.  You may also require further surgical procedures to replace 
the IPG device when the battery expires.   
 
Additional risks of having a DBS system: 
 
You should not be exposed to diathermy (deep heating) treatments that are sometimes used for 
muscle relaxation. Energy from diathermy can be transferred through the implanted system and 
can cause tissue damage at the location of the implanted electrodes, resulting in severe injury or 
death. Please be aware that you should always inform your health care providers that you have 
an implanted DBS system and should not be exposed to any type of diathermy. 
 
You should not be exposed to repeat Magnetic Resonance Imaging (MRI). MRIs have the 
potential to induce repositioning, rotation, and heating in implanted medical devices. Exposure to 
MRI with an implanted DBS system may also cause permanent neurological damage or even 
death. If you need regular MRI to monitor another medical condition, you cannot participate in 
this study.  
 
The risks of performing electroconvulsive therapy (ECT) with DBS are not known, but may 
include serious neurological injury or death. You should not have ECT with an implanted DBS 
system whether the device is active (ON) or inactive (OFF).  If your depression worsens and you 
choose to have ECT after the first 6 month period or withdrawal from the study we will discuss 
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with you whether the DBS device should be removed beforehand.  In addition, you should not 
receive rTMS or MST therapy with an implanted DBS system. 
 
The long-term effects of DBS for depression are not known. There may be side effects or risks 
that are not yet known. You will be monitored carefully to determine if you are experiencing a 
reaction to DBS.  
 
Reproductive Risks 
If you are a female of childbearing potential, you will be asked to take a urine pregnancy test to 
ensure you are currently not pregnant.  You will also be required to use proper birth control 
methods for the duration of the study.  Women who are currently nursing a child are not allowed 
to take part in this study. 
 
Safeguards 
 
If you agree to participate in this study, you must report all of your past and present diseases to 
the Investigator.  Any allergies you have must also be reported.  
 
Potential Benefit 
 
Deep brain stimulation has the potential to improve your depression.  However, it cannot be 
guaranteed that the treatment you receive will be more effective than classical antidepressant 
treatments.  This study may help future patients suffering from major depression.  You may not 
directly benefit from participating in this study.  
 
Alternatives to Being in this Study 
 
If you are not to be able to have an implant or if you choose not to undergo the surgical 
procedure to implant the system, you will have the chance to discuss other treatment options with 
your doctor.  There may be other medications or forms of psychotherapy that may help you.  
Electro-convulsive therapy (ECT) is another alternative that has been used to treat depression 
that is unresponsive to conventional treatments.  There is also an FDA approved potential 
surgical alternative treatment called vagus nerve stimulation.  Another option will be to continue 
your current method of treatment.  You should discuss other treatment alternatives with your 
psychiatrist before choosing to participate in this study. 
   
Confidentiality 
 
We will protect information about you and your taking part in this research study to the best of 
our ability.  If information about this study is published, your name will not be given.  However, 
the U.S. Food and Drug Administration (FDA), the ______________________ Institutional 
Review Board (IRB), your doctors and designated representatives of the study sponsor, 
Advanced Neuromodulation Systems, Inc. (ANS), may sometimes look at the medical records 
and study information of those who take part in this study.  Representatives of ANS may be 
given permission to be present during the surgical procedure.    
 
A court of law could order medical records shown to other people, but that is unlikely.  However, 
absolute confidentiality cannot be guaranteed.  
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Payment for Medical Care for Injury Related to this Study 
 
Complications or any unexpected events are possible in any research study.  Advanced 
Neuromodulation Systems, Inc. (ANS) will pay for emergency treatment for any injury or 
adverse condition that appears while you are involved in the study that is not covered by your 
insurance company.  The injury or adverse condition must have occurred as a direct result of 
treatment that was being administered in accordance with the study protocol.  Payment for non-
emergency treatment is not available.  Payment for lost wages, disability or discomfort is not 
available.  You do not give up any of your rights by signing this form. 
 
Cost of Being in the Study 
 
The charges for implanting the DBS system and for the follow up visits required by the study 
protocol will be covered by the study sponsor.  You will not be billed for any of the procedure or 
device costs required by the study.  The sponsor will also cover your expenses for any tests 
performed for study purposes.   
 
You will be compensated for your travel costs and for your time involved in the study.  You will 
receive $50 for each of the eighteen study visits completed and parking vouchers to cover travel-
related expenses.  If you decide to drop out of the study before you have completed the 12-month 
study visit, your payment will be prorated.  You would then be paid for the visits that you 
completed during your time taking part in the study.  MODIFY AS NEEDED TO DETAIL 
HOW PAYMENT WILL BE PROCESSED 
 
Post-study Care 
 
At the end of the 12 month study period or if you exit the study prior to the end of the 12 month 
study period, you will continue to be followed by your study psychiatrist so he/she can program 
your DBS system.  ANS will cover the customary costs associated with these visits up to a 
maximum of 4 programming visits a year and will cover surgical costs and expenses for care 
directly related to the DBS system, such as costs associated with removing or replacing the 
device.  This coverage will continue until the DBS system is approved by the FDA for the 
treatment of major depressive disorder, ANS discontinues this study or the FDA denies approval 
of the DBS system, whichever occurs first.  Once one of the preceding events takes place, you 
will be notified by the study doctor or his/her staff. Post study care is limited to reasonable and 
necessary care and does not include any non-device related care or other psychiatric care such as 
hospitalizations, counseling, psychiatric visits, etc.  Please discuss all plans and questions 
regarding your ongoing care with your study physician.   
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Whom to Contact with Questions 
 
If you should experience an adverse event, or have a study related question please contact 
immediately: ________________at (XXX) XXX-XXXX or after hours at (XXX)XXX-
XXXX. 
 
If you are considering suicide right now, please immediately call 911 or the National Suicide 
Prevention Hotline at 1-800-273-TALK (8255). The National Suicide Prevention Hotline is a 
24-hour, toll-free suicide prevention service available to anyone in suicide crisis.  Alternatively, 
please contact your study doctor __________ or staff ___________ immediately at (XXX) XXX-
XXXX or after hours at (XXX) XXX-XXXX. 
 
If you have any questions or concerns about your rights regarding research in human subjects 
please contact.  The________________ Institutional Review Board at (XXX) XXX-XXXX or 
after hours at (XXX) XXX-XXXX 
 
Voluntary Participation/Withdrawal from Study 
 
Your participation in this study is strictly voluntary and will not prejudice you from future 
relations with your psychiatrist, or Advanced Neuromodulation Systems.  If you decide to 
participate, you are free to stop participating at any time.  If you decided to withdraw, notify your 
study psychiatrist.  This will allow your study psychiatrist to tell you if there are any potential 
medical risks of withdrawal.  If you withdraw from this study your device will be turned off and 
you will have two options.  The first option is to have the DBS system removed.  The second 
option is to enroll in a long-term follow up study.  To be eligible to enroll in the long term follow 
up study, you must have your DBS system implanted for 6 months.  You must also understand 
that your study psychiatrist or Advanced Neuromodulation Systems may stop the project or your 
participation in it at any time.   
 
You will be kept informed of any significant findings throughout this study that may affect your 
willingness to continue to participate. 
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Authorization  
 
The protocol has been explained to me along with the possible discomforts, inconveniences, and 
risks of the study.  I understand that if I refuse to participate or withdraw at any time, my 
treatment will not be affected in any way.  I have had an adequate chance to ask questions and I 
know I may ask questions at any time during the study.  I do not waive any rights I would 
otherwise have by signing this form. 
 
_______________________________________  
Printed name of Patient or Responsible Party 
 
_______________________________________ ______________ 
Signature of Patient or Responsible Party Date 
 
_______________________________________  
Printed name of Witness 
 
_______________________________________ _______________ 
Signature of Witness Date 
 
_______________________________________ 
Printed name of Investigator 
 
_____________________________________ _______________ 
Signature of Investigator Date 
 
 
I WILL BE GIVEN A SIGNED COPY OF THIS INFORMED CONSENT 
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Date of Visit: ___/___/_____ 
Name of Visit: ___________ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
Informed Consent Process 
ICF Date: ____/____/_______        ICF Time: ____: ____AM/PM 
 
ICF IRB Approved: ____/____/_______ 
 
ICF Copy to Patient    Yes    No   
                                 If  No, specify why:________________________          
California Bill of Rights   Yes     NO      NA 
 
If No, specify why:______________________________________ 
              
 If yes, Date ____/____/________      Time: ____: ____AM/PM   
 
Copy to Patient     NA  Yes    No     If  No, specify why:____________ 
 
 
 
 
 
NOTES:  
 
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________ 
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Date of Visit: ___/___/_____ 
Name of Visit: ___________ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Inclusion Criteria  
YES 
 Men and women (non-pregnant) age 21-70; 
 Diagnosed with non-psychotic major depressive disorder, single or recurrent episode by 
DSM-IV-TR criteria derived from the MINI;  
 First episode onset before age 45; 
 Current episode > 12 months duration;  
 In the current episode: Documented resistance (i.e. persistence of the major 
depressive episode) to a minimum of 4 adequate depression treatments from at least 3 
different treatment categories (e.g. SSRI’s, SNRI’s, TCA’s, MAO-inhibitors, 
Mirtazipine, Nefazodone, Trazodone, Bupropion, lithium augmentation, thyroid 
augmentation, ECT); Adequacy of treatments as defined by a score of at least 3 
according to the amended Antidepressant Treatment History Form (ATHF) criteria;  
 In Lifetime: Received a course of psychotherapy for depression;  
 Montgomery Asberg Depression Rating Scale (MADRS) of ≥ 22 at 3 separate baseline visits, 
rated by 2 separate psychiatrists, Baseline 2 and Baseline 3 MADRS scores cannot be 
separated by > 6 weeks and cannot improve ≥ 20%;  
 Global Assessment of Function, score <50;  
 Modified mini-mental state examination (MMSE) score >24;  
 No change in current antidepressant medication regimen or medication free ≥4 weeks prior to 
study entry (with exception to sleep, cholesterol, blood pressure, sexual dysfunction, non-
migraine headache medication, or medication for other medical reasons not related to 
depression, in which changes to dose or type will be allowed during course of study);  
 Able to give informed consent in accordance with institutional policies;  
o Date signed: ____/____/________  
 Able to comply with all testing and follow-up requirements as defined by the study protocol;  
 Must be determined medically stable by surgeon, to undergo deep brain stimulation surgical 
procedure.  
 Must have platelet count, PT and PTT within normal limits of the laboratory.  
 During last 6 months in the current episode documented treatment under the care of a 
licensed psychiatrist/psychologist. 
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Date of Visit: ___/___/_____ 
Name of Visit: ___________ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Exclusion Criteria 
    NO 
 A diagnosis of a bipolar I or bipolar II disorder by DSM-IV-TR criteria, derived from the 
MINI;  
 Meets criteria for borderline or antisocial personality disorder in the last 12 months by DSM-
IV-TR criteria, derived from the Cluster B Personality Disorders Sections 301.7 – 301.83, 
and screened via SCID-II at Baseline visit;  
 In the current depressive episode, has been diagnosed with General Anxiety Disorder (GAD) 
- as defined by the DSM-IV-TR, and GAD is the primary diagnosis;  
 Has an intracranial Central Nervous System (CNS) disease that impairs motor, sensory or 
cognitive function or that requires intermittent or chronic medication (e.g., Parkinson’s 
Disease, chronic migraine, stroke, Huntington’s, head trauma, etc.) with exception to non-
migraine headaches;  
 Has been diagnosed with fibromyalgia or has a current condition which requires chronic pain 
narcotic usage (e.g. morphine, methadone);  
 Has been currently diagnosed with chronic fatigue syndrome;  
 Substantial suicidal risk as defined by (1) MADRS item 10 score of 5 or 6, (2) a current plan 
and intent, (3) clinician judgment that there is a clear immediate intent for self-harm, (4) more 
than 3 suicide attempts within the last 12 months;  
 Co-morbid obsessive compulsive disorder, post-traumatic stress disorder, panic disorder, 
bulimia or anorexia nervosa if previously present, must be in remission for 6 months as 
defined by DSM-IV-TR criteria, derived from the MINI;  
 Alcohol, medication, or illegal substance dependence or abuse within last 12 months derived 
from the MINI;  
 Diagnosis of sleep apnea confirmed by a sleep test that is not adequately treated;  
 Advanced cardiovascular disease which renders anesthesia and surgery as unsafe as 
determined by neurosurgeon;  
 Clinically relevant abnormality (e.g. tumor or growth) on study MRI;  
 Has cardiac pacemaker/defibrillator or other implanted active stimulator;  
 Has a medical condition requiring a repetitive MRI body scan;  
 Requires chemotherapy for the treatment of malignancy or requiring chronic oral or 
intravenous (immunosuppressive or) steroid therapy;  
 Is unable to comply with study visit schedule and timeline;  
 Past ablative or relevant intracranial surgery;  
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Date of Visit: ___/___/_____ 
Name of Visit: ___________ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
 
Exclusion Criteria 
    NO 
 A female lactating or of child bearing potential, with a positive pregnancy test or not using 
adequate contraception;  
 Lifetime psychotic disorders, schizophrenia, or schizoaffective disorder defined by DSM-IV-
TR;  
 Psychotic features in current depressive episode as diagnosed by DSM-IV-TR criteria;  
 Other medical conditions likely to require hospitalization within the next year;  
 Received ECT within 3 months prior to enrollment, or requires ECT for the duration of the 
study;  
 Has a history of epilepsy or history of status epilepticus;  
 Plans to use diathermy;  
 Has any metallic implants such as aneurysm clips or cochlear implants;  
 Currently participating in another investigational device, drug or surgical trial.  
 
 
 
 
I have reviewed the above criteria and this patient is qualified to participate in the 
study: 
Investigator Signature ___________________________________________ 
4 of 165
Page 126 of 291
ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit: ___________ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
 
 
 
 
 
 
 
DEMOGRAPHICS 
Date of Birth: 
 
         
  Month       Day          Year 
Gender: 
 Male  
 Female 
Height: 
 
____ft. __ in 
Race: 
 Caucasian          African American 
 Hispanic            Asian 
 Other _________________ 
LIVING STATUS  
What is the subject’s marital status?  Single   Married   Divorced   Separated   Other:_________ 
What is the subject’s current living 
situation? 
 Lives alone  Lives with spouse/partner and/or children                      
 Lives with other family   Lives in boarding home   Hospitalized  
 Other:___________________ 
INSURANCE INFORMATION 
What is the subject’s current insurance 
status? 
 Private Insurance   Self Pay    Medicaid    Medicare  
 Other  ______________________ 
PSYCHIATRIC HISTORY 
Age of onset of MDD: _______________  years of age 
Number of lifetime episodes: _______________  number of episodes 
Date of onset of current episode:  _____/____/_______   (mm/dd/yyyy) 
Is the subject of the melancholic subtype?   YES    NO 
 
Has the subject ever had an electroconvulsive therapy 
(ECT)? 
  Full Course    Partial Course    Never had ECT 
                                        ↓ 
If partial, why? _________________________________ 
Last treatment date:  ____/____/_____ (mm/dd/yy) 
Has subject ever been hospitalized for an MDD episode?    Current    Lifetime   Both Lifetime/Current   
   Never hospitalized for MDD 
Has the subject attempted suicide in the last: 
Past 12 Months 
> 12 months, but < 2 years 
> 2 years, but <3 years 
   Never attempted 
   YES    NO    Number of times ______ 
   YES    NO    Number of times ______ 
   YES    NO    Number of times ______              
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Date of Visit: ___/___/_____ 
Name of Visit: ___________ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
 
PSYCHIATRIC HISTORY CONTINUED 
Does the subject have a family history of mood 
disorders? 
 YES    NO 
 If yes, which family members had the mood 
disorders? 
 1st Degree (immediate family)    
 Other    Both 
Indicate the type of psychotherapy the subject has participated in: 
Cognitive Behavioral 
Therapy 
 
Current     Yes       No 
 
Past           Yes       No 
 
 Successful Unsuccessful 
 
 Successful Unsuccessful 
 
Duration in months: _____ 
 
Duration in months: _____ 
 
Group Therapy 
 
 
Current     Yes       No 
 
Past           Yes       No 
 Successful Unsuccessful 
 
 Successful Unsuccessful 
 
Duration in months: _____ 
 
Duration in months: _____ 
 
Interpersonal  
Therapy 
 
Current     Yes       No 
 
Past           Yes       No 
 Successful Unsuccessful 
 
 Successful Unsuccessful 
 
Duration in months: _____ 
 
Duration in months: _____ 
 
Psychodynamic 
Therapy 
 
Current     Yes       No 
 
Past           Yes       No 
 Successful Unsuccessful 
 
 Successful Unsuccessful 
 
Duration in months: _____ 
 
Duration in months: _____ 
 
Supportive  
 
Current     Yes       No 
 
Past           Yes       No 
 Successful Unsuccessful 
 
 Successful Unsuccessful 
 
Duration in months: _____ 
 
Duration in months: _____ 
 
Other: 
__________________ 
 
Current     Yes       No 
 
Past           Yes       No 
 Successful Unsuccessful 
 
 Successful Unsuccessful 
 
Duration in months: _____ 
 
Duration in months: _____ 
 
Other: 
__________________ 
 
Current     Yes       No 
 
Past           Yes       No 
 Successful Unsuccessful 
 
 Successful Unsuccessful 
 
Duration in months: _____ 
 
Duration in months: _____ 
 
MADRS SCORE 
Is the subject’s MADRS score ≥ 22 for this visit?  YES→   ________ (score)  
 NO →   Do not proceed. Subject does not qualify. 
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Date of Visit: ___/___/_____ 
Name of Visit: ___________ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
Clinically Significant Medical History 
System Description 
 HEENT 
 Yes   No    
 
Endocrine 
 Yes   No    
 
Cardiovascular 
 Yes   No    
 
 Respiratory 
 Yes   No    
 
 Gastrointestinal 
 Yes   No    
 
 Musculoskeletal 
 Yes   No    
 
 Psychological 
 Yes   No    
 
 Neurological 
 Yes   No    
 
 Skin 
 Yes   No    
 
 Other: ___________________________ 
 Yes   No    
 
Other:  ___________________________ 
 Yes   No    
 
 Additional comments  None 
 
_________________________________________________________________________________ 
_________________________________________________________________________________ 
_________________________________________________________________________________ 
_________________________________________________________________________________ 
_________________________________________________________________________________ 
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Date of Visit: ___/___/_____ 
Name of Visit: ___________ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
 
 
Brief Physical Exam 
VITAL SIGNS 
Blood Pressure (Systolic/ Diastolic)  ______/_____     mmHg Heart Rate (Beats Per Minute)            _________ BPM 
PREGNANCY TEST 
 Positive                  Negative                N/A (Male)                N/A (Female non child bearing potential) 
BRIEF PHYSICAL EXAM 
System IF ABNORMAL, PROVIDE DETAILS BELOW 
HEENT 
  Normal             Abnormal        Not Done 
 
Endocrine 
  Normal            Abnormal        Not Done 
 
Cardiovascular 
  Normal            Abnormal         Not Done 
 
Respiratory 
  Normal             Abnormal        Not Done 
 
Gastrointestinal 
  Normal             Abnormal        Not Done 
 
Musculoskeletal 
  Normal             Abnormal        Not Done 
 
Psychological 
  Normal             Abnormal        Not Done 
 
Neurological 
  Normal             Abnormal        Not Done 
 
Skin 
  Normal             Abnormal        Not Done 
 
Other: ___________________________ 
  Normal             Abnormal        Not Done 
 
Additional comments  None 
____________________________________________________________________________________________________ 
 
____________________________________________________________________________________________________ 
 
____________________________________________________________________________________________________ 
Physical Exam performed by: 
_____________________________________________ ______________________________ 
Signature Date (mm/ dd/ yyyy) 
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Date of Visit: ___/___/_____ 
Name of Visit: ___________ 
 
Modified ATHF Rating for Antidepressant Potency – DBS for TRD 
 
 Page 1 of 18  
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
FOR EACH TREATMENT, INDICATE WHETHER IT IS A LIFETIME 
AND/OR CURRENT TREATMENT. RATE EACH TREATMENT TRIAL 
SEPARATELY, EVEN IF TAKEN AT SAME TIME. 
 
TCA/Tetracyclic 
I.  Amitriptyline (Elavil, Endep)   ____ LIFETIME     ____ CURRENT 
 By dosage: 
 1 < 4 wks   OR  < 100 mg/d 
 2 4 wks or more and 100-199 mg/d 
 3 4 wks or more and 200-299 mg/d 
4 4 wks or more and ≥ 300 mg/d  
 
II. Imipramine (Tofranil)     ____ LIFETIME     ____ CURRENT 
 By dosage: 
 1 < 4 wks   OR  < 100 mg/d 
 2 4 wks or more and 100-199 mg/d 
 3 4 wks or more and 200-299 mg/d 
4 4 wks or more and ≥ 300 mg/d  
 
By  blood level (levels take precedence over dose) 
 4 4 wks or more and DMI level ≥ 125 ng/ml  
4 4 wks or more and IMI + DMI ≥ 225 ng/ml  
 
III. Desipramine (Norpramine, Pertofrane)     ____ LIFETIME     ____ CURRENT 
 By dosage: 
 1 < 4 wks   OR  < 100 mg/d 
 2 4 wks or more and 100-199 mg/d 
 3 4 wks or more and 200-299 mg/d 
4 4 wks or more and ≥ 300 mg/d 
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Date of Visit: ___/___/_____ 
Name of Visit: ___________ 
 
Modified ATHF Rating for Antidepressant Potency – DBS for TRD 
 
 Page 2 of 18  
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
By  blood level (levels take precedence over dose) 
 4 4 wks or more and DMI level ≥ 125 ng/ml  
             
IV. Trimipramine (Surmontil)                             ____ LIFETIME     ____ CURRENT 
 By dosage: 
 1  < 4 wks   OR   < 100 mg/d 
 2 4 wks or more and 100-199 mg/d 
 3 4 wks or more and 200-299 mg/d 
4 4 wks or more and ≥ 300 mg/d  
 
V. Clomipramine (Anafranil)                                  ____ LIFETIME     ____ CURRENT 
 By dosage: 
 1  < 4 wks   OR   < 100 mg/d 
 2 4 wks or more and 100-199 mg/d 
 3 4 wks or more and 200-299 mg/d 
4 4 wks or more and ≥ 300 mg/d  
 
VI. Maprotiline (Ludiomil)                                   ____ LIFETIME     ____ CURRENT 
 By dosage: 
 1  < 4 wks   OR   < 100 mg/d 
 2 4 wks or more and 100-199 mg/d 
 3 4 wks or more and 200-299 mg/d 
4 4 wks or more and ≥ 300 mg/d  
 
VII. Doxepin (Sinequan, Adapin)       ____ LIFETIME     ____ CURRENT 
 By dosage: 
 1  < 4 wks   OR   < 100 mg/d 
 2 4 wks or more and 100-199 mg/d 
 3 4 wks or more and 200-299 mg/d 
4 4 wks or more and ≥ 300 mg/d  
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Date of Visit: ___/___/_____ 
Name of Visit: ___________ 
 
Modified ATHF Rating for Antidepressant Potency – DBS for TRD 
 
 Page 3 of 18  
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
VIII. Nomifensine    ____ LIFETIME     ____ CURRENT 
 By dosage: 
 1  < 4 wks   OR   < 100 mg/d 
 2 4 wks or more and 100-199 mg/d 
 3 4 wks or more and 200-299 mg/d 
4 4 wks or more and ≥ 300 mg/d  
 
IX.  Nortriptyline (Pamelor, Aventyl)    ____ LIFETIME     ____ CURRENT 
By dosage: 
 1 NT < 4 wks   OR   4 wks or more and NT < 50 mg/d 
 2 4 wks or more and NT 50-75 mg/d 
 3 4 wks or more and NT 76-100 mg/d 
 4 4 wks or more and NT > 100 mg/d 
 
By blood level:  levels take precedence 
 1 Nortriptyline < 4 wks 
 2 4 wks or more and level < 50 ng/ml  
 3 4 wks or more and level  50-99 ng/ml 
 4 4 wks or more and level  > 100 ng/ml 
 
X.  Protriptyline (Vivactil)     ____ LIFETIME     ____ CURRENT 
 1 drug < 4 wks   OR   4 wks or more and dosage ≤ 30 mg/d 
 2 4 wks or more and dosage 31-40 mg/d 
 3 4 wks or more and dosage 41-60 mg/d 
 4 4 wks or more and dosage  > 60 mg/d 
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Date of Visit: ___/___/_____ 
Name of Visit: ___________ 
 
Modified ATHF Rating for Antidepressant Potency – DBS for TRD 
 
 Page 4 of 18  
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSNRI) 
 
I.  Duloxetine (Cymbalta)   ____ LIFETIME     ____ CURRENT 
1 drug < 4 wk or 4 wk or more and dosage <30 mg/d 
2 4 wk or more and dosage 30 – 39 mg/d 
3 4 wk or more and dosage 40 – 59 mg/d 
4 4 wk or more and dosage > 60 mg/d  
 
II.  Venlafaxine (Effexor and Effexor XR)     ____ LIFETIME     ____ CURRENT 
 1 less than 4 wks  OR   4 wks or more and dosage  < 75 mg/d 
 2 4 wks or more and dosage 75-224 mg/d 
 3 4 wks or more and dosage 225-374 mg/d 
 4 4 wks or more and dosage ≥ 375 mg/d 
 
III.  Desvenlafaxine (Pritiq)                             ____ LIFETIME     ____ CURRENT 
 1 less than 4 weeks 
 2 4 wks or more and dosage 25-49 mg/d 
 3 4 wks or more and dosage 50-100 mg/d 
 4 4 wks or more and dosage ≥ 100 mg/d 
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Date of Visit: ___/___/_____ 
Name of Visit: ___________ 
 
Modified ATHF Rating for Antidepressant Potency – DBS for TRD 
 
 Page 5 of 18  
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
SSRIs 
 
I.  Fluoxetine (Prozac)      ____ LIFETIME     ____ 
CURRENT 
 1 drug < 4 wks   OR   4 wks or more and dosage 1-9 mg/d 
 2 4 wks or more and dosage 10-19 mg/d 
 3 4 wks or more and dosage 20-39 mg/d 
 4 4 wks or more and dosage ≥ 40 mg/d 
 
II.  Fluvoxamine (Luvox)     ____ LIFETIME     ____ CURRENT 
 1  drug < 4 wks OR   drug < 100 mg/d 
 2 4 wks or more and 100-199 mg/d 
 3  4 wks or more and 200-299 mg/d 
 4 4 wks or more and ≥ 300 mg/d 
  
Please document both below, but only one paroxetine trial (either Paxil or Paxil CR) can 
count as an adequate therapy, not both. 
III a.   Paroxetine (Paxil)  ____ LIFETIME     ____ CURRENT 
 1 drug < 4 wks  OR   4 wks or more and dosage 1-9 mg/d 
 2 4 wks or more and dosage 10-19 mg/d 
 3 4 wks or more and dosage 20-29 mg/d 
 4 4 wks or more and dosage ≥ 30 mg/d 
 
OR 
III b. Paroxetine CR (Paxil CR)    ____ LIFETIME     ____ CURRENT 
 
1 drug < 4 wk or 4 wk or more and dosage <12.5 mg/d 
2 4 wk or more and dosage 12.5 mg/d 
3 4 wk or more and dosage 25-50 mg/d 
 4 4 wk or more and dosage > 62.5 mg/d 
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IV.  Sertraline (Zoloft)      ____ LIFETIME     ____ CURRENT 
 1 drug < 4 wks   OR   4 wks or more and dosage < 50 mg/d 
 2 4 wks or more and dosage 50-149 mg/d 
 3 4 wks or more and dosage 150-199 mg/d 
 4 4 wks or more and dosage ≥ 200 mg/d 
 
V. Citalopram (Celexa)      ____ LIFETIME     ____ CURRENT 
 
1 drug < 4 wk or 4 wk or more and dosage 1-9 mg/d 
2 4 wk or more and dosage 10-19 mg/d 
3 4 wk or more and dosage 20-39 mg/d 
4 4 wk or more and dosage > 40 mg/d 
 
VI. Escitalopram (Lexapro)     ____ LIFETIME     ____ CURRENT 
 
1 drug < 4 wk or 4 wk or more and dosage 1-4 mg/d 
2 4 wk or more and dosage 5-9 mg/d 
3 4 wk or more and dosage 10-19 mg/d 
4 4 wk or more and dosage > 20 mg/d 
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Other Antidepressants 
 
I.  Bupropion (Wellbutrin, Wellbutrin SR, Wellbutrin XL)   ____ LIFETIME     ____ 
CURRENT 
 1 drug < 4 wks   OR   4 wks or more and dosage < 150 mg/d 
 2 4 wks or more and dosage 150-299 mg/d 
 3 4 wks or more and dosage 300-449 mg/d 
 4 4 wks or more and dosage ≥ 450 mg/d 
 
II.  Mirtazapine (Remeron)   ____ LIFETIME     ____ CURRENT 
 1 less than 4 wks   OR   4 wks or more and dosage < 15 mg/d 
 2 4 wks or more and dosage 15-29 mg/d 
 3 4 wks or more and dosage 30-44 mg/d 
 4 4 wks or more and dosage ≥ 45 mg/d  
 
III.  Nefazodone (Serzone)   ____ LIFETIME     ____ CURRENT 
 1 drug < 4 wks OR   4 wks or more and dosage < 150 mg/d 
 2 4 wks or more and dosage 150-299 mg/d  
 3 4 wks or more and dosage 300-599 mg/d 
 4 4 wks or more and dosage ≥ 600 mg/d  
 
IV.  Trazodone (Desyrel)     ____ LIFETIME     ____ CURRENT 
 1 drug < 4 wks   OR   4 wks or more and dosage < 200 mg/d 
 2 4 wks or more and dosage 200-399 mg/d 
 3 4 wks or more and dosage 400-599 mg/d 
 4 4 wks or more and dosage ≥ 600 mg/d  
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VII. Amoxapine (Ascendin)   ____ LIFETIME     ____ CURRENT 
 1 drug < 4 wks   OR   4 wks or more and dosage < 200 mg/d 
 2 4 wks or more and dosage 200-399 mg/d 
 3 4 wks or more and dosage 400-599 mg/d 
 4 4 wks or more and dosage ≥ 600 mg/d  
 
VIII. Reboxetine    ____ LIFETIME     ____ CURRENT 
1 drug < 4 wk or 4 wk or more and dosage <4 mg/d 
2 4 wk or more and dosage 4 – 7 mg/d 
3 4 wk or more and dosage 8 mg/d 
4 4 wk or more and dosage > 8 mg/d  
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MAOIs 
 
I.  Phenelzine (Nardil) ____ LIFETIME     ____ CURRENT 
 1 drug < 4 wks   OR   4 wks or more and dosage ≤ 30 mg/d 
 2 4 wks or more and dosage 31-60 mg/d 
 3 4 wks or more and dosage 61-90 mg/d 
 4 4 wks or more and dosage 91 mg/d or greater 
 
II. Tranylcypromine (Parnate)  ____ LIFETIME     ____ CURRENT 
 1 drug < 4 wks   OR   4 wks or more and dosage ≤ 20 mg/d 
 2 4 wks or more and dosage 21-40 mg/d 
 3 4 wks or more and dosage 41-60 mg/d 
 4 4 wks or more and dosage ≥ 61 mg/d  
 
III. Isocarboxazid (Marplan)  ____ LIFETIME     ____ CURRENT 
 1 drug < 4 wks   OR   4 wks or more and dosage ≤ 20 mg/d 
 2 4 wks or more and dosage 21-40 mg/d 
 3 4 wks or more and dosage 41-60 mg/d 
 4 4 wks or more and dosage ≥ 61 mg/d  
IV. Moclobemide ____ LIFETIME     ____ CURRENT 
 1 drug < 4 wks OR   4 wks or more and dosage  < 150 mg/d 
 2 4 wks or more and dosage 150-299 mg/d  (100-200mg =30mg Nardil) 
 3 4 wks or more and dosage 300-599 mg/d  (300mg =60mg Nardil) 
4   4 wks or more and dosage ≥ 600 mg/d (600mg = 90mg Nardil) 
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Please document both below, but only either Eldepryl or EMSAM count as a therapy, not both. 
Va.  Selegiline (Eldepryl) ____ LIFETIME     ____ CURRENT 
 1 drug < 4 wks   OR   4 wks or more and dosage ≤ 20 mg/d 
 2 4 wks or more and dosage 21 - 40 mg/d 
 3 4 wks or more and dosage 41 - 59 mg/d 
 4 4 wks or more and dosage ≥ 60 mg/d  
 
Vb.  Transdermal Selegiline (EMSAM) ____ LIFETIME     ____ CURRENT 
 1 drug < 4 wks   OR   4 wks or more and dosage ≤ 6 mg/d 
 2 4 wks or more and dosage 6mg/d 
 3 4 wks or more and dosage 9 mg/d 
 4 4 wks or more and dosage ≥ 12 mg/d  
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Psychotherapy 
 
I. Cognitive behavioral therapy   ____ LIFETIME     ____ CURRENT 
 1 Less than 4 visits 
 2 4-11 visits 
 3 12-15 visits 
 4 16 or more visits 
 
II. Interpersonal therapy    ____ LIFETIME     ____ CURRENT 
 1 Less than 4 visits 
 2 4-11 visits 
 3 12-15 visits 
 4 16 or more visits 
 
III. Behavioral activation therapy   ____ LIFETIME     ____ CURRENT 
 1 Less than 4 visits 
 2 4-11 visits 
 3 12-15 visits 
 4 16 or more visits 
 
Note if subject has had other forms of psychotherapy (these will not count for definition of 
treatment resistance): 
 
 
 
 
 
 
 
 
19 of 165
Page 141 of 291
ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit: ___________ 
 
Modified ATHF Rating for Antidepressant Potency – DBS for TRD 
 
 Page 12 of 18  
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
ECT 
I.  Unilateral or unilateral/bilateral combination ____ LIFETIME     ____ CURRENT 
 1 1 - 3 treatments 
 2 4 - 6 treatments 
 3 7 - 9 treatments 
 4 ≥ 10 treatments 
 
II. Bilateral ECT     ____ LIFETIME     ____ CURRENT 
 1 1 - 3 treatments 
 2 4 - 6 treatments 
 3 7 - 9 treatments 
 4 ≥ 10 treatments 
 
II. ECT type unknown  (but number of treatments are documented in acceptable medical 
records) 
        ____ LIFETIME     ____ CURRENT 
 1 1 - 3 treatments 
 2 4 - 6 treatments 
 3 7 - 9 treatments 
 4 ≥ 10 treatments 
 
If ECT was attempted but not tolerated, please describe: 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
_____________________________________________________________________________ 
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Non-pharmacologic Somatic Therapies 
 
I.  VNS      ____ LIFETIME     ____ CURRENT 
1 < 6 Months 
2 6-11 Months 
3 12-24 Months 
4 > 24 Months 
 
II. TMS (left dorsolateral, >=5 Hz, >=100% motor threshold, >=1600 pulses per session) 
        ____ LIFETIME     ____ CURRENT 
1 < 10 Sessions 
2 10– 19 Sessions  
3 20-29 Sessions 
4 ≥ 30 Sessions 
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Augmentation Therapies 
 
I.  Lithium alone for MDD   ____ LIFETIME     ____ CURRENT 
 1 drug < 4 wks  OR  4 wks or more  
 
II. Lithium as an augmenting agent for MDD ____ LIFETIME     ____ CURRENT 
 4 Any antidepressants rated level 3 or higher Li used for at least 2 wks at 
  level ≥ 0.6 mEq/L 
  
III. Lamotrigine (Lamictal)     ____ LIFETIME     ____ CURRENT 
 1 drug  < 4 wks OR 
  4 wks or more and dosage  < 50 mg/d 
 2 4 wks or more and dosage  > 50 mg/d 
 
IV. Valproic acid/valproate/Depakote/Depakene  ____ LIFETIME     ____ CURRENT 
 1 drug < 4 wks OR 4 wks or more and level < 50 
 2 4 wks or more and level > 50 
 
V. Carbamazepine (Tegretol)   ____ LIFETIME     ____ CURRENT 
 1 CBZ < 4 wks   OR 4 wks or more and level < 6 
 2 4 wks or more and level >6 
 
VI. Thyroid Hormone    ____ LIFETIME     ____ CURRENT 
1 drug < 4 wks 
2 drug > 4 wks and dosage <25 mcg 
3 drug > 4 wks and dosage 25-49 mcg 
4 drug > 4 wks and dosage >=50 mcg 
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VII. Buspirone   ____ LIFETIME     ____ CURRENT 
1 drug < 4 wks or dosage <= 15 mg/d 
2 drug >4 wks and dosage 15-29 mg/d 
3 drug >4 wks and dosage 30-59 mg/d 
4 drug >4 wks and dosage >=60 mg/d 
 
VI. Aripiprazole ( Abilify )  ____ LIFETIME     ____ CURRENT 
1 drug < 4 wks 
2 drug > 4 wks and dosage <10 mg/d 
3 drug > 4 wks and dosage 10-29 mg/d 
4 drug > 4 wks and dosage >=30 mg/d 
 
VII. Ziprasidone  (Geodon)  ____ LIFETIME     ____ CURRENT 
1 drug < 4 wks 
2 drug > 4 wks; give highest dose achieved > 4 wks: ____________________ 
 
IX. Risperidone (Risperdal)  ____ LIFETIME     ____ CURRENT 
1 drug < 4 wks 
2 drug > 4 wks; give highest dose achieved > 4 wks: ____________________ 
 
X. Quetiapine (Seroquel )  ____ LIFETIME     ____ CURRENT 
1 drug < 4 wks 
2 drug > 4 wks; give highest dose achieved > 4 wks: ____________________ 
 
XI. Olanzapine (Zyprexa)  ____ LIFETIME     ____ CURRENT 
1 drug < 4 wks 
2 drug > 4 wks; give highest dose achieved > 4 wks: ____________________ 
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XII. Olanzapine/fluoxetine (Symbax 6mg/25mg )  ____ LIFETIME     ____ CURRENT 
1 drug < 4 wks 
2 drug > 4 wks; give highest dose achieved > 4 wks: ____________________ 
 3 Only score 3 if the fluoxetine/Prozac option in the SSRI section  is not scored 3 or 
  higher 
 
XIII. Pramipexole ( Mirapex )  ____ LIFETIME     ____ CURRENT 
1 drug < 4 wks 
2 drug > 4 wks; give highest dose achieved > 4 wks: ____________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
24 of 165
Page 146 of 291
ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit: ___________ 
 
Modified ATHF Rating for Antidepressant Potency – DBS for TRD 
 
 Page 17 of 18  
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Other medications and treatments (cannot be used for definition of treatment resistance) 
Include benzodiazepines, psychostimulants, light therapy, and all other pharmacologic and 
somatic treatments (e.g., testosterone, acupuncture) for depression or symptoms of depression. 
Treatment Dose Duration Comments 
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SUMMARY 
 
Confidence rating for treatment history: 
 1 Minimal confidence 
 2 Moderate confidence 
 3 Good confidence (required for up to four antidepressant treatment 
 4 Excellent confidence (requires confirmatory records) 
 
Comments on confidence rating: 
 
Lifetime Summary 
1. Total number of lifetime antidepressant medications and acceptable medication 
augmentation strategies:  ____ 
2. Total number of lifetime antidepressant medications rated 3 or higher with at least good 
confidence:  ____ 
3. Total number of lifetime antidepressant treatments rated 3 or higher (can include 
psychotherapy, ECT, VNS, TMS):  ____ 
4. Total number of lifetime treatments for depression (including all others listed on this 
document):  ____ 
 
Current Summary 
1. Total number of current antidepressant medications and acceptable medication 
augmentation strategies:  ____ 
2. Total number of current antidepressant medications rated 3 or higher:  ____ 
3. Total number of current antidepressant treatments rated 3 or higher (can include 
psychotherapy, ECT, VNS, TMS):  ____ 
4. Total number of current treatments for depression (including all others listed on this 
document):  ____ 
 
26 of 165
Page 148 of 291
  
 
M.I.N.I. PLUS 
 
 
 
 
 
MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW 
 
 
 
English  Version  5.0.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
USA:  D. Sheehan, J. Janavs, R. Baker, K.Harnett-Sheehan, E. Knapp, M. Sheehan 
University of South Florida - Tampa 
 
FRANCE:   Y. Lecrubier, E. Weiller,  T. Hergueta, P. Amorim, L.I. Bonora, J.P. Lépine,  
                                                                                    Hôpital de la Salpétrière - Paris 
 
 
 
 
 
© Copyright 1994-2005 Sheehan DV & Lecrubier Y 
 
 
All rights reserved.  No part of this document may be reproduced or transmitted in any form, or by any means, 
electronic or mechanical, including photocopying, or by any information storage or retrieval system, without 
permission in writing from Dr. Sheehan or Dr. Lecrubier.  Researchers and clinicians working in nonprofit or 
publicly owned settings (including universities, nonprofit hospitals, and government institutions) may make copies of 
a M.I.N.I. instrument for their own clinical and research use. 
 
 
 
 
M.I.N.I. Plus 5.0.0  (January 1, 2005) 
70 of 165
Page 149 of 291
M.I.N.I. Plus 5.0.0 (January 1, 2005) -2- 
  
Patient Name: Patient Number:  
Date of Birth:   Time Interview Began:  
Interviewer’s Name: Time Interview Ended:  
Date of Interview:   Total Time:  
     
 
  MEETS 
 MODULES TIME FRAME CRITERIA DSM-IV ICD-10 
 
A MAJOR DEPRESSIVE EPISODE Current (2 weeks)  ❏ 296.20-296.26  Single F32.x 
  Recurrent  ❏ 296.30-296.36    Recurrent F33.x 
 MOOD DISORDER DUE TO A GENERAL MEDICAL CONDITION Current  ❏ 293.83 F06.xx 
  Past  ❏ 293.83 F06.xx 
 SUBSTANCE INDUCED MOOD DISORDER Current  ❏ 29x.xx none 
  Past  ❐ 29x.xx none 
 MDE WITH MELANCHOLIC FEATURES Current (2 weeks)  ❏ 296.20-296.26  Single F32.x 
     296.30-296.36    Recurrent F33.x 
B DYSTHYMIA Current (Past 2 years)  ❏ 300.4  F34.1 
  Past  ❏ 300.4  F34.1 
C SUICIDALITY Current (Past Month)  ❏ none  none 
  Risk: ❏ Low  ❏ Medium ❏ High 
D MANIC EPISODE Current  ❏ 296.00-296.06 F30.x-F31.9 
  Past  ❏ 296.00-296.06 F30.x-F31.9 
 HYPOMANIC EPISODE Current  ❏ 296.80-296.89 F31.8-F31.9/F34.0 
  Past  ❏ 296.80-296.89 F31.8-F31.9/F34.0 
 BIPOLAR I DISORDER Current  ❏ 296.0x-296.6x F30.x-F31.9 
  Past  ❏ 296.0x-296.6x F30.x-F31.9 
 BIPOLAR II DISORDER Current  ❏ 296.89  F31.8 
  Past  ❏ 296.89  F31.8 
 MANIC EPISODE DUE TO A GENERAL MEDICAL CONDITION Current  ❏ 293.83 F06.30 
  Past  ❏ 293.83 F06.30 
 HYPOMANIC EPISODE DUE TO A GENERAL MEDICAL CONDITION Current  ❏ 293.83 none 
  Past  ❏ 293.83 none 
 SUBSTANCE INDUCED MANIC EPISODE Current  ❏ 291.8-292.84 none 
  Past  ❏ 291.8-292.84 none 
 SUBSTANCE INDUCED HYPOMANIC EPISODE Current  ❏ 291.8-292.84 none 
  Past  ❏ 291.8-292.84 none 
E PANIC DISORDER Current (Past Month)  ❏ 300.01/300.21 F40.01-F41.0 
  Lifetime  ❏ 300.01/300.21 F40.01-F41.0 
 ANXIETY DISORDER WITH PANIC ATTACKS DUE TO A  Current  ❏ 293.89  F06.4 
       GENERAL MEDICAL CONDITION 
 SUBSTANCE INDUCED ANXIETY DISORDER WITH PANIC  Current  ❏ 291.8-292.89  none 
 ATTACKS 
F AGORAPHOBIA Current  ❏ 300.22  F40.00 
G SOCIAL PHOBIA (Social Anxiety Disorder) Current (Past Month)  ❏ 300.23  F40.1 
H SPECIFIC PHOBIA Current  ❏ 300.29  F40.2 
I OBSESSIVE-COMPULSIVE DISORDER Current (Past Month)  ❏ 300.3  F42.8 
 OCD DUE TO A GENERAL MEDICAL CONDITION Current  ❏ 293.89  F06.4 
 SUBSTANCE INDUCED OCD Current  ❏ 291.8-292.89  none 
J POSTTRAUMATIC STRESS DISORDER Current (Past Month)  ❏ 309.81  F43.1 
K ALCOHOL DEPENDENCE Past 12 Months  ❏ 303.9  F10.2x 
 ALCOHOL DEPENDENCE Lifetime   ❏ 303.9  F10.2x 
 ALCOHOL ABUSE Past 12 Months  ❏ 305.00  F10.1  
 ALCOHOL ABUSE Lifetime   ❏ 305.00  F10.1 
L SUBSTANCE DEPENDENCE (Non-alcohol) Past 12 Months  ❏ 304.00-.90/305.20-.90 F11.0-F19.1 
 SUBSTANCE DEPENDENCE (Non-alcohol) Lifetime   ❏ 304.00-.90/305.20-.90 F11.0-F19.1 
 SUBSTANCE ABUSE (Non-alcohol) Past 12 Months  ❏ 304.00-.90/305.20-.90 F11.0-F19.1 
M PSYCHOTIC DISORDERS Lifetime   ❏ 295.10-295.90/297.1/ F20.xx-F29 
  Current  ❏ 297.3/293.81/293.82/ 
     293.89/298.8/298.9 
 MOOD DISORDER WITH PSYCHOTIC FEATURES Current  ❏ 296.24  F32.3/F33.3 
 SCHIZOPHRENIA Current  ❏ 295.10-295.60 F20.xx 
  Lifetime   ❏ 295.10-295.60 F20.xx  
 SCHIZOAFFECTIVE DISORDER Current  ❏ 295.70  F25.x 
  Lifetime   ❏ 295.70  F25.x 
 SCHIZOPHRENIFORM DISORDER Current  ❏ 295.40  F20.8 
  Lifetime   ❏ 295.40  F20.8 
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 BRIEF PSYCHOTIC DISORDER Current  ❏ 298.8  F23.80-F23.81 
  Lifetime   ❏ 298.8  F23.80-F23.81 
 
 
 DELUSIONAL DISORDER Current  ❏ 297.1  F22.0 
  Lifetime   ❏ 297.1  F22.0 
 PSYCHOTIC DISORDER DUE TO A GENERAL MEDICAL CONDITION  Current  ❏ 293.xx  F06.0-F06.2 
  Lifetime  ❏ 293.xx  F06.0-F06.2 
 SUBSTANCE INDUCED PSYCHOTIC DISORDER Current  ❏ 291.5-292.12  none 
  Lifetime  ❏ 291.5-292.12  none 
 PSYCHOTIC DISORDER NOS Current  ❏ 298.9  F29 
  Lifetime   ❏ 298.9 296.24  F29 
 MOOD DISORDER WITH PSYCHOTIC FEATURES Lifetime   ❏   F31.3/F31.2/F31.5 
 MOOD DISORDER NOS Lifetime   ❏ 296.90  F39 
 MAJOR DEPRESSIVE DISORDER WITH PSYCHOTIC FEATURES  Current  ❏ 296.24  F33.X3 
  Past  ❏ 296.24  F33.X3 
 BIPOLAR I DISORDER WITH PSYCHOTIC FEATURES Current  ❏ 296.04-296.64 F31.X2/F31.X5 
  Past  ❏ 296.04-296.64 F31.X2/F31.X5 
N ANOREXIA NERVOSA Current (Past 3 Months)  ❏ 307.1  F50.0 
O BULIMIA NERVOSA Current (Past 3 Months)  ❏ 307.51  F50.2 
 BULIMIA NERVOSA PURGING TYPE Current  ❏ 307.51  F50.2 
 BULIMIA NERVOSA NONPURGING TYPE Current  ❏ 307.51  F50.2 
 ANOREXIA NERVOSA, BINGE EATING/PURGING TYPE Current  ❏ 307. 1  F50.0 
 ANOREXIA NERVOSA, RESTRICTING TYPE Current  ❏ 307. 1  F50.0 
P GENERALIZED ANXIETY DISORDER Current (Past 6 Months)  ❏ 300.02  F41.1 
 GENERALIZED ANXIETY DISORDER DUE TO A GENERAL  Current  ❏ 293.89  F06.4 
 MEDICAL CONDITION  
 SUBSTANCE INDUCED GAD Current  ❏ 291.8-292.89  none 
Q ANTISOCIAL PERSONALITY DISORDER Lifetime  ❏ 301.7  F60.2 
R SOMATIZATION DISORDER Lifetime ❏ 330.81 F45.0 
  Current ❏  
S HYPOCHONDRIASIS Current ❏ 300.7 F45.2 
T BODY DYSMORPHIC DISORDER Current ❏ 300.7 F45.2 
U PAIN DISORDER Current ❏ 300.89/307.8 F45.4 
V CONDUCT DISORDER Past 12 Months ❏ 312.8 F91.8 
W ATTENTION DEFICIT/HYPERACTIVITY  Past 6 Months ❏ 314.00/314.01 F90.0/F90.9/ 
 DISORDER  (Children/Adolescents)    F98.8 
 ATTENTION DEFICIT/HYPERACTIVITY Lifetime  ❏ 314.00/314.01 F90.0/F98.8 
 DISORDER  (Adults) Current ❏ 
X ADJUSTMENT DISORDERS Current ❏ 309.xx F43.xx 
Y PREMENSTRUAL DYSPHORIC DISORDER Current ❏  
Z MIXED ANXIETY-DEPRESSIVE DISORDER Current ❏  
 
  
WARNING 
 
 EVEN IF A PATIENT HAS A CLEAR LIFE STRESS AGGRAVATING THEIR SYMPTOMS FIRST EXPLORE THE 
OTHER DIAGNOSES ABOVE.  NEVER USE AN ADJUSTMENT DISORDER DIAGNOSIS IF THE DISTURBANCE 
MEETS CRITERIA FOR ANY OF THE ABOVE DISORDERS. 
 
 
DISCLAIMER 
 
Our aim is to assist in the assessment and tracking of patients with greater efficiency and accuracy.  Before action is 
taken on any data collected and processed by this program, it should be reviewed and interpreted by a licensed 
clinician. 
 
This program is not designed or intended to be used in the place of a full medical and psychiatric evaluation by a 
qualified licensed physician – psychiatrist.  It is intended only as a tool to facilitate accurate data collection and 
processing of symptoms elicited by trained personnel. 
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GENERAL INSTRUCTIONS 
 
 
The M.I.N.I. was designed as a brief structured interview for the major Axis I psychiatric disorders in DSM-IV and ICD-10.  
Validation and reliability studies have been done comparing the M.I.N.I. to the SCID-P for DSM-III-R and the CIDI (a 
structured interview developed by the World Health Organization for lay interviewers for ICD-10).  The results of these 
studies show that the M.I.N.I. has acceptably high validation and reliability scores, but can be administered in a much shorter 
period of time (mean 18.7 ± 11.6 minutes, median 15 minutes) than the above referenced instruments.  It can be used by 
clinicians, after a brief training session.  Lay interviewers require more extensive training.  The M.I.N.I. Plus is a more 
detailed edition of the M.I.N.I.  Symptoms better accounted for by an organic cause or by the use of alcohol or drugs should 
not be coded positive in the M.I.N.I.  The M.I.N.I. Plus has questions that investigate these issues.   
 
INTERVIEW: 
 In order to keep the interview as brief as possible, inform the patient that you will conduct a clinical interview that is more 
structured than usual, with very precise questions about psychological problems which require a yes or no answer. 
 
GENERAL FORMAT: 
 The M.I.N.I. Plus is divided into modules identified by letters, each corresponding to a diagnostic category. 
 •At the beginning of each diagnostic module (except for psychotic disorders module), screening question(s) corresponding to 
the main criteria of the disorder are presented in a gray box. 
 •At the end of each module, diagnostic box(es) permit the clinician to indicate whether diagnostic criteria are met. 
 
CONVENTIONS: 
 Sentences written in « normal font » should be read exactly as written to the patient in order to standardize the assessment of 
diagnostic criteria. 
Sentences written in « CAPITALS » should not be read to the patient.  They are instructions for the interviewer to assist in the 
scoring of the diagnostic algorithms. 
Sentences written in « bold » indicate the time frame being investigated.  The interviewer should read them as often as 
necessary.  Only symptoms occurring during the time frame indicated should be considered in scoring the responses. 
Answers with an arrow above them ( ➨ ) indicate that one of the criteria necessary for the diagnosis(es) is not met. In this 
case, the interviewer should go to the end of the module and circle « NO » in all the diagnostic boxes and move to the next 
module. 
When terms are separated by a slash (/) the interviewer should read only those symptoms known to be present in the patient  
(for example, questions M20-M23). 
Phrases in (parentheses) are clinical examples of the symptom.  These may be read to the patient to clarify the question. 
 
RATING INSTRUCTIONS: 
 
All questions must be rated. The rating is done at the right of each question by circling either Yes or No.  Clinical judgment 
by the rater should be used in coding the responses.  The rater should ask for examples when necessary, to ensure accurate 
coding.  The patient should be encouraged to ask for clarification on any question that is not absolutely clear. 
 
The clinician should be sure that each dimension of the question is taken into account by the patient (for example, time 
frame, frequency, severity, and/or alternatives). 
Symptoms better accounted for by an organic cause or by the use of alcohol or drugs should not be coded positive in the 
M.I.N.I.  The M.I.N.I. Plus has questions that investigate these issues. 
 
For any questions, suggestions, need for a training session, or information about updates of the M.I.N.I., please contact : 
 
David V Sheehan, M.D., M.B.A.    Yves Lecrubier, M.D. / Thierry Hergueta, M.S.  
University of South Florida     INSERM U302  
Institute for Research in Psychiatry    Hôpital de la Salpétrière  
3515 East Fletcher Avenue      47, boulevard de l’Hôpital  
Tampa, FL USA 33613-4788     F. 75651 PARIS, FRANCE  
tel : +1 813 974 4544     tel : +33 (0) 1 42 16 16 59  
fax : +1 813 947 4575     fax : +33 (0) 1 45 85 28 00 
e-mail : dsheehan@hsc.usf.edu    e-mail : hergueta@ext.jussieu.fr 
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 A.  MAJOR DEPRESSIVE EPISODE 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE) 
 
FOR PATIENTS WHO APPEAR PSYCHOTIC BEFORE STARTING THE INTERVIEW, OR WHO ARE SUSPECTED TO HAVE SCHIZOPHRENIA, PLEASE ADOPT 
THE FOLLOWING ORDER OF ADMINISTRATION OF MODULES: 
 
1) PART 1 OF MODULE M (PSYCHOTIC DISORDERS M1-M18). 
2) SECTIONS A-D (DEPRESSION TO (HYPO)MANIC EPISODE). 
3) PART 2 OF MODULE M (PSYCHOTIC DISORDERS M19-M23). 
4) OTHER MODULES IN THEIR USUAL SEQUENCE. 
 
IF MODULE M HAS ALREADY BEEN EXPLORED AND PSYCHOTIC SYMPTOMS HAVE BEEN IDENTIFIED (M1 TO M10b), EXAMINE FOR EACH 
POSITIVE RESPONSE TO THE FOLLOWING QUESTIONS IF THE DEPRESSIVE SYMPTOMS ARE NOT BETTER EXPLAINED BY THE  PRESENCE OF 
A PSYCHOTIC DISORDER AND CODE ACCORDINGLY. 
 
 
A1 a Have you ever been consistently depressed or down, most of the day, NO YES   
  nearly every day, for at least two weeks? 
 
  IF A1a = YES: 
 
 b Have you been consistently depressed or down, most of the day, nearly every day, NO YES   
  for the past 2 weeks? 
 
A2 a Have you ever been much less interested in most things or much less able to enjoy NO YES   
  the things you used to enjoy most of the time over at least 2 weeks? 
 
  IF A2a = YES: 
 
 b In the past 2 weeks, have you been much less interested in most things or much NO YES   
  less able to enjoy the things you used to enjoy most of the time. 
 
   ➨ 
  IS A1a OR A2a CODED YES? NO YES 
 
   
  IF CURRENTLY DEPRESSED (A1b OR A2b = YES): EXPLORE ONLY CURRENT EPISODE.   
  IF NO: EXPLORE THE MOST SYMPTOMATIC PAST EPISODE. 
 
A3  Over the  two week period when you felt depressed or uninterested, 
   Current Episode Past Episode 
  
 a Was your appetite decreased or increased nearly every day?  Did NO YES  NO YES  
  your weight decrease or increase without trying intentionally  
  (I.E., BY ±5% OF BODY WEIGHT OR ±8 LBS. OR ±3.5 KGS.  
  FOR A 160 LB./70 KGS. PERSON IN A MONTH)? 
  IF YES TO EITHER, CODE YES. 
 
 b Did you have trouble sleeping nearly every night (difficulty falling asleep,  NO YES  NO YES  
  waking up in the middle of the night, early morning wakening or sleeping  
  excessively)? 
 
 c Did you talk or move more slowly than normal or were you fidgety, NO YES  NO YES  
  restless or having trouble sitting still almost every day? 
 
 d Did you feel tired or without energy almost every day? NO YES  NO YES  
 
 e Did you feel worthless or guilty almost every day? NO YES  NO YES  
 
  IF A3e = YES: ASK FOR AN EXAMPLE. 
  THE EXAMPLE IS CONSISTENT WITH A DELUSIONAL IDEA.    ❏ NO     ❏ YES 
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 f Did you have difficulty concentrating or making decisions almost every day? NO YES  NO YES  
 
 g Did you repeatedly consider hurting yourself, feel suicidal, or wish that you  NO YES  NO YES  
  were dead? 
     ➨ 
A4  ARE  3 OR MORE  A3 ANSWERS CODED YES (OR 4 A3 ANSWERS, NO YES  NO YES 
  IF A1a OR A2a ARE CODED NO FOR PAST EPISODE 
  OR IF A1b OR A2b ARE CODED NO FOR CURRENT EPISODE)? 
 
  VERIFY IF THE POSITIVE SYMPTOMS OCCURRED DURING THE SAME 2 WEEK TIME FRAME. 
 
  IF A4 IS CODED NO FOR CURRENT EPISODE THEN EXPLORE A3a - A3g FOR MOST  
  SYMPTOMATIC PAST EPISODE.  
     ➨ 
A5  Did the symptoms of depression cause you significant distress or impair   NO YES  
  your ability to function at work, socially, or in some other important way?     
 
A6  Are the symptoms due entirely to the loss of a loved one (bereavement) 
  and are they similar in severity, level of impairment, and duration to 
  what most others would suffer under similar circumstances? 
  If so, this is uncomplicated bereavement. 
     ➨ 
  HAS UNCOMPLICATED BEREAVEMENT BEEN RULED OUT? NO YES   
 
A7 a Were you taking any drugs or medicines just before these symptoms began? 
   ❐ No      ❐ Yes 
 
 b Did you have any medical illness just before these symptoms began? 
   ❐ No      ❐ Yes 
 
  IN THE CLINICIAN’S JUDGMENT: ARE EITHER OF THESE LIKELY TO BE DIRECT 
  CAUSES OF THE PATIENT'S DEPRESSION?  IF NECESSARY ASK ADDITIONAL  
  OPEN-ENDED QUESTIONS. 
    
  A7 (SUMMARY): HAS AN ORGANIC CAUSE BEEN RULED OUT? NO YES  UNCERTAIN  
 
 
  
  
 A8     CODE YES IF A7(SUMMARY) = YES OR UNCERTAIN. 
 
            SPECIFY IF THE EPISODE IS CURRENT AND/ OR PAST OR BOTH (RECURRENT). 
       NO                        YES 
 
   Major Depressive Episode 
 
Current ❏ 
Past   ❏ 
 
  
  
 A9      CODE YES IF A7b = YES AND A7 (SUMMARY) = NO. 
 
             SPECIFY IF THE EPISODE IS CURRENT AND/ OR PAST OR BOTH (RECURRENT). 
       NO                          YES 
 
Mood Disorder Due to a 
General Medical Condition 
 
Current ❏ 
Past  ❏
 
  
  
 A10    CODE YES IF A7a = YES AND A7 (SUMMARY) = NO. 
 
             SPECIFY IF THE EPISODE IS CURRENT AND/ OR PAST OR BOTH (RECURRENT). 
           
            
       NO                           YES 
 
Substance Induced Mood 
Disorder 
 
Current ❏ 
Past  ❏ 
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  CHRONOLOGY 
   
A11      How old were you when you first began having symptoms of depression?  age   
 
A12     During your lifetime, how many distinct times did you have these symptoms     
     of depression (daily for at least 2 weeks)? 
 
 
 MAJOR DEPRESSIVE EPISODE WITH MELANCHOLIC FEATURES (optional) 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
IF THE PATIENT CODES POSITIVE FOR A CURRENT MAJOR DEPRESSIVE EPISODE (A8 = YES, CURRENT), EXPLORE THE FOLLOWING:  
 
 
A13 a During the most severe period of the current depressive episode, did you lose almost NO YES  
  completely your ability to enjoy nearly everything ? 
 
 b During the most severe period of the current depressive episode, did you lose your ability  NO YES  
  to respond to things that previously gave you pleasure, or cheered you up?  
       IF NO, DOUBLE CHECK ANSWER BY ASKING:  
       When something good happens, does it fail to make you feel better, even temporarily? 
  
 ➨ 
  IS EITHER A13a OR A13b CODED YES? NO YES  
 
   
A14  Over the past two week period, when you felt depressed and uninterested: 
 
 a Did you feel depressed in a way that is different from the kind of feeling  NO YES  
  you experience when someone close to you dies? 
 
 b Did you feel regularly worse in the morning, almost every day? NO YES  
 
 c Did you wake up at least 2 hours before the usual time of awakening and  NO YES  
  have difficulty getting back to sleep, almost every day? 
 
 d IS A3c CODED YES (PSYCHOMOTOR RETARDATION OR AGITATION)? NO YES  
 
 e IS A3a CODED YES FOR ANOREXIA OR WEIGHT LOSS? NO YES  
   
 f Did you feel excessive guilt or guilt out of proportion to the reality of the situation? NO YES  
 
  
  
               ARE 3 OR MORE A14 ANSWERS CODED YES?      
                
     NO                             YES 
 
Major Depressive Episode 
with  
Melancholic Features,       
Current 
 
76 of 165
Page 155 of 291
M.I.N.I. Plus 5.0.0 (January 1, 2005) -8- 
 
SUBTYPES OF MAJOR DEPRESSIVE EPISODE Mark all that apply. 
 Mild ❏ 296.21/296.31 
 Moderate ❏ 296.22/296.32 
 Severe without psychotic features ❏ 296.23 
 Severe with psychotic features ❏ 296.24 
 In partial remission ❏ 296.25 
 In full remission ❏ 296.26 
 Chronic ❏ 
 With catatonic features ❏ 
 With melancholic features ❏ 
 With atypical features ❏ 
 With postpartum onset ❏ 
 With seasonal pattern ❏ 
 With full interepisode recovery ❏ 
 Without full interepisode recovery ❏ 
 
IF A8 OR A9 OR A10 = YES, SKIP TO SUICIDALITY ➨ 
 
 
B.  DYSTHYMIA 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
If patient's symptoms currently meet criteria for major depressive episode, do NOT explore current dysthymia, but do explore 
PAST dysthymia.  Make sure that the past dysthymia explored is not one of the past major depressive episodes, and that it was 
separated from any prior major depressive episode by at least 2 months of full remission.  [APPLY THIS RULE ONLY IF YOU 
ARE INTERESTED IN EXPLORING DOUBLE DEPRESSION.] 
 
 SPECIFY WHICH TIME FRAME IS EXPLORED BELOW: ❏ Current 
  ❏ Past 
 
   ➨ 
B1  Have you felt sad, low or depressed most of the time for the last two years? NO YES  
  (OR IF EXPLORING PAST DYSTHYMIA: "In the past, did you ever feel sad, low or 
  depressed for 2 years continuously?") 
    ➨ 
B2  Was this period interrupted by your feeling OK for two months or more? NO YES  
 
 
B3  During this period of feeling depressed most of the time: 
 
 a Did your appetite change significantly? NO YES  
 
 b Did you have trouble sleeping or sleep excessively? NO YES  
 
 c Did you feel tired or without energy? NO YES  
 
 d Did you lose your self-confidence? NO YES  
 
 e Did you have trouble concentrating or making decisions? NO YES  
 
 f Did you feel hopeless? NO YES  
   ➨ 
  ARE 2 OR MORE B3 ANSWERS CODED YES? NO YES 
    ➨ 
B4  Did the symptoms of depression cause you significant distress or impair your NO YES  
  ability to function at work, socially, or in some other important way? 
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B5  Were you taking any drugs or medicines just before these symptoms began? 
  Did you have any medical illness just before these symptoms began? 
  IN THE CLINICIAN’S JUDGMENT: ARE EITHER OF THESE LIKELY TO BE DIRECT  
  CAUSES OF THE PATIENT'S DEPRESSION? 
 
  HAS AN ORGANIC CAUSE BEEN RULED OUT? NO YES  
 
  
  
              IS B5 CODED YES? 
            
 
     NO                             YES 
 
DYSTHYMIA 
 
      Current   ❏ 
      Past                           ❏ 
 CHRONOLOGY 
 
B6  How old were you when you first began having symptoms of 2 years of continuous depression?  age   
 
 
 
 
C.  SUICIDALITY 
 
  In the past month did you: 
             Points 
C1  Think you would be better off dead or wish you were dead? NO YES 1 
 
C2  Want to harm yourself? NO YES 2 
 
C3  Think about suicide? NO YES 6 
 
C4  Have a suicide plan? NO YES 10 
 
C5  Attempt suicide? NO YES 10 
 
  In your lifetime: 
 
C6  Did you ever make a suicide attempt? NO YES 4 
 
 
  
   IS AT LEAST 1 OF THE ABOVE CODED YES? 
 
 
 
                 IF YES, ADD THE TOTAL NUMBER OF POINTS FOR THE ANSWERS (C1-C6)  
                   CHECKED ‘YES’ AND SPECIFY THE LEVEL OF SUICIDE RISK AS FOLLOWS: 
                    
 
            
 
  NO                         YES 
 
SUICIDE  RISK 
CURRENT 
 
   1-5 points     Low             ❐ 
   6-9 points     Moderate     ❐ 
   > 10 points   High            ❐ 
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D. (HYPO) MANIC EPISODE 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE) 
 
FOR PATIENTS WHO APPEAR PSYCHOTIC BEFORE STARTING THE INTERVIEW OR WHO ARE SUSPECTED TO HAVE SCHIZOPHRENIA, PLEASE ADOPT THE 
FOLLOWING ORDER OF ADMINISTRATION OF MODULES: 
 
1) PART 1 OF MODULE M (PSYCHOTIC DISORDERS M1-M18). 
2) SECTIONS A-D (DEPRESSION TO (HYPO)MANIC EPISODE). 
3) PART 2 OF MODULE M (PSYCHOTIC DISORDERS M19-M23). 
4) OTHER MODULES IN THEIR USUAL SEQUENCE. 
 
 IF MODULE M HAS ALREADY BEEN EXPLORED AND PSYCHOTIC SYMPTOMS HAVE BEEN IDENTIFIED (M1 TO M10b), EXAMINE FOR 
 EACH POSITIVE RESPONSE TO THE FOLLOWING QUESTIONS IF THE (HYPO)MANIC SYMPTOMS ARE NOT BETTER EXPLAINED BY THE 
 PRESENCE OF A PSYCHOTIC DISORDER AND CODE ACCORDINGLY. 
 
 
D1 a Have you ever had a period of time when you were feeling 'up' or 'high' or ‘hyper’ NO YES   
  or so full of energy or full of yourself that you got into trouble, or that 
  other people thought you were not your usual self?   
  (Do not consider times when you were intoxicated on drugs or alcohol.) 
 
  IF NO, CODE NO TO D1b:  IF YES ASK: 
 
 b Are you currently feeling ‘up’ or ‘high’ or ‘hyper’ or full of energy? NO YES   
 
  IF PATIENT IS PUZZLED OR UNCLEAR ABOUT WHAT YOU MEAN BY 'UP' OR 'HIGH', 
  CLARIFY AS FOLLOWS:   BY 'UP' OR 'HIGH' OR ‘HYPER’  I MEAN: HAVING ELATED MOOD; INCREASED ENERGY; 
  NEEDING LESS SLEEP; HAVING RAPID THOUGHTS; BEING FULL OF IDEAS; HAVING AN INCREASE 
  IN PRODUCTIVITY, MOTIVATION , CREATIVITY, OR IMPULSIVE BEHAVIOR. 
 
D2 a Have you ever been persistently irritable, for several days, so that you NO YES   
  had arguments or verbal or physical fights, or shouted at people outside 
  your family?  Have you or others noticed that you have been more irritable 
  or over reacted, compared to other people, even in situations that you felt 
  were justified? 
 
  IF NO, CODE NO TO D2b:  IF YES ASK: 
 
 b Are you currently feeling persistently irritable? NO YES   
    ➨ 
  IS D1a OR D2a CODED YES?  NO YES  
 
 
D3  IF D1b OR D2b = YES: EXPLORE ONLY CURRENT EPISODE, OTHERWISE 
  IF D1b AND D2b = NO: EXPLORE THE MOST SYMPTOMATIC PAST EPISODE 
 
  During the times when you felt high, full of energy, or irritable did you: 
   Current Episode Past Episode 
 
 a Feel that you could do things others couldn't do, or that you were an NO YES NO YES  
  especially important person?   
  IF YES, ASK FOR EXAMPLES. 
  THE EXAMPLES ARE CONSISTENT WITH A DELUSIONAL IDEA.     ❐ No      ❐ Yes 
 
 b Need less sleep (for example, feel rested after only a few hours sleep)? NO YES NO YES  
 
 c Talk too much without stopping, or so fast that people had difficulty NO YES NO YES  
  understanding? 
 
 d Have racing thoughts? NO YES  NO YES   
 
79 of 165
Page 158 of 291
M.I.N.I. Plus 5.0.0 (January 1, 2005) -11- 
 e Become easily distracted so that any little interruption could distract you? NO YES NO YES  
 
 f Become so active or physically restless that others were worried about you? NO YES NO YES  
 
 g Want so much to engage in pleasurable activities that you ignored the risks or NO YES NO YES  
  consequences (for example, spending sprees, reckless driving, or sexual  
  indiscretions)? 
     ➨ 
  D3(SUMMARY):  ARE 3 OR MORE D3 ANSWERS CODED YES  NO YES NO YES 
  (OR 4 OR MORE  IF D1a IS NO (IN RATING PAST EPISODE) OR D1b IS NO (IN RATING CURRENT EPISODE)?     
  RULE:  ELATION/EXPANSIVENESS REQUIRES ONLY THREE D3 SYMPTOMS WHILE  
  IRRITABLE MOOD ALONE REQUIRES 4 OF THE D3 SYMPTOMS. 
 
  VERIFY IF THE SYMPTOMS OCCURRED DURING THE SAME TIME PERIOD. 
 
D4 a Were you taking any drugs or medicines just before these symptoms began? 
   ❐ No      ❐ Yes 
 
 b Did you have any medical illness just before these symptoms began? 
   ❐ No      ❐ Yes 
 
  IN THE CLINICIAN’S JUDGMENT: ARE EITHER OF THESE LIKELY TO BE DIRECT CAUSES OF THE  
  PATIENT'S (HYPO)MANIA?  IF NECESSARY, ASK ADDITIONAL OPEN ENDED QUESTIONS. 
 
 
  D4 (SUMMARY): HAS AN ORGANIC CAUSE BEEN RULED OUT? NO YES UNCERTAIN  
 
D5  Did these symptoms last at least a week and cause problems beyond your NO YES NO YES  
  control at home, work, school, or were you hospitalized for these problems? 
 
  IF D5 IS CODED NO FOR CURRENT EPISODE, THEN EXPLORE D3, D4  
  AND D5 FOR THE MOST SYMPTOMATIC PAST EPISODE. 
   
D6  
 
              IF D3 (SUMMARY) = YES AND D4 (SUMMARY) = YES OR UNCERTAIN 
               AND D5 = NO, AND NO DELUSIONAL IDEA WAS DESCRIBED IN D3a, 
               CODE YES FOR HYPOMANIAC EPISODE. 
  
              SPECIFY IF THE EPISODE IDENTIFIED IS CURRENT OR PAST. 
 
      
   NO                                YES 
        
HYPOMANIC EPISODE 
 
 
  Current    ❏ 
  Past    ❏ 
 
  
D7       IF D3 (SUMMARY) = YES AND D4 (SUMMARY) = YES OR UNCERTAIN 
               AND EITHER D5 = YES OR A DELUSIONAL IDEA WAS DESCRIBED IN D3a, 
               CODE YES FOR MANIC EPISODE. 
  
              SPECIFY IF THE EPISODE IDENTIFIED IS CURRENT OR PAST. 
 
     NO                              YES 
 
MANIC EPISODE 
  
 
 Current    ❏ 
  Past    ❏ 
 
  
D8        IF D3 (SUMMARY) AND D4b AND D5  = YES AND D4 (SUMMARY) = NO,  
                CODE YES? 
  
               SPECIFY IF THE EPISODE IDENTIFIED IS CURRENT OR PAST. 
 
     NO                               YES 
 
(Hypo) Manic Episode 
Due to a General Medical 
Condition 
  Current    ❏ 
  Past    ❏ 
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D9        IF D3 (SUMMARY) AND D4a AND D5  = YES AND D4 (SUMMARY) = NO,  
                 CODE YES? 
  
               SPECIFY IF THE EPISODE IDENTIFIED IS CURRENT OR PAST. 
 
     NO                              YES 
 
Substance Induced 
(Hypo) Manic Episode 
  Current    ❏ 
  Past    ❏ 
 
  IF D8 OR D9 = YES, GO TO NEXT MODULE. 
 
SUBTYPES 
  
 Rapid Cycling 
                 
              Have you had four or more episodes of mood disturbance in 
              12 months? 
                                                  
     NO                           YES 
 
Rapid Cycling  
 
 
  
 Mixed Episode 
                 
              PATIENT MEETS CRITERIA FOR BOTH MANIC EPISODE AND MAJOR DEPRESSIVE 
               EPISODE NEARLY EVERY DAY DURING AT LEAST A ONE WEEK PERIOD. 
                                                  
     NO                           YES 
 
Mixed Episode  
 
 
  
             Seasonal Pattern 
                 
             THE ONSET AND REMISSIONS OR SWITCHES FROM DEPRESSION TO MANIA OR 
               HYPOMANIA CONSISTENTLY OCCUR AT A PARTICULAR TIME OF YEAR. 
                                                  
     NO                           YES 
 
Seasonal Pattern 
 
 
  
             With Full Inter-episode Recovery 
                 
             Between the two most recent mood episodes did you fully recover? 
             
                                                 
     NO                           YES 
 
With  Full 
Interepisode Recovery 
 
   CIRCLE ONE 
 
  MOST RECENT EPISODE WAS A MANIC / HYPOMANIC / MIXED / DEPRESSED EPISODE 
 
 
  SEVERITY 
 
  X1 Mild ❏ 
  X2 Moderate ❏ 
  X3 Severe without psychotic features ❏ 
  X4 Severe with psychotic features ❏ 
  X5 In partial remission ❏ 
  X6 In full remission ❏ 
 
  CHRONOLOGY 
 
D10      How old were you when you first began having symptoms of manic/hypomanic episodes?  age   
 
D11       Since the first onset how many distinct times did you have significant symptoms of mania/     
  hypomania? 
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E. PANIC DISORDER 
 
(➨  MEANS:  GO TO E6 AND E7 AND E8 AND E9 AND E10, CIRCLE  NO TO ALL AND MOVE TO NEXT MODULE – MODULE F) 
 
 
   ➨ 
E1 a Have you, on more than one occasion, had spells or attacks when you suddenly felt anxious, NO YES  
  frightened, uncomfortable or uneasy, even in situations where most people would not feel 
  that way? 
    ➨ 
 b Did the spells surge to a peak within 10 minutes of starting?  NO YES  
 
   ➨ 
E2  At any time in the past, did any of those spells or attacks come on unexpectedly or NO YES  
  spontaneously, or occur in an unpredictable or unprovoked manner? 
  
E3  Have you ever had one such attack followed by a month or more of persistent concern NO YES  
  about having another attack, or worries about the consequences of the attack? 
 
E4  During the worst spell that you can remember: 
   
  a Did you have skipping, racing or pounding of your heart? NO YES  
 
  b Did you have sweating or clammy hands? NO YES  
 
  c Were you trembling or shaking? NO YES  
 
  d Did you have shortness of breath or difficulty breathing? NO YES  
 
  e Did you have a choking sensation or a lump in your throat? NO YES  
 
  f Did you have chest pain, pressure or discomfort? NO YES  
 
  g Did you have nausea, stomach problems or sudden diarrhea? NO YES  
 
  h Did you feel dizzy, unsteady, lightheaded or faint? NO YES  
 
  i Did things around you feel strange, unreal, detached or unfamiliar, or did you feel   NO YES  
   outside of or detached from part or all of your body? 
   
  j Did you fear that you were losing control or going crazy? NO YES  
 
  k Did you fear that you were dying? NO YES  
 
  l Did you have tingling or numbness in parts of your body? NO YES  
 
  m Did you have hot flushes or chills? NO YES  
 
   E4 (SUMMARY):  ARE 4 OR MORE E4 ANSWERS CODED YES? NO YES 
 
E5 a  Were you taking any drugs or medicines just before these symptoms began? 
   ❐ No      ❐ Yes 
 
 b  Did you have any medical illness just before these symptoms began? 
    ❐ No      ❐ Yes 
 
  IN THE CLINICIAN’S JUDGMENT: ARE EITHER OF THESE LIKELY TO BE DIRECT 
  CAUSES OF THE PATIENT'S PANIC DISORDER? 
 
  E5 (SUMMARY): HAS AN ORGANIC CAUSE BEEN RULED OUT? NO YES  
   IF E5 (SUMMARY) IS CODED NO, SKIP TO E9.   
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E6  DOES E3 AND E4 (SUMMARY) AND E5 (SUMMARY) = YES? NO YES 
      PANIC DISORDER 
                       LIFETIME 
  IF E6 = YES, SKIP TO E8. 
   
  
E7  IF E6 = NO, ARE ANY E4 ANSWERS CODED YES? NO YES  
         LIMITED SYMPTOM  
        ATTACKS 
  THEN SKIP TO F1.           LIFETIME 
 
E8  In the past month, did you have such attacks repeatedly (2 or more), followed by NO YES  
  persistent concern about having another attack?      PANIC DISORDER 
               CURRENT 
  (IF THIS IS DENIED BY THE PATIENT—CHALLENGE BY REVIEWING THE  
  SYMPTOMS ENDORSED IN E4). 
 
  
E9  ARE E3 AND E4 (SUMMARY) AND E5b ALL CODED YES 
                AND E5 (SUMMARY) CODED NO? 
   
   
 
 
                                         
     NO                           YES 
 
Anxiety Disorder with Panic 
Attacks Due to a 
General Medical Condition 
CURRENT 
 
  
E10  ARE E3 AND E4 (SUMMARY) AND E5a ALL CODED YES 
                AND E5 (SUMMARY) CODED NO? 
   
   
 
 
   NO                           YES 
 
Substance Induced 
Anxiety Disorder with Panic 
Attacks 
CURRENT 
 
 CHRONOLOGY 
 
E11      How old were you when you first began having symptoms of panic attacks?  age   
 
E12     During the past year, for how many months did you have significant symptoms of panic     
     attacks or worries about having an attack? 
 
83 of 165
Page 162 of 291
M.I.N.I. Plus 5.0.0 (January 1, 2005) -15- 
F.  AGORAPHOBIA 
 
    
F1  Have you ever felt anxious or uneasy in places or situations where you might have a panic   NO YES  
  attack or the panic-like symptoms we just spoke about , or where help might not be  
  available or escape might be difficult: like being in a crowd, standing in a line (queue),   
  when you are alone away from home or alone at home, or when crossing a bridge,  
  traveling in a bus, train or car? 
 
   
  IF F1 = NO, CIRCLE NO IN  F2 AND  IN F3. 
  
F2  Have you ever feared these situations so much that you avoided them, or suffered 
through  them, or needed a companion to face them? 
 
 
                                               
NO                             YES  
 
AGORAPHOBIA 
LIFETIME 
 
  
F3  Do you NOW fear or avoid these places or situations?  
 
 
            
                                                 
     NO                           YES   
 
AGORAPHOBIA 
CURRENT 
 
   CHECK ONLY IF YES 
  IS AGORAPHOBIA CODED YES? F2 ❏ lifetime F3 ❏ current 
  IS PANIC DISORDER CODED YES? E6 ❏ lifetime E8 ❏ current 
 
  
F4 a IS PANIC DISORDER, CURRENT (E8), CODED YES, 
 
                AND 
 
                IS AGORAPHOBIA, CURRENT (F3), CODED NO? 
 
 
     NO                           YES 
 
Panic Disorder, Current 
without 
AGORAPHOBIA 
 
  
 b IS PANIC DISORDER, CURRENT (E8), CODED YES, 
 
                AND 
 
                IS AGORAPHOBIA, CURRENT (F3), CODED YES? 
 
 
     NO                           YES 
 
Panic Disorder, Current 
with 
AGORAPHOBIA 
 
  
 c IS PANIC DISORDER, LIFETIME (E6), CODED NO, 
 
                AND 
 
                IS AGORAPHOBIA, CURRENT (F3), CODED YES? 
 
 
     NO                           YES 
 
AGORAPHOBIA, CURRENT 
without history of 
Panic Disorder 
 
  
 d IS AGORAPHOBIA, CURRENT (F3) CODED YES, 
 
                AND IS PANIC DISORDER CURRENT (E8) CODED NO, 
 
                AND IS PANIC DISORDER, LIFETIME (E6) CODED YES? 
 
                                        
     NO                           YES 
 
AGORAPHOBIA, CURRENT 
without current Panic 
Disorder but with a past 
history of Panic Disorder 
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 e IS AGORAPHOBIA, CURRENT (F3) CODED YES, 
 
                AND LIMITED SYMPTOM ATTACKS (E7) CODED NO? 
 
            
                                        
     NO                           YES 
 
AGORAPHOBIA, CURRENT 
without history of 
Limited Symptom Attacks 
  CHRONOLOGY 
 
F5       How old were you when you first began to fear or avoid these situations (agoraphobia)?  age   
 
F6       During the past year,  for how many months did you have significant fear or avoidance      
  of these situations (agoraphobia)? 
  
 
 
G.  SOCIAL PHOBIA (Social Anxiety Disorder) 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
 
   ➨ 
G1  In the past month, were you fearful or embarrassed being watched, being the focus of NO YES  
  attention, or fearful of being humiliated?  This includes situations like speaking in public, 
  eating in public or with others, writing while someone watches, or being in social situations. 
  
   ➨ 
G2  Is this fear excessive or unreasonable? NO YES  
   ➨ 
G3  Do you fear these situations so much that you avoid them or suffer through them? NO YES  
 
  
G4  Does this fear disrupt your normal work or social functioning or cause you 
  significant distress? 
 
 
            
                                                
     NO                           YES 
 
SOCIAL PHOBIA 
(Social Anxiety Disorder) 
CURRENT 
   
 SUBTYPES 
 
  Do you fear and avoid 4 or more social situations? NO YES 
  If YES →  generalized social phobia (social anxiety disorder) 
  If NO →   social phobia (social anxiety disorder), not generalized 
 
  CHRONOLOGY 
 
G5       How old were you when you first began to fear social situations?  age   
   
G6       During the past year, for how many months did have you have significant fear of social     
       situations? 
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H.  SPECIFIC PHOBIA 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
 
   ➨ 
H1  In the past month, have you been excessively afraid of things like: flying, NO YES  
  driving, heights, storms, animals, insects, or seeing blood or needles? 
 
   ➨ 
H2  Is this fear excessive or unreasonable? NO YES  
   ➨ 
H3  Do you fear these situations so much that you avoid them or suffer through NO YES  
  them? 
  
H4  Does this fear disrupt your normal work or social functioning or cause you 
  significant distress? 
 
 
            
                                                   
     NO                           YES 
 
SPECIFIC PHOBIA 
CURRENT 
 
   
  CHRONOLOGY 
 
H5       How old were you when you first began to fear or avoid this situation?  age  
 
H6       During the past year, how many times have you had significant fear of this situation?    
 
 
I.  OBSESSIVE-COMPULSIVE DISORDER 
 
(➨ ABOVE A NO MEANS :  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE) 
    
 
I1  In the past month, have you been bothered by recurrent thoughts, impulses, or images that were NO YES  
  unwanted, distasteful, inappropriate, intrusive, or distressing?  (For example, the idea that you  ➨ to I4 
  were dirty, contaminated or had germs, or fear of contaminating others, or fear of harming  
  someone even though you didn't want to, or fearing you would act on some impulse, or fear  
  or superstitions that you would be responsible for things going wrong, or obsessions with  
  sexual thoughts, images or impulses, or hoarding, collecting, or religious obsessions.)   
   
  (DO NOT INCLUDE SIMPLY EXCESSIVE WORRIES ABOUT REAL LIFE PROBLEMS.  DO NOT INCLUDE OBSESSIONS  
  DIRECTLY RELATED TO EATING DISORDERS, SEXUAL DEVIATIONS, PATHOLOGICAL GAMBLING, OR ALCOHOL OR  
  DRUG ABUSE BECAUSE THE PATIENT MAY DERIVE PLEASURE FROM THE ACTIVITY AND MAY WANT TO RESIST IT  
  ONLY BECAUSE OF ITS NEGATIVE CONSEQUENCES.) 
 
     
I2  Did they keep coming back into your mind even when you tried to ignore or get rid of them? NO YES  
    ➨ to I4 
 
 
I3  Do you think that these obsessions are the product of your own mind and that they are not NO YES  
  imposed from the outside?  obsessions     
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I4  In the past month, did you do something repeatedly without being able to resist doing it, like NO YES  
  washing or cleaning excessively, counting or checking things over and over, or repeating,   compulsions     
  collecting, arranging things, or other superstitious rituals? 
 
    
   ➨ 
  IS I3 OR I4 CODED YES? NO YES 
   ➨ 
I5  Did you recognize that either these obsessional thoughts or compulsive behaviors were NO YES  
  excessive or unreasonable? 
 
I6  Did these obsessions or compulsions significantly interfere with your normal routine, NO YES  
  occupational functioning, usual social activities, or relationships, or did they take 
  more than one hour a day? 
 
I7 a Were you taking any drugs or medicines just before these symptoms began? 
   ❐ No      ❐ Yes 
 
 b Did you have any medical illness just before these symptoms began? 
   ❐ No      ❐ Yes 
 
  IN THE CLINICIAN’S JUDGMENT:  ARE EITHER OF THESE LIKELY TO BE DIRECT 
  CAUSES OF THE PATIENT'S OBSESSIVE COMPULSIVE DISORDER? 
 
  I7 (SUMMARY): HAS AN ORGANIC CAUSE BEEN RULED OUT? NO YES   
 
  
  ARE I6 AND I7 (SUMMARY) CODED YES? 
 
 
            
                                           
     NO                           YES 
 
O.C.D. 
CURRENT 
 
  
I8     ARE I6 AND I7b CODED YES 
 
             AND I7 (SUMMARY) CODED NO? 
            
                                           
     NO                           YES 
 
O.C.D. 
CURRENT 
Due to a General 
Medical Condition
 
  
I9   ARE I6 AND I7a CODED YES 
 
               AND I7 (SUMMARY) CODED NO? 
 
 
                                           
     NO                           YES 
 
Current Substance 
Induced  
O.C.D. 
 
  CHRONOLOGY 
 
I10      How old were you when you first began having symptoms of OCD?  age   
 
I11      During the past year, for how many months did you have significant symptoms of OCD?     
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J.  POSTTRAUMATIC STRESS DISORDER (optional) 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
    
 
   ➨ 
J1  Have you ever experienced or witnessed or had to deal with an extremely traumatic NO YES  
  event that included actual or threatened death or serious injury to you or someone else? 
 
  EXAMPLES OF TRAUMATIC EVENTS INCLUDE:  SERIOUS ACCIDENTS, SEXUAL OR PHYSICAL ASSAULT, 
  A TERROIST ATTACK, BEING HELD HOSTAGE, KIDNAPPING, FIRE, DISCOVERING A BODY, SUDDEN 
  DEATH OF SOMEONE CLOSE TO YOU, WAR, OR NATURAL DISASTER. 
   ➨ 
J2  Did you respond with intense fear, helplessness or horror?  NO YES  
 
   ➨ 
J3  During the past month, have you re-experienced the event in a distressing way NO YES  
  (such as, dreams, intense recollections, flashbacks or physical reactions)? 
 
 
J4  In the past month: 
 
 a Have you avoided thinking about or talking about the event ? NO YES  
 
 b Have you avoided activities, places or people that remind you of the event? NO YES  
   
 c Have you had trouble recalling some important part of what happened? NO YES  
 
 d Have you become much less interested in hobbies or social activities? NO YES  
 
 e Have you felt detached or estranged from others? NO YES  
 
 f Have you noticed that your feelings are numbed? NO YES  
 
 g Have you felt that your life will be shortened or that you will die sooner than other people? NO YES 
   ➨ 
  J4 (SUMMARY):  ARE 3 OR MORE J4 ANSWERS CODED YES? NO YES 
 
J5  In the past month: 
  
 a Have you had difficulty sleeping? NO YES  
 
 b Were you especially irritable or did you have outbursts of anger? NO YES  
 
 c Have you had difficulty concentrating? NO YES  
 
 d Were you nervous or constantly on your guard? NO YES  
 
 e Were you easily startled? NO YES  
   ➨ 
  J5 (SUMMARY):  ARE 2 OR MORE J5 ANSWERS CODED YES? NO YES 
 
J6  During the past month, have these problems significantly interfered with your work or NO YES  
  social activities, or caused significant distress? 
 
  
             IS J6 CODED YES? 
   
 
            
                                                       
     NO                           YES 
 
Posttraumatic Stress Disorder 
CURRENT 
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  CHRONOLOGY 
 
J7 How old were you when you first began having symptoms of PTSD?  age   
 
J8 Since the first onset how many illness periods of PTSD did you have?     
 
J9 During the past year, for how many months did you have significant symptoms of PTSD?     
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K.  ALCOHOL ABUSE AND DEPENDENCE 
 
(➨ MEANS:  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN BOTH AND MOVE TO THE NEXT OPTIONAL K. MODULE)  
 
 
    ➨   
K1  In the past 12 months, have you had 3 or more alcoholic drinks within a 3 hour NO YES  
  period on 3 or more occasions? 
 
K2  In the past 12 months: 
 
 a Did you need to drink more in order to get the same effect that you got when you first NO YES  
  started drinking? 
 
 b When you cut down on drinking, did your hands shake, did you sweat or feel agitated? NO YES  
  Did you drink to avoid these symptoms or to avoid being hungover, for example,  
  "the shakes", sweating or agitation?  If YES to either question, code YES. 
 
 c During the times when you drank alcohol, did you end up drinking more than you  NO YES  
  planned when you started? 
 
 d Have you tried to reduce or stop drinking alcohol but failed? NO YES  
 
 e On the days that you drank, did you spend substantial time in obtaining NO YES  
  alcohol, drinking, or in recovering from the effects of alcohol? 
 
 f Did you spend less time working, enjoying hobbies, or being with others because of NO YES  
  your drinking? 
 
 g Have you continued to drink even though you knew that the drinking caused you health NO YES  
  or mental problems? 
 
  
             ARE 3 OR MORE K2 ANSWERS CODED YES? 
 
* IF YES, SKIP K3 QUESTIONS, CIRCLE N/A IN THE ABUSE BOX AND                    
MOVE TO THE NEXT DISORDER.  DEPENDENCE PREEMPTS ABUSE.      
            
                                                       
     NO                              YES* 
 
ALCOHOL DEPENDENCE 
CURRENT 
 
 
K3  In the past 12 months: 
 
 a Have you been intoxicated, high, or hungover more than once when you had other  NO YES  
  responsibilities at school, at work, or at home?  Did this cause any problems?   
  (CODE YES ONLY IF THIS CAUSED PROBLEMS.) 
 
 b Were you intoxicated more than once in any situation where you were physically at risk, NO YES  
  for example,  driving a car, riding a motorbike, using machinery, boating, etc.? 
   
 c Did you have legal problems more than once because of your drinking, for example, NO YES  
  an arrest or disorderly conduct? 
 
 d Did you continue to drink even though your drinking caused problems with your NO YES  
  family or other people? 
  
        
  ARE 1 OR MORE K3 ANSWERS CODED YES? 
 
 
                                              
     NO         N/A        YES 
 
ALCOHOL ABUSE 
CURRENT 
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(Optional) K.  LIFETIME ALCOHOL ABUSE AND DEPENDENCE  
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN BOTH, AND MOVE TO THE NEXT MODULE) 
 
 
    ➨    
K4  Did you ever have 3 or more alcoholic drinks within a 3 hour NO YES  
  period on 3 or more occasions? 
 
 
K5  In your lifetime: 
 
 a Did you need to drink more in order to get the same effect that you did when you first NO YES  
  started drinking? 
 
 b When you cut down on drinking did your hands shake, did you sweat or feel agitated? NO YES  
  Did you drink to avoid these symptoms or to avoid being hungover, for example,  
  "the shakes", sweating or agitation?  IF YES TO EITHER QUESTION, CODE YES. 
 
 c During the times when you drank alcohol, did you end up drinking more than you  NO YES  
  planned when you started? 
 
 d Have you tried to reduce or stop drinking alcohol but failed? NO YES  
 
 e On the days that you drank, did you spend substantial time in obtaining NO YES  
  alcohol, drinking, or in recovering from the effects of alcohol? 
 
 f Did you spend less time working, enjoying hobbies, or being with others because of NO YES  
  your drinking? 
 
 g Have you continued to drink even though you knew that the drinking caused you health NO YES  
  or mental problems? 
 
  
             ARE 3 OR MORE K5 ANSWERS CODED YES? 
 
* IF YES, SKIP K6 QUESTIONS, CIRCLE N/A IN THE ABUSE BOX AND                    
MOVE TO THE NEXT DISORDER.  DEPENDENCE PREEMPTS ABUSE.      
                                                       
     NO                         YES* 
 
ALCOHOL DEPENDENCE 
LIFETIME 
 
  In your lifetime: 
 
K6 a Have you been intoxicated, high, or hungover more than once when you had  NO YES  
  other responsibilities at school, at work, or at home?  Did this cause any problems?   
  (CODE YES ONLY IF THIS CAUSED PROBLEMS.) 
 
 b Were you intoxicated in any situation where you were physically at risk,  NO YES  
  for example, driving a car, riding a motorbike, using machinery, boating, etc.? 
 
 c Have you had any legal problems because of your drinking, NO YES  
  for example, an arrest or disorderly conduct? 
 
 d Have you continued to drink even though your drinking caused problems with  NO YES  
  your family or other people? 
 
  
             ARE 1 OR MORE K6 ANSWERS CODED YES? 
 
            
                                                       
     NO             N/A            YES 
 
ALCOHOL ABUSE 
LIFETIME 
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L.  NON-ALCOHOL PSYCHOACTIVE SUBSTANCE USE DISORDERS 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE) 
 
  Now I am going to show you/read to you a list of street drugs or medicines. 
 
 
    ➨   
L1 a Have you ever taken any of these drugs more than once to get high, to feel better,  NO YES 
  or to change your mood? 
 
   
  CIRCLE EACH DRUG TAKEN:   
  Stimulants:  amphetamines, "speed", crystal meth, “crank”,”rush”, Dexedrine, Ritalin, diet pills. 
  Cocaine:  snorting, IV, freebase, crack, "speedball".   
  Narcotics: heroin, morphine, Dilaudid, opium, Demerol, methadone, codeine, Percodan, Darvon, OxyContin.     
  Hallucinogens:  LSD ("acid"), mescaline, peyote, PCP ("Angel Dust", "peace pill"), psilocybin, STP, "mushrooms",   
ecstasy, MDA, MDMA or ketamine (“special K”). 
  Inhalants: "glue", ethyl chloride, "rush", nitrous oxide ("laughing gas"), amyl or butyl nitrate ("poppers"). 
  Marijuana: hashish ("hash"), THC, "pot", "grass", "weed", "reefer".   
  Tranquilizers:  Quaalude, Seconal ("reds"), Valium, Xanax, Librium,  Ativan, Dalmane, Halcion, barbiturates,          
Miltown, GHB, Roofinol, “Roofies”.   
  Miscellaneous:  steroids, nonprescription sleep or diet pills.  Any others?  
  Specify MOST USED Drug(s):     
  
   CHECK ONE BOX  
 ONLY ONE DRUG / DRUG CLASS HAS BEEN USED  
   
 ONLY THE MOST USED DRUG CLASS IS INVESTIGATED.  
   
 EACH DRUG CLASS USED IS EXAMINED SEPARATELY    (PHOTOCOPY L2 AND L3 AS NEEDED)  
 
 b SPECIFY WHICH DRUG/DRUG CLASS WILL BE EXPLORED IN THE INTERVIEW BELOW IF THERE IS 
  CONCURRENT OR SEQUENTIAL POLYSUBSTANCE USE:________________________________________ 
 
L2  Considering the (name of drug / drug class selected), in your lifetime: 
 
 a Have you found that you needed to use more (name of drug / drug class selected)  NO YES  
  to get the same effect that you did when you first started taking it? 
 
 b When you reduced or stopped using (name of drug / drug class selected), did you  NO YES  
  have withdrawal symptoms (aches, shaking, fever, weakness, diarrhea, nausea, 
  sweating, heart pounding, difficulty sleeping, or feeling agitated, anxious, irritable,  
  or depressed)?   Did you use any drug(s) to keep yourself from getting sick (withdrawal  
  symptoms) or so that you would feel better?   
  IF YES  TO EITHER QUESTION, CODE YES. 
 c Have you often found that when you used (name of drug / drug class selected),  NO YES  
  you ended up taking more than you thought you would? 
 
 d Have you tried to reduce or stop taking (name of drug / drug class selected), but failed? NO YES  
 
 e On the days that you used (name of drug / drug class selected), did you spend substantial NO YES  
   time (> 2 hours) in obtaining, using or in recovering from drug(s), or thinking about drug(s)? 
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 f Did you spend less time working, enjoying hobbies, or being with family or friends NO YES  
  because of your drug use? 
 
 g Have you continued to use (name of drug / drug class selected) even though it caused  NO YES  
  you health or mental problems? 
 
  
              ARE 3 OR MORE L2 ANSWERS CODED YES?   
 
               SPECIFY DRUG(S): __________________________________ 
  
 
            
                                                       
     NO                           YES 
 
SUBSTANCE DEPENDENCE 
 
LIFETIME 
 
   ➨  
L3 a Have you used (most used drug, any drug) in the past 12 months? NO YES  
 
 b ARE 3 OR MORE  L2 ANSWERS CODED YES WITHIN THE PAST 12 MONTHS? NO YES 
            
  
              ARE L3a AND b CODED YES?  
                
                SPECIFY DRUG(S): __________________________________ 
   
* IF YES, SKIP L4 QUESTIONS, CIRCLE N/A IN THE ABUSE BOX                     
FOR THIS SUBSTANCE AND MOVE TO THE NEXT DISORDER.   
DEPENDENCE PREEMPTS ABUSE.  
                                     
           
                         
     NO                           YES* 
 
SUBSTANCE DEPENDENCE 
CURRENT 
 
  Considering your use of (name the drug / drug class selected), in the past 12 months: 
 
L4 a Have you been intoxicated, high, or hungover from (name of drug / drug class selected)  NO YES  
  more than once, when you had other responsibilities at school, at work, or at home? 
  Did this cause any problem?  (CODE YES ONLY IF THIS CAUSED PROBLEMS.) 
 
 b Have you been high or intoxicated from  (name of drug / drug class selected) NO YES  
  more than once, in any situation where you were physically at risk, (for example,  
  driving a car, riding a motorbike, using machinery, boating, etc.)? 
 
 c Did you have legal problems more than once, because of your drug use, NO YES  
  for example,an arrest or disorderly conduct? 
 
 d Did you continue to use  (name of drug / drug class selected) even though it caused  NO YES  
  problems with your family or other people? 
 
  
            ARE 1 OR MORE L4 ANSWERS CODED YES?
 
              SPECIFY DRUG(S): __________________________________  
            
                                                       
     NO            N/A            YES 
 
SUBSTANCE ABUSE 
CURRENT 
 
  CHRONOLOGY 
 
L5      How old were you when you first began having problems with drug abuse?  age   
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M.  PSYCHOTIC DISORDERS - Part 1 
 
ASK FOR AN EXAMPLE OF EACH QUESTION ANSWERED POSITIVELY.  CODE YES ONLY IF THE EXAMPLES CLEARLY SHOW A DISTORTION OF THOUGHT OR OF 
PERCEPTION OR IF THEY ARE NOT CULTURALLY APPROPRIATE.  BEFORE CODING, INVESTIGATE WHETHER DELUSIONS QUALIFY AS "BIZARRE". 
 
DELUSIONS ARE "BIZARRE" IF: CLEARLY IMPLAUSIBLE, ABSURD, NOT UNDERSTANDABLE, AND CANNOT DERIVE FROM ORDINARY LIFE EXPERIENCE. 
 
HALLUCINATIONS ARE SCORED "BIZARRE" IF: A VOICE COMMENTS ON THE PERSON'S THOUGHTS OR BEHAVIOR, OR WHEN TWO OR MORE VOICES ARE 
CONVERSING WITH EACH OTHER. 
 
ALL OF THE PATIENT’S RESPONSES TO THE QUESTIONS SHOULD BE CODED IN COLUMN A. USE THE CLINICIAN JUDGMENT COLUMN (COLUMN B) ONLY IF THE 
CLINICIAN KNOWS FROM OTHER OUTSIDE EVIDENCE  (FOR EXAMPLE, FAMILY INPUT) THAT THE SYMPTOM IS PRESENT BUT IS BEING DENIED BY THE PATIENT. 
 
  Now I am going to ask you about unusual experiences that some people have. 
 
   COLUMN A      COLUMN B 
   Patient Response      Clinician Judgment 
       (if necessary) 
   BIZARRE          BIZARRE  
M1 a Have you ever believed that people were spying on you, or NO YES YES     YES  YES   
  that someone was plotting against you, or trying to hurt you?        
            
 b IF YES:  Do you currently believe these things?   NO YES YES   YES YES   
  NOTE: ASK FOR EXAMPLES, TO RULE OUT ACTUAL STALKING.    ➡M6  ➡M6  
            
M2 a Have you ever believed that someone was reading your NO YES         YES   
  mind or could hear your thoughts or that you could        
  actually read someone’s mind or hear what another        
  person was thinking?       
         
 b IF YES:  Do you currently believe these things? NO  YES     YES   
     ➡M6  ➡M6  
            
M3 a Have you ever believed that someone or some force outside NO  YES     YES   
  of yourself put thoughts in your mind that were not your       
  own, or made you act in a way that was not your usual self?       
  Have you ever felt that you were possessed?         
  CLINICIAN: ASK FOR EXAMPLES AND DISCOUNT ANY THAT ARE NOT PSYCHOTIC.      
         
 b IF YES:  Do you currently believe these things? NO  YES    YES   
     ➡M6  ➡M6  
          
M4 a Have you ever believed that you were being sent special NO YES YES  YES YES   
  messages through the TV, radio, or newspaper, or that a       
  person you did not personally know was particularly       
  interested in you?        
         
 b IF YES:  Do you currently believe these things? NO YES YES  YES YES   
     ➡M6   ➡M6  
          
M5 a Have your relatives or friends ever considered any of your NO YES YES  YES YES   
  beliefs strange or unusual?       
  INTERVIEWER:  ASK FOR EXAMPLES. CODE YES ONLY IF THE EXAMPLES       
  ARE CLEARLY DELUSIONAL IDEAS (FOR EXAMPLE, SOMATIC OR RELIGIOUS       
  DELUSIONS OR DELUSIONS OF GRANDIOSITY, JEALOUSY, GUILT,       
  RUIN OR DESTITUTION OR OTHERS NOT EXPLORED IN M1 TO M4).       
         
 b IF YES:  Do they currently consider your beliefs strange? NO YES YES  YES YES   
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     BIZARRE    BIZARRE  
         
M6 a Have you ever heard things other people couldn't hear, NO YES   YES  YES   
  such as voices?        
  HALLUCINATIONS ARE SCORED "BIZARRE" ONLY IF PATIENT ANSWERS         
  YES TO THE FOLLOWING:        
          
  IF YES: Did you hear a voice commenting on your thoughts or NO  YES  NO  YES  
  behavior,or did you hear two or more voices talking to each other?       
          
          
 b IF YES:  Have you heard these things in the past month? NO YES YES  YES  YES   
 SCORE AS "YES BIZARRE" IF PATIENT HEARD A VOICE   ➡M8           ➡M8  
  COMMENTING ON THEIR THOUGHTS OR BEHAVIOR OR HEARD 
  TWO OR MORE VOICES TALKING TO EACH OTHER. 
      
M7 a Have you ever had visions when you were awake or have  NO YES   YES  
  you ever seen things other people couldn't see? 
  CLINICIAN: CHECK TO SEE IF THESE ARE CULTURALLY INAPPROPRIATE. 
 
 b IF YES:  Have you seen these things in the past month? NO YES   YES     
 
  CLINICIAN'S JUDGMENT 
 
M8 b Is the patient currently exhibiting incoherence, disorganized speech, or marked loosening NO YES  
  of associations? 
 
M9 b Is the patient currently exhibiting disorganized or catatonic behavior? NO YES  
   
M10 b Are negative symptoms of schizophrenia, for example, significant affective  NO YES  
  flattening, poverty of speech (alogia) or an inability to initiate or persist in goal-   
  directed activities (avolition) prominent during the interview? 
    
M11 a IS THERE AT LEAST ONE “YES” FROM M1 TO M10b? NO YES 
 
M11 b    
 
          ARE THE ONLY SYMPTOMS PRESENT THOSE IDENTIFIED BY THE CLINICIAN FROM  
           M1 TO M7 (COLUMN B) AND FROM M8b OR M9b OR M10b?  
 
  IF YES, SPECIFY IF THE LAST EPISODE IS CURRENT (AT LEAST ONE “b” QUESTION 
IS CODED “YES” FROM M1 TO M10b) AND/OR LIFETIME (ANY QUESTION CODED 
YES FROM M1 TO M10b) AND PASS TO THE NEXT DIAGNOSTIC SECTION. 
 
               IF NO, CONTINUE. 
 
 
 
   NO                                  YES 
  
PSYCHOTIC DISORDER NOT 
OTHERWISE SPECIFIED*   
 
 Current  ❏ 
Lifetime  ❏  
 
*Provisional diagnosis due to 
insufficient information 
available at this time. 
 
WARNING:   IF AT LEAST ONE “b” QUESTION IS CODED YES, CODE M11c AND M11d. 
   IF ALL “b” QUESTIONS ARE CODED NO, CODE ONLY M11d. 
 
M11c             
 
              FROM M1 TO M10b:  ARE ONE OR MORE "b" ITEMS CODED "YES BIZARRE"? 
OR 
              ARE TWO OR MORE "b" ITEMS CODED "YES" BUT NOT "YES BIZARRE"? 
                                                       
     NO  
Then Criterion "A" of 
Schizophrenia 
is not currently met 
   
95 of 165
Page 174 of 291
M.I.N.I. Plus 5.0.0 (January 1, 2005) -27- 
 
       
   
 
 
                                                       
                                        YES 
Then Criterion "A" of 
Schizophrenia 
is currently met 
 
M11d     FROM M1 TO M10b:  ARE ONE OR MORE "a" ITEMS CODED "YES BIZARRE"         
 
OR  
                ARE TWO OR MORE "a" ITEMS CODED "YES" BUT NOT "YES BIZARRE"? 
              (CHECK THAT AT LEAST 2 ITEMS OCCURRED DURING THE SAME TIME PERIOD.)
 
                                                       
   NO            
Then Criterion "A" of 
Schizophrenia 
is not met Lifetime 
 
 
OR      IS M11c CODED “YES”  
       
   
 
                                                       
                                        YES 
Then Criterion "A" of 
Schizophrenia 
is met Lifetime 
 
M12 a Were you taking any drugs or medicines just before these symptoms began?      
   ❐ No      ❐ Yes 
  
 b Did you have any medical illness just before these symptoms began?      
   ❐ No      ❐ Yes 
 
 c IN THE CLINICIAN’S JUDGMENT, ARE EITHER OF THESE LIKELY TO BE       
  DIRECT CAUSES OF THE PATIENT'S PSYCHOSIS?   
  (IF NECESSARY, ASK OTHER OPEN-ENDED QUESTIONS.) 
   ❐ No      ❐ Yes 
 
 d HAS AN ORGANIC CAUSE BEEN RULED OUT? NO YES UNCERTAIN  
 
  IF M12d = NO: SCORE M13 (a, b) AND GO TO THE NEXT DISORDER 
  IF M12d = YES: CODE NO IN M13 (a, b) AND GO TO M14 
  IF M12d = UNCERTAIN:   CODE UNCERTAIN IN M13 (a, b)  AND GO TO M14 
 
  
 M13a    IS M12d CODED NO BECAUSE OF A GENERAL MEDICAL CONDITION? 
 
              IF YES,  SPECIFY IF THE LAST EPISODE IS  
 
              CURRENT (AT LEAST ONE “b” QUESTION IS CODED YES FROM M1 TO M10b) 
              AND/OR LIFETIME (“a” OR “b”) QUESTION IS CODED YES FROM M1 TO M10b. 
                                                
     NO                           YES 
 
PSYCHOTIC DISORDER 
Due to a General Medical 
Condition 
Current  ❏ 
Lifetime  ❏ 
Uncertain, code later ❏ 
 
  
 M13 b   IS M12d CODED NO BECAUSE OF A DRUG?  
 
               IF YES, SPECIFY IF THE LAST EPISODE IS  
 
               CURRENT (AT LEAST ONE QUESTION “b” IS CODED YES FROM M1 TO M10b)  
              AND/OR LIFETIME (ANY “a” OR “b” QUESTION CODED YES FROM M1 TO M10b). 
                                                
     NO                           YES 
 
Substance Induced 
PSYCHOTIC DISORDER 
Current  ❏ 
Lifetime  ❏ 
Uncertain, code later ❏ 
 
M14  How long was the longest period during which you had those beliefs or experiences?    
  IF <1 DAY, GO TO THE NEXT SECTION. 
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M15 a During or after a period when you had these beliefs or experiences, did you have NO YES  
  difficulty working, or difficulty in your relationships with others, or in taking 
  care of yourself? 
 
 b  IF YES, how long did these difficulties last?    
  IF ≥6 MONTHS, GO TO M16. 
 
 c Have you been treated with medications or were you hospitalized because of NO YES   
  these beliefs or experiences, or the difficulties caused by these problems? 
 
 d  IF YES, what was the longest time you were treated with medication or were    
  hospitalized for these problems? 
 
M16 a THE PATIENT REPORTED DISABILITY (M15a CODED YES) OR WAS TREATED OR NO YES  
  HOSPITALIZED FOR PSYCHOSIS (M15c = YES). 
 
 b CLINICIAN’S JUDGMENT:  CONSIDERING YOUR EXPERIENCE, RATE THE PATIENT’S    
  LIFETIME DISABILITY CAUSED BY THE PSYCHOSIS. 
 
   absent ❏ 1 
   mild ❏ 2 
   moderate ❏ 3 
   severe ❏ 4 
     
 
M17   WHAT WAS THE TOTAL DURATION OF THE PSYCHOSIS, TAKING INTO ACCOUNT THE ACTIVE 1 ❏ ≥1 day to <1 month  
  PHASE (M14) AND THE ASSOCIATED DIFFICULTIES (M15b) AND PSYCHIATRIC 2 ❏ ≥1 month to <6 months 
  TREATMENT (M15d). 3 ❏ ≥>6 months 
 
  CHRONOLOGY 
 
M18 a How old were you when you first began having these unusual beliefs or experiences?  age   
 
         b Since the first onset how many distinct times did you have significant episodes of these unusual     
       beliefs or experiences? 
 
 
PSYCHOTIC DISORDERS - PART 2 
 
DIFFERENTIAL DIAGNOSIS BETWEEN PSYCHOTIC AND MOOD DISORDERS 
 
CODE THE QUESTIONS M19 TO M23 ONLY IF THE PATIENT DESCRIBED AT LEAST 1 PSYCHOTIC SYMPTOM (M11a = YES AND M11b = NO), NOT EXPLAINED 
BY AN ORGANIC CAUSE (M12d = YES OR UNCERTAIN). 
 
M19 a  DOES THE PATIENT CODE POSITIVE FOR CURRENT AND/OR PAST MAJOR DEPRESSIVE NO YES  
   EPISODE (QUESTION A8 CODED YES)? 
 
 b  IF YES: IS A1 (DEPRESSED MOOD) CODED YES? NO YES  
 
 c  DOES THE PATIENT CODE POSITIVE FOR CURRENT AND/OR PAST MANIC EPISODE NO YES  
   (QUESTION D7 IS CODED YES)? 
 
 d  IS M19a OR M19c CODED YES? NO YES   
   ↓ 
   STOP.  Skip to M24 
  NOTE:  VERIFY THAT THE RESPONSES TO THE QUESTIONS M20 TO M23 REFER TO THE PSYCHOTIC,  
  DEPRESSIVE (A8) AND MANIC EPISODES (D7), ALREADY IDENTIFIED IN M11c AND M11d, A8 AND D7. 
   IN CASE OF DISCREPANCIES, REEXPLORE THE SEQUENCE OF DISORDERS, TAKING INTO ACCOUNT IMPORTANT  
  LIFE ANCHOR POINTS/MILESTONES AND CODE M20 TO M23 ACCORDINGLY. 
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M20  When you were having the beliefs and experiences you just described NO YES  
  (GIVE EXAMPLES TO PATIENT), were you also feeling depressed/high/irritable ↓ 
  at the same time? STOP.  Skip to M24 
 
M21  Were the beliefs or experiences you just described (GIVE EXAMPLES TO NO YES  
  PATIENT) restricted exclusively to times you were feeling depressed/high/irritable?  ↓ 
   STOP.  Skip to M24 
 
M22  Have you ever had a period of two weeks or more of having these beliefs NO YES  
  or experiences when you were not feeling depressed/high/irritable? ↓ 
   STOP.  Skip to M24 
 
M23  Which lasted longer: these beliefs or experiences or the periods of feeling 1 ❏  mood  
  depressed/high/irritable? 2 ❏  beliefs, experiences 
   3 ❏    same 
 
M24  AT THE END OF THE INTERVIEW, GO TO THE DIAGNOSTIC ALGORITHMS FOR PSYCHOTIC DISORDERS. 
 
  CONSULT ITEMS M11a AND M11b: 
 
  IF THE CRITERION "A" OF SCHIZOPHRENIA IS MET (M11c AND/OR M11d = YES) GO TO DIAGNOSTIC ALGORITHMS I 
 
  IF THE CRITERION "A" OF SCHIZOPHRENIA IS NOT MET (M11c AND/OR M11d = NO) GO TO DIAGNOSTIC ALGORITHMS II 
 
  FOR MOOD DISORDERS GO TO DIAGNOSTIC ALGORITHM III. 
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N.  ANOREXIA NERVOSA 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
N1 a   How tall are you? ft in. 
  cm. 
            
 b   What was your lowest weight in the past 3 months?            lbs. 
             kgs.              
  ➨ 
 IS PATIENT’S WEIGHT EQUAL TO OR BELOW THE THRESHOLD CORRESPONDING TO NO YES 
 HIS / HER HEIGHT?  (SEE TABLE BELOW)   
   
 In the past 3 months:   
N2  ➨ 
 In spite of this low weight, have you tried not to gain weight? NO YES              
   
N3  ➨  
 Have intensely you feared gaining weight or becoming fat, even though you were underweight? NO YES              
 
N4 a    Have you considered yourself too big / fat or that part of your body was too big / fat? NO YES              
  
 b Has your body weight or shape greatly influenced how you felt about yourself? NO YES  
 
 c Have you thought that your current low body weight was normal or excessive? NO YES  
   ➨ 
N5  ARE 1 OR MORE ITEMS FROM N4 CODED YES? NO YES 
   ➨ 
N6  FOR WOMEN ONLY:  During the last 3 months, did you miss all your menstrual NO YES  
  periods when they were expected to occur (when you were not pregnant)? 
 
  
            FOR WOMEN:   ARE N5 AND N6 CODED YES? 
                FOR MEN:          IS N5 CODED YES? 
   
 
     ➨                                              
     NO                              YES 
 
ANOREXIA NERVOSA 
CURRENT 
  CHRONOLOGY 
 
N7 How old were you when you first began having symptoms of anorexia?  age   
 
N8 Since the first onset how many distinct illness periods of anorexia did you have?     
 
N9 During the past year, for how many months did you have significant symptoms of anorexia?     
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TABLE HEIGHT / WEIGHT TABLE CORRESPONDING TO A BMI THRESHOLD OF 17.5 KG/M2  
 
Height/Weight 
ft/in 4'9 4'10 4'11 5'0 5'1 5'2 5'3 5'4 5'5 5'6 5'7 5'8 5'9 5'10 
lbs. 81 84 87 89 92 96 99 102 105 108 112 115 118 122 
cm 145 147 150 152 155 158 160 163 165 168 170 173 175 178 
kgs 37 38 39 41 42 43 45 46 48 49 51 52 54 55 
     
Height/Weight  
ft/in 5'11 6'0 6'1 6'2 6'3  
lbs. 125 129 132 136 140  
cm 180 183 185 188 191  
kgs 57 59 60 62 64 
The weight thresholds above are calculated using a body mass index (BMI) equal to or below 17.5 kg/m2 for the patient's height.  This 
is the threshold guideline below which a person is deemed underweight by the DSM-IV and the ICD-10 Diagnostic Criteria for 
Research for Anorexia Nervosa. 
 
 
O.  BULIMIA NERVOSA 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE) 
   
 
   ➨  
O1  In the past three months, did you have eating binges or times when you ate a very large NO YES  
  amount of food within a 2-hour period?  
   ➨  
O2  In the last 3 months, did you have eating binges as often as twice a week? NO YES  
 
   ➨  
O3  During these binges, did you feel that your eating was out of control? NO YES  
   ➨  
O4  Did you do anything to compensate for, or to prevent a weight gain from these binges, like  NO YES  
  vomiting, fasting, exercising or taking laxatives, enemas, diuretics (fluid pills), or other  
  medications? 
   ➨  
O5  Does your body weight or shape greatly influence how you feel about yourself? NO YES  
 
O6  DO THE PATIENT’S SYMPTOMS MEET CRITERIA FOR ANOREXIA NERVOSA? NO YES  
           ↓ 
   Skip to O8 
    
O7  Do these binges occur only when you are under (          lbs./kgs.)? NO YES  
  INTERVIEWER: WRITE IN THE ABOVE PARENTHESIS THE THRESHHOLD WEIGHT FOR THIS PATIENT’S  
  HEIGHT FROM THE HEIGHT/WEIGHT TABLE IN THE ANOREXIA NERVOSA MODULE.  
  
             
O8        IS O5 CODED YES AND IS EITHER O6 OR O7 CODED NO?  
 
            
                                              
     NO                      YES 
 
BULIMIA NERVOSA 
CURRENT 
  CHRONOLOGY 
 
O9 How old were you when you first began having symptoms of bulimia?  age    
 
O10 Since the first onset how many illness periods of bulimia did you have?     
 
O11 During the past year, for how many months did you have significant symptoms of bulimia?     
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        SUBTYPES OF BULIMIA NERVOSA 
 
               Do you regularly engage in self induced vomiting, misuse of laxatives, diuretics or 
        enemas? 
            
               [IN THE NON-PURGING TYPE THE PATIENT HAS USED OTHER COMPENSATORY BEHAVIORS SUCH AS 
                      FASTING OR EXCESSIVE EXERCISE, BUT NOT PURGING.] 
                                               
    NO                            YES 
 
Non-Purging             Purging 
      Type                      Type 
 
BULIMIA NERVOSA 
  
     
              SUBTYPES OF ANOREXIA NERVOSA 
            
        Binge-Eating/Purging Type 
   
                 IS O7 CODED YES?         
   
                                          
    NO                            YES 
 
ANOREXIA NERVOSA 
Binge Eating/Purging Type
CURRENT 
   
  
        Restricting Type 
   
               Do you lose weight without purging? 
 
            
                                                 
      NO                            YES 
 
ANOREXIA NERVOSA 
Restricting Type 
CURRENT 
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P.  GENERALIZED ANXIETY DISORDER 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE) 
   
 
   ➨ 
P1 a Have you worried excessively or been anxious about several things NO YES  
  over the past 6 months? 
    ➨ 
 b Are these worries present most days? NO YES  
     ➨ 
  IS THE PATIENT’S ANXIETY RESTRICTED EXCLUSIVELY NO YES  
  TO, OR BETTER EXPLAINED BY, ANY DISORDER PRIOR TO THIS POINT? 
 
    ➨ 
P2  Do you find it difficult to control the worries or do they interfere with your ability to NO YES  
  focus on what you are doing? 
 
P3  FOR THE FOLLOWING, CODE NO, IF THE SYMPTOMS ARE CONFINED TO FEATURES  
  OF ANY DISORDER EXPLORED PRIOR TO THIS POINT. 
 
  When you were anxious over the past 6 months, most of the time did you: 
  
  a Feel restless, keyed up or on edge? NO YES  
 
  b Feel tense? NO YES  
 
  c Feel tired, weak or exhausted easily? NO YES  
 
  d Have difficulty concentrating or find your mind going blank? NO YES  
 
  e Feel irritable? NO YES  
 
  f Have difficulty sleeping (difficulty falling asleep, waking up in the middle of the night, NO YES  
   early morning wakening, or sleeping excessively)? 
    ➨ 
   SUMMARY OF P3:  ARE 3 OR MORE P3  ANSWERS CODED YES? NO YES 
    ➨ 
P4  Did these symptoms of anxiety cause you significant distress or impair your ability NO YES  
  to function at work, socially, or in some other important way? 
 
P5 a Were you taking any drugs or medicines just before these symptoms began?   
   ❐ No      ❐ Yes 
 
 b Did you have any medical illness just before these symptoms began?  
   ❐ No      ❐ Yes 
  
  IN THE CLINICIAN’S JUDGMENT:  ARE EITHER OF THESE LIKELY TO BE  
  DIRECT CAUSES OF THE PATIENT'S GENERALIZED ANXIETY DISORDER? 
 
  P5 (SUMMARY): HAS AN ORGANIC CAUSE BEEN RULED OUT? NO YES  
 
  
  IS P5 (SUMMARY) CODED YES? 
 
 
            
                                           
     NO                              YES 
 
Generalized Anxiety Disorder 
CURRENT 
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P6  IS P5 (SUMMARY) CODED NO AND P5b CODED YES? 
 
 
            
                                           
     NO                              YES 
Current 
Generalized Anxiety Disorder. 
Due to a General 
Medical Condition 
 
  
P7  IS P5 (SUMMARY) CODED NO AND P5a CODED YES? 
 
 
            
                                           
     NO                             YES 
Current 
Substance Induced 
Generalized Anxiety Disorder 
  CHRONOLOGY 
 
P8       How old were you when you first began having symptoms of generalized anxiety?  age   
 
P9       During the past year, for how many months did you have significant symptoms of     
       generalized anxiety? 
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Q.  ANTISOCIAL PERSONALITY DISORDER (optional) 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
Q1  Before you were 15 years old, did you: 
 
 a  repeatedly skip school or run away from home overnight? NO YES  
 
 b  repeatedly lie, cheat, "con" others, or steal? NO YES  
 
 c  start fights or bully, threaten, or intimidate others? NO YES  
 
 d  deliberately destroy things or start fires? NO YES  
 
 e  deliberately hurt animals or people? NO YES  
 
 f  force someone to have sex with you? NO YES  
   ➨ 
  ARE  2 OR MORE Q1 ANSWERS CODED YES? NO YES  
 
  DO NOT CODE YES TO THE BEHAVIORS BELOW IF THEY ARE EXCLUSIVELY  
  POLITICALLY OR RELIGIOUSLY MOTIVATED. 
 
Q2  Since you were 15 years old, have you: 
 
 a repeatedly behaved in a way that others would consider irresponsible, like NO YES  
  failing to pay for things you owed, deliberately being impulsive or deliberately 
  not working to support yourself?   
 
 b done things that are illegal even if you didn't get caught (for example, destroying  NO YES  
  property, shoplifting, stealing, selling drugs, or committing a felony)? 
 
 c been in physical fights repeatedly (including physical fights with your NO YES  
  spouse or children)? 
 
 d often lied or "conned" other people to get money or pleasure, or lied just  NO YES  
  for fun? 
 
 e exposed others to danger without caring? NO YES  
 
 f felt no guilt after hurting, mistreating, lying to, or stealing from others, or NO YES  
  after damaging property? 
 
   
 
  ARE 3 OR MORE Q2 QUESTIONS CODED YES? 
 
 
         
   
 
          NO                  YES 
 
ANTISOCIAL PERSONALITY 
DISORDER 
LIFETIME 
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R.  SOMATIZATION DISORDER (optional) 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE) 
 
 
   ➨ 
R1 a Have you had many physical complaints not clearly related to a specific disease  NO YES  
  beginning before age 30? 
 
   ➨ 
 b Did these physical complaints occur over several years? NO YES  
   ➨ 
 c Did these complaints lead you to seek treatment? NO YES  
   ➨ 
 d Did these complaints cause significant problems at school, at work, socially, or in other NO YES  
  important areas? 
 
R2  Did you have pain in your: head NO YES  
   abdomen NO YES  
   back NO YES  
   joints, extremities, chest, rectum NO YES  
   during menstruation NO YES  
   sexual intercourse NO YES  
   urination NO YES  
   ➨ 
  ARE 2 OR MORE R2 ANSWERS CODED YES? NO YES 
 
R3  Did you have any of the following abdominal symptoms: 
   nausea NO YES  
   bloating NO YES  
   vomiting NO YES  
   diarrhea NO YES  
   intolerance of several different foods NO YES  
   ➨ 
  ARE 2 OR MORE R3 ANSWERS CODED YES? NO YES 
 
R4  Did you have any of the following sexual symptoms: 
   loss of sexual interest NO YES  
   erection or ejaculation problems NO YES  
   irregular menstrual periods NO YES  
   excessive menstrual bleeding NO YES  
   vomiting throughout pregnancy NO YES  
   ➨ 
  ARE 2 OR MORE R4 ANSWERS CODED YES? NO YES 
 
R5  Did you have any of the following symptoms: 
   paralysis or weakness in parts of your body NO YES  
   impaired coordination or imbalance NO YES  
   difficulty swallowing or lump in throat NO YES  
   difficulty speaking NO YES  
   difficulty emptying your bladder NO YES  
   loss of touch or pain sensation NO YES  
   double vision or blindness NO YES  
   deafness, seizures, loss of consciousness NO YES  
   significant episodes of forgetfulness NO YES  
   unexplained sensations in your body  NO  YES  
   (CLINICIAN: PLEASE EVALUATE IF THESE ARE SOMATIC HALLUCINATIONS) 
   ➨ 
  ARE 2 OR MORE R5 ANSWERS CODED YES? NO YES  
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R6  Were the symptoms investigated by your physician? NO YES  
 
R7  Was any medical illness found, or were you using any drug or medication     
  that could explain these symptoms? 
   ❐ No      ❐ Yes 
     
  R6 AND R7 (SUMMARY): CLINICIAN: HAS AN ORGANIC CAUSE BEEN RULED OUT? NO YES 
   
    
R8  Were the complaints or disability out of proportion to the patient's physical illness? NO YES  
   ➨ 
  IS R7 (SUMMARY) OR R8 CODED YES? NO YES 
    ➨ 
R9  Were the symptoms a pretense or intentionally produced (as in factitious disorder)? NO YES  
 
   
        
      IS R9 CODED NO? 
 
 
                                                       
     NO                             YES 
 
SOMATIZATION DISORDER
LIFETIME 
  
   
 R10      Are you currently suffering from these symptoms? 
 
 
        
                                                  
     NO                            YES 
 
SOMATIZATION DISORDER
CURRENT 
 
 
S.  HYPOCHONDRIASIS 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
 
   ➨ 
S1  In the past six months, have you worried a lot about having a serious physical illness? NO YES  
  DO NOT CODE YES IF ANY PHYSICAL DISORDER CAN ACCOUNT FOR THE PHYSICAL SENSATIONS 
  OR SIGNS THE PATIENT DESCRIBES. 
 
   ➨ 
S2  Have you had this worry for 6 months or more? NO YES  
   ➨ 
S3  Have you ever been examined by a doctor for these symptoms? NO YES  
   ➨ 
S4  Have your illness fears persisted in spite of the doctor's reassurance? NO YES  
 
S5  Does this worry cause you significant distress, or does it interfere with your ability to NO YES  
  function at work, socially, or in other important ways? 
 
   
              
 S6         IS S5 CODED YES? 
 
 
                                                       
     NO                           YES 
 
HYPOCHONDRIASIS 
CURRENT 
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T.  BODY DYSMORPHIC DISORDER 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
 
   ➨ 
T1  Are you preoccupied with a defect in your appearance? NO YES  
 
 
   ➨ 
T2  Has this preoccupation persisted in spite of others (including a physician) genuinely NO YES  
  feeling that your worry was excessive? 
 
T3  Does this preoccupation cause you significant distress, or does it interfere significantly NO YES  
  with your ability to function at work, socially, or in some other important way? 
 
   
              
T4           IS T3 CODED YES? 
 
 
        
                                                       
     NO                           YES 
 
BODY DYSMORPHIC 
DISORDER 
CURRENT 
 
 
U.  PAIN DISORDER 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOXES, CIRCLE NO IN ALL DIAGNOSTIC BOXES, AND MOVE TO THE NEXT MODULE) 
 
 
   ➨ 
U1  Currently, is pain your main problem? NO YES  
 
 
   ➨ 
U2  Currently, is the pain severe enough to need medical attention? NO YES  
   ➨ 
U3  Currently is the pain causing you significant distress, or interfering significantly with your NO YES  
  ability to function at work, socially, or in some other important way? 
   ➨ 
U4  Did psychological factors or stress have an important role in the onset of the pain, or did NO YES  
  they make it worse, or keep it going? 
    ➨ 
U5  Is the pain a pretense or intentionally produced or feigned?  (As in factitious disorder?) NO YES  
 
U6  Did a medical condition have an important role in the onset of the pain, or did the medical NO YES  
  condition make it worse, or keep it going? 
 
U7  Has the pain been present for more than 6 months? NO YES  
   ↓ ↓ 
   Acute Chronic 
   
U8           IS U6 CODED NO? 
 
 
         
   
 
                                                      
     NO                           YES 
 
PAIN DISORDER 
associated with  
psychological factors 
CURRENT 
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U9         IS U6 CODED YES? 
         
   
             IF U8 OR U9 ARE CODED YES 
              AND U7 = NO, ADD: ACUTE TO DIAGNOSIS TITLE 
              AND U7 = YES, ADD: CHRONIC TO DIAGNOSIS TITLE 
            
                                                       
     NO                           YES 
 
PAIN DISORDER 
associated with  
psychological factors 
and general medical condition 
CURRENT 
 
 
V.  CONDUCT DISORDER  Age 17 or Younger 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
  Please involve the family or significant caregiver in eliciting this information. 
 
 
V1  In the past 12 months have you: 
 
 a bullied, threatened or intimidated others NO YES  
 b started fights NO YES  
 c used a weapon that could harm someone (for example, knife, gun, bat, broken bottle) NO YES  
 d deliberately hurt people NO YES  
 e deliberately hurt animals NO YES  
 f stolen things using force (for example, armed robbery, mugging, purse snatching, extortion) NO YES  
 g forced anyone to have sex with you NO YES  
 h deliberately started fires to damage property NO YES  
 i deliberately destroyed things belonging to others NO YES  
 j broken into someone's house or car NO YES  
 k lied repeatedly to get things or "conned" (tricked) other people NO YES  
 l stolen things NO YES  
 m stayed out late at night in spite of your parents forbidding you, starting before age 13 years NO YES  
 n run away from home at least twice NO YES  
 o often skipped school, starting before age 13 years NO YES  
   ➨ 
  ARE 3 OR MORE V1 ANSWERS CODED YES NO YES 
  WITH AT LEAST ONE CODED YES IN THE PAST 6 MONTHS?  
   ➨ 
V2  Did these behaviors cause significant problems at school, at work, or with friends and family? NO YES  
 
   
              IS V2 CODED YES? 
             
 
 
                                                       
NO                       YES 
 
CONDUCT DISORDER 
CURRENT 
 
  Subtypes Mark all that apply. 
  With ADHD  ❏ 
  With history of physical or sexual abuse  ❏ 
  With history of traumatic divorce  ❏ 
  With history of adoption  ❏ 
  With other stresses  ❏ 
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W.  ATTENTION DEFICIT/HYPERACTIVITY DISORDER 
(Children/Adolescents) 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
  Please involve the family or significant caregiver in eliciting this information. 
 
  In the past 6 months have you often: 
 
W1 a Failed to pay attention to details or made careless mistakes in school, work or other activities? NO YES  
 
 b Had difficulty paying attention when playing or doing some work? NO YES  
 
 c Seemed not to listen when spoken to directly? NO YES  
 
 d Not followed instructions, or failed to finish schoolwork or chores (even though you NO YES  
  understood the instructions and weren't trying to be difficult)? 
 
 e Had difficulty getting organized? NO YES  
 
 f Avoided or disliked things that require a lot of thinking (like schoolwork or homework)? NO YES  
 
 g Lost things you needed? NO YES  
 
 h Become easily distracted by little things? NO YES  
 
 i Become forgetful in your day to day activities? NO YES  
 
  W1 (SUMMARY): ARE 6 OR MORE W1 ANSWERS CODED YES? NO YES 
 
  In the past 6 months have you often: 
 
W2 a Squirmed in your seat or fidgeted with your hands or feet NO YES  
 
 b Left your seat in class when you were not supposed to? NO YES  
 
 c Run around and climbed a lot when you shouldn't or others didn't want you to? NO YES  
 
 d Had difficulty playing quietly? NO YES  
 
 e Felt like you were "driven by a motor" or were always "on the go"? NO YES  
 
 f Talked too much? NO YES  
 
 g Blurted out an answer before the question was completed? NO YES  
 
 h Had difficulty waiting your turn? NO YES  
 
 i Interrupted or intruded on others? NO YES  
   ➨ 
  W2 (SUMMARY): ARE 6 OR MORE W2 ANSWERS CODED YES? NO YES 
   ➨ 
W3  Did you have some of these hyperactive-impulsive or inattentive symptoms before  NO YES  
  you were 7 years old? 
   ➨ 
W4  Have some of these symptoms caused significant problems in two or more of the following NO YES  
  situations: at school, at work, at home, or with family or friends? 
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             IS W4 CODED YES? 
 
 
                                                       
 NO                      YES 
Attention Deficit/Hyperactivity 
Disorder 
CURRENT 
 
 
ATTENTION DEFICIT/HYPERACTIVITY DISORDER 
(Adult) 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
  As a child: 
 
W5 a Were you active, fidgety, restless, always on the go? NO YES  
 
 b Were you inattentive and easily distractible? NO YES  
 
 c Were you unable to concentrate at school or while doing your homework? NO YES  
 
 d Did you fail to finish things, such as school work, projects, etc.? NO YES  
 
 e Were you short tempered, irritable, or did you have a “short fuse”, or tend to explode. NO YES  
 
 f Did things have to be repeated to you many times before you did them? NO YES  
 
 g Did you tend to be impulsive without thinking of the consequences? NO YES  
 
 h Did you have difficulty waiting for your turn, frequently needing to be first? NO YES  
 
 i Did you get into fights and/or bother other children? NO YES  
 
 j Did your school complain about your behavior? NO YES  
   ➨ 
  W5 (SUMMARY): ARE 6 OR MORE W5 ANSWERS CODED YES? NO YES 
   ➨ 
W6  Did you have some of these hyperactive-impulsive or inattentive symptoms before  NO YES  
  you were 7 years old? 
 
  As an adult: 
 
W7 a Are you still distractible? NO YES  
 
 b Are you intrusive, or do you butt in, or say things that you later regret either to friends, NO YES  
  at work, or home? 
 
 c Are you impulsive, even if you have better control than when you were a child? NO YES  
 
 d Are you still fidgety, restless, always on the go, even if you have better control than when NO YES  
  you were a child? 
 
 e Are you still irritable and get angrier than you need to? NO YES  
 
 f Are you still impulsive?  For example, do you tend to spend more money than you really NO YES  
  should? 
 
 g Do you have difficulty getting work organized? NO YES  
 
 h Do you have difficulty getting organized even outside of work? NO YES  
 i Are you under-employed or do you work below your capacity? NO YES  
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 j Are you not achieving according to people's expectations of your ability? NO YES  
 
 k Have you changed jobs or have been asked to leave jobs more frequently than other people? NO YES  
 
 l Does your spouse complain about your inattentiveness or lack of interest in him/her and/or NO YES  
  the family? 
 
 m Have you gone through two or more divorces, or changed partners more than others? NO YES  
 
 n Do you sometimes feel like you are in a fog, like a snowy television or out of focus? NO YES  
   ➨ 
  W7 (SUMMARY): ARE 9 OR MORE W7 ANSWERS CODED YES? NO YES 
   ➨ 
W8  Have some of these symptoms caused significant problems in two or more of the following NO YES  
  situations: at school, at work, at home, or with family or friends? 
 
   
              IS W8 CODED YES? 
 
 
         
                                                       
 NO                      YES 
Adult 
Attention Deficit/Hyperactivity 
Disorder 
 
 
X.  ADJUSTMENT DISORDERS 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
  EVEN IF A LIFE STRESS IS PRESENT OR A STRESS PRECIPITATED THE PATIENT'S DISORDER, DO NOT USE AN ADJUSTMENT DISORDER 
  DIAGNOSIS IF ANY OTHER PSYCHIATRIC DISORDER IS PRESENT.  SKIP THE ADJUSTMENT DISORDER SECTION IF THE PATIENT'S 
  SYMPTOMS MEET CRITERIA FOR ANOTHER SPECIFIC AXIS I DISORDER OR ARE MERELY AN EXACERBATION OF A PREEXISTING 
  AXIS I OR II DISORDER. 
 
  ONLY ASK THESE QUESTIONS IF PATIENT CODES NO TO ALL OTHER DISORDERS. 
 
   ➨ 
X1  Are you having emotional or behavioral symptoms as a result of a life of stress?  [Examples NO YES  
  include anxiety/depression/misbehavior/physical complaints (examples of misbehavior  
  include fighting, driving recklessly, skipping school, vandalism, violating the rights of others, 
  or doing illegal things)]. 
 
   ➨ 
X2  Did these emotional/behavioral symptoms start within 3 months of the onset of the stressor? NO YES  
   ➨ 
X3 a Are these emotional/behavioral symptoms causing marked distress beyond what would be NO YES  
  expected? 
   ➨ 
 b Are these emotional/behavioral symptoms causing significant impairment in your ability to NO YES  
  function socially, at work, or at school? 
 
X4  Are these emotional/behavioral symptoms due entirely to the loss of a loved one (bereavement)  
  and are they similar in severity, level of impairment and duration to what most others would 
  suffer under similar circumstances?  (If so this is uncomplicated bereavement.) 
   ➨ 
  HAS UNCOMPLICATED BEREAVEMENT BEEN RULED OUT? NO YES  
    ➨ 
X5  Have these emotional/behavioral symptoms continued for more than 6 months after the NO YES  
  stress stopped? 
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  WHICH OF THESE EMOTIONAL / BEHAVIORAL SUBTYPES ARE PRESENT? MARK ALL THAT APPLY 
   . 
 A Depression, tearfulness or hopelessness.  ❏ 
 
 B Anxiety, nervousness, jitteriness, worry.  ❏ 
 
 C Misbehavior (for example, fighting, driving recklessly, skipping school, vandalism,   ❏ 
  violating other's rights, doing illegal things). 
 
 D Work problems, school problems, physical complaints or social withdrawal.  ❏ 
 
  IF MARKED: 
 
 • A only, then code as Adjustment disorder with depressed mood.  309.0 
 • B only, then code as Adjustment disorder with anxious mood.  309.24 
 • C only, then code as Adjustment disorder of conduct.  309.3 
 • A and B only, then code as Adjustment disorder with mixed anxiety and depressed mood.  309.28 
 • C and (A or B), then code as Adjustment disorder of emotions and conduct.  309.4  
 • D only, then code as Adjustment Disorder unspecified.  309.9 
 
   
             IF X5 IS CODED NO, THEN CODE DISORDER YES WITH SUBTYPE. 
 
 
 
                                                       
 NO                      YES 
Adjustment Disorder 
with____________________ 
(see above for subtypes) 
 
 
Y.  PREMENSTRUAL DYSPHORIC DISORDER 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOX, CIRCLE NO, AND MOVE TO THE NEXT MODULE) 
 
 
   ➨ 
Y1  During the past year, were most of your menstrual periods preceded by a period lasting about NO YES  
  one week when your mood changed significantly? 
 
   ➨ 
Y2  During these periods, do you have difficulty in your usual activities or relationships with NO YES  
  others, are you less efficient at work, or do you avoid other people? 
 
Y3  During these premenstrual episodes (but not at in the week after your period ends) do you   
  have the following problems most of the time: 
 
 a Do you feel sad, low, depressed, hopeless, or self-critical? NO YES  
 
 b Do you feel particularly anxious, tense, keyed up or on edge? NO YES  
 
 c Do you often feel suddenly sad or tearful, or are you particularly sensitive to others' comments? NO YES  
 
 d Do you feel irritable, angry or argumentative? NO YES  
   ➨ 
  ARE 1 OR MORE Y3 ANSWERS CODED YES? NO YES  
 
 e Are you less interested in your usual activities, such as work, hobbies or meeting with friends? NO YES  
 
 f Do you have difficulty concentrating? NO YES  
 
 g Do you feel exhausted, tire easily, or lack energy? NO YES  
 
 h Does your appetite change, or do you overeat or have specific food cravings? NO YES  
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 i Do you have difficulty sleeping or do you sleep excessively? NO YES  
 
 j Do you feel you are overwhelmed or out of control? NO YES  
 
 k Do you have physical symptoms such as breast tenderness or swelling, headaches, joint or NO YES  
  muscle pain, a sensation of bloating, or weight gain? 
 
   
             ARE 5 OR MORE Y3 ANSWERS CODED YES? 
              
             IF YES, DIAGNOSIS MUST BE CONFIRMED BY PROSPECTIVE DAILY RATINGS 
               DURING AT LEAST 2 CONSECUTIVE CYCLES. 
                                                       
 NO                      YES 
Premenstrual  
Dysphoric Disorder Probable 
CURRENT 
 
 
Z.  MIXED ANXIETY-DEPRESSIVE DISORDER 
 
DO NOT USE THIS MODULE ALONE WITHOUT FIRST COMPLETING ALL THE ANXIETY AND MOOD DISORDERS. 
 
(➨ MEANS :  GO TO THE DIAGNOSTIC BOX AND CIRCLE NO. 
 
[SKIP THIS DISORDER IF PATIENT 'S SYMPTOMS HAVE ALREADY MET CRITERIA FOR ANY OTHER DISORDER AND CODE NO IN THE DIAGNOSTIC BOX.] 
 
 
   ➨ 
Z1  Have you been depressed or down consistently for at least a month? NO YES  
  
 
Z2  When you felt depressed did you have any of the following symptoms for at least one month: 
 
 a. Did you have difficulty concentrating or find your mind going blank? NO YES  
 
 b. Did you have trouble sleeping (difficulty falling asleep, waking up in the middle of the NO YES  
  night, early morning wakening, or sleeping excessively)? 
  
 c. Did you feel tired or low in energy? NO YES  
 
 d. Did you feel irritable? NO YES  
 
 e. Did you worry too persistently for at least a month? NO YES  
 
 f. Did you cry easily? NO YES  
 
 g. Were you always on the lookout for possible dangers? NO YES  
 
 h. Did you fear the worst? NO YES  
 
 i. Did you feel hopeless about the future? NO YES  
 
 j. Was your self-confidence low, or did you feel worthless? NO YES  
   ➨ 
  Summary of Z2:  ARE 4 OR MORE Z2 ANSWERS CODED YES? NO YES 
   ➨ 
Z3  Do these symptoms cause you significant distress or impair your ability to function NO YES  
  at work, socially, or in some other important way? 
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Z4 a Were you taking any drugs or medicines just before these symptoms began?   
 
 b Did you have any medical illness just before these symptoms began?   
 
  IN THE CLINICIAN’S JUDGMENT are either of these likely to be direct causes of the  
  patient's symptoms? 
   ➨ 
  HAS AN ORGANIC CAUSE BEEN RULED OUT? NO YES UNCERTAIN  
   ➨ 
Z5 a. The patient's symptoms meet criteria for: Major Depression LIFETIME NO YES  
    ➨ 
   Dysthymia LIFETIME NO YES  
    ➨ 
   Panic Disorder LIFETIME NO YES  
    ➨ 
   Generalized Anxiety Disorder LIFETIME NO YES  
    ➨ 
 b. The patient's symptoms CURRENTLY meet criteria for: any other anxiety disorder NO YES  
    ➨ 
   any other mood disorder NO YES  
    ➨ 
 c. The patient's symptoms are better accounted for by another psychiatric disorder. NO YES  
    
  
Z6 IS Z5c  CODED YES? 
 
           
                                           
     NO                           YES 
 
MIXED ANXIETY - 
DEPRESSIVE DISORDER 
CURRENT 
  
THIS CONCLUDES THE INTERVIEW
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DSM-IV/ICD-10 DIAGNOSTIC/BILLING CODES FOR M.I.N.I. DIAGNOSES 
 
Major Depressive Disorder Social Phobia (Social Anxiety Disorder) 
 Single Episode/F32.x  300.23/F40.1 
 296.20/F32.9 Unspecified Specific Phobia 
 296.21/F32.0 Mild  300.29/F40.2 
 296.22/F32.1 Moderate Obsessive-Compulsive Disorder 
 296.23/F32.2 Severe Without Psychotic Features  300.30/F42.8 
 296.24/F32.3 Severe With Psychotic Features Generalized Anxiety Disorder 
 296.25/F32.4 In Partial Remission  300.02/F41.1 
 296.26/F32.4 In Full Remission Substance Dependence/Abuse 
 Recurrent/F33.x  303.90/F10.2x Alcohol Dependence 
 296.30/F33.9 Unspecified  305.00/F10.1 Alcohol Abuse 
 296.31/F33.0 Mild  305.20/F12.1 Cannabis Abuse 
 296.32/F33.1 Moderate  305.30/F16.1 Hallucinogen Abuse 
 296.33/F33.2 Severe Without Psychotic Features  305.40/F13.1 Sedative, Hypnotic, or   
 296.34/F33.3 Severe With Psychotic Features       Anxiolytic Abuse 
 296.35/F33.4 In Partial Remission  305.50/F11.1 Opioid Abuse 
 296.36/F33.4 In Full Remission  305.60/F14.1 Cocaine Abuse    
Dysthymia   305.70/F15.1 Amphetamine Abuse 
 300.4/F34.1   305.90/F15.00 Caffeine Intoxication 
Mania   305.90/F18.1 Inhalant Abuse 
 Bipolar I, Single Manic Episode/F30.x  305.90/ Other (or Unknown) Substance 
 296.00 Unspecified  F19.00-F19.1 Abuse 
 296.01/F30.1 Mild  305.90/F19.1 Phencyclidine Abuse 
 296.02/F30.1 Moderate Psychotic Disorders  
 296.03/F30.1 Severe Without Psychotic Features  295.10/F20.1x Schizophrenia, Disorganized  
 296.04/F30.2 Severe With Psychotic Features    Type 
 296.05/F30.8 In Partial Remission  295.20/F20.2x Schizophrenia, Catatonic  
    Type 
 296.06/F30.8 In Full Remission  295.30/F20.0x Schizophrenia, Paranoid Type    
 Bipolar I, Most Recent Episode: Manic/F31.x  295.40/F20.8 Schizophreniform Disorder 
 296.40/F31.0 Hypomanic  295.60/F20.5x Schizophrenia, Residual Type 
 296.40 Unspecified  295.70/F25.x Schizoaffective Disorder 
 296.41/F31.1 Mild  295.90/F20.3x Schizophrenia, Undifferentiated 
 296.42/F31.1 Moderate    Type 
 296.43/F31.1 Severe Without Psychotic Features  297.10/F22.0 Delusional Disorder 
 296.44/F31.2 Severe With Psychotic Features  297.30/F24 Shared Psychotic Disorder    
 296.45/F31.7 In Partial Remission  293.81/F06.2 Psychotic Disorder Due to........ 
 296.46/F31.7 In Full Remission     (Indicate the General Medical 
 Bipolar I, Most Recent Episode: Depression/F31.x     Condition) With Delusions 
 296.50 Unspecified  293.82/F06.0 Psychotic Disorder Due to .......     
 296.51/F31.3 Mild     (Indicate the General Medical    
 296.52/F31.3 Moderate     Condition) With Hallucinations 
 296.53/F31.4 Severe Without Psychotic Features  293.89/F06.4 Anxiety Disorder Due to.......    
 296.54/F31.5 Severe With Psychotic Features      (Indicate the General Medical  
 296.55/F31.7 In Partial Remission      Condition) 
 296.56/F31.7 In Full Remission  293.89/F06.x Catatonic Disorder Due to......    
 Bipolar I, Most Recent Episode: Mixed/F31.6      (Indicate the General Medical 
 296.60 Unspecified      Condition) 
 296.61/F31.3 Mild  298.80/F23.xx Brief Psychotic Disorder    
 296.62/F31.3 Moderate  298.90/F29 Psychotic Disorder NOS     
 296.63/F31.4 Severe Without Psychotic Features Anorexia Nervosa  
 296.64/F31.5 Severe With Psychotic Features  307.10/F50.0 
 296.65/F31.7 In Partial Remission Bulimia Nervosa 
 296.66/F31.7 In Full Remission  307.51/F50.2 
 296.70/F31.9 Bipolar I Disorder, Most Recent Episode: Unspecified Posttraumatic Stress Disorder 
 296.80/F31.9 Bipolar I Disorder, NOS  309.81/F43.1 
 296.89/F31.8 Bipolar II Disorder Suicidality 
      no code assigned 
     Antisocial Disorder 
Panic Disorder/F40.01  301.70/F60.2  
 300.01/F41.0 Without Agoraphobia Somatoform Disorders 
 300.21/F40.01 With Agoraphobia  300.81/F45.0 Somatization Disorder 
Agoraphobia   300.70/F45.2 Hypochondriasis 
 300.22/F40.00 Without History of Panic Disorder  300.70/F45.2 Body Dysmorphic Disorder 
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Pain Disorders 
 307.80/F45.4 Pain Disorder Associated with Psychological Factors 
 307.89/F45.4 Pain Disorder Associated with Both Psychological 
     Factors and a General Medical Condition 
Conduct Disorder 
 312.80/F91.8 
Attention Deficit Disorder 
 314.01/F90.0 Attention Deficit/Hyperactivity Disorder, Combined Type 
 314.00/F98.8 Attention Deficit/Hyperactivity Disorder, Predominately 
     Inattentive Type 
 314.01/F90.0 Attention Deficit/Hyperactivity Disorder, Predominately 
     Hyperactive-Impulsive Type 
Adjustment Disorders 
 309.00/F43.20 Adjustment Disorder with Depressed Mood 
 309.24/F43.28 Adjustment Disorder with Anxiety 
 309.28/F43.22 Adjustment Disorder with Mixed Anxiety & Depressed Mood 
 309.30/F43.24 Adjustment Disorder with Disturbance of Conduct 
 309.40/F43.25 Adjustment Disorder with Mixed Disturbance of Emotions 
     & Conduct 
 309.90/F43.9 Adjustment Disorder, Unspecified 
Premenstrual Dysphoric Disorder 
 no code assigned  
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CRITERION FOR RULING OUT OTHER AXIS I DISORDERS 
 
[In the event of comorbidity, the following algorithm (or hierarchy of disorders based on DSM-IV) can be used to reduce the number 
of comorbid disorders down to those likely to be clinically meaningful.] 
Question    Yes No 
Are the symptoms of X  restricted exclusively to or better explained by        Y, Z? ❏ ❏ 
If diagnosis X is made, call up question, insert diagnosis X in column 1, and the corresponding Y, Z diagnosis in Column 2. 
 
In any mix where: 
               Diagnosis X                           Diagnosis Y, Z, etc.      
A Major Depressive Disorder is present, leave it Manic, Hypomanic, or Mixed Episodes, Schizoaffective Disorder, 
 (MDE) unless disorder is Schizophreniform Disorder, Delusional Disorder or Psychotic Disorder NOS 
                                                       restricted exclusively 
B Dysthymia     to, or better explained MDE or Mania 
  by, diagnosis Y, Z: 
C Suicidality    Can coexist with any other Axis I disorder 
 
D (Hypo)Manic Episode " " MDE concurrently during the same week = mixed episode 
 
E Panic Disorder (PD) " " Social Phobia, Specific Phobia, OCD, PTSD 
 
F Agoraphobia (AG) " " Social Phobia, Specific Phobia, OCD or PTSD 
 
G Social Phobia (Soc Ph) " " PD or Agoraphobia 
 (Social Anxiety Disorder)  
 
H Specific Phobia (Sp Ph) " " PD or AG or OCD or PTSD 
 
I Obsessive-Compulsive Disorder " " Any Axis I Disorder 
 
J Posttraumatic Stress Disorder " " Agoraphobia 
 
K Alcohol Dependence/Abuse " " Can coexist with any other Axis I disorder 
 
L Drug Dependence/Abuse " " Can coexist with any other Axis I disorder 
 (Non-alcohol) 
M Psychotic Disorders (Psy) " " Can coexist with any other Axis I disorder 
 
N Anorexia Nervosa (AN) " " Can coexist with any other Axis I disorder 
 
O Bulimia Nervosa (BN) " " Can coexist with any other Axis I disorder 
 
P Generalized Anxiety Disorder " " MDE, Dys, Mania, PD, Psy, Soc Ph, Sp Ph, OCD, PTSD, Anxiety Disorder  
 
Q Antisocial Personality Disorder " " Mania or Psychotic 
 
R Somatization Disorder " " Can coexist with any other Axis I disorder 
 
S Hypochondriasis " " GAD, OCD, PD, MDE, Separation Anxiety Disorder, another   
    Somatoform disorder, Delusional disorder, Body Dysmorphic Disorder  
T Body Dysmorphic Disorder " " MDE, PD, AN, Soc Ph, Sp Ph, OCD, PTSD, Psychotic 
 
U Pain Disorder " " MDE, Mania, PD, GAD, OCD, PTSD, Soc Ph, Sp Ph, Psy, Dyspareunia 
 
V Conduct Disorder " " Can coexist with any other Axis I disorder, ADHD 
 
W  Attention Deficit Hyperactivity " " Psychotic, Mania, Anxiety Disorder, MDE, Conduct Disorder 
 Disorder (ADHD) 
 
X Adjustment Disorders " " Any Axis I Disorder 
 
Y Premenstrual Dysphoric Dis. " " PD, MDE, Dysthymic Disorder or a Personality Disorder 
 
Z Mixed Anxiety-Depressive Dis. " " Any other psychiatric disorder. 
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Afrikaans R. Emsley W. Maartens 
Arabic   O. Osman, E. Al-Radi 
Bengali   H. Banerjee, A. Banerjee 
Brazilian Portuguese P. Amorim P. Amorim 
Bulgarian L.G.. Hranov 
Chinese   L. Carroll, Y-J. Lee, Y-S. Chen, C-C. Chen, C-Y. Liu,  
   C-K. Wu, H-S. Tang, K-D. Juang, Yan-Ping Zheng.   
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English  D. Sheehan, J. Janavs, R. Baker, K. Harnett-Sheehan,  D. Sheehan, R. Baker, J. Janavs, K. Harnett-Sheehan, 
  E. Knapp, M. Sheehan M. Sheehan 
Estonian   J. Shlik, A.Aluoja, E. Khil 
Farsi/Persian  K. Khooshabi, A. Zomorodi 
Finnish   M. Heikkinen, M. Lijeström, O. Tuominen M. Heikkinen, M. Lijeström, O. Tuominen 
French  Y. Lecrubier, E. Weiller, LI. Bonora, P. Amorim, J.P. Lepine Y. Lecrubier, E. Weiller, P. Amorim, T. Hergueta 
German  I. v. Denffer, M. Ackenheil, R. Dietz-Bauer  G. Stotz, R. Dietz-Bauer, M. Ackenheil   
Greek  S. Beratis T. Calligas, S. Beratis 
Gujarati   M. Patel, B. Patel 
Hebrew  J. Zohar, Y. Sasson R. Barda, I. Levinson, A. Aviv 
Hindi   C. Mittal, K. Batra, S. Gambhir 
Hungarian I. Bitter, J. Balazs  I. Bitter, J. Balazs 
Icelandic   J.G. Stefansson  
Italian  I. Bonora, L. Conti, M. Piccinelli, M. Tansella, G. Cassano, L. Conti, A. Rossi, P. Donda 
  Y. Lecrubier, P. Donda, E. Weiller 
Japanese   T. Otsubo, H. Watanabe, H. Miyaoka, K. Kamijima, 
   J. Shinoda, K. Tanaka, Y. Okajima 
Lithuanian  A. Bacevicius 
Latvian  V. Janavs, J. Janavs, I. Nagobads V. Janavs, J. Janavs 
Norwegian G. Pedersen, S. Blomhoff K.A. Leiknes , U. Malt, E. Malt, S. Leganger 
Polish  M. Masiak, E. Jasiak M. Masiak, E. Jasiak 
Portuguese P. Amorim P. Amorim, T. Guterres 
Punjabi   A. Gahunia, S. Gambhir 
Romanian  O. Driga 
Russian   A. Bystritsky, E. Selivra, M. Bystritsky   
Serbian  I. Timotijevic I. Timotijevic 
Setswana   K. Ketlogetswe 
Slovenian M.Kocmur M. Kocmur 
Spanish  L. Ferrando, J. Bobes-Garcia, J. Gilbert-Rahola, Y. Lecrubier L. Ferrando, L. Franco-Alfonso, M. Soto, J. Bobes-Garcia,  
   O. Soto, L. Franco, G. Heinze  
Swedish  M. Waern, S. Andersch, M. Humble C. Allgulander, M. Waern, A. Brimse, M. Humble, 
   H. Agren    
Turkish  T. Örnek, A. Keskiner, I. Vahip T. Örnek, A. Keskiner, A. Engeler 
Urdu   A. Taj, S. Gambhir 
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Criterion “A” of   
Schizophrenia Met 
Psychotic and Mood Sx Psychotic and Mood SxPsychotic and Mood Sx
always together never together sometimes together
M 21 = YES 
AND AND 
M 21 = NO 
M 22 = NO M 22 = YES 
M 19d = NO
OR
M 20 = NO
Go to Mood Disorders: 
Diagnostic Algorithm III   
Circle the appropriated diagnostic box both for current and life-time diagnosis.  One positive  
diagnosis excludes the others.  If criterion A of schizophrenia is not currently met, but is  
present in life-time, current and life-time diagnosis may be different.
Mood Sx last longer
or the same
M 23 = 1 OR M23 = 3
Psychotic Sx
last longer
M 23 = 2
M 19c = YES
M 19C = NO 
AND 
M 19b = YES 
M 19c = NO
AND
M 19b = NO
  
Mood Disorder 
Features Life-time 
with Psychotic 
Schizoaffective 
Disorder
Current
Life-time
 
  
Duration of Psychotic Sx 
< 1 month 
M 17 = 1 
> 6 months
M 17 = 3
> 1 to < 6 months 
M 17 = 2 
Schizophreniform
Disorder  Current 
Life-time 
Mood Disorder NOS
Psychotic Disorder NOS
Current
Life-time
 
Schizophrenia
Current 
Life-time 
 Brief Psychotic Disorder 
Current 
Life-time 
 
 
 
   
Dysfunction Dysfunction 
Dysfunction DysfunctionAbsent 
Absent
Present 
Present M 16a = NO M 16a = YES 
M 16a = NO M 16a = YES
PSYCHOTIC DISORDERS: DIAGNOSTIC ALGORITHMS I 
Duration of Psychotic SxDuration of Psychotic Sx
and M16b = 1 or M16b >1 
and M16b <2 or M16b >3 
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Criterion “A” of
Schizophrenia Not Met
Psychotic and Mood Sx Psychotic and Mood SxPsychotic and Mood Sx
always together never together sometimes together
M21  = YES
AND AND
M21 = NO
M22  = NO M22 = YES
M19d = NO
OR
M20 = NO
Go to Mood Disorders:
Diagnostic Algorithm III
Circle the appropriated diagnostic box both for current and life-time diagnosis.  One
itidiagnosis excludes the others.  If criterion A of schizophrenia is not currently met, but
ipresent in life-time, current and life-time diagnosis may be
diff t
Mood Sx last longer
or the same
M23 = 1 OR M23 = 3
Psychotic Sx
last longer
M23 = 2
Mood Disorder
Features Life-time
with Psychotic
Disorder
Current
Life-time

Mood Disorder NOS
Psychotic Disorder NOS
Current
Life-time

Brief Psychotic Disorder
Current
Life-time




Dysfunction DysfunctionAbsent Present
M16a = NO M16a = YES
PSYCHOTIC DISORDERS:  DIAGNOSTIC ALGORITHMS II
Delusional
Duration < 1 month
M17 = 1
Duration > 1 month
M17 = 2 or M17 = 3
Either an auditory or
visual hallucination
(M6 or M7 = YES)
There is at least one
non-bizarre delusion
(M1 or M2 or M4
is prominent
 = YES)
and M16b = 1 or M16b = 2, 3 or 4
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MOOD DISORDERS: DIAGNOSTIC ALGORITHM III 
 
 
Consult Modules: A [Major Depressive Episode] 
  D [(Hypo)manic Episode] 
  M [Psychotic Disorders] 
 
 
 
MODULE M: 
 
 1 a IS M20 CODED NO? NO YES ➔  GO TO 2c 
 
  b IS M21 CODED NO AND M22 CODED YES? NO YES ➔  CODE NO IN 2c, 
       2d AND 2e 
  c IS M21  CODED YES OR M22 CODED NO? NO YES 
 
MODULES A and D: 
 
2 a IS A DELUSIONAL IDEA IDENTIFIED IN A3e?             No   ❏      Yes   ❏   
  
         b    IS A DELUSIONAL IDEA IDENTIFIED IN D3a?            No   ❏      Yes   ❏   
 
 
      c    Is A8 = YES (Major Depressive Episode present) 
                   and 
            D6 and D7 = NO (Hypomanic and Manic Episodes absent)? 
  
                   Specify: 
      WITHOUT Psychotic Features: IF 1a = YES and 2a = NO 
                   WITH Psychotic Features: IF 1a = NO and 2a = YES 
              
                  Specify if last depressive episode is current or past  
                  (Question A8) 
                                                       
     NO                              YES 
 
MAJOR DEPRESSIVE 
DISORDER 
 
without PF ❏ 
with PF ❏ 
current  ❏ 
past  ❏ 
 
 
   
 d    Is D7 = YES (Manic Episode present)? 
                   
    Specify: 
                 WITHOUT Psychotic Features: IF 1a = YES and 2a = NO and 2b = NO 
                 WITH Psychotic Features: IF 1a = NO and 2a = YES and 2b = YES 
              
                 Specify if the last mood episode is current or past  
                 (Question A8 or D6 or D7) 
                                                       
     NO                              YES 
 
BIPOLAR I 
DISORDER 
 
without PF ❏ 
with PF ❏ 
current  ❏ 
past  ❏ 
 
 
   
 e    Is A8 = YES (Major Depressive Episode present) 
                    and 
            D6 = YES (Hypomanic Episode present) 
                    and 
                  D7 = NO (Manic Episode absent)? 
 
                  Specify if the last mood episode is current or past 
                  (Question A8 or D6) 
                                                       
     NO                              YES 
 
BIPOLAR II 
DISORDER 
 
current ❏ 
past   ❏ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
 
Systematic Assessment for Treatment Emergent Events (SAFTEE-SI) 
 
 Page 1 of 2                                              Initials_______ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Instructions:  Below is a list of Symptoms people sometimes have.  Please read each item.  Indicate how 
bothersome each symptom has been for you in the last week by circling the appropriate number to the right 
of the item. 
 NONE MILD MODERATE SEVERE 
1.   Trouble Sleeping 0 1 2 3 
2.   Nightmares or other sleep disturbance 0 1 2 3 
3.   Feeling drowsy or sleepy 0 1 2 3 
4.   Feeling nervous or hyper 0 1 2 3 
5.   Weakness or fatigue 0 1 2 3 
6.   Irritable 0 1 2 3 
7.   Poor memory 0 1 2 3 
8.   Trouble concentrating 0 1 2 3 
9.   Feeling strange 0 1 2 3 
10. Hearing or seeing things 0 1 2 3 
11. Abnormal sensations 0 1 2 3 
12. Numbness or tingling 0 1 2 3 
13. Dizziness or faintness 0 1 2 3 
14. Headache 0 1 2 3 
15. Blurred vision 0 1 2 3 
16. Ringing in the ears or trouble hearing 0 1 2 3 
17. Stuffy nose 0 1 2 3 
18. Dry mouth 0 1 2 3 
19. Drooling or increased salivation 0 1 2 3 
20. Muscle cramps or stiffness 0 1 2 3 
21. Muscle twitching or movements 0 1 2 3 
22. Trouble sitting still 0 1 2 3 
23. Tremor or shakiness 0 1 2 3 
24. Poor coordination or unsteadiness 0 1 2 3 
25. Slurred speech 0 1 2 3 
26. Heartbeat rapid or pounding 0 1 2 3 
27. Trouble catching breath or hyperventilation 0 1 2 3 
28. Chest pain 0 1 2 3 
29. Nausea or vomiting 0 1 2 3 
30. Stomach or abdominal discomfort 0 1 2 3 
31. Constipation 0 1 2 3 
32. Diarrhea 0 1 2 3 
33. Difficulty starting urination 0 1 2 3 
34. Frequent need to urinate 0 1 2 3 
35. Menstrual irregularities 0 1 2 3 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
 
Systematic Assessment for Treatment Emergent Events (SAFTEE-SI) 
 
 Page 2 of 2                                              Initials_______ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 NONE MILD MODERATE SEVERE 
36. Loss of sexual interest 0 1 2 3 
37. Problems with sexual arousal (erection or lubrication) 0 1 2 3 
38. Delayed or absent orgasm 0 1 2 3 
39. Sweating excessively 0 1 2 3 
40. Fluid retention or swelling 0 1 2 3 
41. Appetite decreased 0 1 2 3 
42. Appetite increased 0 1 2 3 
43. Weight gain 0 1 2 3 
44. Weight loss 0 1 2 3 
45. Skin rash or allergy 0 1 2 3 
46. Diminished mental acuity/sharpness 0 1 2 3 
47. Difficulties finding words 0 1 2 3 
48. Apathy/Emotional Indifference 0 1 2 3 
49. Dizziness when you stand up 0 1 2 3 
50. Bruising 0 1 2 3 
51. Hair thinning/loss 0 1 2 3 
52. Hot flashes 0 1 2 3 
53. Clenching of teeth at night 0 1 2 3 
54. Strange taste in mouth 0 1 2 3 
55. Unable to sit still 0 1 2 3 
 No 
Side 
Effects 
Mildly Moderately Markedly
How much have all these side-effects bothered 
you/interfered with your daily activities: 
0 1 2 3 
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STRUCTURED INTERVIEW GUIDE FOR THE  
MONTGOMERY AND ASBERG DEPRESSION RATING SCALE (SIGMA) 
 
 
Janet B.W. Williams, D.S.W. and Kenneth A. Kobak, Ph.D. 
 
 
 
INTERVIEWER: The questions in bold for each item should be asked exactly as written.  Often these questions 
will elicit enough information about the severity and frequency of a symptom for you to rate the item with 
confidence.  Follow-up questions are provided, however, for use when further exploration or additional 
clarification of symptoms is necessary.  The specified questions should be asked until you have enough 
information to rate the item confidently.  In some cases, you may also have to add your own follow-up 
questions to obtain necessary information.  Note that questions in parentheses are optional, i.e., if information is 
unknown. 
 
NOTES:  
 
Time period.  The ratings should be based on the patient's condition in the past week. 
 
Change from baseline. In general, a symptom is rated as present only when it reflects a change from before the 
depression began.  The interviewer should try to identify a 2-month period of non-depressed functioning and 
use this as a reference point.  In some cases, such as when the patient has Dysthymia, the referent should be to 
the last time they felt OK (i.e., not depressed or high) for at least a few weeks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
This interview guide is based on the Montgomery and Asberg Depression Rating Scale (MADRS) 
(Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Brit J Psychiat 
134:382-389, 1979).  The scale itself has been retained in its original form, except for reversing the order of the 
first two items.  This guide adds interview questions to aid in the assessment and application of the MADRS.  
Previous versions of this guide appeared in 1988, 1992, 1996, and 2005. 
  
©2006 v.1, Janet B.W. Williams and Kenneth A. Kobak. All rights reserved.  Permission is granted for 
reproduction for use by researchers and clinicians. 
 
For correspondence: Dr. Williams, New York State Psychiatric Institute, Unit 60, 1051 Riverside Drive, New 
York, New York 10032-1001; jbw5@columbia.edu              
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STRUCTURED INTERVIEW GUIDE FOR THE  
MONTGOMERY AND ASBERG DEPRESSION RATING SCALE (SIGMA) 
 
 
 
PT’S INITIALS: ________  PT’S ID: ________ 
 
INTERVIEWER: ________________________ 
 
 
 TIME BEGAN SIGMA: ____________ 
 
DATE: __ __ __ __ __ __ 
 
OVERVIEW:  I’d like to ask you some questions about the past week.  How have you been feeling since last  
(DAY OF WEEK)?  IF OUTPATIENT:  Have you been working?  (What kind of work do you do?)  IF NOT:  Why not? 
 
 
In the last week, have you been feeling sad or unhappy?  
(Depressed at all?)  IF YES: Can you describe what this has 
been like for you?  (IF UNKNOWN: How bad has that 
been?) 
 
 IF DEPRESSED:  Does the feeling lift at all if something 
good happens? How much does your mood lift? Does the 
feeling ever go away completely?  (What things have made 
you feel better?  )   
 
How often did you feel (depressed/OWN EQUIVALENT) 
this past week?  (IF UNKNOWN: How many days this 
week did you feel that way?  How much of each day?)  
 
In the past week, how have you been feeling about the 
future?  (Have you been discouraged or pessimistic?)  What 
have your thoughts been?  How (discouraged or 
pessimistic) have you been?  How often have you felt that 
way?  Do you think things will ever get better for you?   
 
IF ACKNOWLEDGES DEPRESSED MOOD, TO GET 
CONTEXT ASK: How long have you been feeling this 
way? 
 
 
 1.  REPORTED SADNESS.  Representing reports of depressed 
mood, regardless of whether it is reflected in appearance or not.  
Includes low spirits, despondency or the feeling of being beyond 
help and without hope.  Rate according to intensity, duration, and 
the extent to which the mood is reported to be influenced by 
events. 
 
0 -  Occasional sadness in keeping with the circumstances. 
1 –  
2 -  Sad or low but brightens up without difficulty. 
3 –  
4 -  Pervasive feelings of sadness or gloominess.  The mood is still 
influenced by external circumstances. 
5 –  
6 – Continuous or unvarying sadness, misery, or despondency. 
 
RATING BASED ON OBSERVATION DURING 
INTERVIEW AND THE FOLLOWING 
QUESTIONS. 
 
In the past week, do you think you have looked sad or 
depressed to other people?  Did anyone say you looked sad 
or down? 
 
How about when you’ve looked in the mirror?  Did you 
look gloomy or depressed? 
 
IF YES: How sad or depressed do you think you have 
looked?  How much of the time over the past week do you 
think you have looked depressed or down? 
 
IF APPEARANCE WAS DEPRESSED IN PAST WEEK:  
Have you been able to laugh or smile at all during the past 
week?  IF YES: How hard has it been for you to laugh or 
smile, even if you weren’t feeling happy inside? 
 
 
 
2.  APPARENT SADNESS.  Representing despondency, gloom 
and despair.  (More than just ordinary transient low spirits) 
reflected in speech, facial expressions, and posture.  Rate by depth 
and inability to brighten up. 
 
0 – No sadness 
1 –  
2 -  Looks dispirited but does brighten up without difficulty. 
3 -   
4 -  Appears sad and unhappy most of the time. 
5 –  
6 – Looks miserable all the time.  Extremely despondent. 
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Have you felt tense or edgy in the last week? Have 
you felt anxious or nervous? 
IF YES:  Can you describe what that has been like for 
you?  How bad has that gotten?  (Have you felt 
panicky?) 
 
What about feeling fearful that something bad is about to 
happen? 
 
How hard has it been to control these feelings?  (What 
has it taken to help you feel calmer?  Has anything 
worked to calm you down?)   
 
How much of the time have you felt this way over the 
past week? 
 
 
 3.  INNER TENSION.  Representing feelings of ill-defined 
discomfort, edginess, inner turmoil, mental tension mounting to either 
panic, dread, or anguish.  Rate according to intensity, frequency, 
duration and the extent of reassurance called for. 
 
0 -  Placid.  Only fleeting inner tension. 
1 -   
2 -  Occasional feelings of edginess and ill-defined discomfort. 
3 –  
4 – Continuous feelings of inner tension or intermittent panic which 
the patient can master with some difficulty. 
5 –  
6 – Unrelenting dread or anguish.  Overwhelming panic. 
 
 
How has your sleeping been in the last week?  (How 
many hours have you been sleeping, compared to 
usual?) 
 
Have you had trouble falling asleep? (How long has it 
been taking you to fall asleep this past week?) 
 
Have you been able to stay asleep through the night?  
(Have you been waking up at all in the middle of the 
night?  How long does it take you to fall back asleep?)  
 
Has your sleeping been restless or disturbed?   
 
 
 
4.  REDUCED SLEEP.  Representing the experience of reduced 
duration or depth of sleep compared to the subject’s own normal 
pattern when well. 
 
0 -  Sleeps as usual. 
1 -   
2 -  Slight difficulty dropping off to sleep or slightly reduced, light, or 
fitful sleep. 
3 –  
4 – Sleep reduced or broken by at least two hours. 
5 –  
6 – Less than two or three hours sleep. 
 
 
 
 
How has your appetite been this past week?  (What 
about compared to your usual appetite?) 
 
Have you been less interested in food? (How much 
less?) 
 
Does food taste as good as usual?  IF LESS: How much 
less? 
 
Have you had to force yourself to eat? 
 
Have other people had to urge you to eat? 
 
 
 
 
 
5.  REDUCED APPETITE.  Representing the feeling of a loss of 
appetite compared with when well.  Rate by loss of desire for food or 
the need to force oneself to eat. 
 
0 -  Normal or increased appetite. 
1 –  
2 -  Slightly reduced appetite. 
3 –  
4 – No appetite.  Food is tasteless. 
5 –  
6 – Needs persuasion to eat at all. 
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Have you had trouble concentrating or collecting 
your thoughts in the past week?  (How about at home 
or at work?)  IF YES:  Can you give me some examples? 
(Have you been able to concentrate on reading a 
newspaper or magazine?  Do you need to read things 
over and over again?)     
 
How often has that happened in the past week?  Has this 
caused any problems for you?  IF YES: Can you give me 
some examples? 
 
Has your trouble concentrating been so bad at any time 
in the past week that it has been difficult to follow a 
conversation?  (IF YES: How bad has that been?  How 
often has that happened this past week?) 
 
NOTE:  ALSO CONSIDER BEHAVIOR DURING 
INTERVIEW.  
 
6.  CONCENTRATION DIFFICULTIES.  Representing 
difficulties in collecting one’s thoughts mounting to incapacitating 
lack of concentration.  Rate according to intensity, frequency, and 
degree of incapacity produced. 
 
0 -  No difficulties in concentration. 
1 -   
2 -  Occasional difficulties in collecting one’s thoughts. 
3 –  
4 – Difficulties in concentrating and sustaining thought which reduces 
ability to read or hold a conversation. 
5 –  
6 – Unable to read or converse without great difficulty. 
 
 
 
Have you had any trouble getting started at things in 
the past week?  IF YES: What things?   
 
Have you had to push yourself to do things?   
IF YES: What things?  How hard have you had to push 
yourself?  Are you OK once you get started or is it still 
more of an effort to get something done?  What about 
getting started at simple routine everyday things (like 
getting dressed)? 
 
Have you done everyday things more slowly than 
usual?  (Have you been sluggish?)  IF YES: Like what, 
for example?  How bad has that been? 
 
  
 
7.  LASSITUDE.  Representing a difficulty getting started, or 
slowness initiating and performing everyday activities. 
 
0 -  Hardly any difficulty in getting started.  No sluggishness. 
1 -   
2 -  Difficulties in starting activities. 
3 –  
4 – Difficulties in simple routine activities which are carried out with 
effort. 
5 –  
6 – Complete lassitude.  Unable to do anything without help. 
 
 
Have you been less interested in things around you, 
or in activities you used to enjoy?  IF YES:  What 
things? How bad has that been?  How much less 
interested in (those things) are you now compared to 
before?  
 
Have you been less able to enjoy the things you usually 
enjoy?  
  
Has there been any change in your ability to feel 
emotions?  (Do you feel things less intensely than you 
used to, things like anger, grief, pleasure?)  IF YES: Can 
you tell me more about that? (IF UNKNOWN: Are you 
able to feel any emotions at all?)     
  
How do you feel toward your family and friends?  Is that 
different from usual?  IF REDUCED: Do you feel less 
than you used to towards them? 
  
 
8.  INABILITY TO FEEL.  Representing the subjective experience 
of reduced interest in the surroundings, or activities that normally 
give pleasure.  The ability to react with adequate emotion to 
circumstances or people is reduced. 
 
0 -  Normal interest in the surroundings and in other people. 
1 -   
2 -  Reduced ability to enjoy usual interests. 
3 –  
4 – Loss of interest in the surroundings.  Loss of feelings for friends 
and acquaintances. 
5 –  
6 – The experience of being emotionally paralyzed, inability to feel 
anger, grief, or pleasure, and a complete or even painful failure to 
feel for close relatives and friends. 
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Have you been putting yourself down, or feeling that 
you’re a failure in some way, over the past week?  
(Have you been blaming yourself for things that you’ve 
done, or not done?)  IF YES: What have your thoughts 
been?  How often have you felt that way?   
 
Have you been feeling guilty about anything in the 
past week?  What about feeling as if you have done 
something bad or sinful?  IF YES:  What have your 
thoughts been?  How often have you felt that way?   
 
ALSO CONSIDER RESPONSES TO QUESTIONS 
ABOUT PESSIMISM FROM ITEM #1. 
 
 
 
  
 
9.  PESSIMISTIC THOUGHTS.  Representing thoughts of guilt, 
inferiority, self-reproach, sinfulness, remorse, and ruin. 
 
0 -  No pessimistic thoughts. 
1 -   
2 -  Fluctuating ideas of failure, self-reproach, or self-depreciation. 
3 –  
4 – Persistent self-accusations, or definite but still rational ideas of 
guilt or sin.  Increasingly pessimistic about the future. 
5 –  
6 – Delusions of ruin, remorse, or unredeemable sin.  Self-accusations 
which are absurd and unshakable. 
 
This past week, have you felt like life isn’t worth 
living?  IF YES: Tell me about that. IF NO: What about 
feeling like you're tired of living? 
 
This week, have you thought that you would be 
better off dead?  IF YES: Tell me about that. 
 
Have you had thoughts of hurting or even killing 
yourself this past week?  IF YES:  What have you 
thought about?  How often have you had these thoughts?  
How long have they lasted?  Have you actually made 
plans?  IF YES:  What are these plans?  Have you made 
any preparations to carry out these plans?  (Have you 
told anyone about it?) 
 
 
  
10.  SUICIDAL THOUGHTS.  Representing the feeling that life is 
not worth living, that a natural death would be welcome, suicidal 
thoughts, and preparation for suicide.  Suicidal attempts should not in 
themselves influence this rating. 
 
0 -  Enjoys life or takes it as it comes. 
1 –  
2 -  Weary of life.  Only fleeting suicidal thoughts. 
3 -   
4 -  Probably better off dead.  Suicidal thoughts are common, and 
suicide is considered as a possible solution, but without specific 
plans or intention. 
5 –  
6 – Explicit plans for suicide when there is an opportunity.  Active 
preparations for suicide. 
 
 
 
 
 
TOTAL MADRS SCALE SCORE:   ______ _______ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________                                                                                                                           
Hamilton Rating Scale for Depression  (HRSD-17) 
Page 1 of 3 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
For each item, write the correct number on the line next to the item. Select only one response per item.
1.   Depressed Mood:                                         
(sad, blue, gloomy, weepy, pessimistic, 
helpless, hopeless, worthless)            
  (0) Not depressed 
  (1) Feeling state only elicited on questioning  
  (2) Occasional weeping. Spontaneously reports feeling states. 
  (3) Frequent weeping. Obvious behavioral evidences in face, 
posture, voice. Speaks mostly about feeling state. 
  (4) Exhibits virtually only these feeling states verbally and non-
verbally. May have   gone beyond weeping.  
2.  Guilt Feelings and Delusions: 
 
  (0) Absent. 
  (1) Self-reproach, feels they have let people down. 
  (2) Expresses guilt regarding past errors or misdeeds. 
  (3) Present illness is deserved punishment. Ruminates over past   
errors and sins. 
  (4) Severe self-reproach. Guilty delusions, e.g. making other 
people ill. Deserves to die. May have accusatory/denouncing 
hallucinations. 
3.  Suicide:   (0) Absent. 
  (1) Feels life is empty, not worth living. 
  (2) Recurrent thoughts or wishes about death of self. 
  (3) Active suicidal thoughts, threats, gestures.                                     
  (4) Serious suicide attempt. 
4.  Initial Insomnia:   (0) Absent. 
  (1) Mild, infrequent; more than ½ hr occasionally. 
  (2) Obvious and severe; more than ½ hr usually. 
5.  Middle Insomnia:   (0) Absent (rate 1 if hypnotic is being used). 
  (1) Complains of feeling restless and disturbed during night. 
  (2) Wakes during night; reads/smokes in bed, up out of bed except 
to void. 
6.  Delayed Insomnia:   (0) Absent 
  (1) Wakes earlier than usual but goes back to sleep. 
  (2) Wakes 1-3 hours before usual; unable to sleep again.  
Continued On Next CRF Page 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________                                                                                                                           
Hamilton Rating Scale for Depression  (HRSD-17) 
Page 2 of 3 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
         
 
       
For each item, write the correct number on the line next to the item. Select only one response per item.
7. Work And Interests:  
   (Apathy: loss of interest in work, hobbies, social 
life. Anhedonia: unable to feel pleasure) 
  (0) No disturbance. 
  (1) Feels incapable, listless, less efficient (rate fatigue under # 13). 
  (2) Has to push to work/play. No active interests, little satisfaction. 
  (3) Clearly decreased efficiency. No spontaneous activity. Marked 
loss of interest. 
  (4) Stopped working because of present illness. Doesn’t shave, 
bathe, etc. Avoids ward chores, needs urging. 
8.  Psychomotor Retardation: 
     (Slowing of thought, speech, movement) 
 
  (0) Absent. 
  (1) Slightly flattened affect fixed facial expression. 
  (2) Monotonous voice, delayed answering, sits motionless. 
  (3) Interview difficult and prolonged. Moves slowly. 
  (4) Depressive stupor. Interview impossible. 
9. Agitation:  
   (may co-exist with retardation) 
  (0) Absent. 
  (1) Fidgety. Clenching fists or chair arm. Kicking feet. 
  (2)Wringing hands, pulling hair, picking at hands or clothes. 
Restless, pacing 
  (3) Can’t sit still. Much movement and restlessness/pacing. 
  (4) Interview conducted “on the run”, constant pacing, pulling off 
clothes, tearing at hair, constant picking at face/hands. 
10.  Psychic Anxiety:  
(present illness- not prior disposition. Tense, 
irritable, apprehensive, fearful, phobic, panic 
attacks) 
  (0) Absent. 
  (1) Minimal distress, admitted only on direct questioning. 
  (2) Spontaneously expresses discomfort; worries over trivia. 
  (3) Obviously apprehensive in facial expressions and speech. 
  (4) Severely anxious, panicky, forgetful. 
11.  Somatic Anxiety: 
 (Physio symptoms of anxiety; fainting, blurry 
vision, headache, tremor, sweating, flushing, 
hyperventilation, palpatations, indigestion, etc.) 
  (0) Absent. 
  (1) Trivial. 
  (2) Mild. 
  (3) Moderate. 
  (4) Severe. 
12.   Appetite:   (0) Normal. 
  (1) Eats spontaneously, but without pleasure 
  (2) Marked decrease of appetite and food intake. Eats only with 
urging, requests laxatives. 
 
Continued On Next CRF Page 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________                                                                                                                           
Hamilton Rating Scale for Depression  (HRSD-17) 
Page 3 of 3 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
 
 
 
 
 
 
 
 
 
 
For each item, write the correct number on the line next to the item. Select only one response per item.
13.     Somatic Energy:   (0) Normal. 
  (1) Occasional, mild fatigue, easy tiring, aching.  
  (2) Obviously low in energy, constantly tired, heavy dragging 
feeling in limbs. 
14.  Libido: 
 
  (0) Normal for age and marital status. 
  (1) Mildly decreased drive and satisfaction. 
  (2) Definite loss of desire, functional impotence. 
15.  Hypochondreasis:   (0) Absent. 
  (1) Mildly preoccupied w/bodily functions & physical symptoms. 
  (2) Moderately concerned with physical health. 
  (3) Morbid convictions of organic disease – brain tumor, cancer. 
  (4) Bizarre delusions- worms eating head, rotting inside, bowels 
blocked. 
16.  Loss Of Insight:   (0) Acknowledges being depressed and ill. 
  (1) Acknowledges illness but attributes to bad food, climate, work, 
virus, need for rest.  
  (2) Denies being ill at all. 
17.  Weight Loss:   (0) No weight loss; less than 1 lb by scale. 
  (1) Probable weight loss; or greater than 1 lb by scale. 
  (2) Definite weight loss; or greater than 2 lbs by scale.  
SIGNATURE 
HRSD Administered by: 
 
_______________________________________ 
Signature 
Total  Hamilton Rating Scale for Depression (HRSD) Score:  ______________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
Inventory of Depressive Symptomatology (IDS-C) 
Page 1 of 5 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Please check one response to each item that best describes the patient for the last seven days 
1.   Sleep Onset Insomnia:   (0) Never takes longer than 30 minutes to fall asleep. 
  (1) Takes at least 30 minutes to fall asleep, less than half the time. 
  (2) Takes at least 30 minutes to fall asleep, more than half the time. 
   (3) Takes more than 60 minutes to fall asleep, more than half the time. 
2.  Mid-Nocturnal Insomnia: 
 
  (0) Does not wake up at night. 
  (1) Restless, light sleep with few awakenings. 
  (2) Wakes up at least once a night, but goes back to sleep easily. 
  (3) Awakens more than once a night and stays awake for 20 minutes or more,  
              more than half the time. 
3.  Early Morning Insomnia:   (0) Less than half the time, awakens no more than 30 minutes before necessary. 
  (1) More than half the time, awakens more than 30 minutes before need be. 
  (2) Awakens at least one hour before need be, more than half the time. 
  (3) Awakens at least two hours before need be, more than half the time.        
4.  Hypersomnia:   (0) Sleeps no longer than 7-8 hours/night, without naps. 
  (1) Sleeps no longer than 10 hours in a 24 hour period (include naps). 
  (2) Sleeps no longer than 12 hours in a 24 hour period (include naps). 
  (3) Sleeps longer than 12 hours in a 24 hour period (include naps). 
5.  Mood (Sad):   (0) Does not feel sad. 
  (1) Feels sad less than half the time. 
  (2) Feels sad more than half the time. 
  (3) Feels intensely sad virtually all of the time. 
6.  Mood (Irritable):   (0) Does not feel irritable. 
  (1) Feels irritable less than half the time. 
  (2) Feels irritable more than half the time. 
  (3) Feels extremely irritable virtually all of the time. 
7.     Mood (Anxious):  
 
  (0) Does not feel anxious or tense. 
  (1) Feels anxious/tense less than half the time. 
  (2) Feels anxious/tense more than half the time. 
  (3) Feels extremely anxious/tense virtually all of the time. 
8.     Reactivity of Mood: 
 
  (0) Mood brightens to normal level and lasts several hours when good events  
               occur. 
  (1) Mood brightens but does not feel like normal self when good events occur. 
  (2) Mood brightens only somewhat with few selected, extremely desired events. 
  (3) Mood does not brighten at all, even when very good or desired events occur. 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
Inventory of Depressive Symptomatology (IDS-C) 
Page 2 of 5 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
         
Please check one response to each item that best describes the patient for the last seven days 
9.     Mood Variation: 
 
 
9A. Is mood typically worse: 
 in morning, afternoon, or night?   (circle one). 
 
9B. Is mood variation attributed to environment by the 
patient?  
yes  or  no  (circle one) 
 
  (0) Notes no regular relationship between mood and time of day. 
  (1) Mood often relates to time of day due to environmental circumstances. 
  (2) For most of the week, mood appears more related to time of day than to events. 
  (3) Mood is clearly, predictably, better or worse at fixed time each day. 
 
 
10.   Quality of Mood: 
 
  (0) Mood is virtually identical to feelings associated with bereavement or is  
              undisturbed. 
  (1) Mood is largely like sadness in bereavement, although it may lack explanation, be 
              associated with more anxiety, or be much more intense. 
  (2) Less than half the time, mood is qualitatively distinct from grief and therefore  
              difficult to explain to others. 
  (3) Mood is qualitatively distinct from grief nearly all of the time. 
Complete either 11 or 12  
11.   Appetite (Decreased):   (0) No change from usual appetite. 
  (1) Eats somewhat less often and/or lesser amounts than usual. 
  (2) Eats much less than usual and only with personal effort. 
  (3) Eats rarely within a 24-hour period, and only with extreme personal effort with  
                persuasion by others. 
12.   Appetite (Increased):   (0) No change from usual appetite. 
  (1) More frequently feels a need to eat than usual. 
  (2) Regularly eats more often and/or greater amounts than usual. 
  (3) Feels driven to overeat at and between meals 
Complete either 13 or 14 
13.   Weight (Decrease) Within the Last Two 
        Weeks: 
  (0) Has experienced no weight change. 
  (1) Feels as if some slight weight loss has occurred. 
  (2) Has lost 2 pounds or more. 
  (3) Has lost 5 pounds or more. 
14.   Weight (Increase) Within the Last Two 
        Weeks: 
  (0) Has experienced no weight change. 
  (1) Feels as if some slight weight gain has occurred. 
  (2) Has gained 2 pounds or more. 
  (3) Has gained 5 pounds or more. 
133 of 165
Page 212 of 291
ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
Inventory of Depressive Symptomatology (IDS-C) 
Page 3 of 5 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
 
 
Check the one response to each item that best describes you for the past seven days. 
15.    Concentration/Decision:   (0) No change in usual capacity to concentrate and decide. 
  (1) Occasionally feels indecisive or notes that attention often wanders. 
  (2) Most of the time struggles to focus attention or make decisions. 
  (3) Cannot concentrate well enough to read or cannot make even minor decisions. 
16.    Outlook (Self): 
 
  (0) Sees self as equally worthwhile and deserving as others. 
  (1) Is more self-blaming than usual. 
  (2) Largely believes that he/she causes problems for others. 
  (3) Ruminates over major and minor defects in self. 
17.    Outlook (Future):   (0) Views future with usual optimism. 
  (1) Occasionally has pessimistic outlook that can be dispelled by others or events. 
  (2) Largely pessimistic for the near future. 
  (3) Sees no hope for self/situation anytime in the future. 
18.    Suicidal Ideation:   (0) Does not think of suicide or death. 
  (1) Feels life is empty or is not worth living. 
  (2) Thinks of suicide/death several times a week for several minutes. 
  (3) Thinks of suicide/death several times a day in depth, or has made specific plans, or  
              attempted suicide. 
19.    Involvement:    (0) No change from usual level of interest in other people and activities. 
  (1) Notices a reduction if former interests/activities. 
  (2) Finds only one or two former interests remain. 
  (3) Has virtually no interest in formerly pursued activities. 
20.    Energy/Fatiguability:   (0) No change in usual level of energy. 
  (1) Tires more easily than usual. 
  (2) Makes significant personal effort to initiate or maintain usual daily activities. 
  (3) Unable to carry out most of usual daily activities due to lack of energy. 
21.    Pleasure/Enjoyment (exclude 
sexual activity): 
  (0) Participates in and derives usual sense of enjoyment from pleasurable activities. 
  (1) Does not feel usual enjoyment from pleasurable activities. 
  (2) Rarely derives pleasure from any activities. 
  (3) Is unable to register any sense of pleasure/enjoyment from anything 
22.    Sexual Interest:   (0) Has usual interest in or derives usual pleasure from sex. 
  (1) Has near usual interest in or derives some pleasure from sex. 
  (2) Has little desire for or rarely derives pleasure from sex. 
  (3) Has absolutely no interest in or derives no pleasure from sex. 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
Inventory of Depressive Symptomatology (IDS-C) 
Page 4 of 5 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
 
 
Check the one response to each item that best describes you for the past seven days. 
23.    Psychomotor:   (0) Normal speed of thinking, gesturing, and speaking. 
  (1) Patient notes slowed thinking, and voice modulation is reduced. 
  (2) Takes several seconds to respond to most questions; reports slowed thinking. 
  (3) Is largely unresponsive to most questions without strong encouragement. 
24.    Psychomotor Agitation:   (0) No increased speed or disorganization in thinking or gesturing. 
  (1) Fidgets, wrings hands and shifts positions often. 
  (2) Describes impulse to move about and displays motor restlessness. 
  (3) Unable to stay seated. Paces about with or without permission. 
25.    Somatic Complaints:   (0) States there is no feeling of limb heaviness or pains. 
  (1) Complains of headaches, abdominal, back or joint pains that are intermittent and not  
               disabling. 
  (2) Complains that the above pains are present most of the time. 
  (3) Functional impairment results from the above pain. 
26.    Sympathetic Arousal:   (0) Reports no palpitations, tremors, blurred vision, tinnitus or increased sweating,  
               dyspnea, hot and cold flashes, chest pain. 
  (1) The above are mild and only intermittently present. 
  (2) The above are moderate and present more than half the time. 
  (3) The above result in functional impairment. 
27.    Panic/Phobic Symptoms:   (0) Has neither panic episodes nor phobic symptoms. 
  (1) Has mild panic episodes or phobias that do not usually alter behavior or  
               incapacitate. 
  (2) Has significant panic episodes or phobias that modify behavior or incapacitate. 
  (3) Has incapacitating panic episodes at least once a week or severe phobias that lead to  
               complete and regular avoidance behavior. 
28.    Gastrointestinal:   (0) Has no change in usual bowel habits. 
  (1) Has intermittent constipation and/or diarrhea that is mild. 
  (2) Has diarrhea and/or constipation most of the time that does not impair functioning. 
  (3) Has intermittent presence of constipation and/or diarrhea that requires treatment or  
               causes functional impairment. 
29.    Interpersonal Sensitivity:   (0) Has not felt easily rejected, slighted, criticized or hurt by others at all. 
  (1) Occasionally feels rejected, slighted, criticized or hurt by others. 
  (2) Often feels rejected, slighted, criticized or hurt by others, but with only slight  
               effects on social/occupational functioning. 
  (3) Often feels rejected, slighted, criticized or hurt by others that results in impaired  
                social/occupational functioning. 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
Inventory of Depressive Symptomatology (IDS-C) 
Page 5 of 5 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
 
 
 
 
 
 
 
 
 
 
SIGNATURE 
IDS-C Administered by: 
 
______________________________________ 
Signature 
 
Inventory of Depressive Symptomatology (IDS-C) TOTAL SCORE: 
 
 
______ 
Check the one response to each item that best describes you for the past seven days. 
30.    Leaden Paralysis/Physical Energy:   (0) Does not experience the physical sensation of feeling weighted down and without  
               physical energy. 
  (1) Occasionally experiences periods of feeling physically weighted down and without  
                physical energy, but without a negative effect on work, school, or activity. 
  (2) Feels physically weighted down (without physical energy) more than half the time. 
  (3) Feels physically weighted down (without physical energy) most of the time,  
               several hours per day, several days per week. 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
 
Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR) 
Page 1 of 3                                                      Initials_______ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Check the one response to each item that best describes you for the past seven days. 
1.   Falling Asleep:              (0) I never take longer than 30 minutes to fall asleep. 
  (1) I take at least 30 minutes to fall asleep, less than half the time. 
  (2) I take at least 30 minutes to fall asleep, more than half the time. 
   (3) I take more than 60 minutes to fall asleep, more than half the time. 
2.  Sleep During the Night: 
 
  (0) I do not wake up at night. 
  (1) I have a restless, light sleep with a few brief awakenings each night. 
  (2) I wake up at least once a night, but I go back to sleep easily 
  (3) I awaken more than once a night and stay awake for 20 minutes or more, more than half the  
              time. 
3.  Waking Up Too Early:   (0) Most of the time, I awaken no more than 30 minutes before I need to get up. 
  (1) More than half the time, I awaken more than 30 minutes before I need to get up. 
  (2) I almost always awaken at least one hour or so before I need to, but I go back to sleep  
              eventually. 
  (3) I awaken at least one hour before I need to, and can’t go back to sleep.        
4.  Sleeping Too Much:   (0) I sleep no longer than 7-8 hours/night, without napping during day. 
  (1) I sleep no longer than 10 hours in a 24-hour period including naps. 
  (2) I sleep no longer than 12 hours in a 24-hour period. 
  (3) I sleep longer than 12 hours in a 24-hour period including naps. 
Enter highest score on any 1 of the 4 sleep items  (1-4 above)  
5.  Feeling Sad:   (0) I do not feel sad. 
  (1) I feel sad less than half the time. 
  (2) I feel sad more than half the time. 
  (3) I feel sad nearly all of the time. 
6.  Decreased Appetite:   (0) There is no change in my usual appetite. 
  (1) I eat somewhat less often or lesser amounts of food than usual. 
  (2) I eat much less than usual and only with personal effort. 
  (3) I rarely eat within a 24-hour period, and only with extreme personal effort or  
             when others persuade me to eat. 
7.   Increased Appetite:  
 
  (0) There is no change from my usual appetite. 
  (1) I feel a need to eat more frequently than usual. 
  (2) I regularly eat more often and/or greater amounts of food than usual. 
  (3) I feel driven to overeat both at mealtime and between meals. 
 
137 of 165
Page 216 of 291
ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
 
Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR) 
Page 2 of 3                                                      Initials_______ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
Check the one response to each item that best describes you for the past seven days. 
8.   Decreased Weight (Within the  
      Last Two Weeks):  
 
  (0) I have not had a change in my weight. 
  (1) I feel as if I have had a slight weight loss. 
  (2) I have lost 2 pounds or more. 
  (3) I have lost 5 pounds or more. 
9.   Increased Weight (Within the  
      Last Two Weeks):  
 
  (0) I have not had a change in my weight. 
  (1) I feel as if I have had a slight weight gain. 
  (2) I have gained 2 pounds or more. 
  (3) I have gained 5 pounds or more. 
Enter the highest score on any 1 of 4 appetite/weight change items (6-9 above)  
10.  Concentration/Decision Making: 
 
  (0) There is no change in my usual capacity to concentrate or make decisions. 
  (1) I occasionally feel indecisive or find that my attention wanders. 
  (2) Most of the time, I struggle to focus my attention or to make decisions. 
  (3) I cannot concentrate well enough to read or cannot make even minor decisions. 
11.   View of Myself:   (0) I see myself as equally worthwhile and deserving as other people. 
  (1) I am more self-blaming than usual. 
  (2) I largely believe that I cause problems for others. 
  (3) I think almost constantly about major and minor defects in myself. 
12.   Thoughts of Death or Suicide:   (0) I do not think of suicide or death. 
  (1) I feel that life is empty or wonder if it’s worth living. 
  (2) I think of suicide or death several times a week for several minutes. 
  (3) I think of suicide or death several times a day in some detail, or I have made specific plans  
               for suicide or have actually tried to take my life. 
13.   General Interests:   (0) There is no change from usual in how interested I am in other people or activities. 
  (1) I notice that I am less interested in people or activities. 
  (2) I find I have interest in only one or two of my formerly pursued activities. 
  (3) I have virtually no interest in formerly pursued activities. 
14.   Energy Level:   (0) There is no change in my usual level of energy. 
  (1) I get tired more easily than usual. 
  (2) I have to make big effort to start or finish my usual daily activities (for example,  
              shopping, homework, cooking, or going to work). 
  (3) I really cannot carry out most of my usual daily activities because I just don’t have  
             the energy. 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
 
Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR) 
Page 3 of 3                                                      Initials_______ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
15.   Feeling Slowed Down:   (0) I think, speak, and move at my usual rate of speed. 
  (1) I find that my thinking is slowed down or my voice sounds dull or flat. 
  (2) It takes me several seconds to respond to most questions and I’m sure my thinking 
              is slowed. 
  (3) I am often unable to respond to questions without extreme effort. 
16.   Feeling Restless:   (0) I do not feel restless. 
  (1) I’m often fidgety, wringing my hands, or need to shift how I am sitting. 
  (2) I have impulses to move about and am quite restless. 
  (3) At times, I am unable to stay seated and need to pace around. 
Enter Highest score on either of the 2 psychomotor items (15-16 above)  
TOTAL 
Total QIDS-SR Sore:  
((highest score of 1-4)+5+(highest score of 6-9)+10+11+12+13+14+(highest score of 15-16)) 
 
________________ 
(range 0-27) 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
 
Young Mania Rating Scale (YMRS) 
Page 1 of 2 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
For each item, check one number per item. Select only one response per item 
1.   Elevated Mood                                                      (0) Absent 
  (1) Mildly or possibly increased on questioning  
  (2) Definite subjective elevation; optimistic, self-confident; cheerful; and  
               appropriate  to content 
  (3) Elevated; inappropriate to content; and humorous 
  (4) Euphoric; inappropriate laughter; and singing  
2.  Increased motor activity/energy 
 
  (0) Absent. 
  (1) Subjectively increased 
  (2) Animated; and gestures increased 
  (3) Excessive energy; hyperactive at times; and restless (can be calmed) 
  (4) Motor excitement; and continuous hyperactivity (cannot be calmed) 
3.  Sexual interest   (0) Normal; not increased 
  (1) Mildly or possibly increased 
  (2) Definite subjective increase on questioning 
  (3) Spontaneous sexual content; elaborates on sexual matters; and hypersexual by  
              self-report                                                         
  (4) Overt sexual acts (towards patients, staff or interviewer) 
4.  Sleep   (0) Reports no decrease in sleep 
  (1) Sleeping less than normal amount by up to one hour 
  (2) Sleeping less than normal by at least one hour  
  (3) Reports decreased needs for sleep 
  (4) Denies need for sleep 
5.  Irritability    (0) Absent 
  (2) Subjectively increased 
  (4) Irritable at times during interview; and recent episodes of anger or annoyance  
              on  the ward  
  (6) Frequently irritable during interview; and short curt throughout 
  (8) Hostile, uncooperative; and interview impossible 
6.  Speech (rate and amount)   (0) No increase 
  (2) Subjectively increased 
  (4) Increased rate or amount at times; and verbose at times  
  (6) Push; consistently increased rate and amount; and difficult to interrupt 
  (8) Pressured; and uninterruptible, continuous speech 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
 
Young Mania Rating Scale (YMRS) 
Page 2 of 2 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
      
For each item, check one number per item. Select only one response per item 
7.    Language-thought disorder  
 
  (0) Absent 
  (1) Circumstantial; mild distractibility; and quick thoughts 
  (2) Distractible; loses goal of thought; changes topics frequently; and racing thoughts 
  (3) Push; consistently increased rate and amount; and difficult to interrupt 
  (4) Incoherent; and communication impossible 
8.    Content 
 
 
  (0) Normal 
  (2) Questionable plans, new interests 
  (4) Special projects(s); and hyperreligious 
  (6) Grandiose or paranoid ideas; and terms of reference 
  (8) Delusions; and hallucinations 
9.     Disruptive-aggressive behavior  
 
  (0) Absent. Cooperative 
  (2) Sarcastic; and loud at times; guarded 
  (4) Demanding; and threats on ward 
  (6) Threatens interviewer; shouting; and interview difficult 
  (8) Assaultive; destructive; and interview impossible 
10.     Appearance   (0) Appropriate dress and grooming 
  (1) Minimally unkempt 
  (2) Poorly groomed; moderately disheveled; and overdressed 
  (3) Disheveled; partly clothes; and garish make-up 
  (4) Completely unkempt; decorated; and bizarre garb 
11.  Insight 
   
  (0) Present; admits illness; and agrees with need for treatment 
  (1) Possibly ill 
  (2) Admits change in behavior, but denies illness.  
  (3) Admits possible change in behavior, but denies illness 
  (4) Denies any behavior change 
SIGNATURE 
YMRS Administered by: 
 
________________________________________ 
Signature 
 
Young Mania Rating Scale (YMRS) TOTAL SCORE: 
 
 
______ 
141 of 165
Page 220 of 291
ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
Work and Social Adjustment Scale (WSAS) 
Page 1 of 1                                                            Initials_______ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
TOTAL 
 
Work and Social Adjustment Scale (WSAS) TOTAL SCORE: 
 
 
______ 
 
Instructions:  Rate each of the following questions on a 0 to 8 scale: 0 indicates no impairment at all and 8 
indicates very severe impairment. 
1.   Because of my depression, my ability to 
work is impaired.   
  
Rating: _____________ 
 
0 means not at all impaired and 8 indicates very severe 
impairment.                                                     
2.   Because of my depression, my home 
management (cleaning, tidying, shopping, 
cooking, looking after home or children, paying 
bills) is impaired.   
  
Rating: _____________ 
 
0 means not at all impaired and 8 indicates very severe 
impairment.                                                     
3.   Because of my depression, my social leisure 
activities (with other people, such as parties, 
bars, clubs, outings, visits, dating, home 
entertainment) are impaired.  
  
Rating: _____________ 
 
0 means not at all impaired and 8 indicates very severe 
impairment.                                                     
4.   Because of my depression, my private leisure 
activities (done alone, such as reading gardening, 
collecting, sewing, walking alone) are impaired.  
  
Rating: _____________ 
 
0 means not at all impaired and 8 indicates very severe 
impairment.                                                     
5.   Because of my depression, may ability to 
form and maintain close relationships with 
others, including those I live with, is impaired.      
  
Rating: _____________ 
 
0 means not at all impaired and 8 indicates very severe 
impairment.                                                     
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
 
Page 1 of 1 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Global Assessment of Functioning (GAF) 
                                                                                                                         
Consider psychological, social and occupational functioning on a hypothetical continuum of mental health-illness. Do not 
include impairment in functioning due to physical (or environmental) limitations. 
Code            [Note: Use intermediate codes when appropriate, e.g., 45, 68, 72]   
100 to 91 
 
Superior functioning in a wide range of activities, life’s problems never seem to get out of hand, is sought out 
by others because of his or her many positive qualities. No symptoms. 
90 to 81 
 
Absent or minimal symptoms (e.g., mild anxiety before an exam), good functioning in all areas, interested and 
involved in a wide range of activities, socially effective, generally satisfied with life, no more than everyday 
problems or concerns (e.g., an occasional argument with family members). 
 
80 to 71 
 
If symptoms are present, they are transient and expectable reactions to psychosocial stressors (e.g., difficulty 
concentrating after family argument); no more than slight impairment in social, occupational or school 
functioning (e.g., temporarily falling behind in schoolwork). 
 
70 to 61 
 
Some mild symptoms (e.g., depressed mood and mild insomnia) OR some difficulty in social, occupational or 
school functioning (e.g., occasional truancy or theft within the household), but generally functioning pretty 
well, has some meaningful interpersonal relationships. 
 
60 to 51 
 
Moderate symptoms (e.g., flat affect and circumstantial speech, occasional panic attacks) OR any moderate 
difficulty in social, occupational or school functioning  (e.g., few friends, conflicts with peers or co-workers). 
 
50 to 41 
 
Serious symptoms (e.g., suicidal ideation, severe obsessional rituals, frequent shoplifting) OR any serious 
impairment in social, occupational or school functioning (e.g., no friends, unable to keep a job). 
 
40 to 31 
 
Some impairment in reality testing or communication (e.g., speech is at times illogical, obscure or irrelevant) 
OR major impairment in several areas, such as work or school, family relations, judgment, thinking or mood 
(e.g.,  expressed man avoids friends, neglects family and is unable to work; child frequently beats up younger 
children, is defiant at home and is failing at school). 
30 to 21 
 
Behavior is considerably influenced by delusions or hallucinations OR serious impairment in communication or 
judgment (e.g., sometimes incoherent, acts grossly inappropriately, suicidal preoccupation) OR inability to 
function in almost all areas (e.g., stays in bed all day; no job, home or friends). 
20 to 11 
 
Some danger of hurting self or others (e.g., suicide attempts without clear exception of death; frequently violent, 
manic excitement) OR occasionally fails to maintain minimal personal hygiene (e.g., smears feces) OR gross 
impairment in communication (e.g., largely incoherent or mute). 
 
10 to 1 
 
Persistent danger of severely hurting self or others (e.g., recurrent violence) OR persistent inability to maintain 
minimal personal hygiene OR serious suicidal act with clear exception of death. 
 
0 Inadequate information. 
 
 
Total GAF Score: ____________                                                                                 Performed by: _______________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
Quality of Life Enjoyment and Satisfaction (QOL) 
Page 1 of 3                                                    Initials_______ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Check one response to each item that best describes you for the past seven days.  
1.   Overall physical health—During the past 
week, think about your overall physical health-
feeling well, having aches and pains, your energy, 
coordination and memory, and so forth. How would 
you rate your level of satisfaction with your physical 
health? 
  (1) Very Poor 
  (2) Poor 
  (3) Fair 
  (4) Good 
  (5) Very Good 
2.  Mood—Now think about your mood over the 
past week. In terms of feeling content, relaxed, 
anxious, nervous, sad, or all other emotions, how 
would you rate your level of satisfaction with your 
mood? 
  (1) Very Poor 
  (2) Poor 
  (3) Fair 
  (4) Good 
  (5) Very Good 
3.  Work performance—Think about how you 
have performed your work this past week. By work I 
mean job, volunteering, taking courses or going to 
school, or whatever work you do. This past week 
how would you rate your level of satisfaction with 
your work performance? 
  (1) Very Poor 
  (2) Poor 
  (3) Fair 
  (4) Good 
  (5) Very Good 
4.  Household activities—If you’re responsible for 
any household duties such as cleaning, shopping, 
food preparation, or other household tasks, either for 
yourself or for others, how satisfied have you been 
with your performance of household activities over 
the last week? 
  (1) Very Poor 
  (2) Poor 
  (3) Fair 
  (4) Good 
  (5) Very Good 
5.  Social relationships—How satisfied have you 
been with your social relationships with friends, 
neighbors, co-workers, or other people this week? 
  (1) Very Poor 
  (2) Poor 
  (3) Fair 
  (4) Good 
  (5) Very Good 
6.  Familial relationships—How about family 
relationships?  How would you rate your level of 
satisfaction with family relationships during the past 
week? 
  (1) Very Poor 
  (2) Poor 
  (3) Fair 
  (4) Good 
  (5) Very Good 
7.     Leisure activities—How much satisfaction 
have you had from leisure time activities such as 
watching TV, reading, gardening, hobbies, outings or 
sports events during the past week? 
  (1) Very Poor 
  (2) Poor 
  (3) Fair 
  (4) Good 
  (5) Very Good 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
Quality of Life Enjoyment and Satisfaction (QOL) 
Page 2 of 3                                                    Initials_______ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
 
Check the one response to each item that best describes you for the past seven days. 
8.     Ability to function—Over the past week, 
how satisfied have you been with your ability to 
function in daily life? 
 
  (1) Very Poor 
  (2) Poor 
  (3) Fair 
  (4) Good 
  (5) Very Good 
9.     Sexual drive—During the past week, how 
satisfied have you been with your sexual drive and 
interest? 
 
  (1) Very Poor 
  (2) Poor 
  (3) Fair 
  (4) Good 
  (5) Very Good 
10.  Economic status—What about your 
economic status…how would you rate your level of 
satisfaction with your economic status the past 
week? 
 
  (1) Very Poor 
  (2) Poor 
  (3) Fair 
  (4) Good 
  (5) Very Good 
11.   Housing situation—How satisfied have you 
felt with your living or housing situation this past 
week? 
  (1) Very Poor 
  (2) Poor 
  (3) Fair 
  (4) Good 
  (5) Very Good 
12.   Physical mobility—How satisfied are you 
with your ability to get around physically, without 
feeling dizzy or unsteady, or falling, during this 
past week? 
  (1) Very Poor 
  (2) Poor 
  (3) Fair 
  (4) Good 
  (5) Very Good 
13.   Vision—How satisfied have you been during 
the past week with your vision? Has it impaired 
your ability to do work or hobbies? 
  (1) Very Poor 
  (2) Poor 
  (3) Fair 
  (4) Good 
  (5) Very Good 
14.   Overall well-being—Taking everything 
into consideration during the past week, how 
satisfied have you been with your overall sense of 
well being? 
  (1) Very Poor 
  (2) Poor 
  (3) Fair 
  (4) Good 
  (5) Very Good 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
Quality of Life Enjoyment and Satisfaction (QOL) 
Page 3 of 3                                                    Initials_______ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
      
 
 
 
 
 
 
 
 
 
Quality of Life Enjoyment and Satisfaction Questionnaire   
TOTAL SCORE: 
 
 
_________ 
 
Check the one response to each item that best describes you for the past seven days. 
(Please do not include 15 and 16 in the total score) 
15.   Treatment—During the past week, how 
satisfied have you been with your treatment? 
  (1) Very Poor 
  (2) Poor 
  (3) Fair 
  (4) Good 
  (5) Very Good 
16.   Overall contentment—How would you rate 
your overall life satisfaction and contentment during 
the past week? 
  (1) Very Poor 
  (2) Poor 
  (3) Fair 
  (4) Good 
  (5) Very Good 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
                                                                   
                                      
Page 1 of 1 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Clinical Global Impression of Severity and Improvement (CGI) 
 
Instructions: Circle the appropriate number after each of the following two items. Complete 
item 1- SEVERITY OF ILLNESS at the initial and subsequent assessments. Item 2 will be 
omitted at the initial assessment by marking 0- “Not Assessed”.  
 
 
              1.  Severity of Illness 
 
0 = Not Assessed                                         4 = Moderately ill  
         
1 = Normal, not ill at all           5 = Markedly ill 
   
2 = Borderline mentally ill           6 = Severely ill   
 
              3 = Mildly ill             7 = Among the most extremely ill  
 
 
    
The assessment below will be omitted at the initial assessment by marking “Not Assessed”. 
 
 
 
               2.  Global Improvement 
 
Compared to these conditions on study Day 1, how much has the subject changed? 
 
0 = Not Assessed                                         4 = No change 
         
1 = Very much improved           5 = Minimally worse 
   
2 = Much improved                       6 = Much worse 
 
              3 = Minimally improved                             7 = Very much worse 
 
           
 
CGI Administered by: ________________________             
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
                                     
Page 1 of 1                                                           Initials_______ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Patient Global Impression Index (PGI) 
Instructions: Circle the appropriate number after each of the following two items. 
Complete item 1- SEVERITY OF ILLNESS at the initial and subsequent assessments. 
Item 2 will be omitted at the initial assessment by marking 0- “Not Assessed”.  
1.  Severity of Illness 
 
0 = Not Assessed                                         4 = Moderately ill  
         
1 = Normal, not ill at all           5 = Markedly ill 
   
2 = Borderline mentally ill           6 = Severely ill   
 
            3 = Mildly ill             7 = Among the most extremely ill  
    
 
The assessment below will be omitted at the initial assessment by marking “Not Assessed”
 
2.  Global Improvement 
Compared to these conditions on study Day 1, how much have you changed? 
 
0 = Not Assessed                                         4 = No change 
         
1 = Very much improved           5 = Minimally worse 
   
2 = Much improved                       6 = Much worse 
 
            3 = Minimally improved                             7 = Very much worse  
    
 
148 of 165
Page 227 of 291
ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
                       
Hamilton Anxiety Rating Scale (HAM-A) 
Page 1 of 3 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
1.  Anxious Mood (covers the emotional condition of uncertainty about the future, ranging from worry, insecurity, 
irritability and apprehension to overpowering dread) 
_____      0= Not present; the patient is neither more or less insecure or irritable than usual 
_____      1= Doubtful whether the patient is more insecure or irritable than usual 
_____      2= Patient expresses more clearly to be in a state of anxiety, apprehension or irritability, which he/she may find 
difficult to control.  However, worrying is still about minor matters and thus without influence on the patient’s daily 
life 
_____      3= At times the anxiety or insecurity is more difficult to control because the worrying is about major injuries or harms 
which might occur in the future.  Has occasionally interfered with the patient’s daily life. 
_____      4= Severe.  The feeling of dread is present so often that it markedly interferes with the patient’s daily life 
 
2.  Tension (includes inability to relax, nervousness, bodily tensions, trembling and restless fatigue) 
_____      0= Not present; the patient is neither more nor less tense than usual 
_____      1= Patient seems somewhat more nervous and tense than usual 
_____      2= Patients expresses clearly unable to relax and full of inner unrest, which he/she finds difficult to control, but it is 
still without influence on the patient’s daily life 
_____      3= The inner unrest and nervousness is so intense or frequent that it occasionally interferes with the patient’s daily 
work 
_____      4= Severe.  Tensions and unrest interfere with the patient’s life and work at all times 
 
3.  Fears (includes fear of being in a crowd, of animals, of being in public places, of being alone, of traffic, of strangers, of 
dark, etc.  
_____      0= Not present 
_____      1= Doubtful whether present 
_____      2= Patient experiences phobic anxiety but is able to fight it 
_____      3= It is difficult to fight or overcome the phobic anxiety, which thus to some extent interferes with daily life and work 
_____      4= Severe.  The phobic anxiety clearly interferes with the patient’s daily life and work  
 
4.  Insomnia (covers the patient’s subjective experience of sleep duration and sleep depth during the three preceding 
nights.  Note:  administration of hypnotics or sedatives is disregarded) 
_____      0= Not present; usual sleep duration and sleep depth 
_____      1=  Sleep duration is doubtfully or slightly reduced (e.g. due to difficulties falling asleep), but no change in sleep depth 
_____      2= Sleep depth is also reduced, sleep being more superficial.  Sleep as a whole is somewhat disturbed 
_____      3= Sleep duration and sleep depth is markedly changed.  Sleep periods total only a few hours per 24 hours 
_____      4= Severe.  Sleep depth is so shallow that the patient speaks of short periods of slumber or dozing, but no real sleep 
 
5.  Difficulties in concentration and memory (covers difficulties in concentration, making decisions about everyday 
matters, and memory) 
_____      0= Not present; the patient has neither more nor less difficulty in concentration and/or memory than usual 
_____      1= Doubtful whether the patient has difficulty in concentration and/or memory 
_____      2= Even with a major effort it is difficult for the patient to concentrate on his/her daily routine work 
_____      3= Patient has pronounced difficulties with concentration, memory, or decision making (e.g. in reading a newspaper 
article or watching a television program to the end) 
_____      4= Severe.  During the interview the patient shows difficulty in concentration, memory, or decision making  
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
                       
Hamilton Anxiety Rating Scale (HAM-A) 
Page 2 of 3 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
6.  Depressed Mood (covers both the verbal and non-verbal communication of sadness, depression, despondency,  
helplessness, and hopelessness) 
_____      0= Not present 
_____      1= Doubtful whether the patient is more despondent or sad than usual, or is only vaguely so 
_____      2= Patient is clearly concerned with unpleasant experiences, although he/she still lacks helplessness or hopelessness 
_____      3= Patient shows clear non-verbal signs of depression and/or hopelessness 
_____      4= Severe.  Patient remarks on despondency and helplessness or the non-verbal signs dominate the interview and the 
patient cannot be distracted  
 
7.  General Somatic Complaints/Symptoms: Muscular (weakness, stiffness, soreness or real pain, more or less diffusely 
localized in the muscles, such as jaw ache or neck ache) 
_____      0= Not present; the patient is neither more nor less sore or stiff in the muscles than usual 
_____      1= Patient seems somewhat more stiff or sore in the muscles than usual 
_____      2= Symptoms have the character of pain 
_____      3= Muscle pain interferes to some extent with the patient’s daily work and life 
_____      4= Severe.  Muscle pain is present most of the time and clearly interferes with the patient’s daily work and life 
  
8.  General Somatic Complaints/Symptoms: Sensory (includes increased fatigability and weakness or real functional 
disturbances of the senses, including tinnitus, blurring of vision, hot and cold flashes and prickling sensations 
_____      0= Not present 
_____      1= Doubtful whether the patient’s indications of symptoms are more pronounced than usual 
_____      2= Sensations of pressure reach the character of buzzing in the ears, visual disturbances and prickling or itching 
sensations in the skin 
_____      3= The generalized sensory symptoms interfere to some extent with the patient’s daily life and work 
_____      4= Severe.  Generalized sensory symptoms are present most of the time and clearly interfere with the patient’s daily life 
and work  
 
9.  Cardiovascular Symptoms (includes tachycardia, palpitations, oppression, chest pain, throbbing in the blood vessels, 
and feelings of faintness) 
 
_____      0= Not present 
_____      1= Doubtful whether present 
_____      2= Cardiovascular symptoms are present, but the patient can still control them 
_____      3= Patient has occasional difficulty controlling the cardiovascular symptoms, which thus to some extent interfere with 
his/her daily life and work 
_____      4= Severe.  Cardiovascular symptoms are present most of the time and clearly interfere with the patient’s daily life and 
work  
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
                       
Hamilton Anxiety Rating Scale (HAM-A) 
Page 3 of 3 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
10.  Respiratory Symptoms (feelings of constriction or contraction in throat or chest, dyspnoea or choking sensations and 
sighing respiration) 
_____      0= Not present 
_____      1= Doubtful whether present 
_____      2= Respiratory symptoms are present, but the patient can still control them 
_____      3= Patient has occasional difficulty controlling the respiratory symptoms, which thus to some extent interfere with 
his/her daily life and work 
_____      4= Severe.  Respiratory symptoms are present most of the time and clearly interfere with the patient’s daily life and 
work  
 
11.  Gastrointestinal Symptoms (covers difficulties in swallowing, “sinking” sensations in stomach, dyspepsia (heartburn 
or burning sensation in the stomach, abdominal pains related to meals, fullness, nausea and vomiting), abdominal 
rumbling and diarrhea) 
_____      0= Not present 
_____      1= Doubtful whether present 
_____      2= One or more gastrointestinal symptoms are present, but the patient can still control them 
_____      3= Patient has occasional difficulty controlling the gastrointestinal symptoms, which to some extent interfere with 
his/her daily life and work 
_____      4= Severe.  The gastrointestinal symptoms are present most of the time and interfere clearly with daily life and work 
 
12.  Genitourinary Symptoms (includes non-organic or psychic symptoms such as frequent or more pressing passing of 
urine, menstrual irregularities, anorgasmia, dyspareunia, premature ejaculation, loss of erection) 
______    0= Not present 
_____      1= Doubtful whether present (or doubtful if different from usual) 
_____      2= One or more genitor-urinary symptoms are present, but do not interfere with the patient’s daily life and work 
_____      3= Occasionally, one or more genito-urinary symptoms are present to such a degree that they interfere to some extent 
with the patient’s daily life and work 
_____      4= Severe.  The genitor-urinary symptoms are present most of the time and interfere clearly with life and work 
 
13.  Other Autonomic Symptoms (includes dryness of the mouth, blushing or pallor, sweating and dizziness) 
_____      0= Not present 
_____      1= Doubtful whether present 
_____      2= One or more autonomic symptoms are present, but they do not interfere with the patient’s daily life and work 
_____      3= Occasionally, one or more autonomic symptoms are present to such a degree that they interfere to some extent with 
the patient’s daily life and work 
_____      4= Severe.  Autonomic symptoms are present most of the time and clearly interfere with daily life and work  
 
14.  Behavior During Interview (patient may appear tense, nervous, agitated, restless, tremulous, pale, hyperventilating or 
sweating during the interview.  Based on such observations a global estimate is made) 
_____      0= The patient does not appear anxious 
_____      1= It is doubtful whether the patient is anxious 
_____      2= Patient is moderately anxious 
_____      3= Patient is markedly anxious 
_____      4= Severe.  Patient is overwhelmed by anxiety, for example with shaking and trembling all over  
 
 
                                                                                                                                                             Total Score: __________ 
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COLUMBIA-SUICIDE SEVERITY 
RATING SCALE 
(C-SSRS) 
Baseline 
Version 1/14/09 
 
 Posner, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; Fisher, P.; Zelazny, J.; 
Burke, A.; Oquendo, M.; Mann, J.  
 
 
Disclaimer: 
This scale is intended for use by trained clinicians. The questions contained in the Columbia-Suicide Severity Rating Scale 
are suggested probes. Ultimately, the determination of the presence of suicidality depends on clinical judgment. 
 
 
 
Definitions of behavioral suicidal events in this scale are based on those used in The Columbia Suicide History 
Form, developed by John Mann, MD and Maria Oquendo, MD, Conte Center for the Neuroscience of Mental Disorders 
(CCNMD), New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032. (Oquendo M. A., 
Halberstam B. & Mann J. J., Risk factors for suicidal behavior: utility and limitations of research instruments. In M.B. First 
[Ed.] Standardized Evaluation in Clinical Practice, pp. 103 -130, 2003.) 
 
 For reprints of the C-SSRS contact Kelly Posner, Ph.D., New York State Psychiatric Institute, 1051 Riverside Drive, New 
York, New York, 10032; inquiries and training requirements contact posnerk@childpsych.columbia.edu  
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SUICIDAL IDEATION 
Ask questions 1 and 2.  If both are negative, proceed to “Suicidal Behavior” section. If the answer to question 2 is “yes,” 
ask questions 3, 4 and 5.  If the answer to question 1 and/or 2 is “yes”, complete “Intensity of Ideation” section below. 
 
Lifetime:  
Time He/She 
Felt Most 
Suicidal 
1.  Wish to be Dead  
Subject endorses thoughts about a wish to be dead or not alive anymore, or wish to fall asleep and not wake up.  
Have you wished you were dead or wished you could go to sleep and not wake up?  
   
If yes, describe: 
 
 
Yes       No 
 □    □ 
2.  Non-Specific Active Suicidal Thoughts 
General, non-specific thoughts of wanting to end one’s life/commit suicide (e.g. “I’ve thought about killing myself”) without thoughts of ways to kill 
oneself/associated methods, intent, or plan.  
Have you actually had any thoughts of killing yourself? 
 
If yes, describe: 
 
 Yes      No 
  □    □ 
3.  Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act 
Subject endorses thoughts of suicide and has thought of at least one method during the assessment period. This is different than a specific plan with time, 
place or method details worked out (e.g.  thought of method to kill self but not a specific plan).  Includes person who would say, “I thought about taking an 
overdose but I never made a specific plan as to when, where or how I would actually do it…..and I would never go through with it”.  
Have you been thinking about how you might do this? 
 
If yes, describe: 
 
 
 Yes      No 
  □    □ 
4.  Active Suicidal Ideation with Some Intent to Act, without Specific Plan 
Active suicidal thoughts of killing oneself and subject reports having some intent to act on such thoughts, as opposed to “I have the thoughts but I 
definitely will not do anything about them”. 
Have you had these thoughts and had some intention of acting on them?  
 
If yes, describe: 
 
 
Yes       No 
  □    □ 
5.  Active Suicidal Ideation with Specific Plan and Intent 
Thoughts of killing oneself with details of plan fully or partially worked out and subject has some intent to carry it out. 
Have you started to work out or worked out the details of how to kill yourself? Do you intend to carry out this plan? 
                                                                       
If yes, describe: 
 
 
 Yes      No 
  □    □ 
INTENSITY OF IDEATION 
The following features should be rated with respect to the most severe type of ideation (i.e.,1-5 from above, with 1 being the least severe 
and 5 being the most severe ). Ask about time he/she was feeling the most suicidal.  
                                             
Most Severe Ideation:             _____                      _________________________________________________ 
                                               
                                                                                                           Type # (1-5)                                         Description of  Ideation 
Most 
Severe 
Frequency 
How many times have you had these thoughts?  
(1) Less than once a week    (2) Once a week   (3)  2-5 times in week    (4) Daily or almost daily    (5) Many times each day 
 
____ 
Duration 
When you have the thoughts, how long do they last? 
(1) Fleeting - few seconds or minutes                                                 (4) 4-8 hours/most of day 
(2) Less than 1 hour/some of the time                                                 (5) More than 8 hours/persistent or continuous 
(3) 1-4 hours/a lot of time 
____ 
Controllability 
Could /can you stop thinking about killing yourself or wanting to die if you want to? 
(1) Easily able to control thoughts                                                      (4) Can control thoughts with a lot of difficulty 
(2) Can control thoughts with little difficulty                                     (5) Unable to control thoughts 
(3) Can control thoughts with some difficulty                                    (0) Does not attempt to control thoughts 
____ 
Deterrents 
Are there things - anyone or anything (e.g. family, religion, pain of death) - that stopped you from wanting to die or acting on 
thoughts of committing suicide? 
(1) Deterrents definitely stopped you from attempting suicide            (4) Deterrents most likely did not stop you  
(2) Deterrents probably stopped you                                                    (5) Deterrents definitely did not stop you  
(3) Uncertain that deterrents stopped you                                             (0) Does not apply 
____ 
Reasons for Ideation 
What sort of reasons did you have for thinking about wanting to die or killing yourself?  Was it to end the pain or stop the way 
you were feeling (in other words you couldn’t go on living with this pain or how you were feeling) or was it to get attention, 
revenge or a reaction from others? Or both? 
(1) Completely to get attention, revenge or a reaction from others.       (4) Mostly to end or stop the pain (you couldn’t go on 
(2) Mostly to get attention, revenge or a reaction from others.                     living with the pain or how you were feeling). 
(3) Equally to get attention, revenge or a reaction from others               (5) Completely to end or stop the pain (you couldn’t go on  
       and to end/stop the pain.                                                                         living with the pain or  how you were feeling). 
                                                                                                                 (0)  Does not apply 
 
 
 
 
____ 
Version 1/14/09 
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SUICIDAL BEHAVIOR 
(Check all that apply, so long as these are separate events; must ask about all types) 
 
Lifetime  
Actual Attempt:  
A potentially self-injurious act committed with at least some wish to die, as a result of act. Behavior was in part thought of as method to kill oneself. Intent 
does not have to be 100%.  If there is any intent/desire to die associated with the act, then it can be considered an actual suicide attempt. There does not 
have to be any injury or harm, just the potential for injury or harm. If person pulls trigger while gun is in mouth but gun is broken so no injury results, 
this is considered an attempt.   
Inferring Intent: Even if an individual denies intent/wish to die, it may be inferred clinically from the behavior or circumstances. For example, a highly lethal 
act that is clearly not an accident so no other intent but suicide can be inferred (e.g. gunshot to head, jumping from window of a high floor/story). Also, if 
someone denies intent to die, but they thought that what they did could be lethal, intent may be inferred.  
Have you made a suicide attempt? 
Have you done anything to harm yourself? 
Have you done anything dangerous where you could have died? 
What did you do? 
Did you______ as a way to end your life?  
Did you want to die (even a little) when you_____?  
Were you trying to end your life when you _____? 
Or did you think it was possible you could have died from_____? 
Or did you do it purely for other reasons / without ANY intention of killing yourself (like to relieve stress, feel better, get sympathy, 
or get something else to happen)?  (Self-Injurious Behavior without suicidal intent) 
If yes, describe: 
 
 
Has subject engaged in Non-Suicidal Self-Injurious Behavior? 
 
Yes      No 
□   □ 
 
 
 
 
 
 
 
Total # of 
Attempts 
 
______ 
 
 
 
 
 
 
 
Yes    No 
□   □ 
Interrupted Attempt:   
When the person is interrupted (by an outside circumstance) from starting the potentially self-injurious act (if not for that, actual attempt would have 
occurred). 
Overdose: Person has pills in hand but is stopped from ingesting.  Once they ingest any pills, this becomes an attempt rather than an interrupted attempt. 
Shooting: Person has gun pointed toward self, gun is taken away by someone else, or is somehow prevented from pulling trigger. Once they pull the trigger, 
even if the gun fails to fire, it is an attempt. Jumping: Person is poised to jump, is grabbed and taken down from ledge. Hanging: Person has noose around neck 
but has not yet started to hang - is stopped from doing so. 
Has there been a time when you started to do something to end your life but someone or something stopped you before you 
actually did anything? 
If yes, describe: 
 
Yes      No 
□   □ 
 
 
Total # of 
interrupted 
 
______ 
 
Aborted Attempt:   
When person begins to take steps toward making a suicide attempt, but stops themselves before they actually have engaged in any self-destructive behavior. 
Examples are similar to interrupted attempts, except that the individual stops him/herself, instead of being stopped by something else. 
Has there been a time when you started to do something to try to end your life but you stopped yourself before you actually did 
anything? 
If yes, describe: 
 
 
Yes      No 
□   □ 
 
Total # of 
aborted 
 
______ 
Preparatory Acts or Behavior: 
Acts or preparation towards imminently making a suicide attempt. This can include anything beyond a verbalization or thought, such as assembling a specific 
method (e.g. buying pills, purchasing a gun) or preparing for one’s death by suicide (e.g. giving things away, writing a suicide note).  
Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as collecting pills, getting a gun, 
giving valuables away or writing a suicide note)? 
If yes, describe: 
 
 
Yes      No 
□   □ 
Suicidal Behavior: 
Suicidal behavior was present during the assessment period? 
Yes      No 
□   □ 
Answer for Actual Attempts Only Most Recent  Attempt 
Date: 
Most Lethal          
Attempt 
Date: 
Initial/First  
Attempt 
Date: 
Actual Lethality/Medical Damage:   
0.  No physical damage or very minor physical damage (e.g. surface scratches). 
1.  Minor physical damage (e.g. lethargic speech; first-degree burns; mild bleeding; sprains). 
2.  Moderate physical damage; medical attention needed (e.g. conscious but sleepy, somewhat responsive; second-degree 
burns; bleeding of major vessel). 
3.  Moderately severe physical damage; medical hospitalization and likely intensive care required (e.g. comatose with 
reflexes intact; third-degree burns less than 20% of body; extensive blood loss but can recover; major fractures). 
4.  Severe physical damage; medical hospitalization with intensive care required (e.g. comatose without reflexes; third-
degree burns over 20% of body; extensive blood loss with unstable vital signs; major damage to a vital area). 
5.  Death 
 
Enter Code 
 
 
 
______ 
 
 
 
Enter Code 
 
 
 
______ 
 
 
 
Enter Code 
 
 
 
______ 
 
 
Potential Lethality: Only Answer if Actual Lethality=0 
Likely lethality of actual attempt if no medical damage (the following examples, while having no actual medical damage, 
had potential for very serious lethality: put gun in mouth and pulled the trigger but gun fails to fire so no medical damage; 
laying on train tracks with oncoming train but pulled away before run over). 
 
0 = Behavior not likely to result in injury 
1 = Behavior likely to result in injury but not likely to cause death 
2 = Behavior likely to result in death despite available medical care  
 
Enter Code 
 
 
 
______ 
 
 
Enter Code 
 
 
 
______ 
 
 
Enter Code 
 
 
 
______ 
 
 
 
154 of 165
Page 233 of 291
ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
Health and Labor Questionnaire (HLQ)                                                 
 
Page 1 of 10 
Initials_______ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
                                                                                                     
This questionnaire asks about the effects of health problems on paid and unpaid work 
(domestic). The term 'health problems' refers to acute or chronic physical illnesses symptoms or 
handicaps. Other health problems like chronic fatigue or pain are also covered by this. 
Furthermore, psychological disorders, are also included. At the end of the questionnaire you will 
be asked for your age and some other personal details. These details will assist us in gaining a 
more clear understanding of your answers. There are no 'correct' or 'incorrect' answers to the 
questions asked. We are interested only in your personal opinion. 
 
In addition to the questions relating to paid work there are some concerning unpaid work such as 
domestic chores. Throughout this questionnaire please limit your answers to your personal 
situation during the PAST TWO WEEKS. 
 
1. Do you have paid employment? 
  □ Yes, I work………..hours per WEEK, divided over…………DAYS; my                                   
       profession is……………………………….., function…………………………. 
                            
                                               Go to the section Paid Work 
 □ No 
      Please continue with question 14  
 
If your answer to the above question was yes, please continue by answering questions 2 to 13 
(even if you are suffering from a short term illness at the present moment). If your answer to the 
above question was no please ignore questions 2 to 13 and continue with question 14. 
 
 
PAID WORK 
We would like you to indicate on which working days in the past two weeks you were unable to 
perform paid work due to health problems. You are requested to complete this section using the 
following codes. In filling in the table on the following page you may use more then one letter. 
'W' = performed paid work 
'U' = unable to perform paid work due to health problems 
'O' = no paid work performed due to other reasons (weekend, holidays etc.) 
If you have part-time employment then fill in 'O' for the days on which you were not required to 
work. When you worked for half a day please indicate this e.g. by writing 'W/O' if you did not 
work in that afternoon. 
In case of illness during the weekend fill in 'O' if you were not required to work and 'U' if you 
were required to work. 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit:____________ 
Health and Labor Questionnaire (HLQ)                                                 
 
Page 2 of 10 
Initials_______ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
                                                                                                      
Example: 
Imagine you have four days paid employment per week, but last week you were unable to work n 
Thursday and Friday due to health problems. You always have Wednesdays off. Then the table 
would appear as follows: 
 
MO  TU WE TH FR SA SU MO TU WE TH FR SA SU 
W W O W W O O W W O U U O O 
 
               The week before last                                                 Last Week 
 
2. Please complete the table below in the same manner. Remember that the time period concerned  
is the past two full weeks, counting back from last weekend. 
'W' = performed paid work 
'U' = unable to perform paid work due to health problems 
   'O' = no paid work performed due to other reasons (weekend, holidays etc.) 
 
               The week before last                                                 Last Week 
 
Only answer the following question if you have been completely unable to perform paid 
work dueto health problems during the past two weeks. 
 
3. When did this period of illness start? Enter the date on which you reported sick. 
Day…………Month…………Year……….. 
 
Health problems sometimes force employees to be absent from their work. It is also 
possible that employees go to work but are unable to perform their duties with the same 
efficiency as usual due to health problems. Questions 4 to 13 relate to this subject. 
 
4. Were you hindered by health problems at your paid work over the past two weeks? 
 
□ No, not at all   →                          go to question 13 
□ Yes, to a degree 
 □ Yes, very much 
 
                                                                                                                                                                              
 
  
MO  TU WE TH FR SA SU MO TU WE TH FR SA SU 
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Date of Visit: ___/___/_____ 
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Health and Labor Questionnaire (HLQ)                                                 
 
Page 3 of 10 
Initials_______ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
I did go to work but as a result of health problems …. 
                                
                                                                               Never      Sometimes   Often     Always 
5. …I had a problem concentrating                        □       □      □     □ 
6. …I had to go to work at a slower pace               □       □      □     □ 
7. …I had to seclude myself                                   □       □      □     □ 
9. …I had to put off some of my work                   □       □      □     □   
8. …I found decision-making more difficult          □       □      □     □ 
10. …Others had to take over some of my work    □       □      □     □ 
            
11. …I had other problems, namely (please state)…………………………………  
 
12. How many extra hours would you have to work to catch up on tasks you were unable to 
      complete in normal working hours due to health problems over the past two weeks? 
      NOTE: Do not count the days on which you reported sick……………...…….Hours 
 
13. We would now like to know what your net earnings are from your paid work. 
NOTE: This concerns your income, not including that of your partner (if any). You only need 
to fill out one of the following options. 
 
□My own net income from paid work is approximately: 
          ………………………………… per WEEK 
          ………………………………….per 4 WEEKS 
          ………………………………….per MONTH 
          ………………………………….per YEAR 
□I do not know what my income is or I would rather not say 
Now go to question 15  
 
 
                                                                                                      
 
 
 
 
Below you find a number of statements that could be applicable to people with health problems in relation 
to their current work situation. Please indicate for each statement that is mentioned how often it applied to 
you in the past two weeks. 
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Date of Visit: ___/___/_____ 
Name of Visit:____________ 
Health and Labor Questionnaire (HLQ)                                                 
 
Page 4 of 10 
Initials_______ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Question 14 should only be answered by people who do not/no longer have paid work at the 
present time. 
 
14. You have no paid work. Which of the following situations is most applicable to you? 
 
□I have the daily task of running a household 
□I receive a pension or have taken early retirement 
□I am still at school or a student 
□I am unable to perform paid work due to health problems  
(If you did have paid work before would you fill out your profession and the function you held: 
 
    profession………………...…………………...function held …………….……………) 
□I have no paid work 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                    
                                                            
 
 
158 of 165
Page 237 of 291
ANS C-07-01    
Date of Visit: ___/___/_____ 
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TO BE COMPLETED BY ALL RESPONDENTS 
The following questions concern unpaid work. Here a distinction has been made between work 
in the household; shopping; odd jobs and chores and activities for or with the children. We 
would everyone to please answer these questions. Firstly you will be asked how many hours a 
week you spent on each activity. If you did not perform a particular activity than simply write   
"0” hours. Secondly, we would like to know whether you were hindered in any of the activities 
mentioned by health problems. 
Please remember that your answers should relate to the PAST TWO WEEKS. 
 
 
15. How many hours a week did you spend on: 
  
• Work in the household               
(e.g. preparing meals, cleaning the house, washing 
clothes)                                               
 
           
          …………....hours per week 
• Shopping        
(e.g. shopping for the daily groceries, other types 
of shopping, going to the bank or post office)            
            
           
          ………....…hours per week 
• Odd jobs and chores     
(e.g. house repairs, gardening, fixing the car)            
            
           ..………..…hours per week 
• Doing things for or with your own children     
(e.g. caring for them, taking them to school, 
helping with homework) 
            
          
           ………...…..hours per week 
 
16. It may be that people with health problems who normally do household tasks (cleaning                     
the house, shopping, taking care of the children) must leave these tasks to be done by others 
due to their health problems. 
 
Have others taken over any of your household tasks due to your health problems? (You may 
tick more then one box if applicable) 
□ Yes, family members (e.g. partner, children) have taken over my household tasks for 
. ..…..……….hours per week 
□ Yes, others (e.g. neighbors or volunteers) have taken over my household tasks for 
……………..hours per week 
□ Yes, I have had a home-help for …...….……..hours per week 
□ Yes, I have had another type of paid help for ……..………hours per week 
□ No, I have performed my household tasks myself. 
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Subject Initials:    __________ 
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These were two examples.  
 
Example 1 
During the PAST TWO WEEKS Mrs. Johnson did no go shopping in the city due to her 
health problems. She did manage to go to her local corner shop in spite of her problems. 
She indicates this as follows: 
 
 DID DO DID NOT DO 
 Was hindered 
by health 
problems 
Was not 
hindered by 
health 
problems 
Due to health 
problems 
Other reasons. 
Shopping X    
 
 
Example 2 
Mr. Cook never vacuums. His son always performs this task because Mr. Cook hates doing it. 
Mr. Cook answered the question on vacuuming as follows: 
 
 DID DO DID NOT DO 
 Was hindered 
by health 
problems 
Was not 
hindered by 
health 
problems 
Due to health 
problems 
Other reasons. 
Vacuuming    X 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                              
   
 
In the next table we would like you to indicate which of the following unpaid activities you have 
performed in the PAST TWO WEEKS and whether or not you were hindered by health problems. 
Please tick the appropriate answer. 
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Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
17. Would you now complete the table below in the same way as shown in the two examples. Put 
a cross next to an activity if you have performed it in the PAST TWO WEEKS your                                    
answer is "DID DO" then indicate whether or not you were hindered by health problems. If 
      your answer is "DID NOT DO" then please indicate whether or not this was due to health 
      problems. 
 
 DID DO DID NOT DO 
 Was hindered 
by health 
problems 
Was not 
hindered by 
health 
problems 
Due to health 
problems 
Other reasons. 
Household 
work at home 
(for example, 
preparing meals, 
cleaning, 
washing clothes) 
    
Shopping (for 
example, daily 
groceries, other 
shopping, going 
to the bank or 
post office) 
    
Odd jobs and 
chores 
(for example, 
house repairs, 
gardening, 
fixing the car) 
    
Doing things 
for or with your 
own children 
(for example, 
caring for them, 
playing, taking 
them to school, 
helping with 
homework) 
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The following questions concern a general nature 
1. Are you: 
   □ Male 
   □ Female 
 
2. What is your date of birth? 
      
      day…………month………....19…..……… 
 
3. Which of the following levels of education have you completed? (you may tick more than one 
answer if applicable) 
□ None                                                            □ Intermediate vocation education 
 
□ Primary school                                            □ Grammar school 
 
□ Lower vocational education                       □ Polytechnic Higher vocational education 
 
□ General secondary education                      □University 
 
4. How many people live in your household? 
□I live alone 
□I live with one or more people 
 
5. Are there any children in your household? 
□Yes, the age of the youngest child in the household is……..……………...months/years 
□No 
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Name of Visit:____________ 
Health and Labor Questionnaire (HLQ)                                                 
 
Page 9 of 10 
Initials_______ 
Subject Initials:    __________ 
Subject Number:  __________ 
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6. Below is a list of chronic conditions and illnesses. Would you please indicate whether you 
    are suffering from or have suffered from any of these conditions in the LAST TWELVE 
    MONTHS? 
 
Suffering from now or have suffered in the LAST TWELVE MONTHS: 
                                                                                                                                YES          NO 
Asthma or chronic bronchitis                                                                   
Serious heart condition or heart Infarct                                                   
High blood pressure                                                                                
A stroke or its consequences                                                                    
Stomach or duodenal ulcer                                                                      
Serious intestinal disturbance lasting more than three months                
Gall stones or infection of the gall bladder                                              
Liver condition or cirrhosis of the liver                                                   
Kidney stones                                                                                           
Serious kidney condition                                                                         
Complaint of the prostate gland                                                              
Diabetes                                                                                                   
Thyroid gland condition                                                                           
Back problems of a persistent nature, hernia, ischia or  “worn out” 
back                            
  
Arthritis of the knees, hips or hands                                                        
Rheumatism of the hands and/or feet                                                     
Other rheumatic conditions                                                                      
Epilepsy                                                                                                   
Other nervous disorders such as Parkinson’s disease, multiple 
sclerosis                     
  
Serious headaches   
Migraine   
Malignant condition or cancer   
Overexertion, depression, serious nervousness   
Chronic skin condition or eczema   
Prolapsus   
Varicose veins   
Injury due to an accident in or around the house, a road traffic 
accident, sports injury at school or at work       
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This is the end of the questionnaire. Thank you very much for your co-operation. The space below has been provided 
for any remarks you may wish to make about this questionnaire. 
 
 
 
______________________________________________________________________________ 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
Name of Visit: ___________ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
BASELINE 1 VISIT REQUIREMENTS:  
 
 MADRS  (VIDEO TAPED) 
 HRSD-17 
 IDS-C 
 QIDS-SR 
 MINI PLUS 
 MMSE 
Score: ______ 
 SCID II 
Did any cluster B meet diagnosis? _____ 
 YMRS 
 WSAS 
 GAF 
 QOL 
 CGI 
 PGI 
 HAM-A 
 C-SSRS 
 HLQ 
 ATHF 
 SAFTEE-SI 
 Brief Physical/Neurological exam 
 Urine pregnancy test 
 Psychiatric concomitant med log 
 
 Scheduled Date of Next Visit (within 2-4 weeks): ___/___/_______ 
 
Coordinator Signature: ____________________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
BASELINE 2 VISIT FORM 
 
Have any unscheduled visits taken place since the last study visit?  
 YES→    How many times? _______ (complete form) 
 NO 
 
Have any “depression” related medications changed since the last study visit?  
 YES→    Do not proceed, subject does not qualify 
 NO 
 
 
ADVERSE EVENTS 
Have there been any adverse events since the last visit?  
 YES→    Record details on AE form 
 NO 
 
Have there been any serious adverse events since the last visit?  
 YES→    Record details on AE form and report to sponsor and IRB 
 NO 
 
 
MADRS SCORE 
Is the subject’s MADRS score ≥ 22 for this visit?  
 YES→   Score: ______ 
  NO→   Do not proceed, subject does not qualify 
 
 
 
VISIT REQUIREMENTS:  
 
 MADRS 
 QIDS-SR 
 HAM-A 
 C-SSRS 
 SAFTEE-SI 
 
 Scheduled Date of Next Visit (within 2-6 weeks): ___/___/_______ 
 
 
Coordinator Signature: ____________________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
BASELINE 3 VISIT FORM 
 
Have any unscheduled visits taken place since the last study visit?  
 YES→    How many times? _______(complete form) 
 NO 
 
Have any “depression” related medications changed since the last study visit?  
 YES→    Do not proceed, subject does not qualify 
 NO 
 
ADVERSE EVENTS 
Have there been any adverse events since the last visit?  
 YES→    Record details on AE form 
 NO 
 
Have there been any serious adverse events since the last visit?  
 YES→    Record details on AE form and report to sponsor and IRB 
 NO 
 
MADRS SCORE 
Were the 3 baseline MADRS scales rated by 2 separate psychiatrists? 
 YES    
  NO→   Do not proceed, subject does not qualify 
 
Is the subject’s MADRS score ≥ 22 for this visit?  
 YES→   Score: ______ 
  NO→   Do not proceed, subject does not qualify 
 
Has the MADRS score improved by 20%? 
 YES→    Do not proceed, subject does not qualify 
 NO 
 
Average baseline MADRS score of all visits? _______ 
 
VISIT REQUIREMENTS:  
 MADRS                                   □ C-SSRS 
 QIDS                                        □ SAFTEE-SI 
 HAM-A                                    □ MRI 
 Neuropsych Battery 
 
 Scheduled Date of Next Visit (within 2-4 weeks): ___/___/_______ 
 
Coordinator Signature: ____________________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Baseline Neuropsychological Examination 
  Hopkins Verbal Learning Test Revised (HVLT-R)   Form # ____ (1-6) Initial: ______ 
          Raw Score  T-score 
 Total recall     _________ (0-36) ________ (20-80) 
 Delayed recall     _________ (0-12)  ________ (20-80) 
 Retention %     _________ (0-150+) ________ (20-80) 
 Recognition Discrimination Index      _________ (<4-12) ________ (20-80) 
NOTES: _____________________________________________________________________________ 
_____________________________________________________________________________________ 
  Ruff 2& 7 Selective Attention Test                                                          Initial: ______ 
        Raw Score  T-score 
 Automatic Detection Speed   _______ (0-300)  ___________ (20-80) 
 Automatic Detection Accuracy                        _______ (0-100) ___________ (20-80) 
 Controlled Search Speed                                 _______ (0-300)  ___________ (20-80) 
 Controlled Search Accuracy                            _______ (0-100)  ___________ (20-80) 
 Total Speed                                _______ (40-160) ___________ (20-80) 
 Total Accuracy                                    _______ (40-119) ___________ (20-80) 
NOTES: ______________________________________________________________________________ 
               ______________________________________________________________________________________ 
  Stroop Color Word Test (Golden version)                      Initial: ______ 
        Raw Score  T-score 
 Word score (number correct responses)    _______ (max 150) ___________ (3-98) 
 Color score (number correct responses)     _______ (max 150) ___________ (3-98) 
 Color/Word score (# correct responses)     _______ (max 150) ___________ (3-98) 
 Interference    _______ (max 150)            ___________ (20-80) 
NOTES: ______________________________________________________________________________ 
               ______________________________________________________________________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Baseline Neuropsychological Examination 
  Brief Visual Memory Test- Revised (BVMT-R)      Form #_______ (1,2,3,4,5,6)   Initial: ______ 
          Raw Score  T-score 
 Trial 1          _______ (0-12) ___________ (38-80) 
 Trial 2                                    _______ (0-12) ___________ (38-80) 
 Trial 3                                    _______ (0-12)  ___________ (38-80) 
 Total                                    _______ (0-36) ___________ (38-80) 
 Delayed Recall                                   _______ (0-12) ___________ (38-80) 
 Recognition Hits                                   _______ (0-6)  ___________ NA 
 Recognition Discrimination                                _______ (-6 to +6) ___________ NA 
 NOTES: ________________________________________________________________________________ 
 _______________________________________________________________________________________ 
 Delis-Kaplan Executive Function Scale (D-KEFS)         Form #_______ (1 or 2)     Initial:_______ 
      Raw Score  Scaled Score  
 Letter fluency    ________ (0-> 67) _________ (0-19) 
 Category fluency                  ________ (0-> 61) _________ (0-19) 
 Switching fluency (2 scores)                             
o Total correct  ________(0-> 21) _________(0-19) 
o Switching accuracy ________(0->20)       _________(0-19)  
      
 NOTES:______________________________________________________________________________ 
______________________________________________________________________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Baseline Neuropsychological Examination 
  Wechsler Memory Scale – Third Edition Abbreviated (WMS-III-A )           Initial: ______ 
                                Raw Score                   Age corrected scale score 
 Letter number sequencing                                     __________  ___________  
       NOTES: ______________________________________________________________________________ 
______________________________________________________________________________________ 
 
  Behavior Rating Inventory of Executive Functions (BRIEF-A)                    Initial: ______ 
            Raw Score  T-score 
 Inhibit       _______ (0-24)  ___________ (30-105) 
 Shift                              _______ (0-18)  ___________ (30-105) 
 Emotional Control                            _______ (0-30)  ___________ (30-105) 
 Self-Monitor                             _______ (0-18)  ___________ (30-105) 
 Behavioral Regulation Index              _______ (0-90)  ___________ (30-105) 
 Initiate                              _______ (0-24)  ___________ (30-105) 
       Raw Score  T-score 
 Working Memory                            _______ (0-24)  ___________ (30-105) 
 Plan/Organize                             _______ (0-30)  ___________ (30-105) 
 Task Monitor                            _______ (0-18)  ___________ (30-105) 
 Organization of Materials                        _______ (0-24)   ___________ (30-105) 
 Metacognition Index      _______ (0-120)  ___________ (30-105) 
 Global Executive Composition                        _______ (0-210) ___________ (30-105) 
      NOTES: ______________________________________________________________________________ 
______________________________________________________________________________________ 
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 ANS C-07-01    
Date of Visit: ___/___/_____ 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
 
WEEK 0 
SURGERY FORM  
LEADS/EXTENSIONS 
Lead Implant Date ____/____/______ (mm/dd/yyyy) 
 Right Side  If XP:   □ Lead 1(1-4)       □ Lead 2 (5-8) 
Left Side 
If XP:   □ Lead 1(1-4)     □ Lead 2 (5-8) 
Lead Model Number  □ 6143DE-01 (30 cm)    □ 6145DE-01 (40 cm) 
□ 6143DE-01 (30 cm)    
□ 6145DE-01 (40 cm) 
Extension Model Number □ 6345DE-01 (50 cm)     □ 6346DE-01 (60 cm)     
□ 6345DE-01 (50 cm)     
□ 6346DE-01 (60 cm)     
IPG 
IPG Implant Date  ____/____/______ (mm/dd/yyyy) 
 Right Side                                  □ N/A Left Side                                       □ N/A 
IPG used □ Libra XP 6644DE-01     □ Libra 6608DE-01 
□ Libra XP 6644DE-01      
□ Libra 6608DE-01 
IPG Serial Number  
(on package and IPG) 
Lft. IPG                               
 ___ ___ ___ ___ ___ ___ ___ ___ 
 
Rt. IPG                                
  ___ ___ ___ ___ ___ ___ ___ ___ 
 
What size-tunneling tool was used for 
surgery? 
□ Tunneling tool  (0.156 diameter) 
□  Other: ____________________ 
Were any other ANS components used in 
addition to what was included in the kit? □ No    □ Yes 
If Yes (check all that apply) 
□ Stylet                                                            □ Torque Wrench   
□ Lead                                                             □ Trial Cable   
□ IPG                                                               □ Connector strain relief   
□ Extension                                                      □ Lead Stop  1140DE 
□ Tunneling tool (.156 diameter) 
□ Burr Hole Base and Cap, Unilateral  
□ Other: ____________________________________ 
 
Please Explain why:  
________________________________________________________________________ 
 
________________________________________________________________________ 
 
Did any Adverse Events occur during the 
surgery? □ No        □ Yes – Record details on AE section 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Week 2 Follow-up Visit Form 
 
SUBJECT WELLBEING 
Has the subject had contact with the case worker since the last visit?  
 YES→    How many times? By Phone:_______    In person________ 
 NO          (You do not need to fill out an unscheduled visit form) 
 
Have any unscheduled visits taken place since the last study visit?  
 YES→    How many times? _______(complete form) 
 NO 
 
ADVERSE EVENTS 
Have there been any adverse events since the last visit?  
 YES→    Record details on AE form 
 NO 
 
Have there been any serious adverse events since the last visit?  
 YES→    Record details on AE form and report to sponsor and IRB 
 NO 
 
SUBJECT STATUS 
Have any “depression” related medications changed since the last study visit?  
 YES→    Update con-med log and report to Sponsor 
 NO 
 
Has the subject changed their psychotherapy regimen since the last visit? 
 Decreased     Stopped      Increased      Same     N/A 
 
Did the subject use any “additional” Sleep aids since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
Did the subject use any “additional” anti-anxiolytics since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
Have any additional depression related medications been “added” since the last study 
visit? 
 YES→    Update con-med log and report to Sponsor Immediately 
 NO 
 
 
*Please update the con-med log. 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Week 2 Follow-up Visit Form 
 
 
VISIT REQUIREMENTS 
 MADRS                        
 HAM-A 
 C-SSRS 
 Randomization by  blinded programmer 
                                   
 
 Scheduled Date of Next Visit (14 days): ___/___/_______  
Coordinator Signature: ____________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Week 4 Follow-up Visit Form 
 
SUBJECT STATUS CONTINUED 
Have any additional depression related medications been “added” since the last study 
visit? 
 YES→    Update con-med log and report to Sponsor Immediately 
 NO 
 
Does the subject believe they have been receiving active therapy?  
 YES    NO 
     
    *Why or why not? ______________________________________________________ 
      ____________________________________________________________________ 
 
Does the PI believe they have been receiving active therapy?  
 YES    NO 
     
     *Why or why not? ______________________________________________________ 
      _____________________________________________________________________ 
 
 
VISIT REQUIREMENTS 
 MADRS 
 IDS                        
 QIDS-SR   
 WSAS 
 GAF 
 CGI 
 PGI                     
 HAM-A 
 C-SSRS 
 SAFTEE 
 Programming by blinded programmer 
                                   
 Scheduled Date of Next Visit (14 days): ___/___/_______  
 
 
Coordinator Signature: ____________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Week 6 Follow-up Visit Form 
 
SUBJECT WELLBEING 
Has the subject had contact with the case worker since the last visit?  
 YES→    How many times? By Phone:_______    In person________ 
 NO          (You do not need to fill out an unscheduled visit form) 
 
Have any unscheduled visits taken place since the last study visit?  
 YES→    How many times? _______(complete form) 
 NO 
 
ADVERSE EVENTS 
Have there been any adverse events since the last visit?  
 YES→    Record details on AE form 
 NO 
 
Have there been any serious adverse events since the last visit?  
 YES→    Record details on AE form and report to sponsor and IRB 
 NO 
 
SUBJECT STATUS 
Have any “depression” related medications changed since the last study visit?  
 YES→    Update con-med log and report to Sponsor 
 NO 
 
Has the subject changed their psychotherapy regimen since the last visit? 
 Decreased     Stopped      Increased      Same     N/A 
 
Did the subject use any “additional” Sleep aids since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
Did the subject use any “additional” anti-anxiolytics since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
Have any additional depression related medications been “added” since the last study 
visit? 
 YES→    Update con-med log and report to Sponsor Immediately 
 NO 
 
 
 
*Please update the con-med log. 
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Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Week 8 Follow-up Visit Form 
 
SUBJECT WELLBEING 
Has the subject had contact with the case worker since the last visit?  
 YES→    How many times? By Phone:_______    In person________ 
 NO          (You do not need to fill out an unscheduled visit form) 
 
Have any unscheduled visits taken place since the last study visit?  
 YES→    How many times? _______(complete form) 
 NO 
 
ADVERSE EVENTS 
Have there been any adverse events since the last visit?  
 YES→    Record details on AE form 
 NO 
 
Have there been any serious adverse events since the last visit?  
 YES→    Record details on AE form and report to sponsor and IRB 
 NO 
 
SUBJECT STATUS 
Have any “depression” related medications changed since the last study visit?  
 YES→    Update con-med log and report to Sponsor 
 NO 
 
Has the subject changed their psychotherapy regimen since the last visit? 
 Decreased     Stopped      Increased      Same     N/A 
 
Did the subject use any “additional” Sleep aids since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
Did the subject use any “additional” anti-anxiolytics since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
Week 8 Follow-up Visit Form 
 
SUBJECT STATUS CONTINUED 
Have any additional depression related medications been “added” since the last study 
visit? 
 YES→    Update con-med log and report to Sponsor Immediately 
 NO 
 
Does the subject believe they have been receiving active therapy?  
 YES    NO 
     
    *Why or why not? ______________________________________________________ 
      ____________________________________________________________________ 
 
Does the PI believe they have been receiving active therapy?  
 YES    NO 
     
     *Why or why not? _____________________________________________________ 
      ____________________________________________________________________ 
 
*Please update the con-med log. 
 
VISIT REQUIREMENTS 
 MADRS 
 IDS                        
 QIDS-SR   
 WSAS 
 GAF 
 CGI 
 PGI                     
 HAM-A 
 C-SSRS 
 Programming by blinded programmer 
                                   
 Scheduled Date of Next Visit (1 month not 4 weeks): ___/___/_______  
            Example: if today’s visit is on March 17th, the next visit would be April 17th  
 
Coordinator Signature: ____________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 3 Follow-up Visit Form 
*Must Video Tape MADRS* 
 
SUBJECT WELLBEING 
Has the subject had contact with the case worker since the last visit?  
 YES→    How many times? By Phone:_______    In person________ 
 NO          (You do not need to fill out an unscheduled visit form) 
 
Have any unscheduled visits taken place since the last study visit?  
 YES→    How many times? _______(complete form) 
 NO 
 
ADVERSE EVENTS 
Have there been any adverse events since the last visit?  
 YES→    Record details on AE form 
 NO 
 
Have there been any serious adverse events since the last visit?  
 YES→    Record details on AE form and report to sponsor and IRB 
 NO 
 
SUBJECT STATUS 
Have any “depression” related medications changed since the last study visit?  
 YES→    Update con-med log and report to Sponsor 
 NO 
 
Has the subject’s living situation changed since baseline?  
 No Change                              Lives with spouse and/or children     
 Lives Alone                             Lives in boarding home 
 Hospitalized                            Lives with other family       
 Other:_____________ 
 
Has the subject changed their psychotherapy regimen since the last visit? 
 Decreased     Stopped      Increased      Same     N/A 
 
Did the subject use any “additional” Sleep aids since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 3 Follow-up Visit Form 
 
SUBJECT STATUS CONTINUED 
Did the subject use any “additional” anti-anxiolytics since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
Have any additional depression related medications been “added” since the last study 
visit? 
 YES→    Update con-med log and report to Sponsor Immediately 
 NO 
 
Does the subject believe they have been receiving active therapy?  
 YES    NO 
      *Why or why not? ____________________________________________________ 
      ___________________________________________________________________ 
 
Does the PI believe they have been receiving active therapy?  
 YES    NO 
      *Why or why not? ____________________________________________________ 
      ___________________________________________________________________ 
 
*Please update the con-med log. 
 
VISIT REQUIREMENTS 
 MADRS (Video Taped) 
 HRSD-17 
 IDS                        
 QIDS-SR   
 YMRS 
 WSAS 
 GAF 
 QOL 
 CGI 
 PGI                     
 HAM-A 
 C-SSRS 
 HLQ 
 SAFTEE-SI 
 Programming by blinded programmer 
                                   
 Scheduled Date of Next Visit (1 month not 4 weeks): ___/___/_______  
            Example: if today’s visit is on March 17th, the next visit would be April 17th  
 
Coordinator Signature: ____________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 4 Follow-up Visit Form 
 
SUBJECT WELLBEING 
Has the subject had contact with the case worker since the last visit?  
 YES→    How many times? By Phone:_______    In person________ 
 NO          (You do not need to fill out an unscheduled visit form) 
 
Have any unscheduled visits taken place since the last study visit?  
 YES→    How many times? _______(complete form) 
 NO 
 
ADVERSE EVENTS 
Have there been any adverse events since the last visit?  
 YES→    Record details on AE form 
 NO 
 
Have there been any serious adverse events since the last visit?  
 YES→    Record details on AE form and report to sponsor and IRB 
 NO 
 
SUBJECT STATUS 
Have any “depression” related medications changed since the last study visit?  
 YES→    Update con-med log and report to Sponsor 
 NO 
 
Has the subject changed their psychotherapy regimen since the last visit? 
 Decreased     Stopped      Increased      Same     N/A 
 
Did the subject use any “additional” Sleep aids since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
Did the subject use any “additional” anti-anxiolytics since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
Have any additional depression related medications been “added” since the last study 
visit? 
 YES→    Update con-med log and report to Sponsor Immediately 
 NO 
 
 
 
*Please update the con-med log. 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 4 Follow-up Visit Form 
 
 
VISIT REQUIREMENTS 
 MADRS 
 IDS                        
 QIDS-SR   
 WSAS 
 GAF 
 CGI 
 PGI                     
 HAM-A 
 C-SSRS 
 Programming by blinded programmer 
 
                                   
Scheduled Date of Next Visit (1 month not 4 weeks): ___/___/_______  
            Example: if today’s visit is on March 17th, the next visit would be April 17th  
 
 
Coordinator Signature: ____________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 5 Follow-up Visit Form 
 
SUBJECT WELLBEING 
Has the subject had contact with the case worker since the last visit?  
 YES→    How many times? By Phone: _______    In person________ 
 NO          (You do not need to fill out an unscheduled visit form) 
 
Have any unscheduled visits taken place since the last study visit?  
 YES→    How many times? _______ (complete form) 
 NO 
 
ADVERSE EVENTS 
Have there been any adverse events since the last visit?  
 YES→    Record details on AE form 
 NO 
 
Have there been any serious adverse events since the last visit?  
 YES→    Record details on AE form and report to sponsor and IRB 
 NO 
 
SUBJECT STATUS 
Have any “depression” related medications changed since the last study visit?  
 YES→    Update con-med log and report to Sponsor 
 NO 
 
 
Has the subject changed their psychotherapy regimen since the last visit? 
 Decreased     Stopped      Increased      Same     N/A 
 
Did the subject use any “additional” Sleep aids since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
Did the subject use any “additional” anti-anxiolytics since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
Have any additional depression related medications been “added” since the last study 
visit? 
 YES→    Update con-med log and report to Sponsor Immediately 
 NO 
 
*Please update the con-med log. 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 5 Follow-up Visit Form 
 
 
VISIT REQUIREMENTS 
 MADRS 
 IDS                        
 QIDS-SR   
 WSAS 
 GAF 
 CGI 
 PGI                     
 HAM-A 
 C-SSRS 
 Programming by blinded programmer 
 
                                   
Scheduled Date of Next Visit (1 month not 4 weeks): ___/___/_______  
            Example: if today’s visit is on March 17th, the next visit would be April 17th  
 
 
Coordinator Signature: ____________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 6 Follow-up Visit Form 
*Must Video Tape MADRS* 
 
SUBJECT WELLBEING 
Has the subject had contact with the case worker since the last visit?  
 YES→    How many times? By Phone:_______    In person________ 
 NO          (You do not need to fill out an unscheduled visit form) 
 
Have any unscheduled visits taken place since the last study visit?  
 YES→    How many times? _______(complete form) 
 NO 
 
ADVERSE EVENTS 
Have there been any adverse events since the last visit?  
 YES→    Record details on AE form 
 NO 
 
Have there been any serious adverse events since the last visit?  
 YES→    Record details on AE form and report to sponsor and IRB 
 NO 
 
SUBJECT STATUS 
Have any “depression” related medications changed since the last study visit?  
 YES→    Update con-med log and report to Sponsor 
 NO 
 
Has the subject’s living situation changed since baseline?  
 No Change                              Lives with spouse and/or children     
 Lives Alone                             Lives in boarding home 
 Hospitalized                            Lives with other family       
 Other:_____________ 
 
Has the subject changed their psychotherapy regimen since the last visit? 
 Decreased     Stopped      Increased      Same     N/A 
 
Did the subject use any “additional” Sleep aids since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 6 Follow-up Visit Form 
SUBJECT STATUS CONTINUED 
Did the subject use any “additional” anti-anxiolytics since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
Have any additional depression related medications been “added” since the last study 
visit? 
 YES→    Update con-med log and report to Sponsor Immediately 
 NO 
 
Does the subject believe they have been receiving active therapy?  
 YES    NO 
      *Why or why not? _____________________________________________________ 
      ____________________________________________________________________ 
 
Does the PI believe they have been receiving active therapy?  
 YES    NO 
      *Why or why not? _____________________________________________________ 
      ____________________________________________________________________ 
 
*Please update the con-med log. 
 
VISIT REQUIREMENTS 
 MADRS (Video Taped) 
 HRSD-17 
 IDS                        
 QIDS-SR   
 YMRS 
 WSAS 
 GAF 
 QOL 
 CGI 
 PGI                     
 HAM-A 
 C-SSRS 
 HLQ 
 SAFTEE-SI 
 Programming by blinded programmer 
 Neuropsych Battery 
                                   
 Scheduled Date of Next Visit (1 month not 4 weeks): ___/___/_______  
            Example: if today’s visit is on March 17th, the next visit would be April 17th  
Coordinator Signature: ____________________________ 
Page 2 of 48
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
                                                              Page 1 of 3                                   Initials ________ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
Month 6 Neuropsychological Examination 
  Hopkins Verbal Learning Test Revised (HVLT-R)   Form # ____ (1-6) Initial: ______ 
          Raw Score  T-score 
 Total recall     _________ (0-36) ________ (20-80) 
 Delayed recall     _________ (0-12)  ________ (20-80) 
 Retention %     _________ (0-150+) ________ (20-80) 
 Recognition Discrimination Index      _________ (<4-12) ________ (20-80) 
NOTES: _____________________________________________________________________________ 
_____________________________________________________________________________________ 
  Ruff 2& 7 Selective Attention Test                                                          Initial: ______ 
        Raw Score  T-score 
 Automatic Detection Speed   _______ (0-300)  ___________ (20-80) 
 Automatic Detection Accuracy                        _______ (0-100) ___________ (20-80) 
 Controlled Search Speed                                 _______ (0-300)  ___________ (20-80) 
 Controlled Search Accuracy                            _______ (0-100)  ___________ (20-80) 
 Total Speed                                _______ (40-160) ___________ (20-80) 
 Total Accuracy                                    _______ (40-119) ___________ (20-80) 
NOTES: ______________________________________________________________________________ 
               ______________________________________________________________________________________ 
  Stroop Color Word Test (Golden version)                      Initial: ______ 
        Raw Score  T-score 
 Word score (number correct responses)    _______ (max 150) ___________ (3-98) 
 Color score (number correct responses)     _______ (max 150) ___________ (3-98) 
 Color/Word score (# correct responses)     _______ (max 150) ___________ (3-98) 
 Interference    _______ (max 150)            ___________ (20-80) 
NOTES: ______________________________________________________________________________ 
               ______________________________________________________________________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
                                                              Page 2 of 3                                   Initials ________ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
Month 6 Neuropsychological Examination 
  Brief Visual Memory Test- Revised (BVMT-R)      Form #_______ (1,2,3,4,5,6)   Initial: ______ 
          Raw Score  T-score 
 Trial 1          _______ (0-12) ___________ (38-80) 
 Trial 2                                    _______ (0-12) ___________ (38-80) 
 Trial 3                                    _______ (0-12)  ___________ (38-80) 
 Total                                    _______ (0-36) ___________ (38-80) 
 Delayed Recall                                   _______ (0-12) ___________ (38-80) 
 Recognition Hits                                   _______ (0-6)  ___________ NA 
 Recognition Discrimination                                _______ (-6 to +6) ___________ NA 
 NOTES: ________________________________________________________________________________ 
 _______________________________________________________________________________________ 
 Delis-Kaplan Executive Function Scale (D-KEFS)         Form #_______ (1 or 2)     Initial:_______ 
      Raw Score  Scaled Score  
 Letter fluency    ________ (0-> 67) _________ (0-19) 
 Category fluency                  ________ (0-> 61) _________ (0-19) 
 Switching fluency (2 scores)                             
o Total correct  ________(0-> 21) _________(0-19) 
o Switching accuracy ________(0->20)       _________(0-19)  
      
 NOTES:______________________________________________________________________________ 
______________________________________________________________________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
                                                              Page 3 of 3                                   Initials ________ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 6 Neuropsychological Examination 
  Wechsler Memory Scale – Third Edition Abbreviated (WMS-III-A )           Initial: ______ 
       Raw Score                   Age corrected scale score 
 Letter number sequencing                 ______   ___________  
NOTES: 
______________________________________________________________________________ 
______________________________________________________________________________________ 
 
  Behavior Rating Inventory of Executive Functions (BRIEF-A)                    Initial: ______ 
            Raw Score  T-score 
 Inhibit       _______ (0-24)  ___________ (30-105) 
 Shift                              _______ (0-18)  ___________ (30-105) 
 Emotional Control                            _______ (0-30)  ___________ (30-105) 
 Self-Monitor                             _______ (0-18)  ___________ (30-105) 
 Behavioral Regulation Index              _______ (0-90)  ___________ (30-105) 
 Initiate                              _______ (0-24)  ___________ (30-105) 
       Raw Score  T-score 
 Working Memory                            _______ (0-24)  ___________ (30-105) 
 Plan/Organize                             _______ (0-30)  ___________ (30-105) 
 Task Monitor                            _______ (0-18)  ___________ (30-105) 
 Organization of Materials                        _______ (0-24)   ___________ (30-105) 
 Metacognition Index      _______ (0-120)  ___________ (30-105) 
 Global Executive Composition                        _______ (0-210) ___________ (30-105) 
NOTES: 
______________________________________________________________________________________
______________________________________________________________________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 7 Follow-up Visit Form 
 
SUBJECT WELLBEING 
Has the subject had contact with the case worker since the last visit?  
 YES→    How many times? By Phone: _______    In person________ 
 NO          (You do not need to fill out an unscheduled visit form) 
 
Have any unscheduled visits taken place since the last study visit?  
 YES→    How many times? _______ (complete form) 
 NO 
 
ADVERSE EVENTS 
Have there been any adverse events since the last visit?  
 YES→    Record details on AE form 
 NO 
 
Have there been any serious adverse events since the last visit?  
 YES→    Record details on AE form and report to sponsor and IRB 
 NO 
 
SUBJECT STATUS 
Have any “depression” related medications changed since the last study visit?  
 YES→    Update con-med log  
 NO 
 
Has the subject changed their psychotherapy regimen since the last visit? 
 Decreased     Stopped      Increased      Same     N/A 
 
Did the subject use any “additional” Sleep aids since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
Did the subject use any “additional” anti-anxiolytics since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
 
 
 
 
*Please update the con-med log. 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 7 Follow-up Visit Form 
 
 
VISIT REQUIREMENTS 
 MADRS 
 IDS                        
 QIDS-SR   
 WSAS 
 GAF 
 CGI 
 PGI                     
 HAM-A 
 C-SSRS 
 Programming by blinded programmer 
 
                                   
Scheduled Date of Next Visit (1 month not 4 weeks): ___/___/_______  
            Example: if today’s visit is on March 17th, the next visit would be April 17th  
 
 
Coordinator Signature: ____________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 8 Follow-up Visit Form 
 
SUBJECT WELLBEING 
Has the subject had contact with the case worker since the last visit?  
 YES→    How many times? By Phone:_______    In person________ 
 NO          (You do not need to fill out an unscheduled visit form) 
 
Have any unscheduled visits taken place since the last study visit?  
 YES→    How many times? _______(complete form) 
 NO 
 
ADVERSE EVENTS 
Have there been any adverse events since the last visit?  
 YES→    Record details on AE form 
 NO 
 
Have there been any serious adverse events since the last visit?  
 YES→    Record details on AE form and report to sponsor and IRB 
 NO 
 
SUBJECT STATUS 
Have any “depression” related medications changed since the last study visit?  
 YES→    Update con-med log  
 NO 
 
Has the subject changed their psychotherapy regimen since the last visit? 
 Decreased     Stopped      Increased      Same     N/A 
 
Did the subject use any “additional” Sleep aids since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
Did the subject use any “additional” anti-anxiolytics since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
 
 
 
 
 
*Please update the con-med log. 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 8 Follow-up Visit Form 
 
 
VISIT REQUIREMENTS 
 MADRS 
 IDS                        
 QIDS-SR   
 WSAS 
 GAF 
 CGI 
 PGI                     
 HAM-A 
 C-SSRS 
 Programming by blinded programmer 
 
                                   
Scheduled Date of Next Visit (1 month not 4 weeks): ___/___/_______  
            Example: if today’s visit is on March 17th, the next visit would be April 17th  
 
 
Coordinator Signature: ____________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 9 Follow-up Visit Form 
 
SUBJECT WELLBEING 
Has the subject had contact with the case worker since the last visit?  
 YES→    How many times? By Phone: _______    In person________ 
 NO          (You do not need to fill out an unscheduled visit form) 
 
Have any unscheduled visits taken place since the last study visit?  
 YES→    How many times? _______ (complete form) 
 NO 
 
ADVERSE EVENTS 
Have there been any adverse events since the last visit?  
 YES→    Record details on AE form 
 NO 
 
Have there been any serious adverse events since the last visit?  
 YES→    Record details on AE form and report to sponsor and IRB 
 NO 
 
SUBJECT STATUS 
Have any “depression” related medications changed since the last study visit?  
 YES→    Update con-med log  
 NO 
 
Has the subject changed their psychotherapy regimen since the last visit? 
 Decreased     Stopped      Increased      Same     N/A 
 
Did the subject use any “additional” Sleep aids since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
Did the subject use any “additional” anti-anxiolytics since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
 
 
 
 
 
 
*Please update the con-med log. 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 9 Follow-up Visit Form 
 
 
VISIT REQUIREMENTS 
 MADRS 
 IDS                        
 QIDS-SR  
 YMRS  
 WSAS 
 GAF 
 QOL 
 CGI 
 PGI                     
 HAM-A 
 C-SSRS 
 HLQ 
 SAFTEE 
 Programming by blinded programmer 
 
                                   
Scheduled Date of Next Visit (1 month not 4 weeks): ___/___/_______  
            Example: if today’s visit is on March 17th, the next visit would be April 17th  
 
 
Coordinator Signature: ____________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 10 Follow-up Visit Form 
 
SUBJECT WELLBEING 
Has the subject had contact with the case worker since the last visit?  
 YES→    How many times? By Phone: _______    In person________ 
 NO          (You do not need to fill out an unscheduled visit form) 
 
Have any unscheduled visits taken place since the last study visit?  
 YES→    How many times? _______ (complete form) 
 NO 
 
ADVERSE EVENTS 
Have there been any adverse events since the last visit?  
 YES→    Record details on AE form 
 NO 
 
Have there been any serious adverse events since the last visit?  
 YES→    Record details on AE form and report to sponsor and IRB 
 NO 
 
SUBJECT STATUS 
Have any “depression” related medications changed since the last study visit?  
 YES→    Update con-med log  
 NO 
 
Has the subject changed their psychotherapy regimen since the last visit? 
 Decreased     Stopped      Increased      Same     N/A 
 
Did the subject use any “additional” Sleep aids since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
Did the subject use any “additional” anti-anxiolytics since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
 
 
 
 
 
 
*Please update the con-med log. 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 10 Follow-up Visit Form 
 
VISIT REQUIREMENTS 
 MADRS 
 IDS                        
 QIDS-SR   
 WSAS 
 GAF 
 CGI 
 PGI                     
 HAM-A 
 C-SSRS 
 Programming by blinded programmer 
 
                                   
Scheduled Date of Next Visit (1 month not 4 weeks): ___/___/_______  
            Example: if today’s visit is on March 17th, the next visit would be April 17th  
 
 
Coordinator Signature: ____________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 11 Follow-up Visit Form 
 
SUBJECT WELLBEING 
Has the subject had contact with the case worker since the last visit?  
 YES→    How many times? By Phone: _______    In person________ 
 NO          (You do not need to fill out an unscheduled visit form) 
 
Have any unscheduled visits taken place since the last study visit?  
 YES→    How many times? _______ (complete form) 
 NO 
 
ADVERSE EVENTS 
Have there been any adverse events since the last visit?  
 YES→    Record details on AE form 
 NO 
 
Have there been any serious adverse events since the last visit?  
 YES→    Record details on AE form and report to sponsor and IRB 
 NO 
 
SUBJECT STATUS 
Have any “depression” related medications changed since the last study visit?  
 YES→    Update con-med log  
 NO 
 
Has the subject changed their psychotherapy regimen since the last visit? 
 Decreased     Stopped      Increased      Same     N/A 
 
Did the subject use any “additional” Sleep aids since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
Did the subject use any “additional” anti-anxiolytics since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
 
 
 
*Please update the con-med log. 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 11 Follow-up Visit Form 
 
 
VISIT REQUIREMENTS 
 MADRS 
 IDS                        
 QIDS-SR   
 WSAS 
 GAF 
 CGI 
 PGI                     
 HAM-A 
 C-SSRS 
 Programming by blinded programmer 
 
                                   
Scheduled Date of Next Visit (1 month not 4 weeks): ___/___/_______  
            Example: if today’s visit is on March 17th, the next visit would be April 17th  
 
 
Coordinator Signature: ____________________________ 
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ANS C-07-01    
Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 12 Follow-up Visit Form 
*Must Video Tape MADRS* 
 
SUBJECT WELLBEING 
Has the subject had contact with the case worker since the last visit?  
 YES→    How many times? By Phone: _______    In person________ 
 NO          (You do not need to fill out an unscheduled visit form) 
 
Have any unscheduled visits taken place since the last study visit?  
 YES→    How many times? _______ (complete form) 
 NO 
 
ADVERSE EVENTS 
Have there been any adverse events since the last visit?  
 YES→    Record details on AE form 
 NO 
 
Have there been any serious adverse events since the last visit?  
 YES→    Record details on AE form and report to sponsor and IRB 
 NO 
 
SUBJECT STATUS 
Have any “depression” related medications changed since the last study visit?  
 YES→    Update con-med log  
 NO 
 
Has the subject’s living situation changed since baseline?  
 No Change                              Lives with spouse and/or children     
 Lives Alone                             Lives in boarding home 
 Hospitalized                            Lives with other family       
 Other:_____________ 
 
Has the subject’s marital status changed over the course of the study? 
 YES →      How? ________________________    
 NO 
 
Has the subject changed their psychotherapy regimen since the last visit? 
 Decreased     Stopped      Increased      Same     N/A 
 
Did the subject use any “additional” Sleep aids since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
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Date of Visit: ___/___/_____ 
 
 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 12 Follow-up Visit Form 
 
SUBJECT STATUS CONTINUED 
Did the subject use any “additional” anti-anxiolytics since the last visit?  
 YES→    Number of days used? _____   Update Con-Med form 
 NO 
 
*Please update the con-med log. 
*Please complete the study exit form at this time.  
 
VISIT REQUIREMENTS 
 MADRS (Video Taped) 
 HRSD-17 
 IDS                        
 QIDS-SR   
 YMRS 
 WSAS 
 GAF 
 QOL 
 CGI 
 PGI                     
 HAM-A 
 C-SSRS 
 HLQ 
 SAFTEE-SI 
 Programming by blinded programmer 
 Neuropsych Battery 
 Exit form 
                                   
 
Coordinator Signature: ____________________________ 
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Date of Visit: ___/___/_____ 
 
                                                              Page 1 of 3                                   Initials ________ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
Month 12 Neuropsychological Examination 
  Hopkins Verbal Learning Test Revised (HVLT-R)   Form # ____ (1-6) Initial: ______ 
          Raw Score  T-score 
 Total recall     _________ (0-36) ________ (20-80) 
 Delayed recall     _________ (0-12)  ________ (20-80) 
 Retention %     _________ (0-150+) ________ (20-80) 
 Recognition Discrimination Index      _________ (<4-12) ________ (20-80) 
NOTES: _____________________________________________________________________________ 
_____________________________________________________________________________________ 
  Ruff 2& 7 Selective Attention Test                                                          Initial: ______ 
        Raw Score  T-score 
 Automatic Detection Speed   _______ (0-300)  ___________ (20-80) 
 Automatic Detection Accuracy                        _______ (0-100) ___________ (20-80) 
 Controlled Search Speed                                 _______ (0-300)  ___________ (20-80) 
 Controlled Search Accuracy                            _______ (0-100)  ___________ (20-80) 
 Total Speed                                _______ (40-160) ___________ (20-80) 
 Total Accuracy                                    _______ (40-119) ___________ (20-80) 
NOTES: ______________________________________________________________________________ 
               ______________________________________________________________________________________ 
  Stroop Color Word Test (Golden version)                      Initial: ______ 
        Raw Score  T-score 
 Word score (number correct responses)    _______ (max 150) ___________ (3-98) 
 Color score (number correct responses)     _______ (max 150) ___________ (3-98) 
 Color/Word score (# correct responses)     _______ (max 150) ___________ (3-98) 
 Interference    _______ (max 150)            ___________ (20-80) 
NOTES: ______________________________________________________________________________ 
               ______________________________________________________________________________________ 
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Date of Visit: ___/___/_____ 
 
                                                              Page 2 of 3                                   Initials ________ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
Month 12 Neuropsychological Examination 
  Brief Visual Memory Test- Revised (BVMT-R)      Form #_______ (1,2,3,4,5,6)   Initial: ______ 
          Raw Score  T-score 
 Trial 1          _______ (0-12) ___________ (38-80) 
 Trial 2                                    _______ (0-12) ___________ (38-80) 
 Trial 3                                    _______ (0-12)  ___________ (38-80) 
 Total                                    _______ (0-36) ___________ (38-80) 
 Delayed Recall                                   _______ (0-12) ___________ (38-80) 
 Recognition Hits                                   _______ (0-6)  ___________ NA 
 Recognition Discrimination                                _______ (-6 to +6) ___________ NA 
 NOTES: ________________________________________________________________________________ 
 _______________________________________________________________________________________ 
 Delis-Kaplan Executive Function Scale (D-KEFS)         Form #_______ (1 or 2)     Initial:_______ 
      Raw Score  Scaled Score  
 Letter fluency    ________ (0-> 67) _________ (0-19) 
 Category fluency                  ________ (0-> 61) _________ (0-19) 
 Switching fluency (2 scores)                             
o Total correct  ________(0-> 21) _________(0-19) 
o Switching accuracy ________(0->20)       _________(0-19)  
      
 NOTES:______________________________________________________________________________ 
______________________________________________________________________________________ 
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Date of Visit: ___/___/_____ 
 
                                                              Page 3 of 3                                   Initials ________ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Month 12 Neuropsychological Examination 
  Wechsler Memory Scale – Third Edition Abbreviated (WMS-III-A )           Initial: ______ 
       Raw Score                   Age corrected scale score 
 Letter number sequencing                 ______   ___________  
NOTES: 
______________________________________________________________________________ 
______________________________________________________________________________________ 
 
  Behavior Rating Inventory of Executive Functions (BRIEF-A)                    Initial: ______ 
            Raw Score  T-score 
 Inhibit       _______ (0-24)  ___________ (30-105) 
 Shift                              _______ (0-18)  ___________ (30-105) 
 Emotional Control                            _______ (0-30)  ___________ (30-105) 
 Self-Monitor                             _______ (0-18)  ___________ (30-105) 
 Behavioral Regulation Index              _______ (0-90)  ___________ (30-105) 
 Initiate                              _______ (0-24)  ___________ (30-105) 
       Raw Score  T-score 
 Working Memory                            _______ (0-24)  ___________ (30-105) 
 Plan/Organize                             _______ (0-30)  ___________ (30-105) 
 Task Monitor                            _______ (0-18)  ___________ (30-105) 
 Organization of Materials                        _______ (0-24)   ___________ (30-105) 
 Metacognition Index      _______ (0-120)  ___________ (30-105) 
 Global Executive Composition                        _______ (0-210) ___________ (30-105) 
NOTES: 
______________________________________________________________________________________
______________________________________________________________________________________ 
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Page 1 of 2 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
AE Start Date: ____/____/_______ 
Unanticipated (AE other than listed below)     No     Yes (Specify & Notify Sponsor)_________________ 
Otherwise, please check only one of the following anticipated adverse events: 
AE related to DBS surgical 
procedures: 
 drowsiness 
 dysarthria 
 dystonia  
 DBS battery failure 
 DBS system malfunction 
 edema including periorbital 
 eye disorder 
 fever 
 general erosion or local skin 
erosion over the pulse generator 
(IPG), burr hole cap, and/or 
extension 
 headache 
  hearing and visual disturbance 
  hypomania 
  increase in depressive 
symptoms 
 increase in drug side effects 
 increased salivation 
 initial jolt or tingling during 
stimulation 
 intracranial infarctions 
 lead fracture 
 lead migration 
 loss of therapeutic benefit as a 
result of change in electrode 
positions, lead fracture, loose 
electrical connections, DBS system 
battery failure, DBS system 
malfunction, or inadvertent turning 
off of device 
  mania 
  myoclonus 
  nausea and/or vomiting 
  neuralgia 
  neuropathy 
 
 obsessive compulsive disorder 
(OCD) symptoms 
 panic attacks  
 paresis 
 paresthesia 
 persistent pain or redness at the 
IPG site or the surgery 
site/extension  
 pneumonia 
 pulling sensation along 
extension site 
 psychosis 
 rapid heart rate 
 ruminativeness  
 sensory deficit 
 sleep disturbance 
 skin disorder 
 suicide or suicide attempt 
 sweating 
 symptomatic neumocephalus 
(intracranial air causing confusion 
requiring an extra day stay in the 
hospital) 
 syncope 
 system dislodgement 
 undesirable changes in 
stimulation possibly related to 
cellular changes in tissue around 
the electrodes, changes in the 
electrode position, or loose 
electrical connections and/or lead 
fracture 
 urinary incontinence 
 venous air embolism (air 
entering the veins) 
 venous infarctions 
 
 aphasia 
 cerebrospinal fluid leakage 
 death 
 infection 
 intracranial hemorrhage 
 paralysis 
 post-operative pain 
 post-operative stress 
 post-operative discomfort 
 seizure or convulsion 
 stroke 
 subcutaneous hemorrhage or 
seroma 
 
AE associated with use of the 
device 
 allergic or rejection response to 
implanted materials 
 anxiety (pre-existing) 
 anxiety (new report) 
 apathy 
 asthenia, hemiplegia or 
hemiparesis 
 ataxia 
 attention deficit 
 autonomic instability (change in 
vital signs) 
 cerebrospinal fluid abnormality 
 cognitive impairment, including 
confusion, abnormal thinking, 
hallucinations, alteration of 
mentation, amnesia, delusions, or 
dementia   neuropathy 
 diarrhea 
 difficulty breathing 
 disequilibrium 
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Page 2 of 2 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
AE Form Continued…… 
 
Is AE Device Related (check only one)?       Not related      Unlikely      Possibly      Probably     
                                                                         Definitely 
Is AE Surgery Related?      Not related      Unlikely      Possibly      Probably      Definitely 
Severity of AE:                    Mild      Moderate   Severe     
System Intervention:          None      Patient Education      Stimulation Discontinued      
                                              System Revised      System Explanted   System Replaced     
                                              Other: ___________________________________________________________ 
Other Actions Taken:         None      Medication      Patient Exited Study      
                                              Other: ____________________________________________ 
AE Outcome Date: ____/____/_______      Resolved      Improved      Unchanged      
                                                                        Worsened     Death      Insufficient follow up           
Serious Adverse Event Information 
An event is serious if any of the following are answered YES 
Life threatening or fatal                                                   Yes      No 
Requires or prolongs hospitalization                               Yes      No 
The subject will be disabled                                            Yes      No 
COMMENTS:_____________________________________________________________________________ 
__________________________________________________________________________________________ 
__________________________________________________________________________________________ 
__________________________________________________________________________________________ 
__________________________________________________________________________________________ 
__________________________________________________________________________________________ 
 
SIGNATURE 
I have reviewed all of the information for this Adverse Event and verify that it is correct. 
 
 
________________________________                _________________ 
                                            Investigator Signature                                       Date 
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Date of Visit: ___/___/_____ 
 
 
 
                                                      Page 1 of 3                             Initials _____ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
Depression Exit/Early Withdrawal Form 
 
COMPLETE THIS FORM IN CONJUNCTION WITH THE PATIENT’S LAST VISIT 
FOR THE STUDY 
 
Were any of the following performed on the patient prior to EXIT from the study? 
 
Revision to lead?   □ No     □ Yes (specify)____________________________ 
Revision to extension?  □ No     □ Yes (specify)____________________________ 
Revision to IPG?   □ No     □ Yes (specify)____________________________ 
 
 
Did Subject complete all study related visits? 
□ Yes 
□ No   Reasons for not completing: (Subject could miss a visit but still complete all others) 
 □ Subject’s choice to withdraw 
 □ Adverse Event (Complete AE form) 
  □ Suicide 
  □ Suicide Attempt 
  □ Worsening of depression 
  □ Failed rescue after increase in suicide ideations 
  □ Other: ________________ 
 □ Subject is unwilling or unable to comply with study requirements     
 □ Investigator decision to withdraw subject from study 
 □ Lost to follow-up 
 □ Other: ____________________________________________________________________ 
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Date of Visit: ___/___/_____ 
 
 
 
                                                      Page 2 of 3                             Initials _____ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
If the subject exited the study prior to 6 months, does the patient believe he/she was receiving active 
therapy? 
□ Yes 
□ No      
Please Explain: 
_____________________________________________________________________________ 
__________________________________________________________________________________ 
__________________________________________________________________________________ 
 
If the subject exited the study prior to 6 months, does the PI believe he/she was receiving active 
therapy? 
□ Yes 
□ No      
Please Explain: 
_____________________________________________________________________________ 
__________________________________________________________________________________ 
__________________________________________________________________________________ 
 
Was the system explanted? □ No      □ Yes – Complete additional surgery form 
 
Patient Satisfaction: 
 
Based on your experience to date, would you choose to undergo the process to receive this DBS 
system again?             
□ Yes 
□ No      
Please Explain: 
_____________________________________________________________________________ 
__________________________________________________________________________________ 
__________________________________________________________________________________ 
 
Would you recommend this DBS system to anyone else suffering form the same condition? 
□ Yes 
□ No      
Please Explain: 
_____________________________________________________________________________ 
__________________________________________________________________________________ 
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Date of Visit: ___/___/_____ 
 
 
 
                                                      Page 3 of 3                             Initials _____ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
 
Will the subject enter the C-07-05 Long Term Follow-Up Study?  
□ Yes 
□ No      
 
 
 
 
   
I certify that I have reviewed source documentation, case report forms and  
all other study related documents for this patient, and will verify all changes  
made to the documentation of study materials for this patient.  
 
Principal Investigator 
 
 
Signature:  __________________________     Date:  _____/_____/______       
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Date of Visit: ___/___/_____ 
                               
                                                                                                                 
Initials ______ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
Additional Visit Form 
Any Adverse Events since last visit?             No     Yes – Record details on AE section 
Any change in medications since last visit?   No    Yes – Record details on Con-Med page 
 
 
Any Adverse Events since last visit?             No     Yes – Record details on AE section 
Any change in medications since last visit?   No    Yes – Record details on Con-Med page 
Additional Visit Date: ___/___/____ 
Reason for this visit?   
 Physician request         Worsening of Depression Symptoms  
 Pain at implant site       DBS system malfunction 
              Adverse Event (must fill out “AE Form”)                   Other ________________________________ 
Actions taken during this visit? (procedures and ratings):  
  Reprogramming         Medication adjusted (record on Con-Med page)        Patient education         
  Revision required      No action taken         Other _____________________________  
Additional Visit Date: ___/___/____ 
Reason for this visit?   
 Physician request         Worsening of Depression Symptoms  
 Pain at implant site       DBS system malfunction 
              Adverse Event (must fill out “AE Form”)                   Other ________________________________ 
Actions taken during this visit? (procedures and ratings):  
  Reprogramming         Medication adjusted (record on Con-Med page)        Patient education         
  Revision required      No action taken         Other _____________________________  
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Date of Visit: ___/___/_____ 
 
 
 
                                                                  Initials ______ 
Subject Initials:    __________ 
Subject Number:  __________ 
Site Number:        __________ 
  ADVERSE EVENTS 
Any Adverse Events during the surgery?            No      Yes – Record details on AE section 
 
CONCOMITANT MEDICATION 
 Any change in medications since last visit?       No       Yes – Record details on Con-Med page 
ADDITIONAL SURGERY FORM 
Reason For Surgery: 
  Lead migration                    Lead fracture                       Extension fracture  
  Erosion at extension site     Erosion at IPG site               Erosion at Burr hole cap         
 Infection of entire system     Infection at IPG      Infection at extension    Infection at lead  
  Battery failure        Battery EOL          IPG malfunction            Unacceptable side effects 
  Pain at IPG                          Lead initially not in target            Loss of effectiveness 
  Patient Req: (Reason)___________________  Physician Req (Reason)___________________ 
  Other (Specify)_________________________________________________________________ 
Action Taken: (Check all that apply) 
 Lead revised            Extension revised    IPG revised 
 Lead replaced          Extension replaced   IPG replaced Serial #____________ 
 Lead explanted        Extension explanted   IPG explanted 
 Entire system explanted     Other (Specify)__________________________________________ 
Indicate all ANS components that were used for this surgery. 
  Lead 6143DE-01 (30cm)                 Lead 6145DE-01 (40cm)             IPG and Type: _________        
  Extension 6346DE-01 (60cm)         Extension 6345DE-01 (50cm)         
  Stylet                                             Connector strain relief              Lead stop                    
  Torque Wrench                             Trial cable                                   
  Tunneling tool (.156)                    Tunneling tool (.125)               Burr hole ring and cap 
Other:_______________________________________________________________________ 
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BROADEN STUDY QUICK REFERENCE 
C-07-01  Assessment Schedule
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Clinical Evaluations
Montgomery and Asberg Depression Rating Scale (MADRS) (Psychiatrist Rater ONLY) V X X X X X X V X X V X X X X X V
Hamiltion Rating Scale for Depression (HRSD-17) X X X X
Inventory of Depressive Symptomatology (IDS-C30) X X X X X X X X X X X X X
Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR) X X X X X X X X X X X X X X X X
The Mini-International Neuropsychiatric Interview PLUS (M.I.N.I. PLUS) X
The Mini-Mental State Exam (MMSE) X
Structural Clinical Interview for Personality Disorders (SCID II) X
The Young Mania Rating Scale (YMRS) X X X X X
Work and Social Adjustment Scale (WSAS) X X X X X X X X X X X X X
Global Assessment of Functioning (GAF) X X X X X X X X X X X X X
Quality of Life Enjoyment and Satisfaction (QOL) X X X X X
Clinical Global Impression of Severity and Improvement (CGI) X X X X X X X X X X X X X X
Patient Global Impression Index (PGI) X X X X X X X X X X X X X X
Hamiliton Anxiety Rating Scale (HAM-A) X X X X X X X X X X X X X X X X X
Columbia Suicide-Severity Rating Scale (C-SSRS) (Psychiatrist Rater ONLY) X X X X X X X X X X X X X X X X X
Health and Labor Questionnaire (HLQ) X X X X X
Programming Form (un-blinded programmer) X X X X X X X X X X X X X X
Study Exit Form X
Cognitive Status/Safety Screens
Attention/Working Memory
Wechsler Memory Scale - Letter Numbering Squence X X X
Stroop Color and Word Test (Golden, 1978) X X X
Ruff 2&7 Selective Attention Test (Ruff & Allen, 1996) X X X
Executive Functioning
Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test X X X
Memory
Hopkins Verbal Learning Test - Revised (HVLT-R; Brandt & Benedict, 2001) X X X
Brief Visual Memory Test - Revised (BVMT-R; Benedict, 1997) X X X
Self and Informant Rating of Executive Functions
Behavior Rating Inventory of Exectuive Function - Adult Version (BRIEF-A; Roth et al., 2005) X X X
Tolerability Screens
Andtidepressant Treatment History Form (ATHF) X
Urine Pregnancy Test (if necessary) X
MRI/CT (MRI to be captured after Baseline 3 and prior to implant, CT captured post implant) X X
Brief physical exam X
Brief Neurological exam X
Systematic Assessment for Treatment Emergent Events (SAFTEE-SI) X X X X X X X X
Medical History X
Demographics and prior history X
V = Denotes time points when the MADRS session is Videotaped
Window Visit Schedule for Baselines 1-3 
Baseline 1 to Baseline 2 Window:  ≥ 2 weeks &  4 weeks
Baseline 2 to Baseline 3 Window: ≥ 2 weeks & ≤ 6 weeks
Baseline 3 to Implant (Week 0) Window: ≥ 2 weeks & ≤ 4 weeks
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Figure 1. Participant disposition 
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 Table 1. Demographics and Clinical Characteristics       
 
 
Stimulation (N=60) Control (N=30) 
Female N(%) 
 
30 (50%) 17 (57%) 
Age (mean ± SD) 
 
50.53 ± 9.73 48.70 ± 10.56 
Race: Caucasian N(%) 
 
58 (97%) 26 (87%) 
Family history of mood disorder N(%) 
 
41 (68%) 23 (77%) 
Length of current depressive episode (years, mean± SD)  12.62 + 8.15 9.67 + 4.67 
Lifetime number of episodes (mean ± SD) 
 
4.95 ± 6.43 4.40 ± 3.56 
Hospitalization for current episode: yes N(%)  
18 (30%) 8 (27%) 
Lifetime Hospitalization for MDD: yes N(%)  
10 (17%) 10 (33%) 
History of suicide attempt: yes N(%) 
 
23 (38%) 9 (30%) 
Lifetime number of adequate antidepressant treatments  (Mean ± SD) 7.4 + 3.14 8.8 + 4.39 
Total number of lifetime treatments for MDD (mean ± SD)  
20.5 ± 8.16 22.0 ± 9.32 
Prior ECT N (%) 52 (87%) 22 (73%) 
  No statistically significant differences were identified between groups on any demographic or clinical variable.   
Table
Table 2. Depression severity over time - mean (SD) 
Measure 
Baseline 3 Month 6 Month 9 Month* 12 Month* 
Stimulation  
N= 60 
Control  
N=30 
Stimulation 
N=60 
Control 
N=30 
Stimulation 
N=56 
Control 
N=29 
Stimulation 
N=53 
Control 
N=29 
Stimulation 
N=53 
Control 
N=27 
MADRS 33.8 (4.5) 37.3 (3.8) 29.6 (9.1) 32.5 (10.2) 27.2 (11.3) 30.0 (10.6) 25.1 (11.8) 27.5 (11.6) 23.2 (12.2) 26.7 (12.1) 
GAF 42.0 (4.1) 40.2 (4.9) 48.1 (8.5) 46.6 (12.0) 52.8 (15.9) 50.0 (10.4) 54.5 (16.4) 52.3 (14.0) 53.6 (15.3) 55.2 (12.8) 
QIDS-SR 17.4 (3.3) 19.5 (2.7) 15.0 (5.6) 16.4 (5.6) 14.1 (6.4) 16.3 (5.7) 13.8 (6.5) 15.2 (6.0) 12.8 (6.9) 14.1 (6.0) 
HRSD-17 20.3 (3.8) 22.6 (4.4) * * 17.5 (7.6) 19 (7.9) * * * * 
IDS 37.0 (7.4) 41.1 (38.2) 32.3 (11.4) 36.2 (12.4) 31.0 (12.9) 35.4 (13.4) 28.9 (12.4) 32.5 (12.3)  26.5 (13.9) 31.2 (14.3) 
*Note that at months 9 and 12, the Control group was receiving active stimulation; therefore, for the Control group, 9 months refers to 3 months of active 
stimulation, and 12 months refers to 6 months of active stimulation.  
 
 
Table
Table 3. Response/Remission by study visit. 
 3 Month 
Mean of 
Months 4, 5, 
& 6  6 Month 9 Montha 12 Montha 18 Montha 24 Montha 30 Montha 
N (Active, Control):  60, 30 60 ,30 60, 30 60, 30 60, 30 52, 25 52, 25 52, 25 
Responders [≥40% decrease in MADRS from baseline] – N (%) 
Stimulation Group 7 (12%) 12 (20%) 13 (21.7%) 17 (28.3%) 18 (30%) 28 (54%) 26 (50%) 25 (48%) 
Control Group 3 (10%) 5 (16.7%) 6 (20%) 9 (30%) 8 (27%) 13 (52%) 12 (48%) 11 (44%) 
Responders [≥50% decrease in MADRS from baseline] – N (%) 
Stimulation Group 4 (6.7%) 7 (11.7%) 10 (16.7%) 14 (23.3%) 16 (26.7%) 19 (36.5%) 22 (42.3%) 22 (42.3%) 
Control Group 2 (6.7%) 3 (10%) 5 (16.7%) 6 (20%) 7 (23.3%) 8 (32%) 9 (36%) 9 (36%) 
Remitters [MADRS ≤10] – N (%) 
Stimulation Group 1 (2%) 3 (5%) 6 (10%) 7 (12%) 11 (18%) 9 (17%) 16 (31%) 13 (25%) 
Control Group 2 (7%) 2 (7%) 2 (7%) 2 (7%) 2 (7%) 5 (20%) 4 (16%) 3 (12%) 
a Active stimulation was initiated in the control group at 6 months; therefore, for the control group, 9, 12, 18, 24, and 30 month time points 
reflect 3, 6, 12, 18 and 24 months of active stimulation.  
Table
Table 4. Serious adverse events and non-serious adverse events by group. 
Serious AEs Stimulation Group 
(Implant to 6 Mo, 
n=60) 
Control Group 
(Implant to 6 Mo, 
n=30) 
 
Stimulation Group 
(6 months to 12 
Months, n=60) 
Control Group 
(6 Mo to 12 Mo, 
n=30) 
 
All Patients 
(12 Mo, n = 77 to 24 
Mo, n=68) 
 Number 
of  events  
Number 
of pts (%) 
Number 
of  events  
Number 
of pts (%) 
Number 
of  events  
Number 
of pts (%) 
Number 
of  events  
Number 
of pts 
(%) 
Number of  
events  
Number 
of pts (%) 
Increase in depressive 
symptoms 
8 7 (12%) 1 1 (3%) 4 3 (10%) 1 1(3%) 13 9 (13%) 
Infection 6 5 (8%) 1 1 (3%) 0 0 0 0   
Anxiety 3 3 (5%) 0 0 1 1 (3%) 0 0 0 0 
Suicidal Ideation 1 1 (2%) 0 0 1 1 (3%) 0 0   
Suicide or suicide attempt 1 1 (2%) 0 0 1 1 (3%) 2 2 (7%) 1 1 (1%) 
Seizure or convulsion 1 1 (2%) 1 1 (3%) 0 0 0 0 0 0 
Headache 0 0 0 0 1 1 (3%) 0 0 0 0 
Post-operative discomfort 1 1 (2%) 0 0 0 0 0 0 0 0 
Hearing and visual disturbance 1 1 (2%) 0 0 0 0 0 0 0 0 
General erosion or local skin 
erosion over the pulse 
generator (IPG?, burr hole cap, 
and/or extension 
1 1 (2%) 0 0 0 0 0 0 0 0 
Hospitalization (Elective Surgery 
for Bariatric, Back Surgery, 
Cervical Fusion, Hysterectomy, 
and anti-coagulant therapy) 
0 0 0 0 0 0 1 1 (3%) 4 4 (6%) 
Elective Admission (to eliminate 
burden on caregiver) 
1 1 (2%) 0 0 2 1 (3%) 0 0 0 0 
Death (Unknown cause)         1 1 (1%) 
Non-Serious AEs* Stimulation Group 
(Implant to 6 Mo, 
n=60) 
Control Group 
(Implant to 6 Mo, 
n=30) 
 
Stimulation Group 
(6 months to 12 
Months, n=60) 
Control Group 
(6 Mo to 12 Mo, 
n=30) 
 
All Patients 
(12 Mo, n = 77 to 24 
Mo, n=68) 
 Number 
of  events  
Number 
of pts (%) 
Number 
of  events  
Number 
of pts (%) 
Number 
of  events  
Number 
of pts (%) 
Number 
of  events  
Number 
of pts 
(%) 
Number of  
events  
Number 
of pts (%) 
Headache 12 11 (18%) 8 8 (27%) 7 7 (12%) 2 2 (7%) 4  4 (6%) 
Post-operative discomfort/pain 11 11 (18%) 8 8 (27%) 0 0 0 0 1 1 (1%) 
Persistent pain or redness at the 
IPG site or the surgery 
site/extension 
9 9 (15%) 6 6 (20%) 1 1 (2%) 1 1 (3%) 2 2 (3%) 
Anxiety 3 3 (5%) 5 5 (17%) 3 3 (5%) 3 2 (7%) 1 1 (1%) 
Pulling sensation along 
extension site 
6 6 (10%) 1 1 (3%) 0 0 0 0 3 3 (4%) 
Hearing and visual disturbance 5 5 (8%) 0 0 4 4 (7%) 0 0 2 2 (3%) 
Increase in depressive 
symptoms 
3 3 (5%) 1 1 (3%) 1 1 (2%) 3 3(10%) 0 0 
Nausea and/or vomiting 2 2 (3%) 3 3 (10%) 2 3 (3%) 1 1 (3%) 2 2 (3%) 
Sleep Disturbance 2 2 (3%) 2 2 (7%) 2  2 (3%) 4 4 (13%) 2 2 (3%) 
Paresthesia 2 2 (3%) 2 2 (7%) 0 0 4 4 (13%) 2 2 (3%) 
Infection 2 2 (3%) 3 3 (10%) 0 0 0 0 1 1 (1%) 
Disequilibrium 2 2 (3%) 1 1 (3%) 2 2 (3%) 0 0 1 1 (1%) 
Skin Disorder 1 1 (2%) 2  2 (7%) 1 1 (2%) 1 1 (3%) 1 1 (1%) 
Neuralgia 1 1 (2%) 0 0 4 4 (7%) 0 0 0 0 
*Non-Serious AEs that occurred in 5 or more patients 
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Supplementary Tables. No significant difference between active stimulation (Stim) and sham stimulation (Control) groups was found for any of the below 
variables.  
Table S1. Logistic regression analysis of 4-6 month response rate (≥40% reduction in MADRS from baseline) comparing Stimulation vs. Active groups controlling 
for baseline demographic/clinical variables. LR = logistic regression. 
Source DF Chi-Square Pr > ChiSq Method 
Treatment group 1 0.12 0.7274 LR 
Sex 1 1.00 0.3164 LR 
Site category 2 5.65 0.0593 LR 
Average Baseline MADRS 1 0.39 0.5303 LR 
Total number of lifetime 
antidepressant medications and 
acceptable medication 
augmentation strategies 
1 0.68 0.4087 LR 
Total number of lifetime 
antidepressant medications rated 
3 or higher with at least good 
confidence 
1 0.00 0.9686 LR 
Total number of lifetime 
antidepressant treatments rated 3 
or higher 
(can include psychotherapy, ECT, 
VNS, TMS) 
1 0.19 0.6602 LR 
Total number of lifetime 
treatments for depression 
(including all others listed on this 
document 
1 1.81 0.1783 LR 
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Table S2. Hamilton Anxiety Scale (Ham-A). Note that 9 month and 12 month time points represent 3 and 6 months active stimulation for the control group. 
 Baseline 3 Months 6 Months 9 Months 12 Months 
Group Stim Control Stim Control Stim Control Stim Control Stim Control 
N 40 19 40 19 40 19   40 19 
Mean (SD) 15.9 (6.52) 16.7 (4.81) 14.1 (7.00) 16.7 (6.67) 15.0 (7.54) 18.6 (8.70) * * 12.3 (7.99) 14.2 (7.97) 
 
Table S3. Work and Social Adjustment Scale (WSAS). Note that 9 month and 12 month time points represent 3 and 6 months active stimulation for the control 
group. 
 Baseline 3 Months 6 Months 9 Months 12 Months 
Group Stim Control Stim Control Stim Control Stim Control Stim Control 
N 60 30 60 30 56 29 53 29 53 27 
Mean (SD) 32.9 (4.66) 35.2 (3.06) 28.5 (8.35) 31.7 (9.42) 28.1 (8.52) 31.2 (9.51) 27.1 (10.67) 30.3 (9.58) 25.5 (11.46) 29.6 (9.45) 
 
Table S4. Quality of Life (QOL) scale. Note that 9 month and 12 month time points represent 3 and 6 months active stimulation for the control group. 
 Baseline 3 Months 6 Months 9 Months 12 Months 
Group Stim Control Stim Control Stim Control Stim Control Stim Control 
N 58 28         
Mean (SD) 33.5 (6.08) 28.5 (5.87) 35.6 (8.33) 32.9 (9.99) 37.8 (8.93) 34.6 (8.18) 39.9 (10.18) 35.3 (8.80) 40.1 (10.72) 36.8 (11.35) 
 
Table S5. Change in Young Mania Rating Scale (YMRS) score over time. Note that 9 month and 12 month time points represent 3 and 6 months active stimulation 
for the control group. 
 3 Months 6 Months 9 Months 12 Months 
Group Stim Control Stim Control Stim Control Stim Control 
N 60 30 56 29 53 29 53 27 
Mean (SD) 0.2 (2.41) -0.5 (2.0) -0.1 (1.89) -0.2 (2.01) -0.2 (1.79) -0.2 (3.17) -0.3 (2.03) -0.9 (2.19) 
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Table S6. Health and Labor Questionnaire. Note that 9 month and 12 month time points represent 3 and 6 months active stimulation for the control group. 
 Baseline 3 Months 6 Months 9 Months 12 Months 
Group 
N 
Stim 
60 
Control 
30 
Stim 
58 
Control 
29 
Stim 
56 
Control 
29 
Stim 
53 
Control 
29 
Stim 
53 
Control 
27 
Paid Work 12 13 12 8 14 11 18 12 17 11 
Manage a 
Household 
5 0 5 2 4 1 3 1 4 1 
Pension or Early 
Retirement 
3 1 4 0 4 0 4 1 4 0 
In School or a 
Student 
3 0 0 0 1 0 2 0 2 0 
Unable to Perform 
Paid Work Due to 
Health Problems 
28 11 33 14 29 11 23 12 23 11 
No Paid Work 8 4 2 5 3 5 2 3 4 4 
 
Table S7. Columbia Suicide Severity Scale. Ns represent participants with a change in score over time. Note that 9 month and 12 month time points represent 3 
and 6 months active stimulation for the control group. 
 Baseline Month 3 Month 6 9 Month Month 12                   
 Stim 
(N=39) 
Control 
(N=19) 
Stim 
(N=40) 
Control 
(N=19) 
Stim 
(N=39) 
Control 
(N=18) 
Stim 
(N=36) 
Control 
(N=18) 
Stim 
(N=38) 
Control 
(N=17) 
Suicidal Ideation(1-5) 
1) Wish to be 
dead 
31 16 28 16 26 11 22 11 20 7 
2) Non-specific 
active 
suicidal 
thoughts 
26 14 14 7 13 7 13 7 10 3 
4 
 
3) Active 
suicidal 
ideation with 
any methods 
(not plan) 
without intent 
to act 
17 12 10 4 8 7 7 5 6 3 
4) Active 
suicidal 
ideation with 
some intent 
to act, 
without 
specific plan 
7 7 0 1 4 1 3 0 2 1 
5) Active 
suicidal 
ideation with 
specific plan 
and intent 
5 5 1 0 0 1 0 1 0 1 
Suicidal Behavior 
Actual attempt 13 5 0 0 0 0 0 0 0 1 
Has subject 
engaged in non-
suicidal self-
injurious 
behavior? 
4 4 0 0 0 1 0 0 0 1 
Interrupted 
attempt 
1 2 0 0 0 0 0 0 0 0 
Aborted attempt 4 2 0 0 0 0 0 0 0 0 
Completed 
suicide 
N/A N/A 0 0 0 0 0 0 0 1 
Preparatory acts 
or behavior 
6 4 0 0 0 0 0 0 0 1 
Suicidal Behavior 1 0 1 1 0 0 0 0 0 0 
 
5 
 
Table S8. Clinical Global Impression-Severity (CGI-S) and Patient Global Impression-Severity (PGI-S). Note that 9 month and 12 month time points represent 3 
and 6 months active stimulation for the control group. 
 Baseline 3 Months 6 Months 
Group Stimulation Control Stimulation Control Stimulation Control 
N 60 30 60 30 56 29 
CGI-S 5.35 5.73 4.93 5.1 4.57 4.6 
N 60 30 59 30 56 29 
PGI-S 5.55 5.57 4.92 5.03 4.82 4.86 
 
